---
document_datetime: 2024-04-25 15:29:14
document_pages: 124
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/xtandi-h-c-002639-ii-0063-epar-assessment-report-variation_en.pdf
document_name: xtandi-h-c-002639-ii-0063-epar-assessment-report-variation_en.pdf
version: success
processing_time: 492.8929088
conversion_datetime: 2025-12-30 12:19:04.330195
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

21 March 2024 EMA/CHMP/147735/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Xtandi

International non-proprietary name: Enzalutamide

Procedure No. EMEA/H/C/002639/II/0063

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 6                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6 |                                                                                                            |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................7                                                  |
| 2. Scientific discussion................................................................................                   | 7                                                                                                          |
| 2.1. Introduction                                                                                                          | ........................................................................................................7  |
| 2.1.1. Problem statement                                                                                                   | ............................................................................................7              |
| 2.1.2. About the product                                                                                                   | ........................................................................................... 10             |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice......                                     | 11                                                                                                         |
| 2.1.4. General comments on compliance with                                                                                 | GCP........................................................ 11                                             |
| 2.2. Non-clinical aspects............................................................................................      | 11                                                                                                         |
| 2.2.1. Introduction....................................................................................................    | 11                                                                                                         |
| 2.2.2. Ecotoxicity/environmental risk assessment.........................................................                  | 11                                                                                                         |
| 2.2.3. Discussion on non-clinical aspects                                                                                  | ..................................................................... 13                                   |
| 2.2.4. Conclusion on the non-clinical aspects ...............................................................              | 14                                                                                                         |
| 2.3. Clinical aspects                                                                                                      | .................................................................................................. 14      |
| 2.3.1. Introduction....................................................................................................    | 14                                                                                                         |
| 2.3.2. Clinical pharmacology                                                                                               | ...................................................................................... 15                  |
| 2.3.1. Discussion and conclusion on clinical pharmacology.............................................                     | 15                                                                                                         |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 16      |
| 2.4.1. Dose response study........................................................................................         | 16                                                                                                         |
| 2.4.2. Main study                                                                                                          | ..................................................................................................... 16   |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 76                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy ....................................................................           | 81                                                                                                         |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 81    |
| 2.5.1. Discussion on clinical safety............................................................................           | 111                                                                                                        |
| 2.5.2. Conclusions on clinical safety..........................................................................            | 116                                                                                                        |
| 2.5.3. PSUR cycle                                                                                                          | ................................................................................................... 116    |
| 2.6. Risk management plan                                                                                                  | ..................................................................................... 116                  |
| 2.7. Conclusion                                                                                                            | ...................................................................................................... 118 |
| 2.8. Update of the Product information......................................................................               | 118                                                                                                        |
| 2.8.1. User consultation ..........................................................................................        | 118                                                                                                        |
| 3. Benefit-Risk Balance...........................................................................                         | 118                                                                                                        |
| 3.1. Therapeutic Context .........................................................................................         | 118                                                                                                        |
| 3.1.1. Disease or condition ......................................................................................         | 118                                                                                                        |
| 3.1.2. Available therapies and unmet medical                                                                               | need..................................................... 118                                              |
| 3.1.3. Main clinical studies.......................................................................................        | 119                                                                                                        |
| 3.2. Favourable effects............................................................................................        | 119                                                                                                        |
| 3.3. Uncertainties and limitations about favourable effects...........................................                     | 120                                                                                                        |
| 3.4. Unfavourable effects.........................................................................................         | 120                                                                                                        |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ....................................... 121                                                                |
| 3.6. Effects Table....................................................................................................     | 121                                                                                                        |
| 3.7. Benefit-risk assessment and discussion...............................................................                 | 122                                                                                                        |
| 3.7.1. Importance of favourable and unfavourable effects............................................                       | 122                                                                                                        |

<div style=\"page-break-after: always\"></div>

| 3.7.2. Balance of benefits and risks ..........................................................................        |   123 |
|------------------------------------------------------------------------------------------------------------------------|-------|
| 3.7.3. Additional considerations on the benefit-risk balance .........................................                 |   123 |
| 3.8. Conclusions ..................................................................................................... |   123 |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

Abbreviation

Definition

ADT

androgen deprivation therapy

AE

adverse event

ALT

alanine aminotransferase

AR

androgen receptor

AST

aspartate aminotransferase

BCR

biochemical recurrence

BICR

Blinded Independent Central Review

BMI

body mass index

CI

confidence interval

COVID-19

illness caused by SARS-CoV-2

CRPC

castration-resistant prostate cancer

CSPC

castration-sensitive prostate cancer; also referred to as hormone-sensitive prostate cancer (HSPC)

ECOG

Eastern Cooperative Oncology Group

GCP

Good Clinical Practice

GnRH

gonadotropin-releasing hormone

HR

hazard ratio

ISS

Integrated Summary of Safety

mCRPC

metastatic castration-resistant prostate cancer

mCSPC

metastatic castration-sensitive prostate cancer; also referred to as metastatic

hormone-sensitive prostate cancer (mHSPC)

MFS

metastasis-free survival

NCI-CTCAE

National Cancer Institute - Common Terminology Criteria for Adverse Events

nmCRPC

non-metastatic castration-resistant prostate cancer

nmCSPC

non-metastatic castration-sensitive prostate cancer; also referred to as non- metastatic hormone-sensitive prostate cancer (nmHSPC)

nmPC

non-metastatic prostate cancer

NR

not reached

NSAA

nonsteroidal antiandrogen

OS

overall survival

PFS

progression-free survival

PFS2

progression-free survival on first subsequent therapy

PRES

posterior reversible encephalopathy syndrome

PSA

prostate-specific antigen

PSADT

prostate-specific antigen doubling time

PSUR

Periodic Safety Update Report

RMP

risk management plan

rPFS

radiographic progression-free survival

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                         |
|----------------|------------------------------------|
| SAE            | serious adverse event              |
| SAP            | statistical analysis plan          |
| SCS            | Summary of Clinical Safety         |
| SmPC           | Summary of Product Characteristics |
| SMQ            | Standardized MedDRA query          |
| TEAE           | treatment-emergent adverse event   |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Astellas Pharma Europe B.V. submitted to the European Medicines Agency on 28 August 2023 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of adult men with high-risk biochemical recurrent (BCR) nonmetastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy, for Xtandi, based on final results from study MDV3100-13 (EMBARK); this is a phase 3, randomized, efficacy and safety study of enzalutamide plus leuprolide, enzalutamide monotherapy, and placebo plus leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 18.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package Leaflet.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included (an) EMA Decision(s) CW/0001/2015 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH received Scientific advice from the CHMP on 17 January 2013 (EMEA/H/SA/1612/1/FU/2/2012/III). The Scientific Advice pertained to non-clinical and clinical aspects of the dossier.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Carolina Prieto Fernandez

Co-Rapporteur:

Filip Josephson

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 28 August 2023    |
| Start of procedure:                                  | 16 September 2023 |
| CHMP Rapporteur Assessment Report                    | 14 November 2023  |
| PRAC Rapporteur Assessment Report                    | 17 November 2023  |
| CHMP Co-Rapporteur Assessment                        | 20 November 2023  |
| PRAC Outcome                                         | 30 November 2023  |
| CHMP members comments                                | 04 December 2023  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 8 December 2023   |
| Request for supplementary information (RSI)          | 14 December 2023  |
| CHMP Rapporteur Assessment Report                    | 22 February 2024  |
| PRAC Rapporteur Assessment Report                    | 23 February 2024  |
| PRAC members comments                                | n/a               |
| Updated PRAC Rapporteur Assessment Report            | n/a               |
| PRAC Outcome                                         | 07 March 2024     |
| CHMP members comments                                | 11 March 2024     |
| Updated CHMP Rapporteur Assessment Report            | 14 March 2024     |
| Opinion                                              | 21 March 2024     |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The initial claimed indication was: Xtandi is indicated for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.

The agreed indication is: Xtandi is indicated as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic

<div style=\"page-break-after: always\"></div>

hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy (see section 5.1).

## Epidemiology and risk factors, screening tools/prevention

Prostate cancer is the second most common diagnosed cancer in men, with an estimated 1.4 million diagnoses worldwide in 2020 (Culp, M.B., et al Eur Urol, 2020). Within the EU, an estimated 473,344 new cases were diagnosed, and 108,088 men died of prostate cancer during 2020 [International Agency for Research on Cancer, 2020].  While prostate cancer remains the third leading cause of male cancer mortality in the EU (after lung and colorectal), the death rate has decreased in the EU by 7.1% from 2017 to 2022 and an estimated 69000 deaths due to prostate cancer were predicted for 2022 (Dalmartello M et al, Ann Oncol. 2022). In general, prostate cancer death rates have been decreasing since the early 1990s, which has been attributed to improvements in detection and treatment; however, the pace of decline in cancer death rates appears to have stabilized from 2013 to 2015.

Most cases present at an early stage and often have an indolent course. However, less than 10% of cases will have metastatic disease onset and it is estimated that up to one third of patients will develop eventual metastatic disease at some point of their disease course. Prostate cancer progresses through a series of characteristic clinical states that represent both the natural history of the disease and response to treatment (Scher HI et al, Urology. 2000), from initial diagnosis of either localized or metastatic disease that can then progress with rising PSA levels to metastatic hormone-sensitive disease or to nmCRPC, ultimately leading to mCRPC [Figure 1]. Early in the disease, prostate cancer cells need normal levels of androgens to survive.  Such prostate cancers are referred to as androgen-dependent or hormone-sensitive; therefore, treatments that decrease androgen levels or block androgen activity can inhibit the growth of prostate cancer, and ADT is often initiated in men who experience recurrence or progression of their disease.

Figure 1 Model of Prostate Cancer Progression

<!-- image -->

CRPC: castration-resistant prostate cancer; PSA: prostate-specific antigen.

Source: modified from Scher &amp; Heller [2000]

## Clinical presentation, diagnosis and stage/prognosis

Following the initial evaluation and diagnosis of prostate cancer, the vast majority of men undergo primary localized treatment with curative intent (Marhold M et al, Cancer Lett. 2022; Buglione M et al, PLoS One. 2019; Hager B et al, Prostate Cancer Prostatic Dis. 2017; Cooperberg MR et al, J Clin Oncol. 2010). Of those, approximately one-third experience rising PSA or BCR within 10 years after primary therapy (Ward JF et al, Nat Clin Pract Urol. 2005;   Han M, Partin AW   et al, Urol Clin North Am. 2001) which

<div style=\"page-break-after: always\"></div>

is commonly defined as PSA level &gt; 0.2 ng/mL with a secondary confirmatory level above 0.2 ng/mL following prostatectomy or increase in PSA by ≥ 2 ng/mL above the nadir following radiation (Punnen S et al, Eur Urol. 2013). This rise in PSA uniformly represents recurrence of prostate cancer, the likely presence of micrometastatic disease and an increased risk of morbidity and mortality from prostate cancer (Pound CR   et al, JAMA. 1999; Deguchi T   et al, Br J Cancer. 1997). Although a majority (&gt;70%) of men with BCR after primary therapy do not develop metastases or die from prostate cancer, a subset of patients with rising PSA following primary therapy will develop clinically apparent metastases and will die as a result of the disease (Antonarakis ES et al, BJU Int. 2012; 1 Freedland SJ et al, JAMA. 2005; Freedland SJ    et al, J Clin Oncol. 2007; Ward JF et al, Nat Clin Pract Urol. 2005; Punnen S et al, Eur Urol. 2013). Several parameters (e.g., prostate-specific androgen doubling time (PSADT) and Gleason score) have been studied to distinguish men who are likely to develop 'clinically significant' disease from those who have more indolent disease after biochemical relapse. The PSADT is predictive of both clinical MFS and prostate cancer-specific mortality in men with a rising serum PSA after radical prostatectomy (Ward JF et al, Nat Clin Pract Urol. 2005; Freedland SJ et al, JAMA. 2005; Zhou P et al, J Clin Oncol. 2005; D'Amico AV et al, J Natl Cancer Inst. 2003). In addition, observational data from Johns Hopkins Universtity suggests that patients with biochemical relapse after radical prostatectomy who were at most risk for the development early metastases and death from prostate cancer had a Gleason score of 8 to 10 and a PSADT &lt; 10 months (Han M et al, Urol Clin North Am. 2001;    Punnen S et al, Eur Urol. 2013). In an analysis of 2 independent patient cohorts with biochemical relapse after surgery and PSADT &lt; 12 months, predictors of MFS were identified (Markowski MC et al, Clin Genitourin Cancer. 2019). Results of this multivariate regression analysis suggest that the addition of absolute PSA level can better define an \"atrisk\" population identifying PSADT ≤ 7.5 months, PSA ≥ 0.5 ng/mL and Gleason score as independent predictors of MFS by multivariable analysis Pienta KJ et al, Clin Cancer Res. 2006).

## Management

Monitoring PSA levels after definitive treatment of localized prostate cancer with either radiation therapy or radical prostatectomy leads to the identification of patients with PSA-only biochemical recurrence (Punnen S et al, Eur Urol. 2013). The diagnosis of BCR usually leads to radiological investigation to determine if the recurrence is localized to the prostate gland or the site from where it has been removed from, or metastatic. For patients with BCR in whom there is a significant likelihood that the disease is confined to the prostate or prostatic bed, local salvage therapy (for example, salvage prostatectomy, radiation therapy, brachytherapy or high-intensity focused ultrasound) may result in prolonged diseasefree survival (Fossati N. et al, Eur Urol. 2016). If metastases are detected, these patients are treated as mHSPC. When increases in serum PSA are not accompanied by signs, symptoms or radiographic evidence of locally recurrent or disseminated disease and, testosterone levels are &gt; 50 ng/mL, the underlying disease is generally hormone-sensitive and responsive to conventional ADT with gonadotropin-releasing hormone (GnRH) agonist, GnRH antagonist or orchiectomy. Systemic therapy with conventional ADT has been the primary therapeutic approach for patients in whom the rise in PSA is not accompanied by symptoms or radiographic evidence of disseminated disease and for those who have had local salvage therapy following their initial definitive treatment but who subsequently have a BCR with non-castrate serum levels of testosterone. Immediate, rather than deferred, ADT is recommended for most patients with BCR and the presence of high-risk features for early metastasis (i.e., PSADT &lt; 10 months, Gleason score of 8 to 10) (Virgo KS et al, J Clin Oncol. 2021).

ADT or salvage local therapy is often used early after definitive therapy in patients with nmCSPC with high-risk BCR. Even with available prognostic factors, no therapies are approved for high-risk nmCSPC with evidence of disease recurrence by PSA but without overt metastases. ADT is administered to slow

<div style=\"page-break-after: always\"></div>

the growth of prostate cancer, although there is evidence to suggest that ADT alone may not provide sustained long-term efficacy. After 5 years of treatment with ADT, approximately 10% to 20% of nmCSPC cases will develop into CRPC, defined by rising PSA levels or radiographic disease progression despite androgen suppression (Kirby M et al, J Med Econ. 2010; Alemayehu Bet al, J Med Econ. 2010; Cabrera C et al, Pharmacoepidemiol Drug Saf. 2010). An estimated 33% of patients with nmCRPC were found to develop distant metastases within 2 years of resistance. Despite low or undetectable levels of androgen in such patients, evidence suggests that AR signalling remains active and that their tumours continue to respond to therapies directed at the AR signalling axis ( Pienta KJ   et al, Clin Cancer Res. 2006).

Currently, no novel hormone therapies are approved in the EU or US for nmCSPC and the available treatment options such as ADT for these patients, notably those with high-risk nmPC, have limitations. The primary goal of treatment for this condition is to delay or decrease the risk of developing metastasis and emergence of castration-resistant disease and to prolong OS.  Enzalutamide, which has demonstrated efficacy in other prostate cancer disease states, has the potential to address this unmet medical need in patients with nmCSPC with high-risk BCR.

Intermittent ADT has been proposed as an alternative to continuous ADT for treatment of advanced HSPC, since many of the acute and chronic side effects of ADT are due to castrate levels of testosterone. Periods of time when men are off therapy may be associated with decreases in these side effects, especially those associated with physical and sexual function, thereby improving quality of life. Intermittent ADT typically involves treatment for either a fixed interval of time or until a maximal response is achieved based upon PSA levels. ADT is then withdrawn, and patients are followed for evidence of recurrence. As testosterone production resumes, the side effects of ADT are mitigated, but the risk of disease progression also increases. The patient is followed with PSA measurements, and ADT is reinitiated based on a predefined threshold level of serum PSA. Multiple randomized trials and metaanalysis have addressed the benefit of intermittent androgen deprivation regarding improvements in physical function and quality of life, although questions remain as to the survival impact of intermittent therapy (Pienta KJ et al, Aging Male. 2015; Botrel TEA   et al, BMC Urol. 2014; Brungs D, et al, Prostate Cancer Prostatic Dis. 2014; Niraula S et al, J Clin Oncol. 2013; Tsai H-T    et al, Urology. 2013).

## 2.1.2. About the product

Enzalutamide is an AR inhibitor that targets the AR signal pathway. Enzalutamide competitively inhibits androgen binding to androgen receptors, and consequently; inhibits nuclear translocation of activated receptors and inhibits the association of the activated androgen receptor with DNA even in the setting of androgen receptor overexpression and in prostate cancer cells resistant to anti androgens. Enzalutamide treatment decreases the growth of prostate cancer cells and can induce cancer cell death and tumour regression. In preclinical studies enzalutamide lacks androgen receptor agonist activity (see SmPC section 5.1).

Enzalutamide was first approved in the EU in June 2013 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received docetaxel. The indication for enzalutamide was subsequently extended to include all patients with mCRPC in November 2014. Enzalutamide has also been approved for the treatment of patients with non-metastatic castrationresistant prostate cancer in October 2018 and later, in April 2021, enzalutamide was approved for the treatment of patients with metastatic castration-sensitive cancer (mCSPC), also referred to as metastatic hormone-sensitive prostate cancer (mHSPC).

The MAH applied for an extension of indication for Xtandi as follows: ' as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent

<div style=\"page-break-after: always\"></div>

(BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy (see section 5.1).

The recommended dose is 160 mg enzalutamide (four 40 mg soft capsules) as a single oral daily dose.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice.

The MAH received prior scientific advice (EMEA/H/SA/1612/1/FU/2/2012/III) in January 2013. Questions were included on the acceptability of the design of a new phase 3 trial of enzalutamide added on to GnRH analogue therapy in males with high-risk prostate cancer that is progressing following definitive therapy. The CHMP recommended conducting two separate studies that resulted in dividing the protocol into the studies EMBARK (in nmHSPC) and ARCHES (in mHSPC). The content of this advice included discussion about the primary and secondary endpoints, frequency of imaging, comparator treatment, main inclusion/exclusion criteria and definition of high risk.

## 2.1.4. General comments on compliance with GCP

The MAH claims that the clinical trials were performed in accordance with Good Clinical Practice standards. The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which is considered acceptable. The nonclinical pharmacology, pharmacokinetics and toxicology enzalutamide have been well characterized in a full non-clinical packaged included in the original MAA for Xtandi. However, an updated Environmental Risk Assessment (ERA) has been submitted as part of this application for an extension of the indication.

## 2.2.1. Introduction

The purpose of this submission is to extend the current Marketing Authorization for Xtandi to include patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR). Therefore, an updated environmental risk assessment report for enzalutamide has been provided in accordance with the EMA guidelines. This re-assessment report considers the potential impact of the increased patient population from the new indication on the environmental risk assessment of enzalutamide.

## 2.2.2. Ecotoxicity/environmental risk assessment

An updated environmental risk assessment report for enzalutamide has been submitted in accordance with the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMA/CHMP/SWP/4447/00 corr. 2 1*,  EMA 2006) and the 'Questions and answers on the Guideline' (EMA/CHMP/SWP/44609/2010 Rev. 1, EMA, adopted 26 May 2016). The main studies results are summarised below.

<div style=\"page-break-after: always\"></div>

Table 1. Report providing relevant endpoints of the environmental risk assessment of Enzalutamide

| Substance (INN/Invented Name): Enzalutamide    | Substance (INN/Invented Name): Enzalutamide    | Substance (INN/Invented Name): Enzalutamide                                                              | Substance (INN/Invented Name): Enzalutamide    |
|------------------------------------------------|------------------------------------------------|----------------------------------------------------------------------------------------------------------|------------------------------------------------|
| CAS-number: 915087-33-1                        | CAS-number: 915087-33-1                        | CAS-number: 915087-33-1                                                                                  | CAS-number: 915087-33-1                        |
| PBT screening                                  |                                                | Result                                                                                                   | Conclusion                                     |
| Bioaccumulation potential- log K ow            | OECD107                                        | 2.99                                                                                                     | Not potential PBT                              |
| PBT assessment                                 | PBT assessment                                 | PBT assessment                                                                                           | PBT assessment                                 |
| Parameter                                      | Result relevant for conclusion                 |                                                                                                          | Conclusion                                     |
| Bioaccumulation                                | BCF                                            | Considered to be<2000 L/kg                                                                               | Not B                                          |
| Persistence                                    | DT50                                           | > 180 days fresh sediment (12°C)                                                                         | vP                                             |
| Toxicity                                       | NOEC                                           | No toxicity in the aquatic compartment.                                                                  | Not T                                          |
| PBT-statement                                  | The compound is not considered as BT nor vB.   | The compound is not considered as BT nor vB.                                                             | The compound is not considered as BT nor vB.   |
| Phase I                                        | Phase I                                        | Phase I                                                                                                  | Phase I                                        |
| Calculation                                    | Value                                          | Unit                                                                                                     | Conclusion                                     |
| PEC surfacewater                               | 0.0047                                         | µ g/L                                                                                                    | < 0.01 threshold: Not                          |
| Other concerns                                 |                                                |                                                                                                          | Potential endocrine disruptor                  |
| Phase II Physical-chemical properties and fate | Phase II Physical-chemical properties and fate | Phase II Physical-chemical properties and fate                                                           | Phase II Physical-chemical properties and fate |
| Study type                                     | Test protocol                                  | Results                                                                                                  | Remarks                                        |
| Adsorption-Desorption                          | OECD 106                                       | Koc = 436 (sandy loam) Koc = 612 (clay loam) Koc = 238 (clay loam) Koc = 945 (sludge) Koc = 870 (sludge) | No terrestrial studies triggered               |
| Ready Biodegradability Test                    | OECD 301                                       | Not conducted                                                                                            | Considered not readily biodegradable           |

<div style=\"page-break-after: always\"></div>

Aerobic and Anaerobic

Transformation in Aquatic

Sediment systems

## Phase IIa Effect studies

| Study type                                      | Test protocol     | Endpoint          | value             | Unit              | Remarks                                                                 |
|-------------------------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------------------------------------------------------------|
| Algae, Growth Inhibition Test                   | OECD 201          | NOEC              | 1370              | µg/L              | Growth rate                                                             |
| Daphnia sp . Reproduction Test                  | OECD 211          | NOEC              | 318               | µg/L              | Live neonates                                                           |
| Fish, Eary Life Stage Toxicity Test             | OECD 210          | NOEC              | 971               | µg/L              | All paramenters                                                         |
| Fish, Sexual Development Test                   |                   | NOEC              | 890               | µg/L              | All paramenters                                                         |
| Activated Sludge, Respiration Inhibition Test   | OECD 209          | NOEC              | 1x10 6            | µg/L              |                                                                         |
| Phase IIb Studies                               | Phase IIb Studies | Phase IIb Studies | Phase IIb Studies | Phase IIb Studies | Phase IIb Studies                                                       |
| Bioaccumulation                                 | OECD 305          |                   |                   |                   |                                                                         |
| Sediment dwelling organism, Chironomus riparius | OECD 218          | NOEC              | 82.1              | mg/kg dry weight  | NOEC recalculated for standard sediment (containing 10% organic carbon) |

## 2.2.3. Discussion on non-clinical aspects

No new non-clinical data have been submitted in this application, which is considered acceptable

An environmental risk assessment (ERA) has been submitted in accordance with the current Guideline on the environmental risk assessment of medicinal products for human use (EMA/CHMP/SWP/4447/00 corr 2 1* ). The predicted environmental concentration (PEC) for enzalutamide is 0.047 μ g/L which exceeds the trigger value of 0.01 μ g/L as given by EMEA (2006) and therefore an environmental assessment Phase II-Tier A was performed.

Enzalutamide has a partition coefficient lower than 4.5 (log Kow = 2.99 at pH= 7). A further PBT assessment is not warranted. However, since enzalutamide is not considered biodegradable, the MAH performed a Tier B assessment.

OECD 308

DT50 water = 44.9 and 53 d

DT50 total = 515and 421 d

% shifting to sediment (103

days): 57.5% and 51.9 %

(enzalutamide);

75.8% and 68.7 % (total radioactivity)

Transformation product (19.5%

in total system):

4

-

(3

-

[4

-

cyano

-

3

-

(trifluoromethyl)

-

phenyl]

5,5

-

dimethyl

-

2,4

-

dioxoimidazolidin

-

1

-

yl)

-

2

-

fluoro

-

N

-

ethylbenzamide

<div style=\"page-break-after: always\"></div>

According to the current EMEA Guidance document, since the PEC/PNEC and the PEC/PNEC microorganism are less than 1, no further aquatic tests or tests with microorganisms are required.

Enzalutamide is unlikely to exhibit a BCF &gt; 2000 L/kg and is therefore considered not to bioaccumulate in fish.

Since the PECSEDIMENT/PNECSEDIMENT is less than 1, no further testing on sediment dwelling organisms is required. It is unlikely that there is a risk to sediment dwelling organisms from enzalutamide.

Tier B terrestrial risk assessment is not triggered because of the low absorption of enzalutamide to sewage sludge. Therefore, enzalutamide is unlikely to represent a risk to the aquatic or terrestrial environments.

## 2.2.4. Conclusion on the non-clinical aspects

Based on the updated data submitted in this application, the extended indication does not lead to a significant increase in environmental exposure further to the use of enzalutamide.

Considering the above data, enzalutamide is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

| Study/ Protocol Number/Title   | Status   | Study Design   | Primary Endpoint Analysis   | Treatment Dose/ Number of Participants   |
|--------------------------------|----------|----------------|-----------------------------|------------------------------------------|
| Phase 3                        | Phase 3  | Phase 3        | Phase 3                     | Phase 3                                  |

<div style=\"page-break-after: always\"></div>

| Study/ Protocol Number/Title                                                                                                                                                                                                                               | Status                                        | Study Design                                                                                                                                                                                                                                                                                                                                                                                                             | Primary Endpoint Analysis   | Treatment Dose/ Number of Participants                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| C3431004/EMBARK MDV3100-13/ Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy | Study Start: 17 December 2014 PCD 31 Jan 2023 | Phase 3, randomized, double-blind, placebo-controlled study of enzalutamide plus leuprolide, open- label enzalutamide monotherapy, and placebo plus leuprolide in patients with high risk nonmetastatic castration-sensitive prostate cancer progressing after radical prostatectomy or radiotherapy or both. All patients had a PSADT ≤ 9 months. No prior cytotoxic chemotherapy or ADT (with exceptions) was allowed. | MFS†                        | • 355 patients in enzalutamide 160 mg/day (4 capsules of 40 mg each) plus leuprolide 22.5 mg for 3 months (22.5 mg injection once every 12 weeks formulated for either intramuscular or subcutaneous) • 355 patients in enzalutamide monotherapy 160 mg/day (4 capsules of 40 mg each). • 358 patients in placebo (capsules identical in appearance to enzalutamide capsules, were administered in the same manner as enzalutamide) plus leuprolide 22.5 mg for 3 months (22.5 mg injection once every 12 weeks formulated for either intramuscular or subcutaneous) |

## 2.3.2. Clinical pharmacology

No new pharmacology data were submitted in support of this application.

## 2.3.1. Discussion and conclusion on clinical pharmacology

No additional data have been provided with this submission which is considered acceptable as the clinical pharmacology properties of enzalutamide were described in detail in the original marketing application and previous procedures with new clinical data consistent with results in the original marketing authorisation application. The study included in support of this application used enzalutamide at the approved dose of 160 mg/day, which has been established as a generally safe and efficacious dose in patients with CRPC and mHSPC.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

No new dose responses studies were submitted with this application. The posology for the proposed indication (enzalutamide 160 mg administered orally once daily) is the daily dose authorised for other indications.

## 2.4.2. Main study

## Study MDV3100-13 (EMBARK)

A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men with High Risk Non-metastatic Prostate Cancer Progressing After Definitive Therapy.

Figure 2. Study schematic

<!-- image -->

Primary Assessment: Radiographic imaging approximately every 6 months

This efficacy section presents the primary, secondary, and exploratory endpoints of EMBARK based on a cut-off date of 31 Jan 2023.

## Methods

## Study participants

Eligibility criteria were chosen to include patients with hormone sensitive high risk non-metastatic prostate cancer progressing after definitive therapy and were at high risk of developing metastases. High risk prostate cancer was defined in this study as biochemical recurrence with a PSADT ≤9 months and screening PSA by the central laboratory of ≥1 ng/mL for patients who had prior radical prostatectomy (with or without radiotherapy) and at least 2 ng/mL above the nadir for patients who had prior primary radiotherapy only.

<div style=\"page-break-after: always\"></div>

## Inclusion criteria

1. Age 18 years or older and willing and able to provide informed consent.
2. Histologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or small cell features.
3. Prostate cancer initially treated by radical prostatectomy or radiotherapy (including brachytherapy) or both, with curative intent. Prostate cryoablation is not considered definitive therapy for this study, but its prior use is not exclusionary.
4. PSA doubling time ≤ 9 months as calculated by the sponsor ( Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008 Jun;179(6):2181-6 ).
5. Screening PSA by the central laboratory ≥1 ng/mL for patients who had radical prostatectomy (with or without radiotherapy) as primary treatment for prostate cancer and at least 2 ng/mL above the nadir for patients who had radiotherapy only as primary treatment for prostate cancer.
6. Serum testosterone ≥ 150 ng/dL (5.2 nmol/L) at screening.
7. ECOG performance status of 0 or 1 at screening.
8. Estimated life expectancy of ≥ 12 months.
9. Able to swallow the study drug and comply with study requirements.
10. Throughout the study, the patient and his female partner who was of childbearing potential must have used 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception) from screening through 3 months after the last dose of study drug or per local guidelines where these require additional description of contraceptive methods.
11. Throughout the study, the patient must have used a condom if having sex with a pregnant woman.
12. Must have agreed not to donate sperm from first dose of study drug through 3 months after the last dose of study drug.

## Exclusion criteria

1. Prior or present evidence of distant metastatic disease as assessed by computed tomography (CT) or magnetic resonance imaging (MRI) or chest x-ray for soft tissue disease and whole-body radionuclide bone scan for bone disease. Patients with soft tissue pelvic disease could be eligible if the short axis of the largest lymph node is &lt;20 mm for lymph nodes below aortic bifurcation. If the screening bone scan showed a lesion suggestive of metastatic disease, the patient would have been eligible only if a second imaging modality (plain film, CT, or MRI) didn't not show bone metastasis. If the imaging results were equivocal or consistent with metastasis by central radiology review, the patient was not eligible for enrolment. Positron-emission tomography (PET) was not an evaluable imaging modality for this study.
2. Prior hormonal therapy. Neoadjuvant/adjuvant therapy to treat prostate cancer ≤36 months in duration and ≥9 months before randomization, or a single dose or a short course (≤6 months) of hormonal therapy given for rising PSA ≥9 months before randomization was allowed.
3. Prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone acetate, or enzalutamide for prostate cancer.
4. Prior systemic biologic therapy, including immunotherapy, for prostate cancer.

<div style=\"page-break-after: always\"></div>

5. Major surgery within 4 weeks before randomization date.
6. Treatment with 5α reductase inhibitors (finasteride, dutasteride) within 4 weeks of randomization.
7. For patients who had a prior prostatectomy, a suitable candidate for salvage radiotherapy as determined by the investigator in consideration of appropriate guidelines (eg, American Society for Radiation Oncology/American Urological Association [ASTRO/AUA]; European Association of Urology [EAU]).
8. Participation in a clinical study of an investigational agent that inhibits the androgen receptor or androgen synthesis (eg, TAK-700, ARN-509, ODM-201); patients who received placebo were allowed.
9. Use of any other investigational agent within 4 weeks before randomization date.
10. Known or suspected brain metastasis or active leptomeningeal disease.
11. History of another invasive cancer within 3 years before screening, with the exception of fully treated cancers with a remote probability of recurrence. The medical monitor and investigator must have agreed that the possibility of recurrence was remote.
12. Absolute neutrophil &lt;1500/ μ L, platelet count &lt;100,000/ μ L, or hemoglobin &lt;10 g/dL (6.2 mmol/L) at screening. NOTE: May not have received any growth factors or blood transfusions within 7 days before the hematology values obtained at screening.
13. Total bilirubin (TBili) ≥ 1.5-times the upper limit of normal (except patients with documented Gilbert's disease), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5times the upper limit of normal at screening.
14. Creatinine &gt;2 mg/dL (177 μ mol/L) at screening.
15. Albumin &lt;3.0 g/dL (30 g/L) at screening.
16. History of seizure or any condition that may predispose to seizure (eg, prior cortical stroke or significant brain trauma). History of loss of consciousness (unless of cardiac origin) or transient ischemic attack within 12 months before randomization.
17. Clinically significant cardiovascular disease including different criteria.
18. Gastrointestinal disorder affecting absorption.
19. Hypersensitivity reaction to enzalutamide or any of the capsule components, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene.
20. Contraindication to the use of leuprolide, such as a previous hypersensitivity reaction to an LHRH analogue or any of the excipients in the leuprolide injection.
21. Ongoing drug or alcohol abuse as per investigator judgment.

## Treatments

Patients received either enzalutamide plus leuprolide, enzalutamide monotherapy or placebo plus leuprolide therapy based on randomization.

Enzalutamide was administered at the authorised dose of 160 mg/day (four 40 mg capsules) with or without food.

<div style=\"page-break-after: always\"></div>

Leuprolide acetate (leuprorelin acetate) 22.5 mg was given as a single intramuscular or subcutaneous injection once every 12 weeks (for a minimum of 3 doses, providing 36 weeks of treatment).

Placebo capsules, identical in appearance to enzalutamide capsules, were administered in the same manner as enzalutamide.

PSA was monitored throughout the study. Study treatment was to continue uninterrupted in the absence of disease progression until the central laboratory PSA evaluation at Week 36. At Week 37, study treatment was suspended for participants whose PSA values were undetectable (&lt;0.2 ng/mL) at Week 36 as determined by the central laboratory; PSA and testosterone were measured every 3 months thereafter by the central laboratory.

Based on the latest protocol version (Amendment 4, dated 29 Oct 2021), beginning 22 Feb 2019, investigators started to be notified when any of their patients develop protocol defined PSA progression with a PSA doubling time (PSADT) ≤ 10 months while on study treatment based on central laboratory assessments. This notification was put in place following the approval of Xtandi (enzalutamide) and apalutamide for the treatment of patients with non-metastatic (M0) CRPC in men with high-risk prostate cancer, based on studies which demonstrated that treatment with Xtandi plus ADT or apalutamide plus ADT conferred significant improvement in the primary endpoint of MFS versus ADT alone. Given this, patients participating in EMBARK study who developed non-metastatic (M0) CRPC were eligible to receive an approved treatment for M0 CRPC

## Objectives

The objective of this study was to evaluate the efficacy and safety of enzalutamide plus leuprolide and enzalutamide monotherapy versus placebo plus leuprolide in patients with high-risk BCR.

## Primary objective

To evaluate efficacy of the combination of enzalutamide plus leuprolide versus placebo plus leuprolide, as measured by metastasis-free survival (MFS).

## Secondary objectives

To evaluate efficacy as measured by the following key secondary endpoints:

- o MFS between enzalutamide monotherapy versus placebo plus leuprolide.
- o Time to PSA progression
- o Time to first use of new antineoplastic therapy
- o Overall survival

Other secondary endpoints:

- o Time to distant metastasis;
- o Proportion of patients per group who remain treatment-free 2 years after suspension of study drug treatment at week 37 due to undetectable PSA;
- o Proportion of patients per group with undetectable PSA 2 years after suspension of study drug treatment at week 37 due to undetectable PSA;
- o Proportion of patients per group with undetectable PSA at 36 weeks on study drug;
- o Time to resumption of any hormonal therapy following suspension at week 37 due to undetectable PSA;

<div style=\"page-break-after: always\"></div>

- o Time to first symptomatic skeletal event;
- o Time to castration resistance;
- o Time to symptomatic progression;
- o Time to clinically relevant pain;
- o Quality of life;
- o Safety.

## Exploratory objective/endpoint

- Progression-free survival on first subsequent therapy (PFS2)

## Outcomes/endpoints

An overview of the study endpoints and statistical analyses are presented in table 1.

Table 2. EMBARK Primary, Secondary, and Exploratory Endpoints and Analyses - ITT Population

| Endpoint                                                                              | Description                                                                                                                                                                                          | Analyses                                                                                                                    |
|---------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| Primary Endpoint                                                                      | Primary Endpoint                                                                                                                                                                                     | Primary Endpoint                                                                                                            |
| MFS betwen combination of enzalutamide plus leuprolide versus placebo plus leuprolide | BICR assessed by radiographic progression per RECIST 1.1 (soft tissue disease) and radiographic progression for the appearance of 1 or more metastatic lesion (bone disease) in patients with nmCSPC | - HR (2-sided stratified log rank test) - Kaplan-Meier estimates of medians (2-sided 95% CI) (SAP Section 6.1.1)            |
| Key Secondary Endpoint                                                                | Key Secondary Endpoint                                                                                                                                                                               | Key Secondary Endpoint                                                                                                      |
| MFS between enzalutamide monotherapy versus placebo plus leuprolide                   | BICR assessed by radiographic progression per RECIST 1.1 (soft tissue disease) and radiographic progression for the appearance of 1 or more metastatic lesion (bone disease) in patients with nmCSPC | - HR (2-sided stratified log rank test) - Kaplan-Meier estimates of medians (2-sided 95% CI) (SAP Section 6.2.1)            |
| Time to PSA progression                                                               | Time to PSA progression                                                                                                                                                                              | - Time to event (2-sided stratified log rank test) - Kaplan-Meier estimates of medians (2-sided 95% CI) (SAP Section 6.2.2) |
| Time to first use of new antineoplastic therapy                                       | Time to first use of new antineoplastic therapy after study drugs discontinuation                                                                                                                    | - Time to first use (2-sided stratified log rank test) (SAP Section 6.2.3)                                                  |

<div style=\"page-break-after: always\"></div>

| Endpoint                                                                                                                                  | Description                                                                                                                                                                                                                   | Analyses                                                                                                                          |
|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| OS                                                                                                                                        | Time to death due to any cause based on an interim analysis. Final OS data will be provided after 271 deaths have occurred across the 3 treatment arms.                                                                       | - HR (2-sided stratified log rank test) - Kaplan-Meier estimates of medians (2-sided 95% CI) - Survival rates (SAP Section 6.2.4) |
| Other Secondary Endpoints                                                                                                                 | Other Secondary Endpoints                                                                                                                                                                                                     | Other Secondary Endpoints                                                                                                         |
| Time to distant metastasis                                                                                                                | Duration in months from randomization to the earliest objective evidence of distant soft tissue metastases or metastatic bone disease by BICR                                                                                 | - HR (2-sided stratified log rank test) (SAP Section 6.3.1)                                                                       |
| Proportion of patients per group who remain treatment free 2 years after suspension of study treatment at week 37 due to undetectable PSA | Proportion of patients per group who remain treatment free 2 years after suspension of study treatment at week 37 due to undetectable PSA compared between treatment groups using the stratified Cochran Mantel Haenszel test | - Stratified Cochran Mantel Haenszel test (SAP Section 6.3.2)                                                                     |
| Proportion of patients per group with undetectable PSA 2 years after suspension of study treatment at week 37 due to undetectable PSA     | The proportion of patients per group with undetectable PSA 2 years after suspension of study treatment at week 37 due to undetectable PSA compared between treatment groups                                                   | - Stratified Cochran Mantel Haenszel test (SAP Section 6.3.3)                                                                     |
| Proportion of patients per group with undetectable PSA at 36 weeks on study drug                                                          | The proportion of patients per group with undetectable PSA at 36 weeks compared between treatment groups                                                                                                                      | - Stratified Cochran Mantel Haenszel test (SAP Section 6.3.4)                                                                     |
| Time to resumption of any hormonal therapy following suspension at week 37 due to undetectable PSA                                        | Duration in months between the date of treatment suspension at week 37 due to undetectable PSA and the date that hormonal therapy is restarted                                                                                | - Time to event (2-sided stratified log rank test) (SAP Section 6.3.5)                                                            |
| Time to castration resistance                                                                                                             | Applies only to patients receiving leuprolide treatment. Duration in months to disease progression (BICR, PSA) or symptomatic skeletal event (< 50 ng/dL testosterone levels)                                                 | - Time to event (2-sided stratified log rank test) - Kaplan-Meier estimates of medians (2-sided 95% CI) (SAP Section 6.3.6)       |

<div style=\"page-break-after: always\"></div>

| Endpoint                        | Description                                                                                                                                                                                                                                                                                                     | Analyses                                                                                                                           |
|---------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Time to symptomatic progression | Time to first symptomatic skeletal event                                                                                                                                                                                                                                                                        | - Time to event (2-sided stratified log rank test) - Kaplan-Meier estimates of medians (2-sided 95% CI) (SAP Section 6.3.7; 6.3.8) |
| PROs Pain QoL                   | Time to clinically relevant pain progression from randomization to onset of pain progression - patient-reported pain symptoms per BPI-SF Time to a 10-point decline (deterioration) in global FACT-P score - patient-reported global health status/QoL, functioning, and symptoms per FACT-P, EQ-5D-5L,         | - Descriptive statistics - Kaplan-Meier estimates of medians (2-sided 95% CI) (SAP Section 6.4)                                    |
| Exploratory Endpoint            | Exploratory Endpoint                                                                                                                                                                                                                                                                                            | Exploratory Endpoint                                                                                                               |
| PFS2                            | PFS2 the time in months from date of randomization to date of investigator- determined disease progression (PSA progression, progression on imaging, or clinical progression) or death due to any cause, whichever occurred first, while the patient was receiving first subsequent therapy for prostate cancer | - HR (2-sided stratified log rank test) - Kaplan-Meier estimates of medians (2-sided 95% CI) (SAP Section 6.5)                     |

## Sample size

The following assumptions were used to determine sample size calculation for the MFS endpoint for the primary and key secondary analysis:

- Overall 2-sided Type I error rate: 0.05
- Randomization: 1:1:1
- Median MFS for the control group: 55 months

An observed 142 MFS events in the 2 blinded treatment groups would have provide approximately 90% power to detect a target hazard ratio of 0.58 using a 2-sided log-rank test with a 0.05 level of significance. This target hazard ratio corresponds to a difference of approximately 40 months in median MFS assuming an exponential distribution for MFS and a constant hazard rate for each group. For the key secondary hypothesis of MFS for the monotherapy arm, the target effect size, and expected number of MFS events were the same as the primary hypothesis in the combination arm. As a 2-sided alpha of 0.03

<div style=\"page-break-after: always\"></div>

would have been utilized for the monotherapy comparison, the power for this analysis was to be 86% with 142 MFS events observed. At the time of the final analysis, at least 197 MFS events total were expected for the 3 treatment groups. The study would have required approximately 1050 patients (350 in each group) to achieve the 197 MFS events across the 3 treatment arms. This sample size calculation accounted for a 5% loss to follow-up by the end of 4 years for all 3 treatment groups.

An actual enrolment of 1068 patients would have also allowed for an assessment for the key secondary endpoint of OS.

## Randomisation

A central randomization of 1:1:1 was used to assign patients to one of the following study treatments:

- Enzalutamide 160 mg/day plus leuprolide 22.5 mg IM/SC every 3 months;
- Enzalutamide monotherapy 160 mg/day;
- Placebo (capsules identical in appearance to enzalutamide capsules, were administered in the same manner as enzalutamide) plus leuprolide 22.5 mg IM/SC every 3 months.

Randomization was stratified by the following, as recorded in the Interactive Response Technology (IRT):

- Screening PSA ≤10 ng/mL vs &gt;10 ng/mL
- PSA doubling time ≤3 months vs &gt; 3 to ≤9 months
- Prior hormonal therapy vs no prior hormonal therapy

Unless otherwise specified, stratified analyses utilized strata as defined in the randomization system.

## Blinding (masking)

Treatment with enzalutamide monotherapy was open-label. Treatment with enzalutamide plus leuprolide and placebo plus leuprolide was double blinded.

All patients, study site personnel (including investigators), and sponsor staff and its representatives were blinded to enzalutamide or placebo treatment assignment when administered in combination with leuprolide. The blinded control for enzalutamide were placebo capsules identical in appearance to the enzalutamide capsules.

## Statistical methods

## Analysis populations

Based on the SAP version 3.1, dated on 10-Jan-2023, the following analysis populations were defined:

The intent-to-treat population (ITT) was defined as all patients randomly assigned to study treatment. The intent-to-treat population was used for all efficacy analyses unless otherwise specified, and was analysed based on randomized treatment assignment.

The evaluable ITT (eITT) population was defined as all patients in the ITT population who have confirmed non-metastatic disease at baseline by independent central radiology review. This analysis population was to be used for certain efficacy analyses as specified in the statistical analysis plan.

<div style=\"page-break-after: always\"></div>

The safety population was defined as all patients who receive any amount of study drug. The safety population was to be used for all safety analyses. The safety population was to be analysed based on the treatment received and not the treatment assigned.

## Primary endpoint: MFS

The primary efficacy analysis compared MFS based on BICR assessment between enzalutamide in combination with leuprolide versus placebo in combination with leuprolide using a 2-sided stratified logrank test. The primary population for analysis was the ITT population. Strata were to be based on those specified in the randomization system.

For patients not known to have had radiographic progression and who have not died at the time of the analysis data cut-off, MFS time would have been censored at the date of the last adequate assessment on or before the analysis data cut-off date. For patients who were randomized but later confirmed to have metastatic disease at enrolment or who had no adequate post-baseline tumour assessment, information would have been censored on the date of randomization.

The censoring rules for the primary and sensitivity analyses of MFS are summarized in Table 3.

Table 3 . Censoring Rules for the Primary and Sensitivity Analyses of MFS

|                                  | Censoring Rules                                                                                                                                                                                                                                                                                       | Date of Censoring                                                                                      |
|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Analysis Primary analysis of MFS | Patients with no baseline or no post baseline assessments who have not died within 49 weeks after randomization                                                                                                                                                                                       | Date of randomization                                                                                  |
| Analysis Primary analysis of MFS | Patients who were randomized but confirmed metastatic at baseline                                                                                                                                                                                                                                     | Date ofrandomization                                                                                   |
| Analysis Primary analysis of MFS | Patients who had no confirmed metastasis and did not die prior to data cutoff date                                                                                                                                                                                                                    | Date of the last adequate radiographic tumor assessment prior to data cutoff date                      |
| Analysis Primary analysis of MFS | Patients who initiate antineoplastic therapy such as cytotoxic chemotherapy, abiraterone acetate, hormonal agents, prostate cancer vaccines, nonradioactive bone-targeting agents and systemic radiopharmaceuticals for prostate cancer, or any antineoplastic therapy without evidence of metastasis | Date of the last adequate radiographic tumor assessment prior to first use of any such therapy         |
| Analysis Primary analysis of MFS | Patients with radiation therapy performed for prostate cancer-related lesions without evidence of metastasis                                                                                                                                                                                          | Date of the last adequate radiographic tumor assessment prior to the earliest use of radiation therapy |
| Analysis Primary analysis of MFS | Patients with evidence of metastasis or death after 2 or more consecutive missed tumor assessment visits                                                                                                                                                                                              | Date of the last adequate radiographic tumor assessment prior to the first missed visit date           |

MFS = Metastatic Free Survival; of note, the censoring rules are applied to MFS events by either radiographic progression, or death due to any cause without evidence of radiographic progression; of note, antineoplastic therapies according to the above search criteria undergo medical review to confirm.

## Sensitivity/Robustness Analyses

The following sensitivity analyses were to be performed for MFS.

- Sensitivity 1: Including Events Regardless of Initiation of Antineoplastic Therapies

<div style=\"page-break-after: always\"></div>

Censoring rules were to follow those in the primary MFS analysis except that events occurring for the first time after the initiation of antineoplastic therapy would not be censored and be considered as events. A 2-sided stratified log-rank test (same as the primary analysis) would have been used to compare the treatment groups.

- Sensitivity 2: MFS on eITT Population

MFS for the eITT population was also to be analysed as a sensitivity analysis. The definition of MFS and censoring rules was to be consistent with primary analysis. A 2-sided stratified log-rank test was to be used to compare the treatment groups. All methods from the primary efficacy analysis would have been repeated.

- Sensitivity 3: MFS Based on Investigator Assessment

MFS as assessed by the investigator was also to be analysed as a sensitivity analysis.

The definition of MFS and censoring rule were to be consistent with primary analysis. A 2-sided stratified log-rank test was to be used to analyse the MFS values. Furthermore, the concordance and discordance rates between the independent central radiology review and investigator assessment were to be summarized using the metastasis status by the treatment groups

- Sensitivity 4: Impact of Clinical Progression

In this sensitivity analysis, patients who discontinue study drug primarily due to clinical deterioration prior to protocol-defined evidence of radiographic progression were be considered as having clinical progression. For this analysis, MFS was defined as the duration of time between randomization and the earliest objective evidence of metastatic disease, date of study drug discontinuation for clinical progression, or death, or evidence of clinical progression, whichever occurred first. The censoring rules used for the primary analysis were to be utilized. The hazard ratio and its 95% confidence interval were to be reported.

- Sensitivity 5: Impact of Censoring Due to Discontinuation Prior to Radiographic Progression for Patients Notified of PSA Progression or Progression by Positron Emission Tomography (PET) Imaging of Prostate-specific Membrane Antigen (PSMA).

For the censoring of MFS for the patients who reached PSA progression and discontinued study treatment prior to the development of radiographically detectable metastatic disease, and the potential for this to be informative censoring, a reference-based imputation method based on Bayes Gibbs sampling as outlined by Lu, Li, and Koch (Lu et al. 2015) was to be implemented to assess the impact of the above censoring. If applicable, the inverse probability of censoring weighting (IPCW) method by Robins and Finkelstein could be used to adjust for the above censoring.

In order to assess the impact of patients initiating novel androgen inhibitors (such as enzalutamide, apalutamide, darolutamide and abiraterone) prior to the development of radiographically detectable metastatic disease, if applicable, the following sensitivity analyses could be performed: the RankPreserving Structural Failure Time Model (RPSFTM) (Robins &amp; Tsiatis 1991), IPCW method (Robins &amp; Finkelstein, 2000) and the two-stage method (Latimer &amp; Abrams 2014).

## Key secondary endpoints

## MFS (enzalutamide monotherapy vs. placebo plus leuprolide)

MFS between enzalutamide monotherapy versus placebo plus leuprolide was to be defined as above for primary analysis of the combination comparison. Analysis of this endpoint was to be performed using the 2-sided stratified log-rank test to compare the 2 treatment groups with the same strata described above.

<div style=\"page-break-after: always\"></div>

A Cox proportional hazards model was to be used to evaluate the MFS analysis to calculate the HR and its 95% CI.

The same sensitivity analyses as those specified for the primary comparison between enzalutamide in combination with leuprolide versus placebo in combination with leuprolide was to be implemented.

## Time to PSA Progression

Only results from PSA samples taken before the initiation of any new prostate cancer therapy and after the start of study drug were to be considered.

PSA progression was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 μ g/L (2 ng/mL) above the nadir (or baseline for patients with no PSA decline by week 25) that was confirmed by a second consecutive value at least 3 weeks later. The date of PSA progression was the first date the PSA progression was observed. For patients who have suspended treatment at week 37 and later reinitiated treatment, baseline was to be defined as the last PSA assessment prior to or on the date of reinitiation. The date of PSA progression was the first date the PSA progression was observed.

PSA progression was only defined during active study treatment; therefore, patients meeting PSA progression during the suspension period was to be censored unless the PSA progression criteria were subsequently met following treatment reinitiation. Time to PSA progression was to be censored on the date of the last PSA sample taken. Patients with PSA progression after 2 or more consecutive missed PSA assessments (ie, time interval &gt;6 months or 182 days between 2 consecutive PSA samples) was to be censored on the date of last PSA assessment prior to the missed assessments. In patients with no baseline PSA and patients with no post-baseline PSA results, time to PSA progression was to be censored on the date of randomization.

Time to PSA progression was to be compared between treatment groups using a 2-sided stratified logrank test.

## Time to First Use of New Antineoplastic Therapy

New antineoplastic therapy included medications used specifically for prostate cancer treatment including hormonal treatments, immunotherapy, chemotherapy and investigative agents.

Time to first use of new antineoplastic therapy was to be compared between treatment groups using a 2sided stratified log rank test. In patients with no new antineoplastic therapy initiated for prostate cancer after randomization, time to start of new antineoplastic therapy was to be censored on the last visit date or the date of randomization, whichever occurs last.

## Overall Survival

The overall survival was to be compared between treatment groups using a 2-sided stratified log rank test. Patients without an event date was to be censored at the date of the last contact.

## Decision rules

No interim analysis for the primary endpoint (MFS) were planned. The interim and final analyses for the key secondary endpoint OS were to be performed after the target number of events have occurred in the 3 treatment arms. A maximum of 2 distinct analysis cut-offs were planned according to the numbers of events described below:

- Final MFS and OS interim analyses at the time when 197 MFS events have occurred for the 3 treatment groups;
- Final OS analysis at the time when 271 deaths have occurred for the 3 treatment groups.

<div style=\"page-break-after: always\"></div>

Table 4. MFS Based on Independent Review (2 Blinded Treatment Arms) - Efficacy Boundary

| Analysis   | Analysis Cut-Off Trigger   |   NumberofFS Events (2BlindedArms) | Fraction of Required MFS Events   | p-value (z-value)for Efficacy   |
|------------|----------------------------|------------------------------------|-----------------------------------|---------------------------------|
| FinalMFS   | 197 MFS events in3 arms    |                                142 | 100%                              | ≤0.05 (-1.9600)                 |

MFS=metastasis-freesurvival

Number of events expected for MFS in blinded treatment arms assuming a hazard ratio of 0.58.

Table 5. OS (2 Blinded Treatment Arms) - Efficacy Boundaries

| Analysis   | Analysis Cut- Off Trigger   |   NunberofOS Events (2Blinded Arms) | Fraction of Requirerdl OS Events   | p-value (z-value) for Efficacyb   |
|------------|-----------------------------|-------------------------------------|------------------------------------|-----------------------------------|
| IA OS      | 197MFSeventsin 3 arms       |                                  82 | 43%                                | ≤0.0001 (-3.89059)                |
| Final OS   | 271OSeventsin3 arms         |                                 191 | 100%                               | ≤0.04999 (-1.96001)               |

## Multiplicity adjustment for efficacy analysis

Alpha protected efficacy analyses included tests for the primary endpoint of MFS for enzalutamide plus leuprolide versus placebo plus leuprolide, and all 3 key secondary efficacy endpoints (time to PSA progression, time to first antineoplastic therapy, and overall survival) for the combination comparisons. Additionally, MFS, time to PSA progression, time to first antineoplastic therapy, and overall survival would have been tested for enzalutamide monotherapy versus placebo plus leuprolide.

If the test for the primary endpoint (MFS in the combination arms) was significant at the full 2-sided alpha level of 0.05, the key secondary endpoints for the combination arms was to be tested at a 2-sided alpha of 0.02 utilizing a hierarchical approach to preserve the family-wise Type I error rate. The remaining 0.03 alpha was to be allocated to compare MFS as well as other key secondary endpoints for enzalutamide monotherapy versus placebo plus leuprolide. The efficacy analyses and the multiplicity adjustment rules are summarized in Figure 3

Figure 3. Key efficacy analyses and multiplicity adjustment

<div style=\"page-break-after: always\"></div>

<!-- image -->

*α4=α2+α3=0.05if allCombo and Mono comparisons are significant =α2=0.02if Combo comparisons are significant and Mono are not =α3=0.03if Mono comparisons are significant and Comboare not

Source: Appendix 16.1.9.1, SAP Figure 2

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Figure 4. Participant disposition in the EMBARK Study

<!-- image -->

PSA: prostate-specific antigen.

Source: [Freedland et al, 2023]

## Recruitment

Since December 2014, a total of 1068 participants were enrolled at 174 centres in 17 countries, including 55 centres in North America, 75 centres in Europe, and 44 centres in the rest of the world.

<div style=\"page-break-after: always\"></div>

Table 6. Patient Disposition by Study Treatment Phase (ITT Population)

|                                                        | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)   | Total (N = 1068)   |
|--------------------------------------------------------|-----------------------|----------------------|------------------|--------------------|
| Study Treatment Phase Disposition                      |                       |                      |                  |                    |
| Ongoing                                                | 207 (58.3%)           | 153 (42.7%)          | 197 (55.5%)      | 557 (52.2%)        |
| Patients with Treatment Reinitiation                   | 168 (47.3%)           | 114 (31.8%)          | 171 (48.2%)      | 453 (42.4%)        |
| Patients with Treatment Suspension but no Reinitiation | 34 (9.6%)             | 14 (3.9%)            | 13 (3.7%)        | 61 (5.7%)          |
| Patients without Treatment Suspension                  | 5 (1.4%)              | 25 (7.0%)            | 13 (3.7%)        | 43 (4.0%)          |
| Discontinued                                           | 146 (41.1%)           | 201 (56.1%)          | 157 (44.2%)      | 504 (47.2%)        |
| Patients with Treatment Reinitiation                   | 73 (20.6%)            | 89 (24.9%)           | 99 (27.9%)       | 261 (24.4%)        |
| Patients with Treatment Suspension but no Reinitiation | 46 (13.0%)            | 23 (6.4%)            | 21 (5.9%)        | 90 (8.4%)          |
| Patients without Treatment Suspension                  | 27 (7.6%)             | 89 (24.9%)           | 37 (10.4%)       | 153 (14.3%)        |
| Did Not Receive Study Drug                             | 2 (0.6%)              | 4 (1.1%)             | 1 (0.3%)         | 7 (0.7%)           |
| Primary Reason for Discontinuation of                  |                       |                      |                  |                    |
| Study Drug                                             |                       |                      |                  |                    |
| Centrally Confirmed Radiographic Progression           | 26 (7.3%)             | 66 (18.4%)           | 37 (10.4%)       | 129 (12.1%)        |
| PSA Progression Notification from Sponsor              | 2 (0.6%)              | 20 (5.6%)            | 5 (1.4%)         | 27 (2.5%)          |
| Adverse Event                                          | 73 (20.6%)            | 36 (10.1%)           | 63 (17.7%)       | 172 (16.1%)        |
| Development of Castration Resistance                   | 0 (0.0%)              | 2 (0.6%)             | 0 (0.0%)         | 2 (0.2%)           |
| Patient Decision to Discontinue Study Treatment        | 26 (7.3%)             | 32 (8.9%)            | 25 (7.0%)        | 83 (7.8%)          |
| Protocol Deviation                                     | 2 (0.6%)              | 2 (0.6%)             | 1 (0.3%)         | 5 (0.5%)           |
| Lost to Follow-Up                                      | 0 (0.0%)              | 1 (0.3%)             | 0 (0.0%)         | 1 (< 0.1%)         |
| Study Terminated by Sponsor                            | 0 (0.0%)              | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)           |
| Medication Error Without Associated Adverse Event      | 0 (0.0%)              | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)           |
| Other, Specify†                                        | 17 (4.8%)             | 41 (11.5%)           | 26 (7.3%)        | 84 (7.9%)          |
| Long-Term Follow-up (LTFU) Phase                       |                       |                      |                  |                    |
| Disposition                                            |                       |                      |                  |                    |
| Ongoing (still in LTFU)                                | 67 (18.9%)            | 104 (29.1%)          | 62 (17.5%)       | 233 (21.8%)        |
| Off Study                                              | 81 (22.8%)            | 101 (28.2%)          | 96 (27.0%)       | 278 (26.0%)        |
| Primary Reason for Discontinuation of                  |                       |                      |                  |                    |
| Long-Term Follow-up                                    |                       |                      |                  |                    |
| Death                                                  | 33 (9.3%)             | 54 (15.1%)           | 42 (11.8%)       | 129 (12.1%)        |
| Lost to Follow-up                                      | 3 (0.8%)              | 3 (0.8%)             | 4 (1.1%)         | 10 (0.9%)          |
| Withdrew Consent to be Followed                        | 40 (11.3%)            | 36 (10.1%)           | 38 (10.7%)       | 114 (10.7%)        |
| Sponsor Decision                                       | 0 (0.0%)              | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)           |
| Other, Specify†                                        | 5 (1.4%)              | 8 (2.2%)             | 12 (3.4%)        | 25 (2.3%)          |

The data cut-off date is 31 Jan 2023. Treatment phase is defined as the period of time from the date of the first dose of study drug up to the last dose date. Long-term follow-up (LTFU) phase is the period from study drug discontinuation to the death date or last known survival date. Ongoing patients are defined as patients still in the respective phases. Off study patients are defined as patients who are no longer being followed up for study for any reason (including for overall survival). † Other, specify: Thirty seven patients discontinued from study drug due to PI decision/disease progression by local conventional scans/PSA information (5 patients for ENZA+LA, 11 patients for ENZA and 21 for PBO+LA), ten patients due to PSMA-PET determination of progression (2 patients for ENZA+LA and 8

<div style=\"page-break-after: always\"></div>

for PBO+LA), seven patients due to site closure (2 patients for ENZA+LA, 4 patients for ENZA and 1 for PBO+LA). Thirty patients discontinued due to other miscellaneous reasons as in listing 16.2.1.

Table 7. Patient Disposition by Study Treatment Status (Safety Population)

|                                                             | ENZA + LA (N = 353)   | PBO + LA (N = 354)   | ENZA (N = 354)   | Total (N = 1061)   |
|-------------------------------------------------------------|-----------------------|----------------------|------------------|--------------------|
| Study Treatment Status                                      |                       |                      |                  |                    |
| Patients with Treatment Suspension                          | 321 (90.9%)           | 240 (67.8%)          | 304 (85.9%)      | 865 (81.5%)        |
| Patients with Treatment Reinitiation                        | 241 (68.3%)           | 203 (57.3%)          | 270 (76.3%)      | 714 (67.3%)        |
| Patients with Treatment Suspension and without Reinitiation | 80 (22.7%)            | 37 (10.5%)           | 34 (9.6%)        | 151 (14.2%)        |
| Patients without Treatment Suspension                       | 32 (9.1%)             | 114 (32.2%)          | 50 (14.1%)       | 196 (18.5%)        |

The data cut-off date is 31 Jan 2023.

Table 8. Patient Randomization by Stratum (ITT Population)

|                              | ENZA+LA (N = 355)       | ENZA+LA (N = 355)   | PBO+LA (N = 358)        | PBO+LA (N = 358)   | ENZA (N = 355)          | ENZA (N = 355)   |
|------------------------------|-------------------------|---------------------|-------------------------|--------------------|-------------------------|------------------|
| Randomization Stratum        | IVRS/IWRS (N = 355) CRF | (N = 355)           | IVRS/IWRS (N = 358) CRF | (N = 358)          | IVRS/IWRS (N = 355) CRF | (N = 355)        |
| Screening PSA ≤ 10 ng/mL     | 275 (77.5%)278          | (78.3%)             | 276 (77.1%)273          | (76.3%)            | 274 (77.2%)272          | (76.6%)          |
| Screening PSA > 10 ng/mL     | 80 (22.5%)              | 77 (21.7%)          | 82 (22.9%)              | 83 (23.2%)         | 81 (22.8%)              | 82 (23.1%)       |
| PSADT ≤ 3 months             | 71 (20.0%)              | 69 (19.4%)          | 74 (20.7%)              | 80 (22.3%)         | 73 (20.6%)              | 76 (21.4%)       |
| PSADT > 3 - ≤ 9 months       | 284 (80.0%)285          | (80.3%)             | 284 (79.3%)277          | (77.4%)            | 282 (79.4%)278          | (78.3%)          |
| PSADT > 9 months             | 0 (0.0%)                | 1 (0.3%)            | 0 (0.0%)                | 1 (0.3%)           | 0 (0.0%)                | 1 (0.3%)         |
| Prior Hormonal Therapy - Yes | 110 (31.0%)107          | (30.1%)             | 112 (31.3%)113          | (31.6%)            | 110 (31.0%)112          | (31.5%)          |
| Prior Hormonal Therapy - No  | 245 (69.0%)248          | (69.9%)             | 246 (68.7%)245          | (68.4%)            | 245 (69.0%)243          | (68.5%)          |

The data cut-off date is 31 Jan 2023

IVRS/IWRS: stratification as recorded in Interactive Voice Response System/ Interactive Web Response System at time of randomizatio n. CRF: stratification as recorded in the electronic case report forms.

## Conduct of the study

## Protocol amendments

The original protocol (v 1.0) dated from 3 Sep 2014. Since them, 4 protocol amendments were issued on the following dates:

| Original Protocol   | V 1.0 - 03 Sep 2014   |
|---------------------|-----------------------|

<div style=\"page-break-after: always\"></div>

| Amendment 1         | V 2.0 - 09 Mar 2017   |
|---------------------|-----------------------|
| Amendment 2         | V 3.0 - 20 Aug 2018   |
| V 4.0 - 31 Mar 2020 | Amendment 3           |
| Amendment 4         | V 5.0 - 29 Oct 2021   |

## Amendment 4 (29 Oct 2021)

In this Amendment the study primary endpoint was repowered, and the interim analysis of the primary endpoint was removed. The rationale for repowering the study primary endpoint and removing the MFS interim analysis was based on recent clinical trial results of enzalutamide and other androgen targeting agents in similar comparator populations in which it became apparent that the statistical analysis plan for EMBARK was too conservative with a target hazard ratio of 0.65 for MFS. The PROSPER (HR = 0.29; 95% CI: 0.24, 0.35; P&lt;0.001) and SPARTAN (HR = 0.28; 95% CI: 0.23, 0.35; P&lt;0.001) studies demonstrated statistically significant and clinically meaningful improvement of MFS in patients with non-metastatic castration-resistant prostate cancer. Additionally, recently presented data from a subpopulation of the STAMPEDE study showed robust clinical benefits for abiraterone acetate plus prednisone with or without enzalutamide added to ADT (MFS HR= 0.53; 95% CI: 0.44, 0.64; P&lt;0.0001) in patients similar to EMBARK with non-metastatic hormone sensitive prostate cancer. These results suggested a consistently strong treatment effect observed for Enzalutamide across the prostate cancer disease spectrum using MFS as primary endpoint. Therefore, the interim analysis of MFS was removed and the target hazard ratio for the primary MFS analysis was lowered from 0.65 to 0.58. Based on the lower target hazard ratio of 0.58, the final analysis was to be triggered by a lower number of events (197 instead of 336).

## Protocol deviations .

## Table 9. Major Protocol Deviations (ITT Population)

| Categories                                                 | ENZA+LA (I=355)   | PBO+LA (=358)   | ENZA (I=355)   | Total (N=1068)   |
|------------------------------------------------------------|-------------------|-----------------|----------------|------------------|
| Number ofPatients with At Least OneMajorProtocol Deviation | 17 (4.8%)         | 11 ( 3.1%)      | 23 (6.5%)      | 51 (4.8%)        |
| MajorDeviation                                             |                   |                 |                |                  |
| AdministrativeCriteria                                     | 0（ 0.0%)          | 0（ 0.0%)        | 0（ 0.0%)       | 0 ( 0.0%)        |
| ConcomitantMedicationCriteria                              | 4( 1.1%)          | 3( 0.8%)        | 0（ 0.0%)       | 7 (0.7%)         |
| Efficacy Criteria                                          | 0 0.0%)           | 0（ 0.0%)        | 0（ 0.0%)       | 0 ( 0.0%)        |
| EligibilityandEntryCriteria                                | 3 0.8%)           | 1 C 0.3%)       | 5( 1.4%)       | )6 0.8%)         |
| IP Compliance                                              | 9 2.5%)           | 1.7%)           | 16 ( 4.5%)     | 31（ 2.9%)        |
| Informed Consent                                           | 0.0%)             | 1 0.3%)         | 1 0.3%)        | 2( 0.2%)         |
| LaboratoryAssessmentCriteria                               | 0 0.0%)           | 0 0.0%)         | 0 0.0%)        | 0 0.0%)          |
| SeriousAdverseEventCriteria                                | 0 0.0%)           | 0 C 0.0%)       | 0 0.0%)        | 0 0.0%)          |
| SourceDocumentCriteria                                     | 0 0.0%)           | 0 0.0%)         | 0.0%)          | ）o 0.0%)         |
| StudyProceduresCriteria                                    | 0 0.0%)           | 0 0.0%)         | 2 0.6%)        | 2( 0.2%)         |
| VisitScheduleCriteria                                      | 0.0%)             | ）o 0.0%)        | 1 0.3%)        | 1( <0.1%)        |
| Other Criteria                                             | 1 0.3%)           | 0（ 0.0%)        | 0.3%)          | 2( 0.2%)         |

Thedatacut-offdateis31JAN2023.

<div style=\"page-break-after: always\"></div>

## Baseline data

## Demographics and baseline disease characteristics

## Table 10. Patient Demographic and Baseline Characteristics (ITT Population)

| Baseline Characteristic                   | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)   | Total (N = 1068)   |
|-------------------------------------------|-----------------------|----------------------|------------------|--------------------|
| Age Category (years)                      |                       |                      |                  |                    |
| < 65                                      | 81 (22.8%)            | 91 (25.4%)           | 91 (25.6%)       | 263 (24.6%)        |
| 65 to < 75                                | 201 (56.6%)           | 180 (50.3%)          | 174 (49.0%)      | 555 (52.0%)        |
| ≥ 75                                      | 73 (20.6%)            | 87 (24.3%)           | 90 (25.4%)       | 250 (23.4%)        |
| Age                                       |                       |                      |                  |                    |
| n                                         | 355                   | 358                  | 355              | 1068               |
| Mean (SD)                                 | 69.1 (6.49)           | 69.1 (7.30)          | 69.1 (7.65)      | 69.1 (7.16)        |
| Median                                    | 69.0                  | 70.0                 | 69.0             | 69.0               |
| Min, Max                                  | 51.0, 87.0            | 50.0, 92.0           | 49.0, 93.0       | 49.0, 93.0         |
| Race                                      |                       |                      |                  |                    |
| American Indian or Alaskan Native         | 4 (1.1%)              | 1 (0.3%)             | 0 (0.0%)         | 5 (0.5%)           |
| Asian                                     | 26 (7.3%)             | 26 (7.3%)            | 26 (7.3%)        | 78 (7.3%)          |
| Black or African American                 | 16 (4.5%)             | 16 (4.5%)            | 15 (4.2%)        | 47 (4.4%)          |
| Native Hawaiian or Other Pacific Islander | 1 (0.3%)              | 0 (0.0%)             | 0 (0.0%)         | 1 (< 0.1%)         |
| White                                     | 293 (82.5%)           | 301 (84.1%)          | 295 (83.1%)      | 889 (83.2%)        |
| Multiple                                  | 2 (0.6%)              | 4 (1.1%)             | 4 (1.1%)         | 10 (0.9%)          |
| Other                                     | 3 (0.8%)              | 5 (1.4%)             | 1 (0.3%)         | 9 (0.8%)           |
| Not Reported                              | 10 (2.8%)             | 5 (1.4%)             | 14 (3.9%)        | 29 (2.7%)          |
| Ethnicity                                 |                       |                      |                  |                    |
| Hispanic or Latino                        | 17 (4.8%)             | 24 (6.7%)            | 18 (5.1%)        | 59 (5.5%)          |
| Not Hispanic or Latino                    | 319 (89.9%)           | 322 (89.9%)          | 320 (90.1%)      | 961 (90.0%)        |
| Not Reported/Unknown                      | 19 (5.4%)             | 12 (3.4%)            | 17 (4.8%)        | 48 (4.5%)          |
| Geographic Region                         |                       |                      |                  |                    |
| North America                             | 144 (40.6%)           | 137 (38.3%)          | 133 (37.5%)      | 414 (38.8%)        |
| Europe                                    | 130 (36.6%)           | 128 (35.8%)          | 146 (41.1%)      | 404 (37.8%)        |
| Rest of World                             | 81 (22.8%)            | 93 (26.0%)           | 76 (21.4%)       | 250 (23.4%)        |
| Weight (kg)                               |                       |                      |                  |                    |
| n                                         | 355                   | 357                  | 355              | 1067               |
| Mean (SD)                                 | 87.5 (15.16)          | 87.2 (15.86)         | 87.5 (15.55)     | 87.4 (15.51)       |
| Median                                    | 85.0                  | 85.7                 | 85.0             | 85.4               |
| Min, Max                                  | 55.6, 157.7           | 53.7, 148.2          | 50.0, 171.8      | 50.0, 171.8        |
| Missing                                   | 0                     | 1                    | 0                | 1                  |
| Height (cm)                               |                       |                      |                  |                    |
| n                                         | 353                   | 354                  | 354              | 1061               |
| Mean (SD)                                 | 174.9 (8.20)          | 175.2 (7.84)         | 174.8 (7.66)     | 175.0 (7.90)       |
| Median                                    | 175.0                 | 175.3                | 175.0            | 175.0              |
| Min, Max                                  | 144.8, 196.0          | 150.6, 198.1         | 152.4, 198.1     | 144.8, 198.1       |
| Missing                                   | 2                     | 4                    | 1                | 7                  |
| Body Mass Index (kg/m 2 )                 |                       |                      |                  |                    |
| n                                         | 353                   | 354                  | 354              | 1061               |
| Mean (SD)                                 | 28.5 (4.22)           | 28.3 (4.37)          | 28.6 (4.70)      | 28.5 (4.43)        |

<div style=\"page-break-after: always\"></div>

| Baseline Characteristic           | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)   | Total (N = 1068)   |
|-----------------------------------|-----------------------|----------------------|------------------|--------------------|
| Median                            | 28.1                  | 28.0                 | 27.9             | 28.0               |
| Min, Max                          | 19.9, 47.1            | 18.5, 45.9           | 17.3, 53.2       | 17.3, 53.2         |
| Missing                           | 2                     | 4                    | 1                | 7                  |
| Baseline ECOG Performance Status  |                       |                      |                  |                    |
| 0                                 | 328 (92.4%)           | 336 (93.9%)          | 321 (90.4%)      | 985 (92.2%)        |
| 1                                 | 26 (7.3%)             | 21 (5.9%)            | 34 (9.6%)        | 81 (7.6%)          |
| 2                                 | 1 (0.3%)              | 0 (0.0%)             | 0 (0.0%)         | 1 (< 0.1%)         |
| Missing                           | 0                     | 1 (0.3%)             | 0                | 1 (< 0.1%)         |
| Serum PSA (ng/mL)                 |                       |                      |                  |                    |
| n                                 | 355                   | 356                  | 354              | 1065               |
| Mean (SD)                         | 8.1 (17.56)           | 8.5 (11.76)          | 7.5 (6.54)       | 8.0 (12.77)        |
| Median                            | 5.0                   | 5.5                  | 5.3              | 5.2                |
| Min, Max                          | 1.0, 308.3            | 1.1, 163.3           | 1.1, 37.0        | 1.0, 308.3         |
| Missing                           | 0                     | 2                    | 1                | 3                  |
| Screening PSADT Category (DT)†    |                       |                      |                  |                    |
| ≤ 3 Months                        | 69 (19.4%)            | 80 (22.3%)           | 76 (21.4%)       | 225 (21.1%)        |
| > 3 - ≤ 6 Months                  | 187 (52.7%)           | 142 (39.7%)          | 164 (46.2%)      | 493 (46.2%)        |
| > 6 - ≤ 9 Months                  | 98 (27.6%)            | 135 (37.7%)          | 114 (32.1%)      | 347 (32.5%)        |
| > 9 Months                        | 1 (0.3%)              | 1 (0.3%)             | 1 (0.3%)         | 3 (0.3%)           |
| PSADT (months)                    |                       |                      |                  |                    |
| n                                 | 355                   | 358                  | 355              | 1068               |
| Mean (SD)                         | 4.9 (2.04)            | 5.2 (2.20)           | 5.1 (2.15)       | 5.0 (2.13)         |
| Median                            | 4.6                   | 5.0                  | 5.0              | 4.9                |
| Min, Max                          | 0.9, 9.6              | 1.1, 10.8            | 1.0, 18.9        | 0.9, 18.9          |
| History of Cardiovascular Disease |                       |                      |                  |                    |
| Yes                               | 42 (11.8%)            | 42 (11.7%)           | 47 (13.2%)       | 131 (12.3%)        |
| No                                | 313 (88.2%)           | 316 (88.3%)          | 308 (86.8%)      | 937 (87.7%)        |
| Prior Hormonal Therapy            |                       |                      |                  |                    |
| Yes                               | 107 (30.1%)           | 113 (31.6%)          | 112 (31.5%)      | 332 (31.1%)        |
| No                                | 248 (69.9%)           | 245 (68.4%)          | 243 (68.5%)      | 736 (68.9%)        |
| Prior Prostatectomy               |                       |                      |                  |                    |
| Yes                               | 269 (75.8%)           | 254 (70.9%)          | 265 (74.6%)      | 788 (73.8%)        |
| No                                | 86 (24.2%)            | 104 (29.1%)          | 90 (25.4%)       | 280 (26.2%)        |
| Prior Radiation Therapy           |                       |                      |                  |                    |
| Yes                               | 265 (74.6%)           | 283 (79.1%)          | 256 (72.1%)      | 804 (75.3%)        |
| No                                | 90 (25.4%)            | 75 (20.9%)           | 99 (27.9%)       | 264 (24.7%)        |
| Prior Prostatectomy and Radiation |                       |                      |                  |                    |
| Therapy                           |                       |                      |                  |                    |
| Yes                               | 179 (50.4%)           | 179 (50.0%)          | 166 (46.8%)      | 524 (49.1%)        |
| No                                | 176 (49.6%)           | 179 (50.0%)          | 189 (53.2%)      | 544 (50.9%)        |
| Patients with Pelvic Soft Tissue  |                       |                      |                  |                    |
| Lesion at Baseline (CRF)          |                       |                      |                  |                    |
| n                                 | 16 (4.5%)             | 7 (2.0%)             | 9 (2.5%)         | 32 (3.0%)          |

The data cut-off date is 31 Jan 2023. † PSADT categories are summarized based on data collected in study CRF pages.

<div style=\"page-break-after: always\"></div>

## Medical history, prior and subsequent therapies .

Table 11: Medical History for Prostate Cancer and Disease Characteristics (ITT Population)

| Baseline Characteristic                               | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)   | Total (N = 1068)   |
|-------------------------------------------------------|-----------------------|----------------------|------------------|--------------------|
| Time (Months) from Initial Diagnosis to Randomization |                       |                      |                  |                    |
| n                                                     | 355                   | 358                  | 355              | 1068               |
| Mean (SD)                                             | 67.2 (44.25)          | 70.1 (49.00)         | 72.7 (52.03)     | 70.0 (48.54)       |
| Median                                                | 56.9                  | 63.7                 | 61.7             | 60.9               |
| Min, Max                                              | 5.8, 222.4            | 5.7, 305.5           | 6.0, 297.4       | 5.7, 305.5         |
| Primary Gleason Score                                 |                       |                      |                  |                    |
| n                                                     | 327                   | 335                  | 319              | 981                |
| Mean (SD)                                             | 3.6 (0.57)            | 3.6 (0.61)           | 3.6 (0.58)       | 3.6 (0.59)         |
| Median                                                | 4.0                   | 4.0                  | 4.0              | 4.0                |
| Min, Max                                              | 2.0, 5.0              | 2.0, 5.0             | 2.0, 5.0         | 2.0, 5.0           |
| Missing                                               | 28                    | 23                   | 36               | 87                 |
| Primary Gleason Score Group                           |                       |                      |                  |                    |
| < 4                                                   | 129 (36.3%)           | 141 (39.4%)          | 145 (40.8%)      | 415 (38.9%)        |
| ≥ 4                                                   | 198 (55.8%)           | 194 (54.2%)          | 174 (49.0%)      | 566 (53.0%)        |
| Unknown                                               | 1 (0.3%)              | 1 (0.3%)             | 5 (1.4%)         | 7 (0.7%)           |
| Missing                                               | 27 (7.6%)             | 22 (6.1%)            | 31 (8.7%)        | 80 (7.5%)          |
| Secondary Gleason Score                               |                       |                      |                  |                    |
| n                                                     | 327                   | 335                  | 319              | 981                |
| Mean (SD)                                             | 3.7 (0.70)            | 3.7 (0.73)           | 3.7 (0.75)       | 3.7 (0.73)         |
| Median                                                | 4.0                   | 4.0                  | 4.0              | 4.0                |
| Min, Max                                              | 2.0, 5.0              | 2.0, 5.0             | 2.0, 5.0         | 2.0, 5.0           |
| Missing                                               | 28                    | 23                   | 36               | 87                 |
| Total Gleason Score                                   |                       |                      |                  |                    |
| n                                                     | 354                   | 357                  | 350              | 1061               |
| Mean (SD)                                             | 7.4 (0.96)            | 7.3 (1.01)           | 7.2 (1.03)       | 7.3 (1.00)         |
| Median                                                | 7.0                   | 7.0                  | 7.0              | 7.0                |
| Min, Max                                              | 4.0, 10.0             | 5.0, 10.0            | 4.0, 10.0        | 4.0, 10.0          |
| Missing                                               | 1                     | 1                    | 5                | 7                  |
| Total Gleason Score Group                             |                       |                      |                  |                    |
| Low (2-4)                                             | 1 (0.3%)              | 0 (0.0%)             | 3 (0.8%)         | 4 (0.4%)           |
| Medium (5-7)                                          | 233 (65.6%)           | 244 (68.2%)          | 236 (66.5%)      | 713 (66.8%)        |
| High (8-10)                                           | 120 (33.8%)           | 113 (31.6%)          | 111 (31.3%)      | 344 (32.2%)        |
| Unknown                                               | 1 (0.3%)              | 1 (0.3%)             | 5 (1.4%)         | 7 (0.7%)           |
| Clinical Stage                                        |                       |                      |                  |                    |
| TX                                                    | 34 (9.6%)             | 24 (6.7%)            | 32 (9.0%)        | 90 (8.4%)          |
| T0                                                    | 3 (0.8%)              | 1 (0.3%)             | 2 (0.6%)         | 6 (0.6%)           |

<div style=\"page-break-after: always\"></div>

| Baseline Characteristic   | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)   | Total (N = 1068)   |
|---------------------------|-----------------------|----------------------|------------------|--------------------|
| T1                        | 70 (19.7%)            | 76 (21.2%)           | 82 (23.1%)       | 228 (21.3%)        |
| T2                        | 134 (37.7%)           | 146 (40.8%)          | 146 (41.1%)      | 426 (39.9%)        |
| T3                        | 109 (30.7%)           | 109 (30.4%)          | 91 (25.6%)       | 309 (28.9%)        |
| T4                        | 5 (1.4%)              | 2 (0.6%)             | 2 (0.6%)         | 9 (0.8%)           |
| Pathologic Tumor Stage    |                       |                      |                  |                    |
| pTX (not assessed)        | 15 (4.2%)             | 15 (4.2%)            | 9 (2.5%)         | 39 (3.7%)          |
| pT1 (pT1a, pT1b, pT1c)    | 0 (0.0%)              | 2 (0.6%)             | 0 (0.0%)         | 2 (0.2%)           |
| pT2 (pT2a, pT2b, pT2c)    | 77 (21.7%)            | 85 (23.7%)           | 81 (22.8%)       | 243 (22.8%)        |
| pT3x (a/b Status Unknown) | 10 (2.8%)             | 9 (2.5%)             | 5 (1.4%)         | 24 (2.2%)          |
| pT3a                      | 80 (22.5%)            | 69 (19.3%)           | 91 (25.6%)       | 240 (22.5%)        |
| pT3b                      | 84 (23.7%)            | 73 (20.4%)           | 78 (22.0%)       | 235 (22.0%)        |
| pT4                       | 3 (0.8%)              | 1 (0.3%)             | 1 (0.3%)         | 5 (0.5%)           |
| Lymph Nodes Stage         |                       |                      |                  |                    |
| pNX (not assessed)        | 68 (19.2%)            | 65 (18.2%)           | 65 (18.3%)       | 198 (18.5%)        |
| pN0                       | 171 (48.2%)           | 156 (43.6%)          | 165 (46.5%)      | 492 (46.1%)        |
| pN1                       | 30 (8.5%)             | 33 (9.2%)            | 35 (9.9%)        | 98 (9.2%)          |

The data cut-off date is 31 Jan 2023.

## Prior anticancer therapy

Prior therapy for prostate cancer was generally similar across the 3 treatment groups.

- 32.2% patients had at least 1 unique prior prostate cancer therapy (31.3% in the enzalutamide plus leuprolide group, 32.7% in the placebo plus leuprolide group, and 32.7% in the enzalutamide monotherapy group).
- 16.2% patients had at least 1 unique prior hormonal therapy (14.1% in the enzalutamide plus leuprolide group, 16.5% in the placebo plus leuprolide group, and 18.0% in the enzalutamide monotherapy group).
- 23.0% patients had prior non-hormonal therapies (22.3% in the enzalutamide plus leuprolide group, 23.5% in the placebo plus leuprolide group, and 23.4% in the enzalutamide monotherapy group).
- 0.4% patients used prior bisphosphonate or denosumab for non-prostate cancer therapy at baseline (0.6% in the enzalutamide plus leuprolide group, 0% in the placebo plus leuprolide group, and 0.6% in the enzalutamide monotherapy group).
- The majority of patients had received no prior hormonal therapy (69.9% in the enzalutamide plus leuprolide group, 68.4% in the placebo plus leuprolide group, and 68.5% in the enzalutamide monotherapy group).

The most frequent (&gt; 5% patients in any treatment group) prior drug therapies for prostate cancer were leuprorelin (17.7% in the enzalutamide plus leuprolide group vs 19.8% in the placebo plus leuprolide group, and 18.6% in the enzalutamide monotherapy group), bicalutamide (9.0% vs 10.9% vs 10.7%), and goserelin (7.3% vs 5.6% vs 6.2%).

<div style=\"page-break-after: always\"></div>

## Subsequent anticancer therapy

Table 12. Subsequent Antineoplastic Therapy Initiated After Treatment Discontinuation Reported for at Least 1% of Patients in Any Treatment Group (ITT Population)

| ATC Level Description† Generic Name   | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)   | Total (N = 1068)   |
|---------------------------------------|-----------------------|----------------------|------------------|--------------------|
| Number of Patients Taking at Least    |                       |                      |                  |                    |
| One Subsequent Antineoplastic         | 58 (16.3%)            | 139 (38.8%)          | 84 (23.7%)       | 281 (26.3%)        |
| Therapy                               |                       |                      |                  |                    |
| Antineoplastic Agents                 | 9 (2.5%)              | 38 (10.6%)           | 18 (5.1%)        | 65 (6.1%)          |
| Docetaxel                             | 6 (1.7%)              | 31 (8.7%)            | 15 (4.2%)        | 52 (4.9%)          |
| Cabazitaxel                           | 2 (0.6%)              | 14 (3.9%)            | 7 (2.0%)         | 23 (2.2%)          |
| Cyclophosphamide                      | 0 (0.0%)              | 4 (1.1%)             | 1 (0.3%)         | 5 (0.5%)           |
| Corticosteroids                       | 6 (1.7%)              | 10 (2.8%)            | 3 (0.8%)         | 19 (1.8%)          |
| Prednisone‡                           | 6 (1.7%)              | 10 (2.8%)            | 3 (0.8%)         | 19 (1.8%)          |
| Drugs For Treatment Of Bone Diseases  | 5 (1.4%)              | 3 (0.8%)             | 5 (1.4%)         | 13 (1.2%)          |
| Denosumab                             | 3 (0.8%)              | 3 (0.8%)             | 4 (1.1%)         | 10 (0.9%)          |
| Endocrine Therapy                     | 56 (15.8%)            | 132 (36.9%)          | 76 (21.4%)       | 264 (24.7%)        |
| Leuprorelin                           | 40 (11.3%)            | 79 (22.1%)           | 44 (12.4%)       | 163 (15.3%)        |
| Enzalutamide                          | 9 (2.5%)              | 44 (12.3%)           | 11 (3.1%)        | 64 (6.0%)          |
| Abiraterone                           | 11 (3.1%)             | 37 (10.3%)           | 15 (4.2%)        | 63 (5.9%)          |
| Bicalutamide                          | 9 (2.5%)              | 18 (5.0%)            | 20 (5.6%)        | 47 (4.4%)          |
| Triptorelin                           | 6 (1.7%)              | 9 (2.5%)             | 13 (3.7%)        | 28 (2.6%)          |
| Goserelin                             | 4 (1.1%)              | 9 (2.5%)             | 9 (2.5%)         | 22 (2.1%)          |
| Darolutamide                          | 3 (0.8%)              | 15 (4.2%)            | 3 (0.8%)         | 21 (2.0%)          |
| Degarelix                             | 3 (0.8%)              | 6 (1.7%)             | 12 (3.4%)        | 21 (2.0%)          |
| Apalutamide                           | 1 (0.3%)              | 6 (1.7%)             | 4 (1.1%)         | 11 (1.0%)          |
| Immunostimulants                      | 5 (1.4%)              | 11 (3.1%)            | 5 (1.4%)         | 21 (2.0%)          |
| Sipuleucel-T                          | 5 (1.4%)              | 11 (3.1%)            | 5 (1.4%)         | 21 (2.0%)          |
| Therapeutic Radiopharmaceuticals      | 1 (0.3%)              | 6 (1.7%)             | 3 (0.8%)         | 10 (0.9%)          |
| Radium Ra 223 Dichloride              | 0 (0.0%)              | 6 (1.7%)             | 1 (0.3%)         | 7 (0.7%)           |
| Uncoded                               | 0 (0.0%)              | 8 (2.2%)             | 1 (0.3%)         | 9 (0.8%)           |
| Blinded Therapy                       | 0 (0.0%)              | 5 (1.4%)             | 0 (0.0%)         | 5 (0.5%)           |

The data cut-off date is 31 Jan 2023.

All Subsequent Antineoplastic therapies used to treat prostate cancer which occurred in the study are included. Therapeutic class is based on WHODRUG version 2022-03. At each level of summarization (overall, drug class, and generic name), patients are counted only once.† ATC Level 2 description is used. If unavailable, ATC Level 1 description is used.‡

Systemic prednisone was reported for some patients with other antineoplastic therapy as a combination regimen.

## Numbers analysed

## Populations analysed

The number of participants included in each analysis population is provided in Table 12.

<div style=\"page-break-after: always\"></div>

Table 13. Patient populations

| PatientPopulation      | ENZA+LA (I=355)   | PBO +LA (IN=358)   | ENZA (IN=355)   | Total (I=1068)   |
|------------------------|-------------------|--------------------|-----------------|------------------|
| ITTPopulation          | 355 (100.0%)      | 358 (100.0%)       | 355 (100.0%)    | 1068 (100.0%)    |
| EvaluableITTPopulation | 354 (99.7%)       | 356 (99.4%)        | 354 (99.7%)     | 1064 ( 99.6%)    |
| SafetyPopulation       | 353 (99.4%)       | 354 ( 98.9%)       | 354 ( 99.7%)    | 1061 ( 99.3%)    |

Thedatacut-offdateis31JAN2023.

## Outcomes and estimation

The efficacy analyses were performed using the data up to the primary completion date (PCD) cut-off date of 31 January 2023. The analysis of the key secondary endpoint OS was a prespecified interim analysis. Analyses of all other secondary efficacy endpoints were final analyses.

## Primary efficacy endpoint

## BICR assessed MFS (Enzalutamide Plus Leuprolide vs Placebo Plus Leuprolide)

Table 14. MFS Based on BICR Assessment for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups - Primary Efficacy Analysis (ITT Population)

|                                                   | ENZA + LA (N = 355)   | PBO + LA (N = 358)   |
|---------------------------------------------------|-----------------------|----------------------|
| Status of MFS Follow-up                           |                       |                      |
| Events†                                           | 45 (12.7%)            | 92 (25.7%)           |
| Progression by Independent Central Review         | 37 (10.4%)            | 84 (23.5%)           |
| Bone Progression                                  | 12 (3.4%)             | 24 (6.7%)            |
| Soft Tissue Progression                           | 23 (6.5%)             | 54 (15.1%)           |
| Concurrent Bone and Soft Tissue Progression       | 2 (0.6%)              | 6 (1.7%)             |
| Death Without Documented Radiographic Progression | 8 (2.3%)              | 8 (2.2%)             |
| Status of MFS Follow-up                           |                       |                      |
| Censored‡                                         | 310 (87.3%)           | 266 (74.3%)          |
| No Postbaseline Assessments                       | 11 (3.1%)             | 7 (2.0%)             |
| Metastatic Disease at Randomization               | 1 (0.3%)              | 2 (0.6%)             |
| Initiation of Antineoplastic Therapy              | 36 (10.1%)            | 67 (18.7%)           |
| Abiraterone Acetate                               | 0 (0.0%)              | 3 (0.8%)             |
| Cytotoxic Chemotherapy                            | 9 (2.5%)              | 4 (1.1%)             |
| Cytotoxic Chemotherapy + Other                    | 0 (0.0%)              | 1 (0.3%)             |
| First Prostate Cancer Antineoplastic Therapy Date | 0 (0.0%)              | 1 (0.3%)             |
| Hormonal Therapy                                  | 25 (7.0%)             | 56 (15.6%)           |
| Hormonal Therapy + Prostate Cancer Vaccine        | 0 (0.0%)              | 1 (0.3%)             |
| Other                                             | 1 (0.3%)              | 1 (0.3%)             |
| Prostate Cancer Vaccine                           | 1 (0.3%)              | 0 (0.0%)             |
| 2+ Missed Visits                                  | 4 (1.1%)              | 5 (1.4%)             |
| No Metastatic Disease or Death                    | 258 (72.7%)           | 185 (51.7%)          |
| MFS Based on K-M Estimates (in Months)            |                       |                      |
| n                                                 | 355                   | 358                  |
| 25th Percentile                                   | NR                    | 53.3                 |

<div style=\"page-break-after: always\"></div>

|                                                                            | ENZA + LA (N = 355)   | PBO + LA (N = 358)   |
|----------------------------------------------------------------------------|-----------------------|----------------------|
| Median (95% CI)                                                            | NR (NR, NR)           | NR (85.1, NR)        |
| 75th Percentile                                                            | NR                    | NR                   |
| P-value§                                                                   | < 0.0001              |                      |
| Hazard Ratio (95% CI)§                                                     | 0.424 (0.296, 0.607)  |                      |
| Probability of Being Event Free Based on K-M Estimates at:                 |                       |                      |
| Year 1 (95% CI)                                                            | 0.979 (0.957, 0.990)  | 0.976 (0.953, 0.988) |
| Year 2 (95% CI)                                                            | 0.951 (0.922, 0.970)  | 0.901 (0.863, 0.929) |
| Year 3 (95% CI)                                                            | 0.929 (0.895, 0.952)  | 0.835 (0.789, 0.872) |
| Observed Follow-up Time for Censored Patients¶ (in Months)                 |                       |                      |
| n                                                                          | 310                   | 266                  |
| 25th Percentile                                                            | 49.8                  | 33.9                 |
| Median                                                                     | 60.7                  | 56.3                 |
| 75th Percentile                                                            | 71.4                  | 66.3                 |
| Min, Max                                                                   | 0.03, 88.41           | 0.03, 93.90          |
| Follow-up Time Based on Reverse K-M Estimates for All Patients (in Months) |                       |                      |
| n                                                                          | 355                   | 358                  |
| 25th Percentile                                                            | 54.8                  | 44.1                 |
| Median (95% CI)                                                            | 60.7 (60.6, 60.8)     | 60.6 (55.8, 60.7)    |
| 75th Percentile                                                            | 71.7                  | 71.6                 |

The data cut-off date is 31 Jan 2023.NR = Not Reached.† Based on the earliest contributing event (radiographic progression or death).‡ Patients who were not known to have had an MFS event at the time of analysis data cutoff, started new antineoplastic therapy, systemic radiopharmaceuticals, or any other anti-cancer therapy are censored at date of last assessment showing no objective evidence of radiographic progression.

Patients randomized but later confirmed to have metastatic disease are censored on date of randomization.§ Two-sided P-value is based on a stratified log-rank test by screening PSA, PSADT, and prior hormonal therapy. Hazard ratio is based on a Cox regression model stratified by factors defined above and is relative to PBO+LA with &lt; 1 favoring ENZA+LA.¶ Calculated as (date of last assessment showing no evidence of radiograp hic progression - randomization date + 1) / 30.4375.

<div style=\"page-break-after: always\"></div>

Figure 5. K-M Curves for MFS by BICR for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups - Primary Efficacy Analysis (ITT Population)

<!-- image -->

ENZA+LA: Event/Cum.Events 0/02/23/50/5270/71/80/88/161/172/191/203/235/283/313/340/343/371/381/390/394/430/430/431/440/441/450/450/450/450/450/450/45 Patients at Risk 5 0 0 PBO+LA: Event/Cum.Events Patients at Risk The data cut-off date is 31JAN2023. NR=NotReached

Hazard ratio is based ona Cox regression model (with treatment as the only covariate) stralified by factors defined above, and is relative to PBO+LA with &lt; 1 favoring ENZA+LA. PFIZER CONFIDENTIAL Source:IIn78/Volumes/data/usrflles/programmlng/mdv3100/mdv3100\\_13/csr/prod/programs/liff\\_14\\_02\\_01\\_01\\_01\\_mfslcr.s3s 12APR23:18:04 Output Fle:f\\_14\\_02\\_01\\_01\\_01\\_mfslcr.rtf

Note: Two sided P-value is based on a stratified log-rank test by screening PSA, PSA doubling time, and prior homonal therapy as per IWRS.

## Key secondary endpoints

## MFS (Enzalutamide Monotherapy vs Placebo Plus Leuprolide)

Table 15: MFS Based on BICR Assessment for Enzalutamide vs Placebo plus Leuprolide Groups - Key Secondary Efficacy Analysis (ITT Population)

|                                                   | ENZA (N = 355)   | PBO + LA (N = 358)   |
|---------------------------------------------------|------------------|----------------------|
| Status of MFS Follow-up                           |                  |                      |
| Events†                                           | 63 (17.7%)       | 92 (25.7%)           |
| Progression by Independent Central Review         | 54 (15.2%)       | 84 (23.5%)           |
| Bone Progression                                  | 24 (6.8%)        | 24 (6.7%)            |
| Soft Tissue Progression                           | 29 (8.2%)        | 54 (15.1%)           |
| Concurrent Bone and Soft Tissue Progression       | 1 (0.3%)         | 6 (1.7%)             |
| Death Without Documented Radiographic Progression | 9 (2.5%)         | 8 (2.2%)             |
| Status of MFS Follow-up                           |                  |                      |
| Censored‡                                         | 292 (82.3%)      | 266 (74.3%)          |
| No Postbaseline Assessments                       | 4 (1.1%)         | 7 (2.0%)             |
| Metastatic Disease at Randomization               | 1 (0.3%)         | 2 (0.6%)             |
| Initiation of Antineoplastic Therapy              | 44 (12.4%)       | 67 (18.7%)           |
| Abiraterone Acetate                               | 0 (0.0%)         | 3 (0.8%)             |
| Bone Targeting Agent + Hormonal Therapy           | 2 (0.6%)         | 0 (0.0%)             |
| Cytotoxic Chemotherapy                            | 3 (0.8%)         | 4 (1.1%)             |
| Cytotoxic Chemotherapy + Other                    | 0 (0.0%)         | 1 (0.3%)             |
| First Prostate Cancer Antineoplastic Therapy Date | 0 (0.0%)         | 1 (0.3%)             |
| Hormonal Therapy                                  | 38 (10.7%)       | 56 (15.6%)           |
| Hormonal Therapy + Prostate Cancer Vaccine        | 0 (0.0%)         | 1 (0.3%)             |
| Other                                             | 1 (0.3%)         | 1 (0.3%)             |

<div style=\"page-break-after: always\"></div>

|                                                                            | ENZA (N = 355)       | PBO + LA (N = 358)   |
|----------------------------------------------------------------------------|----------------------|----------------------|
| 2+ Missed Visits                                                           | 4 (1.1%)             | 5 (1.4%)             |
| No Metastatic Disease or Death                                             | 239 (67.3%)          | 185 (51.7%)          |
| MFS Based on K-M Estimates (in Months)                                     |                      |                      |
| n                                                                          | 355                  | 358                  |
| 25th Percentile                                                            | NR                   | 53.3                 |
| Median (95% CI)                                                            | NR (NR, NR)          | NR (85.1, NR)        |
| 75th Percentile                                                            | NR                   | NR                   |
| P-value§                                                                   | 0.0049               |                      |
| Hazard Ratio (95% CI)§                                                     | 0.631 (0.456, 0.871) |                      |
| Probability of Being Event Free Based on K-M Estimates at:                 |                      |                      |
| Year 1 (95% CI)                                                            | 0.986 (0.966, 0.994) | 0.976 (0.953, 0.988) |
| Year 2 (95% CI)                                                            | 0.914 (0.878, 0.940) | 0.901 (0.863, 0.929) |
| Year 3 (95% CI)                                                            | 0.878 (0.837, 0.909) | 0.835 (0.789, 0.872) |
| Observed Follow-up Time for Censored Patients ¶ (in Months)                |                      |                      |
| n                                                                          | 292                  | 266                  |
| 25th Percentile                                                            | 49.5                 | 33.9                 |
| Median                                                                     | 60.7                 | 56.3                 |
| 75th Percentile                                                            | 71.5                 | 66.3                 |
| Min, Max                                                                   | 0.03, 88.48          | 0.03, 93.90          |
| Follow-up Time Based on Reverse K-M Estimates for All Patients (in Months) |                      |                      |
| n                                                                          | 355                  | 358                  |
| 25th Percentile                                                            | 49.9                 | 44.1                 |
| Median (95% CI)                                                            | 60.7 (60.6, 60.8)    | 60.6 (55.8, 60.7)    |
| 75th Percentile                                                            | 71.7                 | 71.6                 |

The data cut-off date is 31 Jan 2023.NR = Not Reached.† Based on the earliest contributing event (radiographic progression or death).‡ Patients who were not known to have had an MFS event at the time of analysis data cutoff, started new antineoplastic therapy, systemic radiopharmaceuticals, or any other anti-cancer therapy are censored at date of last assessment showing no objective evidence of radiographic progression.

Patients randomized but later confirmed to have metastatic disease are censored on date of randomization§ Two-sided P-value is based on a stratified log-rank test by screening PSA, PSADT, and prior hormonal therapy. Hazard ratio is based on a Cox regression model stratified by factors defined above and is relative to PBO+LA with &lt; 1 favoring ENZA

¶ Calculated as (date of last assessment showing no evidence of radiographic progression - randomization date + 1) / 30.4375.

<div style=\"page-break-after: always\"></div>

Figure 6: K-M Curves for MFS by BICR for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups - Key Secondary Efficacy Analysis (ITT Population)

<!-- image -->

ENZA: Event/Cum. Events 0/00/03/30/32/50/58/130/1315/280/286/342/363/395/441/458/533/562/580/583/810/611/620/620/820/820/620/621/830/630/630/630/630/63 Patients at Risk 5 0 PBO+LA: Event/Cum.Events Patients at Risk Thedatacut-off dateis31JAN2023.

NR=Not Reached

Note: Two sided P-value is based on a stratified log-rank test by screening PSA, PSA doubling time, and priorhomonal therapy as per IWRS. PFIZERCONFIDENTIALSource:In78/Volumes/data/usrileS/programmlng/mdv3100/mdv3100\\_13/csr/prodlprograms/lilf\\_14\\_02\\_01\\_01\\_02\\_mfslcr.s3s12APR23:19:33Output Fle:f\\_14\\_02\\_01\\_01\\_02\\_mslcr.rtf

## Time to PSA progression

Table 16. Time to PSA Progression - Key Secondary Efficacy Analysis (ITT Population)

|                                                                                  | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)       |
|----------------------------------------------------------------------------------|-----------------------|----------------------|----------------------|
| Status of Prostate-Specific Antigen Follow- up                                   |                       |                      |                      |
| Prostate-Specific Antigen Progression†                                           | 8 (2.3%)              | 93 (26.0%)           | 37 (10.4%)           |
| Censored‡                                                                        | 347 (97.7%)           | 265 (74.0%)          | 318 (89.6%)          |
| Time to Prostate-Specific Antigen Progression Based on K-M Estimates (in Months) |                       |                      |                      |
| n                                                                                | 355                   | 358                  | 355                  |
| 25th Percentile                                                                  | NR                    | 47.1                 | NR                   |
| Median (95% CI)                                                                  | NR (NR, NR)           | NR (NR, NR)          | NR (NR, NR)          |
| 75th Percentile                                                                  | NR                    | NR                   | NR                   |
| P-value§                                                                         | < 0.0001              |                      | < 0.0001             |
| Hazard Ratio (95% CI)§                                                           | 0.068 (0.033, 0.141)  |                      | 0.331 (0.226, 0.486) |
| Probability of Being Event Free Based on K- M Estimates at:                      |                       |                      |                      |

<div style=\"page-break-after: always\"></div>

|                                                                            | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)       |
|----------------------------------------------------------------------------|-----------------------|----------------------|----------------------|
| Year 1 (95% CI)                                                            | 1.000 (1.000, 1.000)  | 0.967 (0.941, 0.982) | 0.997 (0.979, 1.000) |
| Year 2 (95% CI)                                                            | 0.994 (0.975, 0.998)  | 0.898 (0.859, 0.926) | 0.978 (0.954, 0.989) |
| Year 3 (95% CI)                                                            | 0.990 (0.970, 0.997)  | 0.827 (0.780, 0.866) | 0.944 (0.911, 0.965) |
| Observed Follow-up Time for Censored Patients¶ (in Months)                 |                       |                      |                      |
| n                                                                          | 347                   | 265                  | 318                  |
| 25th Percentile                                                            | 38.8                  | 28.7                 | 38.7                 |
| Median                                                                     | 60.6                  | 58.0                 | 60.6                 |
| 75th Percentile                                                            | 70.1                  | 69.0                 | 69.1                 |
| Min, Max                                                                   | 0.03, 88.48           | 0.03, 91.37          | 0.03, 93.90          |
| Follow-up Time Based on Reverse K-M Estimates for All Patients (in Months) |                       |                      |                      |
| n                                                                          | 355                   | 358                  | 355                  |
| 25th Percentile                                                            | 41.0                  | 36.3                 | 42.3                 |
| Median (95% CI)                                                            | 60.7 (58.0, 60.9)     | 60.6 (58.0, 61.0)    | 60.7 (58.0, 60.9)    |
| 75th Percentile                                                            | 71.7                  | 69.3                 | 71.2                 |

The data cut-off date is 31 Jan 2023. NR = Not Reached.

† Based on the PSA Progression compliant with Prostate Cancer Clinical Trials Working Group 2 criteria. ‡ Include patients who did not have confirmed PSA progression at the time of analysis data cutoff, or with anti-prostate cancer therapy, or with PSA progression after 2 or more consecutive missed PSA assessments, or without baseline and post-baseline PSA results, with time to PSA progression are censored at date of last assessment indicating no evidence of confirmed PSA progression, last assessment date prior to therapy, the date of last PSA assessment prior to the missed assessments, or the date of randomization respectively. § Two-sided P-value is based on a stratified log-rank test by screening PSA, PSADT, and prior hormonal therapy. Hazard ratio is based on a Cox regression model stratified by factors defined above and is relative to PBO+LA with &lt; 1 favoring ENZA+LA and PBO+LA with &lt; 1 favoring ENZA.

¶ Calculated as (date of last assessment showing no evidence of PSA progression - randomization date + 1) / 30.4375.

<div style=\"page-break-after: always\"></div>

Figure 7.K-M Curves for Time to PSA Progression for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups - Key Secondary Efficacy Analysis (ITT Population)

<!-- image -->

ENZA+LA: Event/Cum.Events 0/00/00/00/00/00/00/02/20/20/20/21/30/30/31/40/41/51/61/70/70/71/80/80/80/80/80/80/80/80/80/80/8 Patients at Risk 7553 337 25 12 5 0 PBO+LA: Event/Cum.Events 0/00/00/08/83/115/169/255/303/334/370/378/458/536/593/626/685/731/746/801/813/844/882/901/912/930/930/930/930/930/930/930/93 PatientsatRisk 358347341324314305293283268260253240223209201190182178168154128105836642282013 7530

Thedatacut-offdateis31JAN2023

Note:Two sided P-value is based ona stratified log-rank test by screeningPSA,PSA doubling time, and priorhormonal therapy as per IWRS. HazardratioisbasedonaCoxregressionmodel(with treatment astheonlycovariate)stratifiedbyfactors defined above,andisrelativetoPBO+LA with&lt;1favoringENZA+LA. PFIZER CONFIDENTIAL Source:lin78 /Volumes/data/usriles/programming/mdv3100/mdv3100\\_13/csr/prod/programs/iff\\_14\\_02\\_02\\_01\\_01\\_psaprog.sas12APR23:19:35Output File:f\\_14\\_02\\_02\\_01\\_01\\_psaprog.rf

Figure 8. K-M Curves for Time to PSA Progression for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups - Key Secondary Efficacy Analysis (ITT Population)

<!-- image -->

Time to Start of New Antineoplastic Therapy

<div style=\"page-break-after: always\"></div>

Table 17. Time to First Use of New Antineoplastic Therapy - Key Secondary Efficacy Analysis (ITT Population)

|                                                                                | ENZA + LA (N = 355)                                 | PBO + LA (N = 358)                                  | ENZA (N = 355)                                      |
|--------------------------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Status of Antineoplastic Therapy Follow-up                                     |                                                     |                                                     |                                                     |
| Event†                                                                         | 58 (16.3%)                                          | 140 (39.1%)                                         | 84 (23.7%)                                          |
| Censored                                                                       | 297 (83.7%)                                         | 218 (60.9%)                                         | 271 (76.3%)                                         |
| Time to First Use of Antineoplastic Therapy Based on K-M Estimates (in Months) |                                                     |                                                     |                                                     |
| n                                                                              | 355                                                 | 358                                                 | 355                                                 |
| 25th Percentile                                                                | NR                                                  | 43.7                                                | 64.4                                                |
| Median (95% CI)                                                                | NR (NR, NR)                                         | 76.2 (71.3, NR)                                     | NR (NR, NR)                                         |
| 75th Percentile                                                                | NR                                                  | NR                                                  | NR                                                  |
| P-value‡                                                                       | < 0.0001                                            |                                                     | < 0.0001                                            |
| Hazard Ratio (95% CI)‡                                                         | 0.358 (0.263, 0.488)                                |                                                     | 0.540 (0.411, 0.709)                                |
| Probability of Being Event Free Based on K-M Estimates at:                     |                                                     |                                                     |                                                     |
| Year 1 (95% CI)                                                                | 0.980 (0.958, 0.990)                                | 0.966 (0.940, 0.980)                                | 0.986 (0.966, 0.994)                                |
| Year 2 (95% CI)                                                                | 0.953 (0.924, 0.971)                                | 0.898 (0.861, 0.926)                                | 0.916 (0.881, 0.941)                                |
| Year 3 (95% CI)                                                                | 0.916 (0.881, 0.942)                                | 0.807 (0.761, 0.846)                                | 0.844 (0.801, 0.879)                                |
| Observed Follow-up Time for Censored Patients§ (in Months)                     |                                                     |                                                     |                                                     |
| n                                                                              | 297                                                 | 218                                                 | 271                                                 |
| 25th Percentile                                                                | 55.4                                                | 55.2                                                | 57.9                                                |
| Median                                                                         | 63.5                                                | 63.3                                                | 63.5                                                |
| 75th Percentile                                                                | 74.5                                                | 71.8                                                | 74.4                                                |
| Min, Max                                                                       | 0.03, 94.13                                         | 0.03, 93.90                                         | 0.03, 93.90                                         |
| Follow-up Time Based on Reverse K-M Estimates for All Patients (in Months)     |                                                     |                                                     |                                                     |
| n                                                                              | 355                                                 | 358                                                 | 355                                                 |
| 25th Percentile                                                                | 55.7                                                | 58.0                                                | 58.0                                                |
| Median (95% CI)                                                                | 63.6 (61.5, 66.3)63.7 (63.4, 66.3)63.5 (63.0, 66.3) | 63.6 (61.5, 66.3)63.7 (63.4, 66.3)63.5 (63.0, 66.3) | 63.6 (61.5, 66.3)63.7 (63.4, 66.3)63.5 (63.0, 66.3) |
| 75th Percentile                                                                | 74.5                                                | 74.4                                                | 74.5                                                |

The data cut-off date is 31 Jan 2023. NR = Not Reached. † Based on the first postbaseline use of antineoplastic therapy for prostate cancer. ‡ Two-sided P-value is based on a stratified log-rank test by screening PSA, PSADT, and prior hormonal therapy. Hazard ratio is based on a Cox regression model stratified by factors defined above and is relative to PBO+LA with &lt; 1 favoring ENZA+LA and PBO+LA with &lt; 1 favoring ENZA. § Calculated as (date of last assessment prior to analysis data cutoff date - randomization date + 1) / 30.4375.

<div style=\"page-break-after: always\"></div>

Figure 9. K-M Curves for Time to First Use of New Antineoplastic Therapy for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups - Key Secondary Efficacy Analysis (ITT Population)

<!-- image -->

Figure 10. K-M Curves for Time to First Use of New Antineoplastic Therapy for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups - Key Secondary Efficacy Analysis

<!-- image -->

## Overall survival

At the interim analysis, the OS data was immature, with 130 (48.0%) OS events out of the required 271 OS events in the 3 treatment groups for final OS analysis [Table 17]. The median OS was NR in any of the treatment groups. The median follow-up time of OS was 65.0 months for enzalutamide plus leuprolide, 66.2 months for placebo plus leuprolide, and 63.7 months for enzalutamide monotherapy.

<div style=\"page-break-after: always\"></div>

Table 18. OS - Key Secondary Efficacy Analysis (ITT Population)

|                                                            | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)       |
|------------------------------------------------------------|-----------------------|----------------------|----------------------|
| Survival Status                                            |                       |                      |                      |
| Death                                                      | 33 (9.3%)             | 55 (15.4%)           | 42 (11.8%)           |
| Censored†                                                  | 322 (90.7%)           | 303 (84.6%)          | 313 (88.2%)          |
| Alive at Data Analysis Cutoff Date                         | 274 (77.2%)           | 257 (71.8%)          | 259 (73.0%)          |
| Lost to Follow-up                                          | 3 (0.8%)              | 3 (0.8%)             | 4 (1.1%)             |
| Withdrew Consent to be Followed                            | 40 (11.3%)            | 35 (9.8%)            | 38 (10.7%)           |
| Sponsor Decision                                           | 0 (0.0%)              | 0 (0.0%)             | 0 (0.0%)             |
| Other                                                      | 5 (1.4%)              | 8 (2.2%)             | 12 (3.4%)            |
| Overall Survival Based on K-M Estimates (in Months)        |                       |                      |                      |
| n                                                          | 355                   | 358                  | 355                  |
| 25th Percentile                                            | 86.7                  | 81.7                 | NR                   |
| Median (95% CI)                                            | NR (NR, NR)           | NR (NR, NR)          | NR (NR, NR)          |
| 75th Percentile                                            | NR                    | NR                   | NR                   |
| P-value‡                                                   | 0.0153                |                      | 0.2304               |
| Hazard Ratio (95% CI)‡                                     | 0.589 (0.382, 0.908)  |                      | 0.782 (0.523, 1.170) |
| Probability of Being Event Free Based on K-M Estimates at: |                       |                      |                      |
| Year 1 (95% CI)                                            | 0.997 (0.980,1.000)   | 0.989 (0.970,0.996)  | 0.997 (0.980,1.000)  |
| Year 2 (95% CI)                                            | 0.983 (0.962,0.992)   | 0.983 (0.962,0.992)  | 0.991 (0.973,0.997)  |
| Year 3 (95% CI)                                            | 0.977 (0.954,0.988)   | 0.948 (0.919,0.967)  | 0.968 (0.942,0.982)  |
| Observed Follow-up Time for Censored Patients§ (in         |                       |                      |                      |
| Months)                                                    |                       |                      |                      |
| n                                                          | 322                   | 303                  | 313                  |
| 25th Percentile                                            | 57.9                  | 58.0                 | 58.0                 |
| Median                                                     | 63.8                  | 63.7                 | 63.6                 |
| 75th Percentile                                            | 74.5                  | 74.6                 | 74.4                 |
| Min, Max                                                   | 0.39,94.13            | 0.03,93.93           | 0.62,93.90           |
| Follow-up Time Based on Reverse K-M Estimates for          |                       |                      |                      |
| All Patients (in Months)                                   |                       |                      |                      |
| n                                                          | 355                   | 358                  | 355                  |
| 25th Percentile                                            | 58.0                  | 58.1                 | 58.0                 |
| Median (95% CI)                                            | 65.0 (63.5, 66.3)     | 66.2 (63.5, 67.0)    | 63.7 (63.5, 66.3)    |
| 75th Percentile                                            | 74.6                  | 74.9                 | 74.5                 |

The data cut-off date is 31 Jan 2023. NR = Not Reached.

†Patients who were not known to have died at the analysis date are censored at date last know alive or data analysis cutoff date, which ever occurs first. ‡ Two-sided P-value is based on a stratified log-rank test by screening PSA, PSADT, and prior hormonal therapy. Hazard ratio is based on a Cox regression model stratified by factors defined above and is relative to PBO+LA with &lt; 1 favoring ENZA+LA and PBO+LA with &lt; 1 favoring ENZA.

§Calculated as (date last know alive or data analysis cutoff date, whichever occurs first - randomization date + 1) / 30.4375.

<div style=\"page-break-after: always\"></div>

Figure 11. K-M Curves for OS for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups - Key Secondary Efficacy Analysis (ITT Population)

<!-- image -->

Figure 12. K-M Curves for OS for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups - Key Secondary Efficacy Analysis (ITT Population)

<!-- image -->

## Other secondary endpoints

Time to distant metastasis

<div style=\"page-break-after: always\"></div>

Table 19: Time to Distant Metastasis Based on BICR Assessment - Other Secondary Efficacy Analysis (ITT Population)

|                                                            | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)       |
|------------------------------------------------------------|-----------------------|----------------------|----------------------|
| Distant Metastasis Status                                  |                       |                      |                      |
| Distant Metastasis†                                        | 30 (8.5%)             | 59 (16.5%)           | 40 (11.3%)           |
| Bone Progression                                           | 14 (3.9%)             | 29 (8.1%)            | 25 (7.0%)            |
| Soft Tissue Progression                                    | 15 (4.2%)             | 27 (7.5%)            | 14 (3.9%)            |
| Concurrent Bone and Soft Tissue Progression                | 1 (0.3%)              | 3 (0.8%)             | 1 (0.3%)             |
| Distant Metastasis Status                                  |                       |                      |                      |
| Censored‡                                                  | 325 (91.5%)           | 299 (83.5%)          | 315 (88.7%)          |
| No Postbaseline Assessments                                | 11 (3.1%)             | 9 (2.5%)             | 4 (1.1%)             |
| Metastatic Disease at Randomization                        | 1 (0.3%)              | 2 (0.6%)             | 1 (0.3%)             |
| Initiation of Antineoplastic Therapy                       | 41 (11.5%)            | 88 (24.6%)           | 52 (14.6%)           |
| Abiraterone Acetate                                        | 0 (0.0%)              | 5 (1.4%)             | 0 (0.0%)             |
| Abiraterone Acetate + Horm                                 | 0 (0.0%)              | 1 (0.3%)             | 0 (0.0%)             |
| Bone Targeting Agent (BTA) + Horm                          | 0 (0.0%)              | 0 (0.0%)             | 2 (0.6%)             |
| Cytotoxic Chemotherapy                                     | 11 (3.1%)             | 5 (1.4%)             | 4 (1.1%)             |
| Cytotoxic Chemotherapy + Horm                              | 0 (0.0%)              | 1 (0.3%)             | 1 (0.3%)             |
| Cytotoxic Chemotherapy + Other                             | 0 (0.0%)              | 1 (0.3%)             | 0 (0.0%)             |
| Hormonal Therapy                                           | 28 (7.9%)             | 72 (20.1%)           | 44 (12.4%)           |
| Prostate Cancer Vaccine                                    | 1 (0.3%)              | 0 (0.0%)             | 0 (0.0%)             |
| Other Anti-Cancer Therapy                                  | 1 (0.3%)              | 1 (0.3%)             | 1 (0.3%)             |
| 2+ Missed Visits                                           | 4 (1.1%)              | 5 (1.4%)             | 4 (1.1%)             |
| Unknown Distant Metastasis Disease Status                  | 1 (0.3%)              | 0 (0.0%)             | 3 (0.8%)             |
| No Distant Metastatic Disease                              | 267 (75.2%)           | 195 (54.5%)          | 251 (70.7%)          |
| Time to Distant Metastasis based on K-M                    |                       |                      |                      |
| Estimates (in Months)                                      |                       |                      |                      |
| n                                                          | 355                   | 358                  | 355                  |
| 25th Percentile                                            | NR                    | 85.1                 | NR                   |
| Median (95% CI)                                            | NR (NR, NR)           | NR (85.1, NR)        | NR (NR, NR)          |
| 75th Percentile                                            | NR                    | NR                   | NR                   |
| P-value§                                                   | 0.0002                |                      | 0.0171               |
| Hazard Ratio (95% CI)§                                     | 0.443 (0.284, 0.690)  |                      | 0.614 (0.409, 0.920) |
| Probability of Being Event Free Based on K-M Estimates at: |                       |                      |                      |
| Year 1 (95% CI)                                            | 0.988 (0.969, 0.996)  | 0.985 (0.964, 0.994) | 0.988 (0.969, 0.996) |
| Year 2 (95% CI)                                            | 0.963 (0.936, 0.979)  | 0.937 (0.904, 0.959) | 0.929 (0.895, 0.952) |
| Year 3 (95% CI)                                            | 0.950 (0.919, 0.969)  | 0.889 (0.848, 0.919) | 0.926 (0.891, 0.950) |
| Observed Follow-up Time for Censored Patients¶             |                       |                      |                      |
| (in Months)                                                |                       |                      |                      |
| n                                                          | 325                   | 299                  | 315                  |
| 25th Percentile                                            | 45.4                  | 33.1                 | 38.7                 |

<div style=\"page-break-after: always\"></div>

|                                                                            | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)    |
|----------------------------------------------------------------------------|-----------------------|----------------------|-------------------|
| Median                                                                     | 60.6                  | 55.2                 | 60.6              |
| 75th Percentile                                                            | 67.9                  | 66.2                 | 66.9              |
| Min, Max                                                                   | 0.03, 88.41           | 0.03, 93.90          | 0.03, 88.48       |
| Follow-up Time Based on Reverse K-M Estimates for All Patients (in Months) |                       |                      |                   |
| n                                                                          | 355                   | 358                  | 355               |
| 25th Percentile                                                            | 49.6                  | 38.5                 | 44.1              |
| Median (95% CI)                                                            | 60.6 (60.3, 60.8)     | 55.6 (55.2, 60.6)    | 60.6 (60.3, 60.8) |
| 75th Percentile                                                            | 71.3                  | 66.3                 | 68.8              |

The data cut-off date is 31 Jan 2023. NR = Not Reached.

† Based on the earliest objective evidence of distant soft tissue metastases or metastatic bone disease by BICR.

‡ Censoring rules will follow those in the primary MFS analysis except the situation in previous footnote. § Two-sided P-value is based on a stratified log-rank test by screening PSA, PSADT, and prior hormonal therapy. Hazard ratio is based on a Cox regression model stratified by factors defined above and is relative to PBO+LA with &lt; 1 favoring ENZA+LA and PBO+LA with &lt; 1 favoring ENZA.

¶ Calculated as (date of last assessment showing no evidence of distant metastasis - randomization date + 1) / 30.4375.

Figure 13: K-M Curves for Time to Distant Metastasis Based on BICR Review Assessment for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups - Other Secondary Efficacy Analysis (ITT Population)

<!-- image -->

ENZA+LA: Event/Cum.Events Patients at Risk 5000 PBO+LA: Event/Cum.Events 0/00/00/01/14/50/56/112/137/202/228/301/313/344/380/383/410/414/451/465/510/513/540/542/562/580/580/580/580/581/590/590/590/59 Patients at Risk 358344334333321320303301279276260257239227223207205187185142139928766322715146 5 1 0 Thedatacut-offdateis31JAN2023 NR=Not Reached

Note:Two sidedP-value is basedona stratified log-rank test by screeningPSA,PSA doubling time, and priorhomonal therapy asperIWRS.

PFIZERCONFIDENTIAL Source:lin78 /Volumes/data/usrfiles/programming/mdv3100/mdv3100\\_13/csrlprod/programs/lf\\_14\\_02\\_03\\_00\\_01\\_disticr.sas 12APR23:19:38Output File:f\\_14\\_02\\_03\\_09\\_01\\_disticr.rtf

<div style=\"page-break-after: always\"></div>

Figure 14. K-M Curves for Time to Distant Metastasis Based on BICR Review Assessment for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups - Other Secondary Efficacy Analysis (ITT Population)

<!-- image -->

## Proportion of participants with undetectable PSA at 36 weeks on study treatment

The proportion of patients (95% CI) with undetectable PSA at 36 weeks on study treatment was 97.3% (95% CI: 94.9%, 98.7%) in the enzalutamide plus leuprolide group, 71.4% (95% CI: 66.3%, 76.2%) in the placebo plus leuprolide group, and 90.2% (95% CI: 86.5%, 93.2%) in the enzalutamide monotherapy group (Table 19).

Table 20. Proportion of Patients with Undetectable PSA at Week 36 - Other Secondary Efficacy Analysis (ITT Population)

|                                                                       | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)       |
|-----------------------------------------------------------------------|-----------------------|----------------------|----------------------|
| Number of Patients with PSA Values at Week 36                         | 331 (93.2%)           | 336 (93.9%)          | 337 (94.9%)          |
| Patients with Undetectable Prostate Specific Antigen (PSA) at Week 36 | 322 (97.3%)           | 240 (71.4%)          | 304 (90.2%)          |
| Proportion (95% CI)†                                                  | 97.3% (94.9%, 98.7%)  | 71.4% (66.3%, 76.2%) | 90.2% (86.5%, 93.2%) |
| Difference of Proportion (95% CI)‡                                    | 25.9% (20.7%, 31.0%)  |                      | 18.8% (13.0%, 24.6%) |
| P-value§                                                              | 0.0001                |                      | 0.0001               |

The data cut-off date is 31 Jan 2023. † Clopper-Pearson exact binomial confidence interval (CI). ‡ Proportion in ENZA+LA minus proportion in PBO+LA, or proportion in ENZA minus proportion in PBO+LA. 95% CI is based on Wald type method. § Pvalue is based on a Cochran-Mantel-Haenszel test stratified by screening PSA, PSADT, and prior hormonal therapy.

<div style=\"page-break-after: always\"></div>

## Proportion of participants who remain treatment-free 2 years after suspension of study treatment at week 37 due to undetectable PSA

Table 21. Proportion of Patients Who Remained Treatment Free 2 Years After Suspension of Study Treatment - Other Secondary efficacy Analysis (ITT Population)

|                                                             | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)         |
|-------------------------------------------------------------|-----------------------|----------------------|------------------------|
| Number of Patients with Treatment Suspension                | 321 (90.4%)           | 240 (67.0%)          | 304 (85.6%)            |
| Remain Treatment Free at 2 Years after Treatment Suspension | 111 (34.6%)           | 65 (27.1%)           | 43 (14.1%)             |
| Proportion (95% CI)†                                        | 34.6% (29.4%, 40.1%)  | 27.1% (21.6%, 33.2%) | 14.1% (10.4%, 18.6%)   |
| Difference of Proportion (95% CI)‡                          | 7.5% (-0.2%, 15.2%)   |                      | -12.9% (-19.8%, -6.1%) |
| P-value§                                                    | 0.0439                |                      | 0.0004                 |

The data cut-off date is 31 Jan 2023.† Clopper-Pearson exact binomial confidence interval (CI).‡ Proportion in ENZA+LA minus proportion in PBO+LA, or proportion in ENZA minus proportion in PBO+LA. 95% CI is based on Wald type method.§ Pvalue is based on a Cochran-Mantel-Haenszel test stratified by screening PSA, PSADT, and prior hormonal therapy.

## Serum testosterone in safety population

The mean baseline serum testosterone levels were comparable across the 3 treatment groups and in line with the inclusion criteria of the EMBARK protocol for serum testosterone (enzalutamide plus leuprolide: 329.3 ng/dL; placebo plus leuprolide: 329.7 ng/dL; and enzalutamide monotherapy: 316.7 ng/dL).

During therapy, leuprolide-containing groups showed a decrease in mean testosterone serum levels by week 37, whereas the enzalutamide monotherapy group showed an increase in serum testosterone levels (enzalutamide plus leuprolide: 44.5 ng/dL; placebo plus leuprolide: 38.8 ng/d; and enzalutamide monotherapy: 564.5 ng/dL) (Figure 15).

Following treatment suspension, mean serum testosterone level increased on leuprolide-containing groups (enzalutamide plus leuprolide [229.6 ng/dL] and placebo plus leuprolide [218.2 ng/dL] by week 85); in contrast mean serum testosterone level decreased following suspension of enzalutamide monotherapy (407.2 ng/dL [week 61]) (Figure 16). With continued follow-up and increasing numbers of patients undergoing treatment re-initiation mean serum testosterone levels were consistently suppressed in leuprolide containing groups and consistently elevated in enzalutamide monotherapy groups when compared to the respective mean baseline level.

<div style=\"page-break-after: always\"></div>

Figure 15. Mean (95% CI) Testosterone (ng/dL) Levels in Patients by Visit (Safety Population)

<!-- image -->

Study Week

Study Week

351 268 257 250 249 251 243 234 241 231 223 217 210 328 191 164 142 112 97 83 68 49 33 23 294 12 5 278 281 278 273 272 354 253 247 238 232 222 219 213 210 192 193 188 178 329 154 132 107 84 74 62 40 26 22 13 304 8 5 291 286 286 281 266 354 279 268 265 258 243 251 233 234 219 212 203 199 333 182 165 126 103 92 78 60 44 35 22 314 9 5 305 303 296 298 287 ENZA+LA PBO+LA ENZA

The data cut-off date is 31 Jan 2023.

Figure 16. Mean (95%) Testosterone (ng/dL) Levels in Patients by Treatment Arm and Suspension Status by Visit (Safety Population)

<!-- image -->

181

193

205

217

181

193

205

217

Study Week

Study Week

BL

BL

25

37

49

61

73

85

97

109

121

25

37

49

61

73

85

97

109

121

The data cut-off date is 31 Jan 2023.

Proportion of participants with undetectable PSA at 2 years after suspension of study treatment at week 37 due to undetectable PSA

The proportion (95% CI) of patients with undetectable PSA 2 years after treatment suspension at week 37 due to undetectable PSA was 16.8% (95% CI: 12.9%, 21.4%) in the enzalutamide plus leuprolide

133

133

145

145

157

157

169

169

229

229

241

241

253

253

265

265

277

277

289

289

301

301

313

313

325

325

337

337

349

349

361

361

373

373

385

385

<div style=\"page-break-after: always\"></div>

group, 9.6% (95% CI: 6.2%, 14.0%) in the placebo plus leuprolide group, and 4.6% (95% CI: 2.5%, 7.6%) in the enzalutamide monotherapy group [Table 22].

Table 22: Proportion of Patients with Undetectable PSA 2 Years After Suspension of Study Treatment - Other Secondary Efficacy Analysis (ITT Population)

|                                                             | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)       |
|-------------------------------------------------------------|-----------------------|----------------------|----------------------|
| Number of Patients with Treatment Suspension                | 321 (90.4%)           | 240 (67.0%)          | 304 (85.6%)          |
| Remain Treatment-free at 2 Years after Treatment Suspension | 54 (16.8%)            | 23 (9.6%)            | 14 (4.6%)            |
| Proportion (95% CI)†                                        | 16.8% (12.9%, 21.4%)  | 9.6% (6.2%, 14.0%)   | 4.6% (2.5%, 7.6%)    |
| Difference of Proportion (95% CI)‡                          | 7.2% (1.7%, 12.8%)    |                      | -5.0% (-9.4%, -0.6%) |
| P-value§                                                    | 0.0089                |                      | 0.0326               |

The data cut-off date is 31 Jan 2023.† Clopper-Pearson exact binomial confidence interval (CI).‡ Proportion in ENZA+LA minus proportion in PBO+LA, or proportion in ENZA minus proportion in PBO+LA. 95% CI is based on Wald type method.§ P-value is based on a Cochran-Mantel-Haenszel test stratified by screening PSA, PSADT, and prior hormonal therapy.

## Time to resumption of any hormonal therapy

Table 23. Time to Resumption of Any Hormonal Therapy - Other Secondary Efficacy Analysis (ITT Population)

|                                                                               | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)       |
|-------------------------------------------------------------------------------|-----------------------|----------------------|----------------------|
| Number of Patients with Treatment Suspension                                  | 321 (90.4%)           | 240 (67.0%)          | 304 (85.6%)          |
| Status of Time to Resumption of any Hormonal Therapy                          |                       |                      |                      |
| Event†                                                                        | 256 (79.8%)           | 217 (90.4%)          | 279 (91.8%)          |
| Censored‡                                                                     | 65 (20.2%)            | 23 (9.6%)            | 25 (8.2%)            |
| Time to Resumption of any Hormonal Therapy Based on K-M Estimates (in Months) |                       |                      |                      |
| n                                                                             | 321                   | 240                  | 304                  |
| 25th Percentile                                                               | 13.9                  | 11.5                 | 6.0                  |
| Median (95% CI)                                                               | 19.6 (17.2, 22.3)     | 16.8 (14.3, 17.1)    | 10.5 (8.9, 11.5)     |
| 75th Percentile                                                               | 36.6                  | 25.6                 | 17.3                 |
| P-value§                                                                      | < 0.0001              |                      | < 0.0001             |
| Hazard Ratio (95% CI)§                                                        | 0.693 (0.577, 0.834)  |                      | 1.655 (1.381, 1.984) |
| Probability of Being Event Free Based on K-M Estimates at:                    |                       |                      |                      |

<div style=\"page-break-after: always\"></div>

|                                                                            | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)       |
|----------------------------------------------------------------------------|-----------------------|----------------------|----------------------|
| Year 1 (95% CI)                                                            | 0.764 (0.713, 0.807)  | 0.695 (0.632, 0.749) | 0.383 (0.328, 0.438) |
| Year 2 (95% CI)                                                            | 0.395 (0.341, 0.449)  | 0.282 (0.226, 0.340) | 0.156 (0.117, 0.200) |
| Year 3 (95% CI)                                                            | 0.275 (0.226, 0.327)  | 0.136 (0.096, 0.184) | 0.084 (0.056, 0.119) |
| Observed Follow-up Time for Censored Patients¶ (in Months)                 |                       |                      |                      |
| n                                                                          | 65                    | 23                   | 25                   |
| 25th Percentile                                                            | 27.5                  | 46.6                 | 6.0                  |
| Median                                                                     | 50.2                  | 52.6                 | 52.6                 |
| 75th Percentile                                                            | 60.8                  | 63.3                 | 57.9                 |
| Min, Max                                                                   | 0.95, 85.82           | 5.45, 82.83          | 0.03, 77.08          |
| Follow-up Time Based on Reverse K-M Estimates for All Patients (in Months) |                       |                      |                      |
| n                                                                          | 321                   | 240                  | 304                  |
| 25th Percentile                                                            | 49.4                  | 52.4                 | 52.7                 |
| Median (95% CI)                                                            | 55.0 (52.5, 60.8)     | 55.6 (52.6, 63.5)    | 55.3 (52.9, 63.8)    |
| 75th Percentile                                                            | 69.0                  | 66.2                 | 66.7                 |

The data cut-off date is 31 Jan 2023.

NR = Not Reached.The time to resumption of any hormonal therapy is defined as the time between the date of treatment suspension at week 37 due to undetectable PSA and the date that hormonal therapy is restarted.†

Based on the hormonal therapy restarted after treatment suspension at week 37 due to undetectable PSA‡Patients without observed re sumption of any hormonal therapy at the time of analysis will be censored at the date of last visit.§ Two-sided P-value is based on a stratified log-rank test by screening PSA, PSADT, and prior hormonal therapy. Hazard ratio is based on a Cox regression model stratified by factors defined above and is relative to PBO+LA with &lt; 1 favoring ENZA+LA and PBO+LA with &lt; 1 favoring ENZA.¶Calculated as (date of last assessment with out resumption of any hormonal therapy prior to analysis data cutoff date - randomization date + 1) / 30.4375.

<div style=\"page-break-after: always\"></div>

Figure 17. K-M Curves for Time to Resumption of any Hormonal Therapy for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups - Other Secondary Efficacy Analysis (ITT Population)

<!-- image -->

Figure 18. K-M Curves for Time to Resumption of any Hormonal Therapy for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups - Other Secondary Efficacy Analysis (ITT Population)

<!-- image -->

## Time to castration resistance

<div style=\"page-break-after: always\"></div>

A total of 14 (3.9%) patients in the enzalutamide plus leuprolide group and 120 (33.5%) patients in the placebo plus leuprolide group developed castration resistance as of the data cut-off date.

Table 24. Time to Castration Resistance for Patients Receiving Leuprolide Treatment - Other Secondary Efficacy Analysis (ITT Population)

|                                                                            | ENZA + LA (N = 355)   | PBO + LA (N = 358)   |
|----------------------------------------------------------------------------|-----------------------|----------------------|
| Status of Time to Castration Resistance                                    |                       |                      |
| Event†                                                                     | 14 (3.9%)             | 120 (33.5%)          |
| Censored                                                                   | 341 (96.1%)           | 238 (66.5%)          |
| Time to Castration Resistance Based on K-M Estimates (in Months)           |                       |                      |
| n                                                                          | 355                   | 358                  |
| 25th Percentile                                                            | NR                    | 46.9                 |
| Median (95% CI)                                                            | NR (NR, NR)           | NR (NR, NR)          |
| 75th Percentile                                                            | NR                    | NR                   |
| p-value‡                                                                   | < 0.0001              |                      |
| Hazard Ratio (95% CI)‡                                                     | 0.090 (0.051, 0.157)  |                      |
| Probability of Being Event Free Based on K-M Estimates at:                 |                       |                      |
| Year 1 (95% CI)                                                            | 0.997 (0.980, 1.000)  | 0.960 (0.933, 0.976) |
| Year 2 (95% CI)                                                            | 0.988 (0.969, 0.996)  | 0.890 (0.852, 0.919) |
| Year 3 (95% CI)                                                            | 0.985 (0.965, 0.994)  | 0.821 (0.776, 0.858) |
| Observed Follow-up Time for Censored Patients§ (in Months)                 |                       |                      |
| n                                                                          | 341                   | 238                  |
| 25th Percentile                                                            | 55.4                  | 55.3                 |
| Median                                                                     | 63.5                  | 63.3                 |
| 75th Percentile                                                            | 74.2                  | 71.9                 |
| Min, Max                                                                   | 0.03, 94.13           | 0.03, 93.90          |
| Follow-up Time Based on Reverse K-M Estimates for All Patients (in Months) |                       |                      |
| n                                                                          | 355                   | 358                  |
| 25th Percentile                                                            | 55.4                  | 57.8                 |
| Median (95% CI)                                                            | 63.5 (61.4, 66.1)     | 63.5 (63.2, 66.3)    |
| 75th Percentile                                                            | 74.4                  | 74.3                 |

The data cut-off date is 31 Jan 2023.NR = Not Reached.† Based on the first occurrence of radiographic disease progression by BICR, PSA progression, or SSE whichever occurs first with castrate levels of testosterone (&lt; 50 ng/dL).‡ Two-sided P-value is based on a

<div style=\"page-break-after: always\"></div>

stratified log-rank test by screening PSA, PSADT, and prior hormonal therapy. Hazard ratio is based on a Cox regression model stratified by factors defined above and is relative to PBO+LA with &lt; 1 favoring ENZA+LA.§ Calculated as (date of last assessment showing no evidence of castration resistance prior to analysis data cutoff date - randomization date + 1) / 30.4375.

Figure 19. K-M Curves for Time to Castration Resistance for Participants Receiving Leuprolide Treatment - Other Secondary Efficacy Analysis (ITT Population)

<!-- image -->

## Time to symptomatic progression

Table 25. Time to Symptomatic Progression - Other Secondary Efficacy Analysis (ITT Population)

|                                                                    | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)   |
|--------------------------------------------------------------------|-----------------------|----------------------|------------------|
| Status of Time to Symptomatic Progression                          |                       |                      |                  |
| Events†                                                            | 104 (29.3%)           | 169 (47.2%)          | 117 (33.0%)      |
| New Systemic Antineoplastic Therapy                                | 46 (13.0%)            | 115 (32.1%)          | 77 (21.7%)       |
| Opiate Use                                                         | 52 (14.6%)            | 43 (12.0%)           | 35 (9.9%)        |
| Skeletal-related Event                                             | 6 (1.7%)              | 11 (3.1%)            | 5 (1.4%)         |
| Censored                                                           | 251 (70.7%)           | 189 (52.8%)          | 238 (67.0%)      |
| No first symptomatic Progression - last visit date                 | 250 (70.4%)           | 187 (52.2%)          | 237 (66.8%)      |
| No first symptomatic Progression - Randomization date              | 1 (0.3%)              | 2 (0.6%)             | 1 (0.3%)         |
| Time to Symptomatic Progression based on K-M Estimates (in Months) |                       |                      |                  |
| n                                                                  | 355                   | 358                  | 355              |
| 25th Percentile                                                    | 52.5                  | 34.1                 | 44.2             |
| Median (95% CI)                                                    | NR (NR, NR)           | 63.8 (56.4, 74.9)    | NR (83.6, NR)    |

<div style=\"page-break-after: always\"></div>

|                                                                            | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)       |
|----------------------------------------------------------------------------|-----------------------|----------------------|----------------------|
| 75th Percentile                                                            | NR                    | NR                   | NR                   |
| p-value‡                                                                   | < 0.0001              |                      | < 0.0001             |
| Hazard Ratio (95% CI)‡                                                     | 0.546 (0.427, 0.699)  |                      | 0.619 (0.488, 0.785) |
| Probability of Being Event Free Based on K-M Estimates at:                 |                       |                      |                      |
| Year 1 (95% CI)                                                            | 0.945 (0.916, 0.965)  | 0.934 (0.903, 0.956) | 0.960 (0.934, 0.976) |
| Year 2 (95% CI)                                                            | 0.877 (0.837, 0.908)  | 0.839 (0.795, 0.873) | 0.867 (0.826, 0.898) |
| Year 3 (95% CI)                                                            | 0.813 (0.767, 0.851)  | 0.730 (0.680, 0.774) | 0.778 (0.730, 0.819) |
| Observed Follow-up Time for Censored Patients§ (in Months)                 |                       |                      |                      |
| n                                                                          | 251                   | 189                  | 238                  |
| 25th Percentile                                                            | 55.4                  | 55.2                 | 57.9                 |
| Median                                                                     | 63.5                  | 61.8                 | 63.5                 |
| 75th Percentile                                                            | 72.1                  | 71.8                 | 74.4                 |
| Min, Max                                                                   | 0.03, 94.13           | 0.03, 93.90          | 0.03, 93.90          |
| Follow-up Time Based on Reverse K-M Estimates for All Patients (in Months) |                       |                      |                      |
| n                                                                          | 355                   | 358                  | 355                  |
| 25th Percentile                                                            | 57.9                  | 58.0                 | 58.0                 |
| Median (95% CI)                                                            | 63.7 (63.5, 66.3)     | 63.6 (63.4, 66.5)    | 63.6 (63.5, 66.4)    |
| 75th Percentile                                                            | 74.5                  | 74.3                 | 74.6                 |

The data cut-off date is 31 Jan 2023.NR = Not Reached.† Based on the earliest contributing event (skeletal-related event, new systemic antineoplastic therapy, opiate use, surgical intervention or radiation therapy).‡ Two-sided P-value is based on a stratified log-rank test by screening PSA, PSADT, and prior hormonal therapy. Hazard ratio is based on a Cox regression model stratified by factors defined above and is relative to PBO+LA with &lt; 1 favoring ENZA+LA and PBO+LA with &lt; 1 favoring ENZA.

§Calculated as (date of last assessment showing no symptomatic progression prior to analysis data cutoff date - randomization date + 1 ) / 30.4375.

<div style=\"page-break-after: always\"></div>

Figure 20. K-M Curves for Time to Symptomatic Progression for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups - Other Secondary Efficacy Analysis (ITT Population)

<!-- image -->

<!-- image -->

The datacut-off date is31JAN2023.

Note:TwosidedP-value isbasedonastratified log-ranktest byscreeningPSA,PSAdoubling time,andpriorhomonal therapy asperIWRS. HazardratioisbasedonaCoxregressionmodel(withtreatmentastheonlycovariate)stratifiedbyfactorsdefinedabove，andisrelativetoPBO+LAwith&lt;1favoringENZA+LA. PFIZER CONFIDENTIAL Source:lin78 /Volumes/data/usrfiles/programming/mdv3100/mdv3100\\_13/csriprod/programs/lf\\_14\\_02\\_03\\_07\\_01\\_ttsympd.sas 12APR23:19:37 Output File:f\\_14\\_02\\_03\\_07\\_01\\_tsympd.rtf

Figure 21. K-M Curves for Time to Symptomatic Progression for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups - Other Secondary Efficacy Analysis (ITT Population)

<!-- image -->

## Time to first symptomatic skeletal event

Table 26. Time to First SSE - Other Secondary Efficacy Analysis (ITT Population)

|                                              | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)   |
|----------------------------------------------|-----------------------|----------------------|------------------|
| Status of Time to Symptomatic Skeletal Event |                       |                      |                  |

<div style=\"page-break-after: always\"></div>

|                                                                       | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)       |
|-----------------------------------------------------------------------|-----------------------|----------------------|----------------------|
| Events†                                                               | 9 (2.5%)              | 32 (8.9%)            | 14 (3.9%)            |
| Radiation Therapy to Bone                                             | 3 (0.8%)              | 14 (3.9%)            | 5 (1.4%)             |
| Surgery to Bone                                                       | 0 (0.0%)              | 1 (0.3%)             | 0 (0.0%)             |
| Pathological Bone Fracture                                            | 5 (1.4%)              | 2 (0.6%)             | 3 (0.8%)             |
| Spinal Cord Compression                                               | 0 (0.0%)              | 2 (0.6%)             | 1 (0.3%)             |
| Initiation/Change of Antineoplastic Therapy to treat Bone Pain        | 0 (0.0%)              | 0 (0.0%)             | 0 (0.0%)             |
| Opiate use due to Bone Pain                                           | 1 (0.3%)              | 12 (3.4%)            | 5 (1.4%)             |
| Censored                                                              | 346 (97.5%)           | 326 (91.1%)          | 341 (96.1%)          |
| No First Symptomatic Skeletal Event - Last Visit Date                 | 345 (97.2%)           | 324 (90.5%)          | 340 (95.8%)          |
| No First Symptomatic Skeletal Event - Randomization date              | 1 (0.3%)              | 2 (0.6%)             | 1 (0.3%)             |
| Time to Symptomatic Skeletal Event Based on K-M Estimates (in Months) |                       |                      |                      |
| n                                                                     | 355                   | 358                  | 355                  |
| 25th Percentile                                                       | NR                    | NR                   | NR                   |
| Median (95% CI)                                                       | NR (NR, NR)           | NR (NR, NR)          | NR (NR, NR)          |
| 75th Percentile                                                       | NR                    | NR                   | NR                   |
| p-value‡                                                              | 0.0001                |                      | 0.0057               |
| Hazard Ratio (95% CI)‡                                                | 0.261 (0.125, 0.548)  |                      | 0.423 (0.226, 0.794) |
| Probability of Being Event Free Based on K-M Estimates at:            |                       |                      |                      |
| Year 1 (95% CI)                                                       | 0.997 (0.980, 1.000)  | 0.991 (0.973, 0.997) | 0.997 (0.980, 1.000) |
| Year 2 (95% CI)                                                       | 0.991 (0.973, 0.997)  | 0.977 (0.954, 0.988) | 0.994 (0.977, 0.999) |
| Year 3 (95% CI)                                                       | 0.988 (0.969, 0.996)  | 0.962 (0.935, 0.978) | 0.982 (0.961, 0.992) |
| Observed Follow-up Time for Censored Patients§ (in Months)            |                       |                      |                      |
| n                                                                     | 346                   | 326                  | 341                  |
| 25th Percentile                                                       | 55.4                  | 55.4                 | 55.3                 |
| Median                                                                | 63.5                  | 63.5                 | 63.5                 |

<div style=\"page-break-after: always\"></div>

|                                                                            | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)    |
|----------------------------------------------------------------------------|-----------------------|----------------------|-------------------|
| 75th Percentile                                                            | 74.2                  | 74.4                 | 72.3              |
| Min, Max                                                                   | 0.03, 94.13           | 0.03, 93.90          | 0.03, 93.90       |
| Follow-up Time Based on Reverse K-M Estimates for All Patients (in Months) |                       |                      |                   |
| n                                                                          | 355                   | 358                  | 355               |
| 25th Percentile                                                            | 55.4                  | 55.6                 | 55.3              |
| Median (95% CI)                                                            | 63.5 (61.4, 66.1)     | 63.5 (61.8, 66.1)    | 63.5 (61.2, 63.6) |
| 75th Percentile                                                            | 74.4                  | 74.4                 | 72.4              |

The data cut-off date is 31 Jan 2023.

NR = Not Reached.† Based on first symptomatic skeletal event in CRF form‡ Two-sided P-value is based on a stratified log-rank test by screening PSA, PSADT, and prior hormonal therapy. Hazard ratio is based on a Cox regression model stratified by factors defined above and is relative to PBO+LA with &lt; 1 favoring ENZA+LA and PBO+LA with &lt; 1 favoring ENZA.§Calculated as (date of last assessment sho wing no symptomatic skeletal event prior to analysis data cutoff date - randomization date + 1) / 30.4375.

Figure 22. K-M Curves for Time to First SSE for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups - Other Secondary Efficacy Analysis (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 23. K-M Curves for Time to First SSE for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups - Other Secondary Efficacy Analysis (ITT Population)

<!-- image -->

ENZA: Event/Cum.Events 0/00/01/10/10/10/10/10/11/21/31/42/60/61/72/90/90/91/101/111/121/131/140/140/140/140/140/140/140/140/140/140/140/14 Patients at Risk 35535335235134534133933833733232932431630930129229028627724622117714511490624730158 3 PBO+LA: Event/Cum.Events 0/00/01/11/21/31/42/61/71/82/101/112/130/131/144/180/181/192/214/252/270/272/291/301/311/320/320/320/320/320/320/320/320/32 Patients at Risk 358352347344341339337335330322317313308303293292286281269241213179145118886242271510410

Thedatacut-offdateis31JAN2023.

Note:TwosidedP-value isbasedona stratified log-ranktest byscreeningPSA,PSA doubling time,andpriorhomonal therapy asperIWRS. HazardratioisbasedonaCoxregressionmodel(with treatmentastheonlycovariate)stratified byfactors definedaboveandisrelative toPBO+LAwith1favoring ENZA. PFIZER CONFIDENTIAL Source: lin78 /Volumes/data/usrfiles/programming/mdv3100/mdv3100\\_13/csr/prod/programs/liff\\_14\\_02\\_03\\_08\\_02\\_tse.sas 12APR23:19:37 Output File: f\\_14\\_02\\_03\\_08\\_02\\_ttsse.rtf

## Exploratory endpoint

## PFS2

Table 27. PFS2 Based on Investigator Review - Exploratory Endpoint Analysis (ITT Population)

|                                         | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)   |
|-----------------------------------------|-----------------------|----------------------|------------------|
| Status of PFS2 Follow-up                |                       |                      |                  |
| Events†                                 | 36 (10.1%)            | 63 (17.6%)           | 48 (13.5%)       |
| Progression by investigator             | 8 (2.3%)              | 18 (5.0%)            | 17 (4.8%)        |
| PSA Progression                         | 4 (1.1%)              | 6 (1.7%)             | 5 (1.4%)         |
| Progression by Imaging                  | 3 (0.8%)              | 12 (3.4%)            | 8 (2.3%)         |
| Clinical Progression                    | 1 (0.3%)              | 0 (0.0%)             | 4 (1.1%)         |
| Death                                   | 28 (7.9%)             | 45 (12.6%)           | 31 (8.7%)        |
| Censored‡                               | 319 (89.9%)           | 295 (82.4%)          | 307 (86.5%)      |
| No Metastatic Disease or Death          | 293 (82.5%)           | 235 (65.6%)          | 282 (79.4%)      |
| Start of New Antineoplastic Therapy     | 2 (0.6%)              | 7 (2.0%)             | 6 (1.7%)         |
| Withdrawal of Consent                   | 1 (0.3%)              | 4 (1.1%)             | 3 (0.8%)         |
| Lost to Follow-up                       | 0 (0.0%)              | 0 (0.0%)             | 0 (0.0%)         |
| Ongoing Without PFS2 Event              | 23 (6.5%)             | 49 (13.7%)           | 16 (4.5%)        |
| PFS2 Based on K-M Estimates (in Months) |                       |                      |                  |

<div style=\"page-break-after: always\"></div>

|                                                            | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)       |
|------------------------------------------------------------|-----------------------|----------------------|----------------------|
| n                                                          | 355                   | 358                  | 355                  |
| 25th Percentile                                            | 86.7                  | 75.0                 | NR                   |
| Median (95% CI)                                            | NR (NR, NR)           | NR (NR, NR)          | NR (NR, NR)          |
| 75th Percentile                                            | NR                    | NR                   | NR                   |
| P-value§                                                   | 0.0016                |                      | 0.1121               |
| Hazard Ratio (95% CI)§                                     | 0.521 (0.345, 0.786)  |                      | 0.739 (0.507, 1.077) |
| Probability of Being Event Free Based on K-M Estimates at: |                       |                      |                      |
| Year 1 (95% CI)                                            | 0.997 (0.979, 1.000)  | 0.988 (0.970, 0.996) | 0.997 (0.980, 1.000) |
| Year 2 (95% CI)                                            | 0.976 (0.953, 0.988)  | 0.974 (0.950, 0.986) | 0.991 (0.973, 0.997) |
| Year 3 (95% CI)                                            | 0.973 (0.949, 0.986)  | 0.934 (0.901, 0.956) | 0.960 (0.932, 0.977) |
| Observed Follow-up Time for Censored Patients¶ (in Months) |                       |                      |                      |
| n                                                          | 319                   | 295                  | 307                  |
| 25th Percentile                                            | 55.1                  | 55.0                 | 55.1                 |
| Median                                                     | 60.8                  | 60.7                 | 60.8                 |
| 75th Percentile                                            | 71.8                  | 71.8                 | 71.7                 |
| Min, Max                                                   | 0.03, 94.13           | 0.03, 93.90          | 0.03, 88.48          |

The data cut-off date is 31 Jan 2023.NR = Not Reached.† Based on the earliest contributing event after first PD (investigator assessed clinical progression, radiographic progression or PSA progression) or death due to any cause, whichever occurred first.‡ Patients who do not meet event criteria are censored based on hierarchy in SAP§ Two-sided P-value is based on a stratified log-rank test by screening PSA, PSADT, and prior hormonal therapy. Hazard ratio is based on a Cox regression model stratified by factors defined above and is relative to PBO+LA with &lt; 1 favoring ENZA+LA and PBO+LA with &lt; 1 favoring ENZA.¶ Calculated as (date of censoring - randomization date + 1) / 30.4375.

<div style=\"page-break-after: always\"></div>

Figure 24. K-M Curves for PFS2 Based on Investigator Review for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups - Exploratory Endpoint Analysis (ITT Population)

<!-- image -->

Figure 25. K-M Curves for PFS2 Based on Investigator Review for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups - Exploratory Endpoint Analysis (ITT Population)

<!-- image -->

## Efficacy results related to PROs and Quality of Life

## Time to clinically relevant pain progression

Time to clinically relevant pain progression was defined as the time from randomization to onset of pain progression, where pain progression is defined as a 2-point or more increase from baseline in the BPI-SF question 3 score.

<div style=\"page-break-after: always\"></div>

A total of 228 (64.2%) patients in the enzalutamide plus leuprolide group, 217 (60.6%) patients in the placebo plus leuprolide group, and 229 (64.5%) patients in the enzalutamide monotherapy group had clinically relevant pain progression as of the data cutoff date (Table 28).

Table 28. Time to Clinically Relevant Pain Progression - PRO Efficacy Analysis (ITT Population)

|                                                                                 | ENZA + LA (N = 355)       | PBO + LA (N = 358)   | ENZA (N = 355)             |
|---------------------------------------------------------------------------------|---------------------------|----------------------|----------------------------|
| Status of Clinically Relevant Pain Progression                                  |                           |                      |                            |
| Event†                                                                          | 228 (64.2%)               | 217 (60.6%)          | 229 (64.5%)                |
| Censored                                                                        | 127 (35.8%)               | 141 (39.4%)          | 126 (35.5%)                |
| Time to Clinically Relevant Pain Progression Based on K-M Estimates (in Months) |                           |                      |                            |
| n                                                                               | 355                       | 358                  | 355                        |
| 25th Percentile                                                                 | 5.6                       | 5.6                  | 5.6                        |
| Median (95% CI)                                                                 | 13.9 (11.9, 19.4)         | 19.4 (13.8, 24.9)    | 16.6 (12.3, 19.4)          |
| 75th Percentile                                                                 | 77.3                      | NR                   | 63.7                       |
| P-value‡                                                                        | 0.4321                    |                      | 0.3702                     |
| Hazard Ratio (95% CI)‡                                                          | 1.078 (0.894, 1.301)      |                      | 1.090 (0.904, 1.314)       |
| Probability of Being Event Free Based on K-M Estimates at:                      |                           |                      |                            |
| Year 1 (95% CI)                                                                 | 0.553 (0.496, 0.606)0.573 | (0.517,              | 0.625)0.555 (0.499, 0.608) |
| Year 2 (95% CI)                                                                 | 0.417 (0.361,             | 0.471)0.457 (0.401,  | 0.511)0.410 (0.355, 0.463) |
| Year 3 (95% CI)                                                                 | 0.352 (0.299,             | 0.406)0.374 (0.320,  | 0.428)0.341 (0.288, 0.394) |
| Observed Follow-up Time for Censored Patients§ (in Months)                      |                           |                      |                            |
| n                                                                               | 127                       | 141                  | 126                        |
| 25th Percentile                                                                 | 0.0                       | 5.8                  | 3.9                        |
| Median                                                                          | 52.4                      | 52.7                 | 49.7                       |
| 75th Percentile                                                                 | 66.2                      | 66.3                 | 63.2                       |
| Min, Max                                                                        | 0.03, 88.34               | 0.03, 91.37          | 0.03, 91.24                |
| Follow-up Time Based on Reverse K-M Estimates for All Patients (in Months)      |                           |                      |                            |
| n                                                                               | 355                       | 358                  | 355                        |
| 25th Percentile                                                                 | 45.8                      | 41.4                 | 44.2                       |
| Median (95% CI)                                                                 | 59.4 (57.9, 63.5)         | 59.4 (57.9, 63.5)    | 58.0 (55.3, 60.8)          |
| 75th Percentile                                                                 | 71.8                      | 73.5                 | 69.0                       |

The data cut-off date is 31 Jan 2023.

<div style=\"page-break-after: always\"></div>

NR = Not Reached.† Clinically relevant pain progression is defined as a 2-point or greater increase from baseline in the BPISF question 3.‡ Two-sided P-value is based on a stratified log-rank test by screening PSA, PSADT, and prior hormonal therapy. Hazard ratio is based on a Cox regression model stratified by factors defined above and is relative to PBO+LA with &lt; 1 favoring ENZA+LA and PBO+LA with &lt; 1 favoring ENZA.§ Calculated as (date of last pain assessment prior to analysis data cutoff date - randomization date + 1) / 30.4375.

Figure 26. K-M Curves for Time to Clinically Relevant Pain Progression for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups - Other Secondary Efficacy Analysis (ITT Population)

<!-- image -->

Hazand ratio is based on a Cox regressin n model (with treatment as the onhy cnvariste) strstified by factars defined sbove, andis relstive to PBO +LA with ≤ 1 favaring ENzA+LA .

Note: Two sided P-value is based on a stratified log-rankc best by soeening P SA, PSA doubling time, and prior hormmonal therapy as per IVRS.

Figure 27: K-M Curves for Time to Clinically Relevant Pain Progression for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups - Other Secondary Efficacy Analysis (ITT Population)

<!-- image -->

<!-- image -->

The data cut-off date is 31JAN2023.

Hazard ratio is based on a Cox regressin n model (with tre atment as the only covariate) stratified by factars defined above , andis relative to PB O +LA mith ≤ 1 favoring ENZA.

Nate: Two sided P-vslue is bssed on a stratified Iog-rark test by sureening P'SA, PSA doubling time, and prior hormanal therapy as per IVVRS,

## Time to deterioration in FACT-P Total Score

<div style=\"page-break-after: always\"></div>

The time to deterioration of the FACT-P total score was defined as the time from randomization to first assessment with at least a 10-point decrease from baseline in the FACT-P total score for each patient.

A total of 257 (72.4%) patients in the enzalutamide plus leuprolide group, 248 (69.3%) patients in the placebo plus leuprolide group, and 263 (74.1%) patients in the enzalutamide monotherapy group had first deterioration in FACT-P total score as of the data cutoff date (Table 29)

Table 29. Time to First Deterioration of the FACT-P Total Score - PRO Efficacy Analysis (ITT Population)

|                                                                          | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)       |
|--------------------------------------------------------------------------|-----------------------|----------------------|----------------------|
| Status of First Deterioration of FACT-P                                  |                       |                      |                      |
| Event†                                                                   | 257 (72.4%)           | 248 (69.3%)          | 263 (74.1%)          |
| Censored‡                                                                | 98 (27.6%)            | 110 (30.7%)          | 92 (25.9%)           |
| Time to First Deterioration of FACT-P Based on K-M Estimates (in Months) |                       |                      |                      |
| n                                                                        | 355                   | 358                  | 355                  |
| 25th Percentile                                                          | 2.9                   | 5.4                  | 2.9                  |
| Median (95% CI)                                                          | 8.3 (5.7, 11.1)       | 11.1 (8.3, 14.0)     | 8.4 (5.8, 13.0)      |
| 75th Percentile                                                          | 44.1                  | 52.7                 | 38.8                 |
| P-value§                                                                 | 0.1567                |                      | 0.0855               |
| Hazard Ratio (95% CI)§                                                   | 1.138 (0.954, 1.357)  |                      | 1.168 (0.981, 1.391) |
| Probability of Being Event Free Based on K- M Estimates at:              |                       |                      |                      |
| Year 1 (95% CI)                                                          | 0.414 (0.359, 0.467)  | 0.482 (0.426, 0.535) | 0.450 (0.395, 0.503) |
| Year 2 (95% CI)                                                          | 0.340 (0.288, 0.392)  | 0.353 (0.302, 0.406) | 0.340 (0.288, 0.392) |
| Year 3 (95% CI)                                                          | 0.282 (0.233, 0.333)  | 0.291 (0.242, 0.341) | 0.266 (0.218, 0.316) |
| Observed Follow-up Time for Censored Patients¶ (in Months)               |                       |                      |                      |
| n                                                                        | 98                    | 110                  | 92                   |
| 25th Percentile                                                          | 0.0                   | 0.8                  | 0.0                  |
| Median                                                                   | 46.9                  | 51.1                 | 35.1                 |
| 75th Percentile                                                          | 63.4                  | 63.5                 | 60.8                 |
| Min, Max                                                                 | 0.03, 88.34           | 0.03, 93.90          | 0.03, 85.52          |

<div style=\"page-break-after: always\"></div>

|                                                                            | ENZA + LA (N = 355)   | PBO + LA (N = 358)   | ENZA (N = 355)    |
|----------------------------------------------------------------------------|-----------------------|----------------------|-------------------|
| Follow-up Time Based on Reverse K-M Estimates for All Patients (in Months) |                       |                      |                   |
| n                                                                          | 355                   | 358                  | 355               |
| 25th Percentile                                                            | 49.7                  | 41.4                 | 44.0              |
| Median (95% CI)                                                            | 60.8 (58.0, 63.7)     | 60.7 (58.2, 63.4)    | 60.7 (55.9, 63.5) |
| 75th Percentile                                                            | 71.8                  | 71.8                 | 71.8              |

The data cut-off date is 31 Jan 2023.NR = Not Reached.† Deterioration of FACT-

P is defined as at least 10 point decrease from baseline for the total score.‡ Patients who have not had deterioration at the time of analysis data cutoff are censored at date of last assessment showing no deterioration. Patients with no baseline or postbaseline score assessments are censored at randomization.§ Two-sided P-value is based on a stratified log-rank test by screening PSA, PSADT, and prior hormonal therapy. Hazard ratio is based on a Cox regression model stratified by factors defined above and is relative to PBO+LA with &lt; 1 favoring ENZA+LA and PBO+LA with &lt; 1 favoring ENZA.¶

Calculated as (date of last assessment prior to analysis data cutoff date - randomization date + 1) / 30.4375.

Figure 28. K-M Curves for Time to Deterioration of the FACT-P Total Score for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups (ITT Population)

<!-- image -->

<!-- image -->

The data cut-off dale s 31JAk2D23.

Y+f2Na fujioae, L &gt; im ++DBa 0q awqeeuisi pue exoqe peuyapisiopej Aq peuleps (aqep es no.ljio aq se jueureaq yw) (epou uo ssaiDeu soe uo paseq si 0pej pue2eH

Note: Twa sided P-va lue is based on a strotf ied Iog- Rank test by rcreen ing PsA, PSA doua ling time, and arigr homonal theropy' as per TvVF5.

<div style=\"page-break-after: always\"></div>

Figure 29. K-M Curves for Time to First Deterioration of the FACT-P Total Score for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups (ITT Population)

<!-- image -->

The data cut-off dnte is 31.LAk20 23

Nate: Twa sided P-value is based on a stnairied log-ranktest by scree ning PSA, PSA doub ing time, arne prior hormonal therap y as per IvVRS. Hazard ratio is based on a Ceox regressi on mo de [wifl treatmert as the orly oorvariate] stfratified by fesctors defineel abo ve, and is relative to PBO+LA will -c 1 fevo iing ENZA.

## Ancillary analyses

## Subgroup analyses

Figure 30. Forest Plot for MFS by BICR for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups - Primary Efficacy Subgroup Analysis (ITT Population)

| Subgroup                                                   | ENZA+LA / PBO+LA Number of Patients   | ENZA+LA / PBO+LA Number of Events   | Hazard Ratio for MFS                       | (95% CI)            |
|------------------------------------------------------------|---------------------------------------|-------------------------------------|--------------------------------------------|---------------------|
| All Patients                                               | 355 / 358                             | 45 / 92                             |                                            | 0.424 (0.296,0.607) |
| PSA DoublingTime(<=3 Months)                               | 69 / 80                               | 14 / 30                             |                                            | 0.461 (0.242,0.875) |
| PSA DoublingTime(>3 to <=6 Months)                         | 187 / 142                             | 18 / 35                             |                                            | 0.331 (0.187,0.585) |
| PSA DoublingTime(>6 to <=9 Months)                         | 98 / 135                              | 13 / 27                             |                                            | 0.628 (0.324,1.218) |
| BaselineUseof aBoneTargetingAgent (No)                     | 355 / 358                             | 45 / 92                             |                                            | 0.427 (0.299,0.610) |
| Baseline AgeCategory (<65 Years)                           | 81 / 91                               | 11 / 28                             |                                            | 0.402 (0.200,0.809) |
| Baseline AgeCategory (>=65 Years)                          | 274 / 267                             | 34 / 64                             |                                            | 0.441 (0.291,0.668) |
| Race(White)                                                | 293 / 301                             | 37 / 75                             |                                            | 0.434 (0.293,0.644) |
| Body MassIndex Calculatedfrom Height and Weight (<=Median) | 173 / 179                             | 21 / 39                             |                                            | 0.523 (0.308,0.890) |
| Body MassIndex Calculatedfrom Height andWeight (>Median)   | 180 / 175                             | 24 / 53                             |                                            | 0.347 (0.214,0.563) |
| ECOGPerformanceS tatusat Baseline (0)                      | 328 / 336                             | 39 / 87                             |                                            | 0.394 (0.270,0.575) |
| Geographic Region (North America)                          | 144 / 137                             | 22 / 32                             |                                            | 0.618 (0.358,1.064) |
| Geographic Region (Europe)                                 | 130 / 128                             | 14 / 33                             |                                            | 0.351 (0.188,0.657) |
| Total Gleason Score at Baseline (<=7) at Diagnosis         | 234 / 244                             | 25 / 61                             |                                            | 0.385 (0.242,0.614) |
| Total Gleason Score at Baseline (>=8) at Diagnosis         | 120 / 113                             | 20 / 30                             |                                            | 0.501 (0.284,0.883) |
| Prior Hormonal Therapy (Yes)                               | 107 / 113                             | 19 / 34                             |                                            | 0.482 (0.275,0.847) |
| Prior Hormonal Therapy (No)                                | 248 / 245                             | 26 / 58                             |                                            | 0.393 (0.247,0.624) |
| Prior Radiation Therapy (Yes)                              | 265 / 283                             | 37 / 76                             |                                            | 0.447 (0.301,0.662) |
| Prior Prostatectomy (Yes)                                  | 269 / 254                             | 26 / 61                             |                                            | 0.363 (0.230,0.575) |
| Prior Prostatectomy (No)                                   | 86 / 104                              | 19 / 31                             |                                            | 0.565 (0.319,1.001) |
| History of Cardiovascular Disease (No)                     | 313 / 316                             | 38 / 81                             |                                            | 0.409 (0.278,0.601) |
| PSA Value at Baseline (<=10 ng/mL)                         | 278 / 273                             | 31 / 64                             |                                            | 0.419 (0.272,0.643) |
| PSA Value at Baseline (>10 ng/mL)                          | 77 / 83                               | 14 / 28                             |                                            | 0.448 (0.235,0.851) |
|                                                            |                                       |                                     | 0.0 0.5 1.0 1.5 FavorsENZA+LA FavorsPBO+LA |                     |

The data cut-off date is 31 Jan 2023.If the subgroups are too small (&lt; 10 events), the analyses would not be provided.Hazard ratio and its 95% CI for subgroups are based on unstratified Cox regression model. Hazard ratio and its 95% CI for all patients are based on a stratified Cox regression model stratified by randomization stratification factors.

<div style=\"page-break-after: always\"></div>

Figure 31. Forest Plot for MFS by BICR for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups - Key Secondary Subgroup Analysis (ITT Population)

<!-- image -->

| Subgroup                                                   | ENZA / PBO+LA Number of Patients   | ENZA / PBO+LA Number of Events   | Hazard Ratio for MFS   | (95% CI)            |
|------------------------------------------------------------|------------------------------------|----------------------------------|------------------------|---------------------|
| All Patients                                               | 355 / 358                          | 63 / 92                          |                        | 0.631 (0.456,0.871) |
| PSA DoublingTime(<=3 Months)                               | 76 / 80                            | 24 / 30                          |                        | 0.792 (0.460,1.365) |
| PSA DoublingTime(>3 to <=6 Months)                         | 164 / 142                          | 24 / 35                          |                        | 0.523 (0.311,0.880) |
| PSA DoublingTime(>6 to <=9 Months)                         | 114 / 135                          | 14 / 27                          |                        | 0.599 (0.314,1.143) |
| BaselineUseof aBoneTargetingAgent (No)                     | 355 / 358                          | 63 / 92                          |                        | 0.633 (0.459,0.872) |
| Baseline AgeCategory (<65 Years)                           | 91 / 91                            | 13 / 28                          |                        | 0.424 (0.220,0.819) |
| Baseline AgeCategory (>=65 Years)                          | 264 / 267                          | 50 / 64                          |                        | 0.730 (0.504,1.057) |
| Race(White)                                                | 295 / 301                          | 55 / 75                          |                        | 0.673 (0.475,0.953) |
| Body MassIndex Calculatedfrom Height and Weight (<=Median) | 185 / 179                          | 31 / 39                          |                        | 0.738 (0.460,1.183) |
| Body MassIndex Calculatedfrom Height and Weight (>Median)  | 169 / 175                          | 32 / 53                          |                        | 0.549 (0.354,0.851) |
| ECOGPerformanceS tatusat Baseline (0)                      | 321 / 336                          | 59 / 87                          |                        | 0.638 (0.459,0.889) |
| Geographic Region (North America)                          | 133 / 137                          | 20 / 32                          |                        | 0.607 (0.347,1.062) |
| Geographic Region (Europe)                                 | 146 / 128                          | 30 / 33                          |                        | 0.678 (0.413,1.112) |
| Geographic Region (Rest of the World)                      | 76 / 93                            | 13 / 27                          |                        | 0.567 (0.293,1.100) |
| Total Gleason Score at Baseline (<=7) at Diagnosis         | 239 / 244                          | 37 / 61                          |                        | 0.606 (0.403,0.912) |
| Total Gleason Score at Baseline (>=8) at Diagnosis         | 111 / 113                          | 25 / 30                          |                        | 0.679 (0.399,1.155) |
| Prior Hormonal Therapy (Yes)                               | 112 / 113                          | 23 / 34                          |                        | 0.595 (0.349,1.014) |
| Prior Hormonal Therapy (No)                                | 243 / 245                          | 40 / 58                          |                        | 0.658 (0.440,0.985) |
| Prior Radiation Therapy (Yes)                              | 256 / 283                          | 43 / 76                          |                        | 0.566 (0.389,0.823) |
| Prior Radiation Therapy (No)                               | 99 / 75                            | 20 / 16                          |                        | 0.928 (0.481,1.793) |
| Prior Prostatectomy (Yes)                                  | 265 / 254                          | 44 / 61                          |                        | 0.632 (0.429,0.933) |
| Prior Prostatectomy (No)                                   | 90 / 104                           | 19 / 31                          |                        | 0.648 (0.366,1.148) |
| History of Cardiovascular Disease (No)                     | 308 / 316                          | 55 / 81                          |                        | 0.638 (0.453,0.899) |
| PSA Value at Baseline (<=10 ng/mL)                         | 272 / 273                          | 51 / 64                          |                        | 0.736 (0.509,1.063) |
| PSA Value at Baseline (>10 ng/mL)                          | 82 / 83                            | 12 / 28                          |                        | 0.377 (0.191,0.746) |

The data cut-off date is 31 Jan 2023.If the subgroups are too small (&lt; 10 events), the analyses would not be provided.Hazard ratio and its 95% CI for subgroups are based on unstratified Cox regression model. Hazard ratio and its 95% CI for all patients are based on a stratified Cox regression model stratified by randomization stratification factors.

Figure 32. Forest Plot of Overall Survival for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups - Key Secondary Efficacy Analysis (ITT Population)

<!-- image -->

| Subgroup                                                       | Number of Patients ENZA+LA/PBO+LA   | Number of Events ENZA+LA/PBO+LA   | Hazard Ratio for OS   | (95% C1)            |
|----------------------------------------------------------------|-------------------------------------|-----------------------------------|-----------------------|---------------------|
| All Patients                                                   | 355/358                             | 33/55                             |                       | 0.589 (0.382,0.908) |
| PSA Doubling Time (>3 to <=6 Months)                           | 187/ 142                            | 16 /23                            | T1                    | 0.488 (0.256,0.928) |
| Baseline Use of a BoneTargeting Agent(No)                      | 355/358                             | 33/55                             | T                     | 0.605 (0.393,0.932) |
| ≥BaselineAge Category (>=65Years)                              | 274 / 267                           | 28 /43                            | T                     | 0.608 (0.378,0.980) |
| G Race(White) 6                                                | 293/301                             | 28 /49                            | T1                    | 0.591 (0.372,0.941) |
| Body Mass Index Calcuiated from Height and Weight (<=Median) 2 | 173 / 179                           | 15 / 26                           | T                     | 0.598 (0.317,1.130) |
| Body Mass Index Calculated from Height and Weight (>Median)    | 180/175                             | 18/29                             |                       | 0.608 (0.338,1.095) |
| ECOGPerformanceSatusatBaseline(0)                              | 328/336                             | 30/49                             | T                     | 0.621 (0.394,0.978) |
| GeographicRegion(North America)                                | 144 / 137                           | 13/22                             |                       | 0.602 (0.303,1.196) |
| Geographic Region(Europe)                                      | 130/128                             | 13/20                             |                       | 0.605 (0.301,1.216) |
| TotalGleasonSoore atBaseline(<=7)atDiagnosis                   | 234 / 244                           | 17 /34                            |                       | 0.519 (0.290,0.929) |
| Total GleasonSbore atBaseline(>=8)atDiagnosis                  | 120 /113                            | 16 / 21                           |                       | 0.720 (0.375,1.381) |
| Prior Hormonal Tharapy(Ycs)                                    | 107/113                             | 15 / 17                           |                       | 0.032 (0.465,1.866) |
| Prior Hormonal Therapy(No)                                     | 248/245                             | 18/38                             | T1                    | 0.469 (0.268,0.822) |
| PriorRadiationTherapy(Yes)                                     | 265/283                             | 27 /48                            | T                     | 0.604 (0.377,0.968) |
| Prior Prostatectomy(Yes)                                       | 269 / 254                           | 19/33                             | T                     | 0.541 (0.308,0.952) |
| PriorProstatectomy(No)                                         | 86 / 104                            | 14 / 22                           |                       | 0.791 (0.404,1.547) |
| History of Cardiovascular Disease(No)                          | 313/316                             | 28 /50                            | T1                    | 0.571 (0.360,0.907) |
| PSA Value at Basline (<=10 ng'mL)                              | 278/ 273                            | 23/36                             | T                     | 0.614 (0.364,1.036) |
| PSA Value at Baseline(>10 ng/mL)                               | 77/ 83                              | 10 / 19                           |                       | 0.604 (0.280,1.302) |

The data cut-off date is 31JAN2023.

If the subgroups are too small (&lt;10 events), the analyses would not be provided.

Hazard ratio andits 95%CIfor subgroups are based on unstratifiedCoxregression mode1.Hazard ratio andits 95%CIfor all patients are based on a stratified Coxregressionmodel stratified by randomization stratification factors.

<div style=\"page-break-after: always\"></div>

Figure 33. Forest Plot of Overall Survival for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups - Key Secondary Efficacy Analysis (ITT Population)

| Subgroup                                                    | Number of Patients ENZA /PBO+LA   | Number of Events ENZA /PBO+LA   | Hazard Ratio for OS   | (95% C1)            |
|-------------------------------------------------------------|-----------------------------------|---------------------------------|-----------------------|---------------------|
| AllPatients                                                 | 355/358                           | 42/55                           |                       | 0.782 (0.523,1.170) |
| PSA Doubling Time (<=3 Months)                              | 76 / 80                           | 15 / 11                         |                       | 1.643 (0.748,3.608) |
| PSA Doubling Time (>3 to <=6 Months)                        | 164 / 142                         | 19 /23                          |                       | 0.698 (0.380,1.281) |
| BaelineUse of aBoneTargeting Agent(No)                      | 355/358                           | 42 /55                          |                       | 0.782 (0.523,1.169) |
| BaselineAgeCategory(>=65Years)                              | 264 / 267                         | 34/43                           |                       | 0.786 (0.502,1.233) |
| 6 Race(White)                                               | 295/ 301                          | 37/49                           | 王                     | 0.776 (0.506,1.189) |
| BodyMassIndexCalculatedfromHeightandWeight(<=Median)        | 185/ 179                          | 20/26                           | T1                    | 0.763 (0.426,1.368) |
| Body Mass Index Calculated from Height and Weight (>Median) | 169 / 175                         | 22 / 29                         | +                     | 0.798 (0.458,1.389) |
| ECOG Performance Satus at Baseline(0)                       | 321/336                           | 38/49                           |                       | 0.817 (0.535,1.248) |
| Geographic Region(Europe)                                   | 146 / 128                         | 27/ 20                          |                       | 1.183 (0.664,2.110) |
| Total Gleason Soore atBaseline(<=7)atDiagnosis              | 239/ 244                          | 25 /34                          |                       | 0.766 (0.457,1.285) |
| TotalGleasonScore atBaseline(>=8)atDiagnosis                | 111/ 113                          | 17 /21                          |                       | 0.801 (0.422,1.520) |
| Prior Hormonal Tharapy(Ycs)                                 | 112/113                           | 15 / 17                         |                       | 0.883 (0.441,1.768) |
| Prior Hormona Therapy (No)                                  | 243 / 245                         | 27/38                           |                       | 0.731 (0.446,1.198) |
| Prior RadiationTherapy (Yes)                                | 256/283                           | 29/48                           |                       | 0.664 (0.419,1.054) |
| Prior Prostatectomy (Yes)                                   | 265 / 254                         | 27/33                           |                       | 0.788 (0.474,1.311) |
| PriorProstatectomy(No)                                      | 90 /104                           | 15 / 22                         | T                     | 0.849 (0.440,1.641) |
| History of Cardiovascular Disease(No)                       | 308/316                           | 35/50                           | T                     | 0.729 (0.473,1.122) |
| PSA Value at Baseine (<=10 ng'mL)                           | 272 / 273                         | 30 / 36                         | 土                     | 0.862 (0.531,1.399) |
| PSA Value at Baseline (>10 ng/mL) 060                       | 82/83                             | 12 / 19                         | 0 1 2 3               | 0.625 (0.304,1.288) |

The data cut-off date is 31JAN2023.

daqoumsesasdrs

Hazardratio and its95%CIfor subgroups are based on unstratifiedCoxregressionmodel.Hazardratioand its 95%CIforall patients arebased ona stratified Coxregressionmode1 stratified byrandomization stratification factors. PFIZER CONFIDENTIAL Source: kuppis /Volumes/data/usrfiles/programming/mdv3100/mdv3100\\_13/cst/prod/programs/f\\_14\\_02\\_02\\_04\\_02\\_os\\_sub.sas 15MA Y23:20:54 Output File: f\\_14\\_02\\_02\\_04\\_02\\_os\\_sub.rff

## Sensitivity analyses

MFS - Enzalutamide Plus Leuprolide vs Placebo Plus Leuprolide

Table 30. Summary of Sensitivity Analysis for MFS for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups (ITT Population)

| MFS Follow-up (in Months)                                                                                                                       | ENZA + LA (N = 355)   | PBO + LA (N = 358)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------|
| Primary - MFS Events                                                                                                                            | 45 (12.7%)            | 92 (25.7%)           |
| Median (95% CI)                                                                                                                                 | NR (NR, NR)           | NR (85.1, NR)        |
| P-value                                                                                                                                         | < 0.0001              |                      |
| Hazard Ratio (95% CI)                                                                                                                           | 0.424 (0.296, 0.607)  |                      |
| Sensitivity 1 - MFS Events Based on Independent Central Review Assessment Including Events Regardless of Initiation of Antineoplastic Therapies | 52 (14.6%)            | 108 (30.2%)          |
| Median (95% CI)                                                                                                                                 | NR (NR, NR)           | 85.1 (82.9, NR)      |
| P-value                                                                                                                                         | < 0.0001              |                      |
| Hazard Ratio (95% CI)                                                                                                                           | 0.435 (0.312, 0.607)  |                      |
| Sensitivity 2 - MFS Events Based on Independent Central Review Assessment (eITT Population)†                                                    | 45 (12.7%)            | 92 (25.8%)           |

<div style=\"page-break-after: always\"></div>

| MFS Follow-up (in Months)                                                                                              | ENZA + LA (N = 355)   | PBO + LA (N = 358)   |
|------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------|
| Median (95% CI)                                                                                                        | NR (NR, NR)           | NR (85.1, NR)        |
| P-value                                                                                                                | < 0.0001              |                      |
| Hazard Ratio (95% CI)                                                                                                  | 0.424 (0.296, 0.607)  |                      |
| Sensitivity 3 - MFS Events Based on Investigator's Assessments                                                         | 49 (13.8%)            | 92 (25.7%)           |
| Median (95% CI)                                                                                                        | NR (NR, NR)           | 85.1 (82.7, NR)      |
| P-value                                                                                                                | < 0.0001              |                      |
| Hazard Ratio (95% CI)                                                                                                  | 0.470 (0.332, 0.668)  |                      |
| Sensitivity 4 - MFS Events Based on Independent Central Review Assessment to Assess the Impact of Clinical Progression | 45 (12.7%)            | 92 (25.7%)           |
| Median (95% CI)                                                                                                        | NR (NR, NR)           | NR (85.1, NR)        |
| P-value                                                                                                                | < 0.0001              |                      |
| Hazard Ratio (95% CI)                                                                                                  | 0.432 (0.302, 0.619)  |                      |

The data cut-off date is 31 Jan 2023. NR = Not Reached. † MFS event percentage for Sensitivity 2 Analysis is based on eITT population of the corresponding treatment group.

Table 31. Concordance and Discordance Between BICR and Investigator Assessment for Enzalutamide plus Leuprolide vs Placebo plus Leuprolide Groups (ITT Population)

|                                            | ENZA+LA   | ENZA+LA   | ENZA+LA   | PBO+LA   | PBO+LA   | PBO+LA   |                |
|--------------------------------------------|-----------|-----------|-----------|----------|----------|----------|----------------|
| Measures for Discordance or Concordance    | N         | n         | %         | N        | n        | %        | Difference (%) |
| Total Event Discrepancy Rate (b+c) / N     | 355       | 28        | 7.9       | 358      | 34       | 9.5      | -1.6           |
| Early Discrepancy Rate (a3+b) / (a+b)      | 49        | 18        | 36.7      | 92       | 24       | 26.1     | 10.6           |
| Late Discrepancy Rate (a2+c) / (a2+a3+b+c) | 35        | 17        | 48.6      | 57       | 33       | 57.9     | -9.3           |
| Overall Discrepancy Rate (a2+a3+b+c) / N   | 355       | 35        | 9.9       | 358      | 57       | 15.9     | -6.0           |
| Overall Concordance Rate (a+d)/N           | 355       | 327       | 92.1      | 358      | 324      | 90.5     | 1.6            |

The data cut-off date is 31 Jan 2023. a = a1 + a2 + a3. N= a+b+c+d representing the number of patients in the ITT population.

a1 = number of agreements on timing and occurrence of PD

a2 = number of times agreement on PD event but investigator declares PD event later than BICR

a3 = number of times agreement on PD event but investigator declares PD event earlier than BICR; PD = progressive disease. b = BICR indicates not an event, but Investigator indicates an event. c = BICR indicates an event, but Investigator indicates not an event. d = Both BICR assessment and Investigator assessment indicate not an event. The timing agreement of progression defined as a window of +/- 7 days.

MFS -Enzalutamide Monotherapy vs Placebo Plus Leuprolide

<div style=\"page-break-after: always\"></div>

Table 32: Summary of Sensitivity Analysis for MFS for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups (ITT Population)

| MFS Follow-up (in Months)                                                                                                                       | ENZA (N = 355)       | PBO + LA (N = 358)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|
| Primary - MFS Events                                                                                                                            | 63 (17.7%)           | 92 (25.7%)           |
| Median (95% CI)                                                                                                                                 | NR (NR, NR)          | NR (85.1, NR)        |
| P-value                                                                                                                                         | 0.0049               |                      |
| Hazard Ratio (95% CI)                                                                                                                           | 0.631 (0.456, 0.871) |                      |
| Sensitivity 1 - MFS Events Based on Independent Central Review Assessment Including Events Regardless of Initiation of Antineoplastic Therapies | 74 (20.8%)           | 108 (30.2%)          |
| Median (95% CI)                                                                                                                                 | NR (NR, NR)          | 85.1 (82.9, NR)      |
| P-value                                                                                                                                         | 0.0036               |                      |
| Hazard Ratio (95% CI)                                                                                                                           | 0.644 (0.478, 0.867) |                      |
| Sensitivity 2 - MFS Events Based on Independent                                                                                                 | 63 (17.8%)           | 92 (25.8%)           |
| Median (95% CI)                                                                                                                                 | NR (NR, NR)          | NR (85.1, NR)        |
| P-value                                                                                                                                         | 0.0049               |                      |
| Hazard Ratio (95% CI)                                                                                                                           | 0.631 (0.456, 0.871) |                      |
| Sensitivity 3 - MFS Events Based on Investigator's Assessments                                                                                  | 56 (15.8%)           | 92 (25.7%)           |
| Median (95% CI)                                                                                                                                 | NR (NR, NR)          | 85.1 (82.7, NR)      |
| P-value                                                                                                                                         | 0.0006               |                      |
| Hazard Ratio (95% CI)                                                                                                                           | 0.561 (0.401, 0.784) |                      |
| Sensitivity 4 - MFS Events Based on Independent Central Review Assessment to Assess the Impact of Clinical Progression                          | 65 (18.3%)           | 92 (25.7%)           |
| Median (95% CI)                                                                                                                                 | NR (NR, NR)          | NR (85.1, NR)        |
| P-value                                                                                                                                         | 0.0074               |                      |
| Hazard Ratio (95% CI)                                                                                                                           | 0.647 (0.470, 0.892) |                      |

The data cut-off date is 31 Jan 2023. NR = Not Reached. † MFS event percentage for Sensitivity 2 Analysis is based on eITT population of the corresponding treatment group

Table 33. Concordance and Discordance Between BICR and Investigator Assessment for Enzalutamide Monotherapy vs Placebo plus Leuprolide Groups (ITT Population)

| Measures for Discordance or            | ENZA   | ENZA   | ENZA   | PBO+LA   | PBO+LA   | PBO+LA   | Difference   |
|----------------------------------------|--------|--------|--------|----------|----------|----------|--------------|
| Concordance                            | N      | n      | %      | N        | n        | %        | (%)          |
| Total Event Discrepancy Rate (b+c) / N | 355    | 33     | 9.3    | 358      | 34       | 9.5      | -0.2         |

<div style=\"page-break-after: always\"></div>

| Measures for Discordance or Concordance    | ENZA   | ENZA   | ENZA   | PBO+LA   | PBO+LA   | PBO+LA   | Difference (%)   |
|--------------------------------------------|--------|--------|--------|----------|----------|----------|------------------|
| Measures for Discordance or Concordance    | N      | n      | %      | N        | n        | %        | Difference (%)   |
| Early Discrepancy Rate (a3+b) / (a+b)      | 56     | 15     | 26.8   | 92       | 24       | 26.1     | 0.7              |
| Late Discrepancy Rate (a2+c) / (a2+a3+b+c) | 43     | 28     | 65.1   | 57       | 33       | 57.9     | 7.2              |
| Overall Discrepancy Rate (a2+a3+b+c) / N   | 355    | 43     | 12.1   | 358      | 57       | 15.9     | -3.8             |
| Overall Concordance Rate (a+d)/N           | 355    | 322    | 90.7   | 358      | 324      | 90.5     | 0.2              |

The data cut-off date is 31 Jan 2023. a = a1 + a2 + a3. N= a+b+c+d representing the number of patients in the ITT population.

a1 = number of agreements on timing and occurrence of PD

a2 = number of times agreement on PD event but investigator declares PD event later than BICR

a3 = number of times agreement on PD event but investigator declares PD event earlier than BICR;PD = progressive disease. b =

BICR indicates not an event, but Investigator indicates an event. c = BICR indicates an event, but Investigator indicates not an event.

d = Both BICR assessment and Investigator assessment indicate not an event.

The timing agreement of progression defined as a window of +/- 7 days.

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 34: Summary of Efficacy for trial MDV3100-13 (EMBARK)

| Monotherapy, and Placebo Plus Leuprolide in Men With High Risk Non-metastatic Prostate Cancer   | Monotherapy, and Placebo Plus Leuprolide in Men With High Risk Non-metastatic Prostate Cancer                                                                                                                                                                                             | Monotherapy, and Placebo Plus Leuprolide in Men With High Risk Non-metastatic Prostate Cancer                                                                                                                                                                                             | Monotherapy, and Placebo Plus Leuprolide in Men With High Risk Non-metastatic Prostate Cancer                                                                                                                                                                                             |
|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                | Definitive Therapy (EMBARK) Study MDV3100-13 (EMBARK)                                                                                                                                                                                                                                     | Definitive Therapy (EMBARK) Study MDV3100-13 (EMBARK)                                                                                                                                                                                                                                     | Definitive Therapy (EMBARK) Study MDV3100-13 (EMBARK)                                                                                                                                                                                                                                     |
| Design                                                                                          | Phase 3, three arms, double blind (combination and control arm) randomized study of enzalutamide plus leuprolide, enzalutamide monotherapy and placebo plus leuprolide in men with high-risk non-metastatic prostate cancer progressing (biochemical recurrence) after definitive therapy | Phase 3, three arms, double blind (combination and control arm) randomized study of enzalutamide plus leuprolide, enzalutamide monotherapy and placebo plus leuprolide in men with high-risk non-metastatic prostate cancer progressing (biochemical recurrence) after definitive therapy | Phase 3, three arms, double blind (combination and control arm) randomized study of enzalutamide plus leuprolide, enzalutamide monotherapy and placebo plus leuprolide in men with high-risk non-metastatic prostate cancer progressing (biochemical recurrence) after definitive therapy |
| Design                                                                                          | Duration of screening phase: Duration of treatment phase: Duration of Extension phase:                                                                                                                                                                                                    | Duration of screening phase: Duration of treatment phase: Duration of Extension phase:                                                                                                                                                                                                    | Day -28 to -1 36 weeks and suspension if PSA undetectable After week 37, PSA and testosterone measured every 3 months. Radiographic imaging every 6 months                                                                                                                                |
| Hypothesis                                                                                      | Superiority                                                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                                               |
| Treatments groups                                                                               | Enzalutamide + ADT                                                                                                                                                                                                                                                                        | Enzalutamide + ADT                                                                                                                                                                                                                                                                        | Enzalutamide 160 mg/day + leuprorelin acetate 22.5 mg/12 weeks, n=355                                                                                                                                                                                                                     |
| Treatments groups                                                                               | Enzalutamide monotherapy                                                                                                                                                                                                                                                                  | Enzalutamide monotherapy                                                                                                                                                                                                                                                                  | Enzalutamide 160 mg/day, n=355                                                                                                                                                                                                                                                            |
| Treatments groups                                                                               | Placebo + ADT                                                                                                                                                                                                                                                                             | Placebo + ADT                                                                                                                                                                                                                                                                             | Placebo + leuprorelin acetate 22.5 mg/12 weeks, n=358                                                                                                                                                                                                                                     |
| Endpoints and definitions                                                                       | Primary endpoint                                                                                                                                                                                                                                                                          | Metastasis- free survival (MFS)                                                                                                                                                                                                                                                           | BICR assessed by radiographic progression per RECIST 1.1 (soft tissue disease) and radiographic progression for the appearance of 1 or more metastatic lesion (bone disease) in patients with nmCSPC                                                                                      |
| Endpoints and definitions                                                                       | Secondary                                                                                                                                                                                                                                                                                 | Time to PSA progression                                                                                                                                                                                                                                                                   | Time from randomisation to the date of the first PSA value demonstrating progression, defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 µg/L (2 ng/mL) above the nadir.                                                                                           |
| Endpoints and definitions                                                                       | Secondary                                                                                                                                                                                                                                                                                 | Time to first use of new antineoplastic therapy                                                                                                                                                                                                                                           | Time to first use of new antineoplastic therapy after study drugs discontinuation                                                                                                                                                                                                         |
| Endpoints and definitions                                                                       | Secondary                                                                                                                                                                                                                                                                                 | OS                                                                                                                                                                                                                                                                                        | Time to death due to any cause based on an interim analysis.                                                                                                                                                                                                                              |
| Database lock                                                                                   | 31-Jan-2023 (Final analysis and OS interim analysis)                                                                                                                                                                                                                                      | 31-Jan-2023 (Final analysis and OS interim analysis)                                                                                                                                                                                                                                      | 31-Jan-2023 (Final analysis and OS interim analysis)                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Analysis description                              |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and                           | Primary Analysis Intent to treat                                                                                                                                                                                | Primary Analysis Intent to treat                                                                                                                                                                                | Primary Analysis Intent to treat                                                                                                                                                                                | Primary Analysis Intent to treat                                                                                                                                                                                | Primary Analysis Intent to treat                                                                                                                                                                                |
| time point description Descriptive statistics and |                                                                                                                                                                                                                 | Enza + ADT                                                                                                                                                                                                      |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 | Enza                                                                                                                                                                                                            |
| time point description Descriptive statistics and | Number of subject                                                                                                                                                                                               | 355                                                                                                                                                                                                             | 358                                                                                                                                                                                                             | 358                                                                                                                                                                                                             | 355                                                                                                                                                                                                             |
| time point description Descriptive statistics and | MFS median (months)                                                                                                                                                                                             | NR                                                                                                                                                                                                              | NR                                                                                                                                                                                                              | NR                                                                                                                                                                                                              | NR                                                                                                                                                                                                              |
| time point description Descriptive statistics and | 95% CI                                                                                                                                                                                                          | (NR, NR)                                                                                                                                                                                                        | (85.1, NR)                                                                                                                                                                                                      | (85.1, NR)                                                                                                                                                                                                      | (NR, NR)                                                                                                                                                                                                        |
| time point description Descriptive statistics and | Time to PSA progression median (months)                                                                                                                                                                         | NR                                                                                                                                                                                                              | NR                                                                                                                                                                                                              | NR                                                                                                                                                                                                              | NR                                                                                                                                                                                                              |
| time point description Descriptive statistics and | 95% CI                                                                                                                                                                                                          | (NR, NR)                                                                                                                                                                                                        | (NR, NR)                                                                                                                                                                                                        | (NR, NR)                                                                                                                                                                                                        | (NR, NR)                                                                                                                                                                                                        |
| Effect estimate per comparison                    | Primary endpoint MFS                                                                                                                                                                                            | Comparison groups HR                                                                                                                                                                                            | Comparison groups HR                                                                                                                                                                                            | Enza + ADT vs ADT                                                                                                                                                                                               | Enza + ADT vs ADT                                                                                                                                                                                               |
| Effect estimate per comparison                    | Primary endpoint MFS                                                                                                                                                                                            |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 | 0.424                                                                                                                                                                                                           | 0.424                                                                                                                                                                                                           |
| Effect estimate per comparison                    | Primary endpoint MFS                                                                                                                                                                                            | (95% CI)                                                                                                                                                                                                        | (95% CI)                                                                                                                                                                                                        | (0.296, 0.607)                                                                                                                                                                                                  | (0.296, 0.607)                                                                                                                                                                                                  |
| Effect estimate per comparison                    | Primary endpoint MFS                                                                                                                                                                                            | P-value                                                                                                                                                                                                         | P-value                                                                                                                                                                                                         | <0.0001                                                                                                                                                                                                         | <0.0001                                                                                                                                                                                                         |
| Effect estimate per comparison                    | Primary endpoint MFS                                                                                                                                                                                            | Comparison groups HR                                                                                                                                                                                            | Comparison groups HR                                                                                                                                                                                            | Enza vs ADT                                                                                                                                                                                                     | Enza vs ADT                                                                                                                                                                                                     |
| Effect estimate per comparison                    | Primary endpoint MFS                                                                                                                                                                                            |                                                                                                                                                                                                                 |                                                                                                                                                                                                                 | 0.631                                                                                                                                                                                                           | 0.631                                                                                                                                                                                                           |
| Effect estimate per comparison                    | Primary endpoint MFS                                                                                                                                                                                            | (95% CI)                                                                                                                                                                                                        | (95% CI)                                                                                                                                                                                                        | (0.456, 0.871)                                                                                                                                                                                                  | (0.456, 0.871)                                                                                                                                                                                                  |
| Effect estimate per comparison                    | Primary endpoint MFS                                                                                                                                                                                            | P-value                                                                                                                                                                                                         | P-value                                                                                                                                                                                                         | P=0049                                                                                                                                                                                                          | P=0049                                                                                                                                                                                                          |
| Effect estimate per comparison                    | Secondary endpoint: Time to PSA progression                                                                                                                                                                     | Comparison groups                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                               | Enza + ADT vs ADT                                                                                                                                                                                               | Enza + ADT vs ADT                                                                                                                                                                                               |
| Effect estimate per comparison                    | Secondary endpoint: Time to PSA progression                                                                                                                                                                     | HR                                                                                                                                                                                                              | HR                                                                                                                                                                                                              | 0.068                                                                                                                                                                                                           | 0.068                                                                                                                                                                                                           |
| Effect estimate per comparison                    | Secondary endpoint: Time to PSA progression                                                                                                                                                                     | (95% CI)                                                                                                                                                                                                        | (95% CI)                                                                                                                                                                                                        | (0.033, 0.141)                                                                                                                                                                                                  | (0.033, 0.141)                                                                                                                                                                                                  |
| Effect estimate per comparison                    | Secondary endpoint: Time to PSA progression                                                                                                                                                                     | P-value                                                                                                                                                                                                         | P-value                                                                                                                                                                                                         | P < 0.0001                                                                                                                                                                                                      | P < 0.0001                                                                                                                                                                                                      |
| Effect estimate per comparison                    | Secondary endpoint: Time to PSA progression                                                                                                                                                                     | Comparison groups                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                               | Enza vs ADT                                                                                                                                                                                                     | Enza vs ADT                                                                                                                                                                                                     |
| Effect estimate per comparison                    | Secondary endpoint: Time to PSA progression                                                                                                                                                                     | HR                                                                                                                                                                                                              | HR                                                                                                                                                                                                              | 0.331                                                                                                                                                                                                           | 0.331                                                                                                                                                                                                           |
| Effect estimate per comparison                    | Secondary endpoint: Time to PSA progression                                                                                                                                                                     | (95% CI)                                                                                                                                                                                                        | (95% CI)                                                                                                                                                                                                        | (0.226, 0.486)                                                                                                                                                                                                  | (0.226, 0.486)                                                                                                                                                                                                  |
| Effect estimate per comparison                    | Secondary endpoint: Time to PSA progression                                                                                                                                                                     | P-value                                                                                                                                                                                                         | P-value                                                                                                                                                                                                         | P < 0.0001                                                                                                                                                                                                      | P < 0.0001                                                                                                                                                                                                      |
| Notes                                             | OS IA at 130 (48%) events of 271 required for FA. Median OS NR in any group. HR=0.589 (95% CI: 0.382, 0.908), P=0.0153 for enza + ADT vs ADT. Enza vs ADT not formally tested, HR=0.782 (95% CI: 0.523, 1.170). | OS IA at 130 (48%) events of 271 required for FA. Median OS NR in any group. HR=0.589 (95% CI: 0.382, 0.908), P=0.0153 for enza + ADT vs ADT. Enza vs ADT not formally tested, HR=0.782 (95% CI: 0.523, 1.170). | OS IA at 130 (48%) events of 271 required for FA. Median OS NR in any group. HR=0.589 (95% CI: 0.382, 0.908), P=0.0153 for enza + ADT vs ADT. Enza vs ADT not formally tested, HR=0.782 (95% CI: 0.523, 1.170). | OS IA at 130 (48%) events of 271 required for FA. Median OS NR in any group. HR=0.589 (95% CI: 0.382, 0.908), P=0.0153 for enza + ADT vs ADT. Enza vs ADT not formally tested, HR=0.782 (95% CI: 0.523, 1.170). | OS IA at 130 (48%) events of 271 required for FA. Median OS NR in any group. HR=0.589 (95% CI: 0.382, 0.908), P=0.0153 for enza + ADT vs ADT. Enza vs ADT not formally tested, HR=0.782 (95% CI: 0.523, 1.170). |

## Efficacy in Special Populations

No additional data regarding efficacy in special populations are included in this submission.

## 2.4.3. Discussion on clinical efficacy

Enzalutamide is currently approved for metastatic HSPC, non-metastatic CRPC and metastatic CRPC, after docetaxel or asymptomatic or mildly symptomatic patients in whom chemotherapy is not yet clinically indicated (see SmPC section 4.1). Within the current procedure, the MAH is seeking authorization for treatment of patients with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.

## Design and conduct of clinical studies

This assessment is based on the results from Study MDV3100-13 (EMBARK), a phase 3, randomized study of enzalutamide plus leuprolide, enzalutamide monotherapy and placebo plus leuprolide in men with high-risk non-metastatic prostate cancer progressing (biochemical recurrence) after definitive therapy.

<div style=\"page-break-after: always\"></div>

The patients enrolled in this study represent a population with a high risk of developing metastases defined, in this case, as prostate-specific antigen doubling time (PSADT) ≤9 months and screening PSA of ≥1 ng/mL for patients with prior radical prostatectomy or, at least, 2 ng/mL above the nadir for patients who had prior primary radiotherapy only. This means that only PSA values were taken into account to select this high-risk population whereas the EAU Guidelines on Prostate Cancer 2023 contemplates also International Society of Urological Pathology (ISUP) grade and interval to biochemical failure. Despite the fact that patients who present a BCR with a PSADT ≤9 months are indeed considered as being at a high risk of developing metastases, the need of immediate treatment in this setting remains controversial.

The target indication is focused on patients initially treated with curative intent who are unsuitable for salvage radiotherapy based on standard guidelines, at the investigator's discretion, in line with the exclusion criteria. It is therefore, expected that the patient candidates would be those for whom immediate systemic treatment is deemed appropriate and were to receive ADT.

The study was double blind for the main comparison (enzalutamide + ADT vs. ADT) but open-label for enzalutamide monotherapy due to the impossibility to mask the LHRH analogue injections.

Patients received treatment until PSA evaluation at Week 36 by central laboratory. If PSA values were undetectable (&lt;0.2 ng/mL) at this time point, treatment was suspended and it could be later resumed if subsequent central lab PSA results increased to ≥2.0 ng/mL for participants with prior prostatectomy or ≥5.0 ng/mL for participants without prostatectomy. Intermittent ADT has been established as a treatment option that could mitigate ADT common side effects, based on the results from different studies and meta-analyses but the impact on survival remains uncertain (Dong Z et al, Aging Male. 2015). A similar approach has been used in the EMBARK study, allowing patients to stop treatment. This strategy can be endorsed, as a threshold for rising PSA values was implemented and treatment could be reinitiated if needed.

The primary study objective was to evaluate the efficacy of the combination of enzalutamide plus leuprorelin in comparison to leuprorelin monotherapy while a secondary objective was to assess the same for enzalutamide monotherapy compared to leuprorelin. Metastases-free survival (MFS) was chosen as the primary endpoint. The relevance of this endpoint, in terms of showing a clinical benefit in a nonmetastatic setting, was previously discussed during the assessment of the PROSPER study (EMEA/H/C/002639/II/0039/G) in which a group of experts were also consulted. It is assumed that a delay in the development of metastasis entails a direct benefit since symptomatic lesions carry a high disease burden on patients. However, it is also acknowledged that some metastatic disease forms can present a slow progress and remain asymptomatic for a long time. Of note, in the previously mentioned PROSPER study, similarly to what happened with the study of apalutamide in nmCRPC (SPARTAN study), the benefit in MFS was translated into an OS advantage. Time to PSA progression, time to first use of new antineoplastic therapy and OS are (key) secondary endpoints included also in the multiplicity adjustment scheme.

Randomization was stratified by screening PSA value (≤10 ng/mL vs &gt;10 ng/mL), PSA doubling time (≤3 months vs &gt; 3 to ≤9 months) and prior hormonal therapy (yes vs no). All these three factors are considered to have prognostic value in this setting and are agreed.

The operating characteristics for the calculation of the sample size are clear and the assumptions for the calculations are endorsed. Based on the SAP (version 3.1, dated 10-Jan-2023), if the test for the primary endpoint (MFS in the combination treatment group) was significant at the full 2-sided alpha level of 0.05, the key secondary endpoints for the combination group were to be tested at a 2-sided alpha of 0.02 utilizing a hierarchical approach to preserve the type I error rate. The remaining 0.03 alpha was to be allocated to compare MFS as well as other key secondary endpoints for enzalutamide monotherapy vs placebo plus leuprolide. The alpha for OS was dependent upon the remaining alpha from earlier tests of the other endpoints from both the combination and monotherapy treatment comparisons and the

<div style=\"page-break-after: always\"></div>

Haybittle-Peto adjustment for the interim OS analysis. The proposal for the OS interim analysis and their efficacy boundaries shows that the final analysis is to be performed using a 0.05 level of significance as usual. Therefore, there are no concerns to the multiple adjustment.

Up to the data cut-off (31-Jan-2023), four protocol amendments were implemented. Amendment 4 (29Oct-2021) included some relevant changes to the primary endpoint (the primary endpoint was repowered and the IA was removed). According to the MAH, these changes were based on external data, mainly the results from the PROSPER and SPARTAN studies of enzalutamide and apalutamide, respectively, in nmCRPC, in addition to a subpopulation from the STAMPEDE platform study similar to the one enrolled in EMBARK study. In these studies, the reported HR for MFS (HR 0.29 [95% CI: 0.24, 0.35] and HR 0.28 [95% CI: 0.23, 0.35] for PROSPER and SPARTAN, respectively, and HR 0.53 [95% CI: 0.44, 0.64] for STAMPEDE) were lower than the original target HR for MFS (0.65) in the EMBARK study. Therefore, the primary endpoint was repowered, aiming at a lower HR of 0.58, and the MFS IA was removed. These studies were published before amendment 4 was issued and, overall, the MAH's rationale can be followed and there were no major concerns with regard to the conduct of the study.

Patients with at least one major protocol deviation were 51 out 1068, with a slight imbalance towards a higher percentage in the enzalutamide monotherapy: 23 out 355 (6.5%) in the enzalutamide monotherapy vs. 11 out 358 (3.1%) in the placebo arm. The most frequently reported protocol deviation category was 'IP Compliance' (4.5% vs 1.7%). This trend was similar in the enzalutamide plus leuprolide arm (4.5% vs 2.5%).

## Efficacy data and additional analyses

A total of 1813 participants were screened and 1068 patients were randomized to the enzalutamide plus leuprolide group (n=355), placebo plus leuprolide group (n=358), or enzalutamide monotherapy group (n=355).

The demographic and baseline characteristics were well balanced between the three treatment groups. The overall median age at randomisation was 69 years (range: 49.0 - 93.0). 23.4% of randomized patients were ≥ 75 years of age, which represents the usual prostate cancer population Most patients in the total population were Caucasian (83.2%), 7.3% were Asian, and 4.4% were Black. Slight differences between treatment arms were identified, especially for patients with PSADT &gt;3 -≤ 6 months vs &gt;6 -≤ 9 months, with a slightly higher rate of poorer prognostic patients in the enzalutamide + ADT group. As previously stated, high risk population to be included in this trial was only defined by PSADT/PSA at screening but there are other poor prognosis risk factors that are usually considered to decide the treatment management in this BCR setting. Baseline median total Gleason score was 7 in all groups with most of the participants being classified in the medium (5-7) Gleason score group and only one third of the patients in the high (8-10) Gleason score group. This is highlighted because patients with a high Gleason score would definitely be considered as high risk but it is not that clear for medium Gleason score, as the majority of participants from the EMBARK study. Nevertheless, this corresponds to the design of the trial, therefore the target population would be the one that meets the inclusion criteria from the EMBARK study. This should be considered in the context of emerging data that suggest cross resistance between enzalutamide and abiraterone, with the risk of restricting successful subsequent treatment options in the metastatic setting 35 . At this stage, this uncertainty remains due to the low number of patients from the enzalutamide + ADT (16.3%) arm and enzalutamide monotherapy (23.7%) group that have received subsequent treatment. As expected, some of these patients received docetaxel in a later disease stage but a non-negligible number of patients, especially from the ADT group, received leuprorelin treatment as subsequent therapy.

<div style=\"page-break-after: always\"></div>

Regarding the protocol established treatment suspension in patients who had undetectable PSA at week 36, in the safety population (n=1061), 321 (90.9%) patients in the enzalutamide plus ADT group, 240 (67.8%) patients in the placebo plus ADT group and 304 (85.9%) patients in the enzalutamide monotherapy group suspended treatment for this reason. Most of these patients required reinitiating treatment, with a lower relative percentage in the enzalutamide plus ADT group (75.1% enzalutamide + ADT arm vs 84.6% placebo + ADT arm vs 88.2% in the enzalutamide monotherapy treatment group). There were 80 (22.7%) patients in the combination arm, 37 (10.5%) in the ADT group and 34 (9.6%) patients in the enzalutamide monotherapy arm that suspended treatment and never reinitiated.

An improvement in MFS in the enzalutamide plus ADT arm compared to the placebo plus leuprolide treatment group was shown, with a HR point estimate of 0.424 (95% CI: 0.296, 0.607; 2-sided stratified log-rank test P &lt;0.0001). Median MFS was not reached in any of these two treatment arms. Median follow-up was of around 61 months in both treatment arms. Of note, at the time of analysis the number of censored patients was high, 310 (87.3%) in the enzalutamide + ADT arm and 266 (74.3%) in the ADT arm. Most patients were censored due to not metastatic disease or death but 36 (10.1%) patients in the enzalutamide + ADT arm and 67 (18.7%) in the ADT treatment arm were censored due to initiation of subsequent antineoplastic therapy. This shows an imbalance favouring the combination arm which, in line with EMA guidance, suggests the possibility of informative censoring. However, the sensitivity analysis conducted confirmed consistent results (see below). Subgroup analyses were overall consistent with the primary analysis and no relevant differences were identified.

Key secondary endpoint results also showed a benefit, in terms of MFS, for enzalutamide monotherapy in comparison with ADT. Estimated HR was 0.631 (95% CI: 0.456, 0.871; 2-sided stratified log-rank test P = 0.0049) and median MFS was not reached for the enzalutamide monotherapy group. A total of 292 (82.3%) patients from the enzalutamide arm and 266 (74.3%) from the leuprolide arm were censored at the time of this analysis, most because no event occurred, as expected. Again, an imbalance favouring enzalutamide arm was observed regarding censored patients due to initiation of antineoplastic therapy.

All the five sensitivity analyses performed for the primary endpoint of MFS support the robustness of the outcomes since all of them were met.

Other secondary endpoints included in the multiplicity adjustment scheme were time to PSA progression, time to first use of new antineoplastic therapy and OS, all favouring the combination arm and enzalutamide monotherapy over ADT.

The pre-specified efficacy boundary (P ≤ 0.0001) was not crossed at this interim OS analysis. Therefore, OS for the monotherapy arm was not formally tested. There was a trend in favour of the enzalutamide monotherapy compared with ADT (HR = 0.782 [95% CI: 0.523, 1.170], although the benefit is not as clear as for the combination arm. Subgroup analyses for OS were generally consistent with the primary analysis although the limited number of events preclude any conclusion. Despite the low number of OS data, a detrimental effect in survival appears unlikely for enzalutamide + ADT over ADT alone and for enzalutamide monotherapy compared with ADT. Considering the immaturity of data, the MAH is recommended to provide the final results of the EMBARK study including OS data when available (REC).

All the other secondary time-to-event endpoints clearly favoured the combination of enzalutamide + ADT. A positive trend was also identified for enzalutamide monotherapy compared to ADT, although the benefit was not as remarkable as for the combination, as previously observed for the other endpoints.

A higher proportion of patients from the enzalutamide + ADT group remained treatment free 2 years after suspension of treatment: 34.6% enzalutamide+ADT vs 27.1% from the ADT group. Interestingly, a quite lower proportion (14.1%) was observed in the enzalutamide monotherapy arm, and the same trend was followed for participants with undetectable PSA at 2 years after suspension. As expected, testosterone

<div style=\"page-break-after: always\"></div>

levels stayed constant during all treatment for patients in the enzalutamide monotherapy group, which can be also seen for the safety profile of this treatment option.

In line with the design of the EMBARK study, a recommendation is included in section 4.2 to suspend treatment with enzalutamide (+ LHRH analogue) if PSA is undetectable (&lt;0.2 ng/mL) at week 36, as well as the possibility to reinitiate treatment if PSA increases to ≥ 2.0 ng/mL for patients who had prior radical prostatectomy or ≥ 5.0 ng/mL for patients who had prior primary radiation therapy. Of note, the majority of patients in EMBARK Study that has suspended treatment required treatment re-initiation and although treatment interruption could be an option to attenuate toxicity, it is not possible to ascertain whether this strategy may have an impact on the efficacy as compared to a continuous administration. However, a clear benefit has been shown for enzalutamide + leuprolide regardless of a high number of patients having stopped treatment at Week 37 (even though most of them reinitiated) therefore no conclusions diverting from that are possible based on the available information. In any case, the criteria established for stopping and reintroducing treatment in the study protocol seemed strict enough and are considered acceptable to support this option. PFS2 was included as an exploratory endpoint. A total of 36 (10.1%) patients in the enzalutamide plus leuprolide group, 63 (17.6%) patients in the placebo plus leuprolide group, and 48 (13.5%) patients in the enzalutamide monotherapy group experienced first investigator-determined disease progression. The HR point estimate was 0.521 (95% CI: 0.345, 0.786) for the enzalutamide + ADT comparison and 0.739 (95% CI: 0.507, 1.077) for the monotherapy, compared to ADT. Even when the number of events included in this analysis is low, these results support the exclusion of any detrimental long-term effect of enzalutamide in this setting.

Time to deterioration in FACT-P total score was also analysed and no relevant differences were identified between treatment groups. Additional PRO analyses in the Embark study support the use of both enzalutamide in combination with ADT and as monotherapy in this setting.

## Wording of the indication

Initially the claimed indication was ' for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy' , followed by a statement in section 4.2 recommending the administration of enzalutamide with an LHRH analogue. During the procedure, the MAH proposed to amend Section 4.2 of the SmPC to reflect the use of enzalutamide also in monotherapy, without an LHRH analogue, as a treatment for nmHSPC with high-risk BCR. MFS data supporting the use of enzulatamide in monotherapy for the proposed patient population were provided as secondary objective in the EMBARK study. Efficacy MFS endpoint and all the remaining secondary endpoints clearly showed a benefit with the use of enzalutamide in monotherapy except for the OS. Although a trend in favour of enzalutamide as monotherapy is observed (the HR point estimate for the OS was &lt;1) the CI was quite wide (HR = 0.782 [95% CI: 0.523, 1.170]; nominal P = 0.2304) when comparing enzalutamide + ADT vs ADT. Based on the study results, there is no indication of detrimental effect in survival. Nevertheless, the OS data are immature and the MAH is recommended to provide updated OS data from study EMBARK when available.  Following assessment of the data submitted, the initial indication has been reviewed and the accepted indication is:

## Xtandi is indicated:

' as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy (see section 5.1). '

Additionally, it was considered relevant to reflect in the SmPC that the monotherapy is not an equivalent treatment option compared to the combination with ADT in patients with high risk BCR nmHSPC, and that the combination with ADT is considered the preferred treatment option, except for cases in which the addition of ADT may result in unacceptable toxicity or risk (see SmPC 4.4).

<div style=\"page-break-after: always\"></div>

## 2.4.4. Conclusions on the clinical efficacy

Based on the efficacy results of study EMBARK, enzalutamide in combination with leuprorelin has shown a clinically relevant benefit over leuprorelin alone in patients with high risk nmCRPC. The benefit has been also shown for enzalutamide as monotherapy compared with leuprorelin alone, although at lower extent.

Uncertainties remain with regard to the maturity of the OS data. The MAH is recommended to provide the final OS analysis from Study MDV3100-13 (EMBARK) when available (REC).

## 2.5. Clinical safety

## Introduction

The integrated summary of safety of this submission includes safety data from 8 clinical studies of enzalutamide in patients with nonmetastatic and metastatic HSPC and nonmetastatic and metastatic CRPC to support the safety profile from the EMBARK study (MDV3100-13). In addition to the EMBARK study in patients with nmCSPC, the integrated safety data include:

- One randomized, placebo-controlled, phase 3 study in patients with nmCRPC (PROSPER [MDV310014])
- One randomized, placebo-controlled, phase 3 study in patients with mHSPC (ARCHES [9785-CL0335])
- One randomized, placebo-controlled, phase 3 study in patients with mCRPC previously treated with docetaxel-based chemotherapy (AFFIRM [CRPC2])
- Two randomized, placebo-controlled, phase 3 studies in chemotherapy-naïve patients with mCRPC (PREVAIL [MDV3100-03] and Asian PREVAIL [9785-CL-0232])
- Two randomized, bicalutamide-controlled phase 2 studies in patients with mCRPC (TERRAIN [9785CL-0222]) and with nonmetastatic or metastatic CRPC (STRIVE [MDV3100-09])

With the exception of patients in the enzalutamide monotherapy arm in the EMBARK study, all other patients in these studies received ADT (medical or surgical) to maintain castration levels of testosterone. Together these studies included 5110 patients treated with enzalutamide 160 mg/day ( ± ADT) that make up the integrated safety population and 2829 patients treated with placebo plus ADT.

<div style=\"page-break-after: always\"></div>

Table 35. Enzalutamide studies included in the safety pool

| StudyIdentifier/ Data Cutoff                               | Phase and Blinding                            | Study Population                                                                                                                        | No.Treated Patientst                                                                                     | StudyDrugsandDose                                                                              | Primary Endpoints   | Safety Data Collected                                               |
|------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|---------------------|---------------------------------------------------------------------|
| EMBARK (MDV3100-13)/ 31 Jan 2023                           | Phase 3 fandomized DB and OL arms in parallel | Patients with high-risk nonmetastatic prostate cancer progressing after eitherradicalprostatectomy or radiotherapy (nmCSPC)             | 1061 patients in total; 353enzalutamide+ADT (DB) 354 placebo + ADT (DB) 354enzalutamide monotherapy (OL) | Enzalutamide160mg/day+ Leuprolide (DB), Placebo + Leuprolide (DB), Enzalutamide 160 mg/day(OL) | MFSt                | Drug exposure, AEs, laboratory assessment, ECGs, vital signs, death |
| PROSPER (MDV3100-14)/ 150ct2019                            | Phase 3 DB period followed by OL extension    | PatientswithnmCRPC                                                                                                                      | 930 enzalutamide, 465placebo (87 crossover)                                                              | Enzalutamide 160 mg/day, Placebo                                                               | MFSS                | Drug exposure, AEs, laboratory assessment,ECGs, vital signs, death  |
| ARCHES (9785-CL-0335)/ 28 May 2021                         | Phase 3 DB period followed by OL extension    | Patientswith mCSPC                                                                                                                      | 572 enzalutamide, 574placebo (180 crossover)                                                             | Enzalutamide 160 mg/day, Placebo                                                               | rPFSI               | Drug exposure, AEs, laboratory assessment,ECGs, vital signs, death  |
| AFFIRM (CRPC2)/ 20 Feb 2018                                | Phase 3 DB period followed by OL extension    | Patients with progressive CRPC who have been previously treated with docetaxel-based chemotherapy                                       | 800 enzalutamide, 399 placebo (50 crossover)                                                             | Enzalutamide 160 mg/day, Placebo                                                               | OS                  | Drug exposure, AEs, laboratory assessment, ECGs, vital signs, death |
| PREVAIL (MDV3100-03)/ 21 Mar 2019                          | Phase 3 DB period followed by OL extension    | Patients with asymptomatic or mildly symptomatic progressive mCRPC                                                                      | 871 enzalutamide, 844 placebo (234 crossover)                                                            | Enzalutamide 160 mg/day, Placebo                                                               | OS, rPFS            | Drug exposure, AEs, laboratory assessment,ECGs, vital signs, death  |
| Asian PREVAIL (9785-CL-0232) (excl. site 105)/ 04 Nov 2020 | Phase 3 DB period followed by OL extension    | Chemotherapy-naive patients with progressive, metastaticprostatecancer whofailed ADT                                                    | 202 enzalutamide, 193 placebo (51 crossover)                                                             | Enzalutamide 160 mg/day, Placebo                                                               | TTPPtt              | Drug exposure, AEs, laboratory assessment,ECGs, vital signs, death  |
| TERRAIN (9785-CL-0222)/ 17Feb 2018                         | Phase 2 DB period followed by OL extension    | Patients with metastatic prostate cancer whohave progressed while on LHRH agonist/antagonist or after receiving a bilateral orchiectomy | 183 enzalutamide, 189bicalutamide (9 crossover)                                                          | Enzalutamide 160 mg/day, Bicalutamide 50 mg/day                                                | PFStt               | Drug exposure, AEs, laboratory assessment, ECGs, vital signs, death |
| STRIVE (MDV3100-09)/ 30 May 2018                           | Phase 2 DB period followed by OL extension    | Patientswithrecurrent prostate cancer who have serologic and/or radiographic disease progression despite primary ADT                    | 197 enzalutamide, 198bicalutamide (37 crossover)                                                         | Enzalutamide 160 mg/day Bicalutamide 50 mg/day                                                 | PFSSS               | Drug exposure, AEs, laboratory assessment, ECGs, vital signs, death |

ADT:androgen deprivation therapy,AE:adverse event;BICR:blinded independent centralreview;CRPC:castration-resistantprostate cancer;DB:double-blind;ECG: electrocardiogram; excl: excluding;ISS: Integrated Summary of Safety;LHRH: luteinizing hormone-releasing hormone; mCRPC: metastatic castration-resistant prostate cancer, mCSPC:metastatic castration-sensitive prostate cancer;MFS:metastasis-free survival;nmCRPC:nonmetastatic castration-resistant prostate cancer, nmCSPC:nonmetastatic castration-sensitive prostate cancer; OL: open-label; OS: overall survival; PCWG2: Prostate Cancer Clinical Trials Working Group 2; PFS: progression-free survival; PSA: prostate-specific antigen; rPFS:radiographic progression-free survival;SAP: statistical analysis plan;SCS:Summary of ClinicalSafety;TTPP:time toPSA progression.

↑Crossoverrefers tothenumber ofpatientstreatedwith enzalutamide inopen-labelphase afterreceivingplacebo/bicalutamide in double-blind phase.

↑ MFS was defined as the time in months between randomization and the earliest objective evidence of radiographic progression as determined by BICR, or death due to any cause without evidence of radiographic progression, whichever occurred first. Primary endpoint was MFS between enzalutamide plus leuprolide and placebo plus leuprolide.

MFSwas defined as the timefrom randomization toradiographic progression at any time or death within112 days of treatment discontinuationwithout evidence of radiographic progression, whichever occurredfirst.

rPFS was defined as objective evidence of radiographic disease progression based on the assessments by the independent radiographic review at any time or death from any cause within 24weeksfrom study drug discontinuation,whichever occurredfirst.

ttTTPPwasdefinedasthetimefromrandomizationtothedateofthefirstconfirmedobservationofPSAprogression.

f PFS was defined as the time from randomization to objective evidence of radiographic disease progression based on the assessments by the independent radiographic review, skeletal-related event,initiationofnewantineoplastictherapyordeathby anycause.

PFSwasdefined asthetimefromrandomizationto theearliestobjectiveevidenceofradiographicprogression,PSAprogressionbyPCWG2criteriaor deathduetoany cause.

<div style=\"page-break-after: always\"></div>

Table 36. Description of integrated safety groups

| Study orPool                               | Studies Included                                                 | TreatmentArms/ StudyPeriod                                                                                                | TreatmentGroupsPresented                                                                      |
|--------------------------------------------|------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| EMBARK (nmCSPC)                            | EMBARK                                                           | DB and OL arms                                                                                                            | Enzalutamide +ADT (DB)(n=353) Placebo +ADT (DB) (n=354) Enzalutamide monotherapy (OL) (n=354) |
| nmPC phase 3 studies                       | EMBARK PROSPER                                                   | Enzalutamide+ADT and Placebo + ADT arms for EMBARK; DB period for PROSPER                                                 | Enzalutamide + ADT (n=1283) Placebo + ADT (n=819)                                             |
| Phase 3 studies                            | EMBARK PROSPER ARCHES AFFIRM PREVAIL Asian PREVAIL               | Enzalutamide+ADTand Placebo + ADT arms for EMBARK; DB period for other studies                                            | Enzalutamide+ADT (n=3728) Placebo+ADT(n=2829)                                                 |
| Total enzalutamide (phase 2 and 3 studies) | EMBARK PROSPER ARCHES AFFIRM PREVAIL AsianPREVAIL TERRAIN STRIVE | Enzalutamide+ADT and Enzalutamide monotherapy arms for EMBARK; Enzalutamide + ADT in DB and/or OLperiod for other studies | Enzalutamide ± ADT (n=5110)                                                                   |

ADT: androgen deprivation therapy; DB: double-blind; ISS: Integrated Summary of Safety, nmCSPC: nonmetastatic castration-sensitive prostate cancer, nmPC: nonmetastatic prostate cancer; OL: open-label; SCS: Summary of Clinical Safety.

## Patient exposure

Table 37. Extent of exposure (Safety Groups)

|                                             | EMBARK                | EMBARK             | EMBARK             | Phase 3↑           | Phase 3↑            | Totalt ENZA+ADT   |
|---------------------------------------------|-----------------------|--------------------|--------------------|--------------------|---------------------|-------------------|
| Category                                    | DB ENZA+ADT (m = 353) | DB PBO+ADT (n=354) | ENZA Mono (n= 354) | ENZA+ADT (n= 3728) | DB PBO+ADT (n=2829) | (n= 5110)         |
| Total treatmentduration,years               | 1525.867              | 1411.261           | 1562.804           | 6933.227           | 3414.768            | 11871.248         |
| Totaltreatnent duration,months              | 18310.407             | 16935.129          | 18753.643          | 83198.722          | 40977.211           | 142454.97         |
| Treatmentduration,months                    |                       |                    |                    |                    |                     |                   |
| Mean (SD)                                   | 51.87 (26.25)         | 47.84 (24.74)      | 52.98 (24.06)      | 22.32 (17.63)      | 14.48 (17.12)       | 27.88 (22.16)     |
| Median                                      | 60.65                 | 55.64              | 60.39              | 19.30              | 8.38                | 22.10             |
| Minimum, Maximum                            | 0.1, 90.4             | 0.7, 94.1          | 0.4, 95.0          | 0.0, 90.4          | 0.1, 94.1           | 0.0, 95.0         |
| Treatiment duration category (months),n (%) |                       |                    |                    |                    |                     |                   |
| <3                                          | 10 (2.8)              | 6 (1.7)            | 6 (1.7)            | 279 (7.5)          | 537 (19.0)          | 386 (7.6)         |
| ≥3to<6                                      | 9 (2.5)               | 8 (2.3)            | 11 (3.1)           | 340 (9.1)          | 623 (22.0)          | 478 (9.4)         |
| ≥6to<12                                     | 49 (13.9)             | 40 (11.3)          | 24 (6.8)           | 625 (16.8)         | 541 (19.1)          | 808 (15.8)        |
| ≥12 to <24                                  | 7 (2.0)               | 29 (8.2)           | 20 (5.6)           | 1073 (28.8)        | 720 (25.5)          | 1043 (20.4)       |
| 224 to <36                                  | 19 (5.4)              | 36 (10.2)          | 25 (7.1)           | 791 (21.2)         | 147 (5.2)           | 702 (13.7)        |
| ≥36 to < 48                                 | 17 (4.8)              | 33 (9.3)           | 34 (9.6)           | 299 (8.0)          | 58 (2.1)            | 622 (12.2)        |
| ≥ 48 to < 60                                | 57 (16.1)             | 59 (16.7)          | 55 (15.5)          | 116 (3.1)          | 60 (2.1)            | 504 (9.9)         |
| ≥60                                         | 185 (52.4)            | 143 (40.4)         | 179 (50.6)         | 205 (5.5)          | 143 (5.1)           | 567 (11.1)        |
| Nunber of dose interruptions, n (%)         |                       |                    |                    |                    |                     |                   |
| 0                                           | 291 (82.4)            | 298 (84.2)         | 283 (79.9)         | 3146 (84.4)        | 2511 (88.8)         | 4276 (83.7)       |
| 1                                           | 41 (11.6)             | 43 (12.1)          | 55 (15.5)          | 433 (11.6)         | 261 (9.2)           | 617 (12.1)        |
| 2                                           | 20 (5.7)              | 10 (2.8)           | 7 (2.0)            | 93 (2.5)           | 44 (1.6)            | 138 (2.7)         |
| 3                                           | 0                     | 3 (0.8)            | 7 (2.0)            | 33 (0.9)           | 10 (0.4)            | 48 (0.9)          |
| 4                                           | 1 (0.3)               | 0                  | 2 (0.6)            | 13 (0.3)           | 2 (0.1)             | 21 (0.4)          |
| 5                                           | 0                     | 0                  | 0                  | 1 (0.0)            | 1 (0.0)             | 1 (0.0)           |
| 6                                           | 0                     | 0                  | 0                  | 5 (0.1)            | 0                   | 5 (0.1)           |

<div style=\"page-break-after: always\"></div>

| >6                                                                                                                         | 0                                                                                                                          | 0                                                                                                                          | 0                                                                                                                          | 4 (0.1)                                                                                                                    | 0                                                                                                                          | 4 (0.1)                                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Reason for dose interruption I, n (%o)                                                                                     | Reason for dose interruption I, n (%o)                                                                                     | Reason for dose interruption I, n (%o)                                                                                     | Reason for dose interruption I, n (%o)                                                                                     | Reason for dose interruption I, n (%o)                                                                                     | Reason for dose interruption I, n (%o)                                                                                     | Reason for dose interruption I, n (%o)                                                                                     |
| Adverse event                                                                                                              | 54 (15.3)                                                                                                                  | 42 (11.9)                                                                                                                  | 65 (18.4)                                                                                                                  | 534 (14.3)                                                                                                                 | 271 (9.6)                                                                                                                  | 760 (14.9)                                                                                                                 |
| Other                                                                                                                      | 14 (4.0)                                                                                                                   | 19 (5.4)                                                                                                                   | 10 (2.8)                                                                                                                   | 77 (2.1)                                                                                                                   | 61 (2.2)                                                                                                                   | 119 (2.3)                                                                                                                  |
| Nunber of dose reductions, n (%)                                                                                           | Nunber of dose reductions, n (%)                                                                                           | Nunber of dose reductions, n (%)                                                                                           | Nunber of dose reductions, n (%)                                                                                           | Nunber of dose reductions, n (%)                                                                                           | Nunber of dose reductions, n (%)                                                                                           | Nunber of dose reductions, n (%)                                                                                           |
| 0                                                                                                                          | 327 (92.6)                                                                                                                 | 336 (94.9)                                                                                                                 | 294 (83.1)                                                                                                                 | 3497 (93.8)                                                                                                                | 2753 (97.3)                                                                                                                | 4724 (92.4)                                                                                                                |
| 1                                                                                                                          | 17 (4.8)                                                                                                                   | 8 (2.3)                                                                                                                    | 32 (9.0)                                                                                                                   | 141 (3.8)                                                                                                                  | 50 (1.8)                                                                                                                   | 232 (4.5)                                                                                                                  |
| 2                                                                                                                          | 4 (1.1)                                                                                                                    | 6 (1.7)                                                                                                                    | 16 (4.5)                                                                                                                   | 51 (1.4)                                                                                                                   | 13 (0.5)                                                                                                                   | 96 (1.9)                                                                                                                   |
| 3                                                                                                                          | 4 (1.1)                                                                                                                    | 2 (0.6)                                                                                                                    | 7 (2.0)                                                                                                                    | 21 (0.6)                                                                                                                   | 7 (0.2)                                                                                                                    | 32 (0.6)                                                                                                                   |
| 4                                                                                                                          | 1 (0.3)                                                                                                                    | 1 (0.3)                                                                                                                    | 3 (0.8)                                                                                                                    | 9 (0.2)                                                                                                                    | 3 (0.1)                                                                                                                    | 14 (0.3)                                                                                                                   |
| 5                                                                                                                          | 0                                                                                                                          | 0                                                                                                                          | 2 (0.6)                                                                                                                    | 6 (0.2)                                                                                                                    | 1 (0.0)                                                                                                                    | 9 (0.2)                                                                                                                    |
| 6                                                                                                                          | 0                                                                                                                          | 0                                                                                                                          | 0                                                                                                                          | 1 (0.0)                                                                                                                    | 0                                                                                                                          | 1 (0.0)                                                                                                                    |
| >6                                                                                                                         | 0                                                                                                                          | 1 (0.3)                                                                                                                    | 0                                                                                                                          | 2 (0.1)                                                                                                                    | 2 (0.1)                                                                                                                    | 2 (0.0)                                                                                                                    |
| Reason for dose reduction I, n (%)                                                                                         | Reason for dose reduction I, n (%)                                                                                         | Reason for dose reduction I, n (%)                                                                                         | Reason for dose reduction I, n (%)                                                                                         | Reason for dose reduction I, n (%)                                                                                         | Reason for dose reduction I, n (%)                                                                                         | Reason for dose reduction I, n (%)                                                                                         |
| Adverse event                                                                                                              | 25 (7.1)                                                                                                                   | 15 (4.2)                                                                                                                   | 53 (15.0)                                                                                                                  | 210 (5.6)                                                                                                                  | 67 (2.4)                                                                                                                   | 345 (6.8)                                                                                                                  |
| Other                                                                                                                      | 3 (0.8)                                                                                                                    | 3 (0.8)                                                                                                                    | 8 (2.3)                                                                                                                    | 40 (1.1)                                                                                                                   | 13 (0.5)                                                                                                                   | 72 (1.4)                                                                                                                   |
| Nunber of dose modifications (includes interruptions, reductions and treatinent suspension due to undetectable PSA), n (%) | Nunber of dose modifications (includes interruptions, reductions and treatinent suspension due to undetectable PSA), n (%) | Nunber of dose modifications (includes interruptions, reductions and treatinent suspension due to undetectable PSA), n (%) | Nunber of dose modifications (includes interruptions, reductions and treatinent suspension due to undetectable PSA), n (%) | Nunber of dose modifications (includes interruptions, reductions and treatinent suspension due to undetectable PSA), n (%) | Nunber of dose modifications (includes interruptions, reductions and treatinent suspension due to undetectable PSA), n (%) | Nunber of dose modifications (includes interruptions, reductions and treatinent suspension due to undetectable PSA), n (%) |
| 0                                                                                                                          | 23 (6.5)                                                                                                                   | 89 (25.1)                                                                                                                  | 28 (7.9)                                                                                                                   | 2821 (75.7)                                                                                                                | 2287 (80.8)                                                                                                                | 3655 (71.5)                                                                                                                |
| 1                                                                                                                          | 263 (74.5)                                                                                                                 | 219 (61.9)                                                                                                                 | 238 (67.2)                                                                                                                 | 608 (16.3)                                                                                                                 | 420 (14.8)                                                                                                                 | (681) 896                                                                                                                  |
| 2                                                                                                                          | 38 (10.8)                                                                                                                  | 31 (8.8)                                                                                                                   | 51 (14.4)                                                                                                                  | 155 (4.2)                                                                                                                  | 81 (2.9)                                                                                                                   | 269 (5.3)                                                                                                                  |
| 3                                                                                                                          | 17 (4.8)                                                                                                                   | 6 (1.7)                                                                                                                    | 11 (3.1)                                                                                                                   | 71 (1.9)                                                                                                                   | 19 (0.7)                                                                                                                   | 104 (2.0)                                                                                                                  |
| 4                                                                                                                          | 7 (2.0)                                                                                                                    | 4 (1.1)                                                                                                                    | 11 (3.1)                                                                                                                   | 34 (0.9)                                                                                                                   | 10 (0.4)                                                                                                                   | 52 (1.0)                                                                                                                   |
| 5                                                                                                                          | 2 (0.6)                                                                                                                    | 2 (0.6)                                                                                                                    | 9 (2.5)                                                                                                                    | 11 (0.3)                                                                                                                   | 5 (0.2)                                                                                                                    | 24 (0.5)                                                                                                                   |
| 6                                                                                                                          | 2 (0.6)                                                                                                                    | 2 (0.6)                                                                                                                    | 2 (0.6)                                                                                                                    | 9 (0.2)                                                                                                                    | 5 (0.2)                                                                                                                    | 12 (0.2)                                                                                                                   |
| >6                                                                                                                         | 1 (0.3)                                                                                                                    | 1 (0.3)                                                                                                                    | 4 (1.1)                                                                                                                    | 19 (0.5)                                                                                                                   | 2 (0.1)                                                                                                                    | 26 (0.5)                                                                                                                   |

definition for EMBARK, study drug includes enzalutamide, leuprolide and placebo (Safety Population). All 1061 treated patients in the EMBARK study received at least 1 dose of enzalutamide orplacebo,the sameas theotherpooled studies.

DatacutoffdatesWere asfollows:EMBARK:31Jan2023;PROSPER:15Oct2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21Mar2019;AsianPREVAIL: 04Nov2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

ADT: androgen deprivation therapy,DB: double-blind; ENZA: enzalutamide;ISS:Integrated Summary of Safety, Mono: monotherapy; OL: open-label; PBO:placebo;SCS: Summary of Clinical Safety.

↑The phase3 studies includeEMBARK(ENZA+ADT andPBO+ADT arms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAIL andAsianPREVAIL

↑Totalenzalutamidesummarizes allenzalutamide-treatedpatients duringDBand/orOLperiodsofEMBARK(ENZA+ADTandENZA Mono arms),PROSPER,ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE

Treatment durationintherespectivephasewas defined as[(thedate oflast dosing)-(the date of first dosing)+1]/30.4375forpatientswhodiscontinued treatment and[(the data cutoff date)-(thedate of first dosing)+1]/30.4375forpatients stillontreatment bythe cutoff date.

[Patientswithmultiplereasonsfordoseintermuptions/reductionswerecountedonlyonceforeachreason.

Per the protocol, treatment was to be suspended in the EMBARK study in patients who had undetectable PSA at week 36. In the safety population, 321/353 (90.9%) patients in the enzalutamide plus ADT group, 240/354 (67.8%) patients in the placebo plus ADT group and 304/354 (85.9%) patients in the enzalutamide monotherapy group had treatment suspended per protocol.

Because study treatment was suspended in the EMBARK study for patients who had undetectable PSA at week 36, a modified treatment duration was calculated excluding the period of treatment suspension.

<div style=\"page-break-after: always\"></div>

Table 38. Enzalutamide / placebo extent of exposure and treatment compliance (EMBARK study, Safety Population)

|                                            | ENZA +LA (N=353)      | PBO +LA (N=354)       | ENZA (N=354)           | Total (N=1061)         |
|--------------------------------------------|-----------------------|-----------------------|------------------------|------------------------|
| TreatmentDuration                          |                       |                       |                        |                        |
| (Months) [1]                               |                       |                       |                        |                        |
|                                            | 353                   | 354                   | 354                    | 1061                   |
| Mean (SD)                                  | 51.9 (26.25)          | 47.8 (24.74)          | 53.0 (24.06)           | 50.9 (25.11)           |
| Median                                     | 60.6                  | 55.6                  | 60.4                   | 59.0                   |
| Min, Max                                   | 0.1, 90.4             | 0.7, 94.1             | 0.4, 95.0              | 0.1, 95.0              |
| Treatment Duration                         |                       |                       |                        |                        |
| Category (Months)                          |                       |                       |                        |                        |
| <6                                         | 19 ( 5.4%)            | 14 ( 4.0%)            | 17 ( 4.8%)             | 50 ( 4.7%)             |
| 6to<12                                     | 49 (13.9%)            | 40 ( 11.3%)           | 24 ( 6.8%)             | 113 ( 10.7%)           |
| 12 to <24                                  | 7( 2.0%)              | 29 ( 8.2%)            | 20 ( 5.6%)             | 56 ( 5.3%)             |
| 24 to <36                                  | 19 ( 5.4%)            | 36 ( 10.2%)           | 25 ( 7.1%)             | 80 ( 7.5%)             |
| 36 to <48                                  | 17 ( 4.8%)            | 33 ( 9.3%)            | 34 ( 9.6%)             | 84 ( 7.9%)             |
| 48 to <60                                  | 57 (16.1%)            | 59 (16.7%)            | 55 (15.5%)             | 171 (16.1%)            |
| 60 to <72                                  | 102 ( 28.9%)          | 81 (22.9%)            | 99 ( 28.0%)            | 282 (26.6%)            |
| >=72                                       | 83 (23.5%)            | 62 (17.5%)            | 80 ( 22.6%)            | 225 (21.2%)            |
| Treatment Suspension Duration (Months) [2] |                       |                       |                        |                        |
| 11                                         | 321                   | 240                   | 304                    | 865                    |
| Mean (SD)                                  | 29.9 (20.61)          | 24.4 (18.68)          | 18.0 (18.14)           | 24.2 (19.88)           |
| Median                                     | 20.2                  | 16.8                  | 11.1                   | 16.8                   |
| Min, Max                                   | 5.7, 87.9             | 3.4, 83.0             | 2.3, 84.9              | 2.3, 87.9              |
| Treatment Suspension                       |                       |                       |                        |                        |
| Duration Category (Months)                 |                       |                       |                        |                        |
| <6                                         | 2 ( 0.6%)             | 5 ( 2.1%)             | 73 (24.0%)             | 80 (9.2%)              |
| 6to<12                                     | 70 ( 21.8%)           | 66 ( 27.5%)           | 108 ( 35.5%)           | 244 (28.2%)            |
| 12 to <24                                  | 108 (33.6%)           | 92 (38.3%)            | 61 (20.1%)             | 261 (30.2%)            |
| 24 to <36                                  | 34 (10.6%)            | 31 (12.9%)            | 20 ( 6.6%)             | 85 ( 9.8%)             |
| 36 to <48                                  | 27 ( 8.4%)            | 5 ( 2.1%)             | 7(2.3%)                | 39 ( 4.5%)             |
| 48 to <60                                  | 41 (12.8%)            | 24 (10.0%)            | 20 ( 6.6%)             | 85 ( 9.8%)             |
| 60 to <72                                  | 27 ( 8.4%)            | 9(3.8%)               | 7( 2.3%)               | 43 ( 5.0%)             |
| >=72                                       | 12 ( 3.7%)            | 8 ( 3.3%)             | 8 ( 2.6%)              | 28 ( 3.2%)             |
| Modified Treatment Duration (Months) [3]   |                       |                       |                        |                        |
| n                                          | 353                   | 354                   | 354                    | 1061                   |
| Mean (SD)                                  | 32.5 (22.31)          | 35.2 (21.46)          | 41.2 (22.49)           | 36.3 (22.37)           |
| Median                                     | 32.4                  | 35.4                  | 45.9                   | 38.7                   |
| Min, Max                                   | 0.1, 83.4             | 0.7, 85.7             | 0.4, 88.9              | 0.1, 88.9              |
| Modified Treatment                         |                       |                       |                        |                        |
| Duration Category (Months)                 |                       |                       |                        |                        |
| <6                                         | 19 ( 5.4%)            | 15 ( 4.2%)            | 17 ( 4.8%)             | 51 ( 4.8%)             |
| 6 to<12                                    | 97 (27.5%)            | 61 ( 17.2%)           | 49 ( 13.8%)            | 207 (19.5%)            |
| 12 to<24                                   | 35 ( 9.9%)            | 52 ( 14.7%)           | 29 ( 8.2%)             | 116 (10.9%)            |
| 24 to <36                                  | 36 (10.2%)            | 52 (14.7%)            | 38 (10.7%)             | 126 (11.9%)            |
| 36 to <48                                  | 66 (18.7%)            | 71 ( 20.1%)           | 63 (17.8%)             | 200 (18.9%)            |
| 48 to <60                                  | 52 (14.7%)            | 54 ( 15.3%)           | 79 ( 22.3%)            | 185 (17.4%)            |
| 60 to<72 >=72                              | 38 (10.8%) 10 ( 2.8%) | 30 ( 8.5%) 19 ( 5.4%) | 54 ( 15.3%) 25 ( 7.1%) | 122 (11.5%) 54 ( 5.1%) |
| Duration of Treatment after Reinitiation   |                       |                       |                        |                        |
| (Months) [4]                               |                       |                       |                        |                        |
| n                                          | 241                   | 203                   | 270                    | 714                    |
| Mean (SD)                                  | 34.0 (17.78)          | 32.0 (16.63)          | 39.0 (18.14)           | 35.3 (17.82)           |
| Median                                     | 35.5                  | 33.1 0.0, 69.5        | 40.4                   | 36.8                   |
| Min, Max                                   | 0.3, 70.8             |                       | 0.3, 77.6              | 0.0, 77.6              |

<div style=\"page-break-after: always\"></div>

| Duration of Treatment                |                  |                  |                  |                  |
|--------------------------------------|------------------|------------------|------------------|------------------|
| after Reinitiation Category (Months) |                  |                  |                  |                  |
| <6                                   | 21 ( 8.7%)       | 17( 8.4%)        | 13 ( 4.8%)       | 51( 7.1%)        |
| 6to<12                               | 15 ( 6.2%)       | 15 ( 7.4%)       | 18 ( 6.7%)       | 48 ( 6.7%)       |
| 12 to <24                            | 34 (14.1%)       | 30 ( 14.8%)      | 30 ( 11.1%)      | 94 (13.2%)       |
| 24 to <36                            | 55 (22.8%)       | 54 (26.6%)       | 40 (14.8%)       | 149 ( 20.9%)     |
| 36 to <48                            | 52 (21.6%)       | 56 (27.6%)       | 76 ( 28.1%)      | 184 (25.8%)      |
| 48 to <60                            | 50 (20.7%)       | 19 ( 9.4%)       | 62 (23.0%)       | 131 (18.3%)      |
| 60 to <72                            | 14 ( 5.8%)       | 12 ( 5.9%)       | 27 (10.0%)       | 53 ( 7.4%)       |
| >=72                                 | 0(0.0%)          | 0(0.0%)          | 4( 1.5%)         | 4( 0.6%)         |
| Total Number of                      |                  |                  |                  |                  |
| Capsules Taken [5]                   |                  |                  |                  |                  |
| n                                    | 352              | 354              | 354              | 1060             |
| Mean (SD)                            | 3694.9 (2594.64) | 4024.0 (2492.73) | 4604.3 (2623.59) | 4108.5 (2595.85) |
| Median                               | 3623.0           | 4067.0           | 5089.0           | 4257.5           |
| Min, Max                             | 0.0,10080.0      | 97.0, 10515.0    | 40.0, 10312.0    | 0.0, 10515.0     |
| Unknown                              | 1                | 0                | 0                | 1                |
| Cumulative Dose                      |                  |                  |                  |                  |
| [9] (Sur)                            |                  |                  |                  |                  |
|                                      | 352              | 354              | 354              | 1060             |
| Mean (SD)                            | 147794.3         | 160959.1         | 184173.0         | 164340.0         |
|                                      | (103785.52)      | (99709.22)       | (104943.68)      | (103833.87)      |
| Median                               | 144920.0         | 162680.0         | 203560.0         | 170300.0         |
| Min, Max                             | 0.0,403200.0     | 3880.0,420600.0  | 1600.0, 412480.0 | 0.0, 420600.0    |
| Unknown                              | 1                | 0                | 0                | 1                |
| Average Daily Dose [L] (Su)          |                  |                  |                  |                  |
|                                      | 352              | 354              | 354              | 1060             |
| Mean (SD)                            | 147.4 (32.17)    | 149.6 (18.83)    | 145.6 (21.52)    | 147.5 (24.86)    |
| Median                               | 154.7            | 155.5            | 154.1            | 154.7            |
| Min, Max                             | 0.0, 507.7       | 20.5,238.1       | 27.1, 177.7      | 0.0, 507.7       |
| Unknown                              | 1                | 0                | 0                | 1                |
| Overall Compliance Rate [8]          |                  |                  |                  |                  |
| n1                                   | 352              | 354              | 354              | 1060             |
| Mean (SD)                            | 103.9 (49.42)    | 100.3 (14.85)    | 100.3 (8.63)     | 101.5 (30.18)    |
| Median                               | 100.0            | 99.7             | 100.1            | 100.0            |
| Min, Max                             | 0.0, 797.9       | 42.3,325.0       | 35.8, 149.4      | 0.0, 797.9       |
| Unknown                              | 1                | 0                | 0                | 1                |
| Category of Overall                  |                  |                  |                  |                  |
| Compliance Rate [8]                  |                  |                  |                  |                  |
| ≤20%                                 | 2 ( 0.6%)        | 0 ( 0.0%)        | 0 ( 0.0%)        | 2 ( 0.2%)        |
| >=20% to <40%                        | 0 ( 0.0%)        | 0 ( 0.0%)        | 1( 0.3%)         | 1 (<0.1%)        |
| >=40% to <60%                        | 3 ( 0.8%)        | 3 ( 0.8%)        | 1( 0.3%)         | 7( 0.7%)         |
| >=60% to <80%                        | 5 ( 1.4%)        | 3 ( 0.8%)        | 5 ( 1.4%)        | 13 ( 1.2%)       |
| >=80% to 100%                        | 168 (47.6%)      | 197 ( 55.6%)     | 167 (47.2%)      | 532 ( 50.1%)     |
| >100% to <105%                       | 116 (32.9%)      | 113 (31.9%)      | 138 ( 39.0%)     | 367 (34.6%)      |
| >=105%                               | 58 (16.4%)       | 38 ( 10.7%)      | 42 (11.9%)       | 138 (13.0%)      |
| Unknown                              | 1 ( 0.3%)        | 0 ( 0.0%)        | 0 ( 0.0%)        | 1 ( <0.1%)       |

The data cutoff date is 31JAN2023.

[1]: (Last dose date of study drug - First dose date of study drug + 1)/30.4375.

[2]:Last date of suspension without drug (i.e.,First dose after suspension -1 or Date of data cutoff, whichever occurs first)-First date of suspension + 1.

[3]:Treatment duration -Treatment suspension duration + 1 for patients who suspended treatment and Reinitiated. Tre atmentdurationotherwise.

[4]: Date of last dose of study drug -First dose after suspension + 1

[5]: The number of capsules dispensed - the number of capsules returmed. Capsules from bottles not returmed are assu med to have not been taken.

- [6]: Number of capsules taken x 40 mg.
- [7]:The cumulative dose divided by themodified treatment duration.

[8]: Number of capsules taken during the study/expected number of capsules during the study multiplied by 100.

<div style=\"page-break-after: always\"></div>

Table 39. Demographic and baseline characteristics (Safety Groups)

|                                           | EMBARK                   | EMBARK                  | EMBARK                   | Phase 3↑                 | Phase 3↑                | Totalt ENZA+ADT         |
|-------------------------------------------|--------------------------|-------------------------|--------------------------|--------------------------|-------------------------|-------------------------|
| BaselineCharacteristics                   | DB ENZA+ADT (n=353)      | DB PBO+ADT (n =354)     | ENZA Mono (n=354)        | DB ENZA+ADT (n =3728)    | DB PBO+ADT (n=2829)     | (n=5110)                |
| Age group (years), n (%)                  |                          |                         |                          |                          |                         |                         |
| ≤65                                       | 79 (22.4)                | 90 (25.4)               | 91 (25.7)                | 805 (21.6)               | 668 (23.6)              | 1122 (22.0)             |
| 65 to ≤ 75                                | 201 (56.9)               | 177 (50.0)              | 173 (48.9)               | 1650 (44.3)              | 1239 (43.8)             | 2285 (44.7)             |
| 75 to ≤ 85                                | 72 (20.4)                | 82 (23.2)               | 84 (23.7)                | 1116 (29.9)              | 811 (28.7)              | 1498 (29.3)             |
| ≥85                                       | 1 (0.3)                  | 5 (1.4)                 | 6 (1.7)                  | 157 (4.2)                | 111 (3.9)               | 205 (4.0)               |
| Age, years                                |                          |                         |                          |                          |                         |                         |
| Mean (SD)                                 | 69.1 (6.5)               | 69.1 (7.3)              | 69.1 (7.7)               | 70.9 (8.2)               | 70.5 (8.3)              | 70.8 (8.2)              |
| Median (min, max)                         | 69.0 (51, 87)            | 69.5 (50, 92)           | 69.0 (49, 93)            | 71.0 (41, 95)            | 71.0 (42, 93)           | 71.0 (41, 96)           |
| Race, n (%)                               |                          |                         |                          |                          |                         |                         |
| AmericanIndian orAlaskaNative             | 4 (1.1)                  | 1 (0.3)                 | 0                        | 6 (0.2)                  | 2 (0.1)                 | 6 (0.1)                 |
| Asian                                     | 26 (7.4)                 | 26 (7.3)                | 26 (7.3)                 | 535 (14.4)               | 479 (16.9)              | 710 (13.9)              |
| Black orAficanAmerican                    | 16 (4.5)                 | 16 (4.5)                | 15 (4.2)                 | 94 (2.5)                 | 67 (2.4)                | 158 (3.1)               |
| Islander NativeHawaiian or Other Pacific  | 1 (0.3)                  | 0                       | 0                        | 6 (0.2)                  | 3 (0.1)                 | 8 (0.2)                 |
| White                                     | 291 (82.4)               | 298 (84.2)              | 294 (83.1)               | 2840 (76.2)              | 2094 (74.0)             | 3932 (76.9)             |
| Multiple                                  | 2 (0.6)                  | 3 (0.8)                 | 4 (1.1)                  | 9 (0.2)                  | 9 (0.3)                 | 16 (0.3)                |
| Other                                     | 3 (0.8)                  | 5 (1.4)                 | 1 (0.3)                  | 50 (1.3)                 | 22 (0.8)                | 60 (1.2)                |
| Not reported                              | 10 (2.8)                 | 5 (1.4)                 | 14 (4.0)                 | 10 (0.3)                 | 5 (0.2)                 | 24 (0.5)                |
| Unknow/missing                            | 0                        | 0                       | 0                        | 178 (4.8)                | 148 (5.2)               | 196 (3.8)               |
| Ethnicity, n (%)                          |                          |                         |                          |                          |                         |                         |
| Hispanic or Latino                        | 17 (4.8)                 | 23 (6.5)                | 18 (5.1)                 | 185 (5.0)                | 141 (5.0)               | 259 (5.1)               |
| Not Hispanic or Latino                    | 317 (89.8)               | 319 (90.1)              | 319 (90.1)               | 3155 (84.6)              | 2339 (82.7)             | 4379 (85.7)             |
| Not reported                              | 19 (5.4)                 | 12 (3.4)                | 17 (4.8)                 | 156 (4.2)                | 123 (4.3)               | 187 (3.7)               |
| Unknown/Missing                           | 0                        | 0                       | 0                        | 232 (6.2)                | 226 (8.0)               | 285 (5.6)               |
| Geographic region, n (%)                  |                          |                         |                          |                          |                         |                         |
| North America                             | 143 (40.5)               | 135 (38.1)              | 133 (37.6)               | 851 (22.8)               | 614 (21.7)              | 1373 (26.9)             |
| Europe                                    | 129 (36.5)               | 127 (35.9)              | 145 (41.0)               | 1849 (49.6)              | 1367 (48.3)             | 2401 (47.0)             |
| Rest of world                             | 81 (22.9)                | 92 (26.0)               | 76 (21.5)                | 1028 (27.6)              | 848 (30.0)              | 1336 (26.1)             |
| Weight, kg                                |                          |                         |                          |                          |                         |                         |
| n                                         | 353                      | 354                     | 354                      | 3718                     | 2822                    | 5095                    |
| Mean (SD)                                 | 87.38 (15.17)            | 87.27 (15.89)           | 87.54 (15.56)            | 83.33 (15.86)            | 83.15 (16.33)           | 84.15 (16.53)           |
| Median (min, max)                         | 85.00 (55.6, 157.7)      | 85.80                   | 85.05 (50.0, 171.8)      | 82.00 (42.7,163.0)       | 81.30 (33.9,167.0)      | 82.40 (36.4, 249.7)     |
| BMI, kg/m²                                |                          | (53.7, 148.2)           |                          |                          |                         |                         |
| n                                         | 351                      | 351                     | 353                      | 2915                     | 2419                    | 4236                    |
| Mean (SD)                                 | 28.51 (4.22)             | 28.38 (4.36)            | 28.61 (4.71)             | 27.84 (4.53)             | 27.69 (4.59)            | 28.03 (4.73)            |
| Median (min, max)                         | 28.10 (19.9, 47.1)       | 28.00 (18.5, 45.9)      | 27.80 (17.3, 53.2)       | 27.29 (15.8, 51.1)       | 27.14 (14.9, 51.5)      | 27.45 (11.4, 60.5)      |
| Baseline absolute neutrophil count (10/L) |                          |                         |                          |                          |                         |                         |
| n                                         | 353                      | 354                     | 354                      | 3717                     | 2825                    | 5040                    |
| Mean (SD)                                 | 3901.76 (1241.30)        | 3996.89 (1308.94)       | 4049.89 (1474.21)        | 4159.71 (1592.07)        | 4238.55 (1726.26)       | 4174.48 (1624.86)       |
| Median (min, max)                         | 3730.00 (1480.0,10050.0) | 3815.00 (1500.0,9550.0) | 3830.00 (1590.0,15300.0) | 3890.00 (600.0, 17540.0) | 3920.00 (860.0,26810.0) | 3900.00 (160.0,17540.0) |
| Baseline hemoglobin (g/L)                 |                          |                         |                          |                          |                         |                         |
| n                                         | 353                      | 354                     | 354                      | 3721                     | 2826                    | 5045                    |
| Mean (SD)                                 | 145.51 (11.80)           | 146.00 (11.39)          | 145.55 (11.70)           | 130.27 (15.33)           | 131.46 (15.08)          | 131.18 (15.33)          |
|                                           | 145.00                   | 146.00                  | 147.00                   | 131.00                   | 132.00                  | 132.00                  |
| Median (min, max)                         | (110.0, 179.0)           | (102.0, 178.0)          | (113.0, 173.0)           | (63.0, 179.0)            | (57.0, 179.0)           | (63.0, 179.0)           |
| Baseline albumin (gL)                     |                          |                         |                          |                          |                         |                         |
| n                                         | 353                      | 354                     | 354                      | 3723                     | 2826                    | 5050                    |
| Mean (SD)                                 | 44.05 (2.47)             | 44.15 (2.52)            | 44.23 (2.68)             | 40.51 (4.09)             | 40.81 (4.11)            | 40.82 (4.15)            |
| Median (min, max)                         | 44.00 (37.0, 52.0)       | 44.00 (34.0, 50.0)      | 45.00 (37.0, 51.0)       | 41.00 (25.0, 56.0)       | 41.00 (24.0, 53.0)      | 41.00 (25.0, 57.7)      |

|                              | EMBARK              | EMBARK             | EMBARK             | Phase3↑              | Phase3↑             |                          |
|------------------------------|---------------------|--------------------|--------------------|----------------------|---------------------|--------------------------|
| Baseline Characteristics     | DB ENZA+ADT (n=353) | DB PBO+ADT (n=354) | ENZA Mono (n =354) | DB ENZA+ADT (n=3728) | DB PBO+ADT (n=2829) | Totalt ENZA±ADT (n=5110) |
| Baseline creatinine (μmol/L) |                     |                    |                    |                      |                     |                          |
| n                            | 353                 | 354                | 354                | 3723                 | 2828                | 5051                     |
| Mean (SD)                    | 88.87 (17.61)       | 88.85 (17.61)      | 88.11 (18.30)      | 86.76 (24.88)        | 87.10 (22.75)       | 88.93 (31.84)            |
| Median (min, max)            | 88.40 (52.0, 185.6) | 88.00 (53.0,185.6) | 85.50 (53.0,176.0) | 82.00 (29.0, 771.0)  | 83.00 (35.0, 345.0) | 83.00 (21.0, 771.0)      |

All patients who received at least 1 dose of study drug (enzalutamide, placebo) in their respective phase 3 study or received at least 1 dose of enzalutamide in phase 2 studies. For EMBARK,study drug includes enzalutamide, leuprolide and placebo (Safety Population).

Data cutoff dates were as follows: EMBARK: 31 Jan 2023; PROSPER: 15 Oct 2019; ARCHES: 28 May 2021; AFFIRM: 20 Feb 2018; PREVAIL: 21 Mar 2019; Asian PREVAIL: 04 Nov 2020; TERRAIN: 17 Feb 2018 and STRIVE: 30 May 2018.

ADT: androgen deprivation therapy; BMI: body mass index; DB: double-blind; ENZA: enzalutamide; ISS: Integrated Summary of Safety; max: maximum; min: minimum; Mono: monotherapy; OL: open-label;PBO: placebo; SCS: Summary of Clinical Safety.

↑ The phase 3 studies include EMBARK (ENZA+ADT and PBO+ADT arms) and DB phase for PROSPER, ARCHES, AFFIRM, PREVAIL and Asian PREVAIL.

Total enzalutamide summarizes all enzalutamide-treated patients during DB and/or OL periods of EMBARK (ENZA+ADT and ENZA Mono arms), PROSPER, ARCHES, AFFIRM, PREVAIL, Asian PREVAIL, TERRAIN and STRIVE.

<div style=\"page-break-after: always\"></div>

Table 40. Baseline disease characteristics and medical history (Safety Groups)

|                                                                           | EMBARK                                                                    | EMBARK                                                                    | EMBARK                                                                    | Phase3↑                                                                   | Phase3↑                                                                   | Totalt ENZA+ADT                                                           |
|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Baseline Characteristics                                                  | DB ENZA+ADT (n= 353)                                                      | DB PBO+ADT (n=354)                                                        | ENZA Mono (n= 354)                                                        | DB ENZA+ADT (n=3728)                                                      | DB PBO+ADT (n=2829)                                                       | (n=5110)                                                                  |
| Disease stage at study entry per investigator, n (%)                      | Disease stage at study entry per investigator, n (%)                      | Disease stage at study entry per investigator, n (%)                      | Disease stage at study entry per investigator, n (%)                      | Disease stage at study entry per investigator, n (%)                      | Disease stage at study entry per investigator, n (%)                      | Disease stage at study entry per investigator, n (%)                      |
| Nonmetastatic (M0)                                                        | 352 (99.7)                                                                | 353 (99.7)                                                                | 353 (99.7)                                                                | 1267 (34.0)                                                               | 807 (28.5)                                                                | 1798 (35.2)                                                               |
| Metastatic (M1)                                                           | 1 (0.3)                                                                   | 1 (0.3)                                                                   | 1 (0.3)                                                                   | 2461 (66.0)                                                               | 2022 (71.5)                                                               | 3312 (64.8)                                                               |
| Baseline ECOG performance status,n (%)                                    | Baseline ECOG performance status,n (%)                                    | Baseline ECOG performance status,n (%)                                    | Baseline ECOG performance status,n (%)                                    | Baseline ECOG performance status,n (%)                                    | Baseline ECOG performance status,n (%)                                    | Baseline ECOG performance status,n (%)                                    |
| 0                                                                         | 326 (92.4)                                                                | 334 (94.4)                                                                | 321 (90.7)                                                                | 2512 (67.4)                                                               | 2023 (71.5)                                                               | 3504 (68.6)                                                               |
| 1                                                                         | 26 (7.4)                                                                  | 19 (5.4)                                                                  | 33 (9.3)                                                                  | 1143 (30.7)                                                               | 773 (27.3)                                                                | 1453 (28.4)                                                               |
| 2                                                                         | 1 (0.3)                                                                   | 0                                                                         | 0                                                                         | 71 (1.9)                                                                  | 32 (1.1)                                                                  | 83 (1.6)                                                                  |
| 23                                                                        | 0                                                                         | 0                                                                         | 0                                                                         | 0                                                                         | 0                                                                         | 2 (0.0)                                                                   |
| Missing                                                                   | 0                                                                         | 1 (0.3)                                                                   | 0                                                                         | 2 (0.1)                                                                   | 1 (0.0)                                                                   | 68 (1.3)                                                                  |
| Category of baseline pain score as assessed by BPI-SF question 3, n (%)   | Category of baseline pain score as assessed by BPI-SF question 3, n (%)   | Category of baseline pain score as assessed by BPI-SF question 3, n (%)   | Category of baseline pain score as assessed by BPI-SF question 3, n (%)   | Category of baseline pain score as assessed by BPI-SF question 3, n (%)   | Category of baseline pain score as assessed by BPI-SF question 3, n (%)   | Category of baseline pain score as assessed by BPI-SF question 3, n (%)   |
| 0 to 1                                                                    | 210 (59.5)                                                                | 219 (61.9)                                                                | 206 (58.2)                                                                | 2183 (58.6)                                                               | 1738 (61.4)                                                               | 3032 (59.3)                                                               |
| 2 to 3                                                                    | 65 (18.4)                                                                 | 71 (20.1)                                                                 | 67 (18.9)                                                                 | 800 (21.5)                                                                | 622 (22.0)                                                                | 1097 (21.5)                                                               |
| 4 to 10                                                                   | 51 (14.4)                                                                 | 41 (11.6)                                                                 | 54 (15.3)                                                                 | 605 (16.2)                                                                | 375 (13.3)                                                                | 755 (14.8)                                                                |
| Missing                                                                   | 27 (7.6)                                                                  | 23 (6.5)                                                                  | 27 (7.6)                                                                  | 140 (3.8)                                                                 | 94 (3.3)                                                                  | 226 (4.4)                                                                 |
| Timefrominitialdiagnosistorandomization,months                            | Timefrominitialdiagnosistorandomization,months                            | Timefrominitialdiagnosistorandomization,months                            | Timefrominitialdiagnosistorandomization,months                            | Timefrominitialdiagnosistorandomization,months                            | Timefrominitialdiagnosistorandomization,months                            | Timefrominitialdiagnosistorandomization,months                            |
| n                                                                         | 353                                                                       | 354                                                                       | 354                                                                       | 3721                                                                      | 2820                                                                      | 5096                                                                      |
| Mean (SD)                                                                 | 67.31 (44.35)                                                             | 70.40 (48.99)                                                             | 72.70 (52.10)                                                             | 72.86 (59.06)                                                             | 65.42 (56.72)                                                             | 71.49 (59.06)                                                             |
| Median (min, max)                                                         | 56.87 (5.8, 222.4)                                                        | 64.36                                                                     | 61.51 (6.0, 297.4)                                                        | 59.80                                                                     | 52.47 (0.1, 305.5)                                                        | 58.06 (0.2, 400.7)                                                        |
| (5.7, 305.5) (0.2,381.8) Total Gleason score at initial diagnosiss, n (%) | (5.7, 305.5) (0.2,381.8) Total Gleason score at initial diagnosiss, n (%) | (5.7, 305.5) (0.2,381.8) Total Gleason score at initial diagnosiss, n (%) | (5.7, 305.5) (0.2,381.8) Total Gleason score at initial diagnosiss, n (%) | (5.7, 305.5) (0.2,381.8) Total Gleason score at initial diagnosiss, n (%) | (5.7, 305.5) (0.2,381.8) Total Gleason score at initial diagnosiss, n (%) | (5.7, 305.5) (0.2,381.8) Total Gleason score at initial diagnosiss, n (%) |
| Low (2 to 4)                                                              | 1 (0.3)                                                                   | 0                                                                         | 3 (0.8)                                                                   | 41 (1.1)                                                                  | 30 (1.1)                                                                  | 52 (1.0)                                                                  |
| Medium (5 to 7)                                                           | 232 (65.7)                                                                | 242 (68.4)                                                                | 235 (66.4)                                                                | 1703 (45.7)                                                               | 1260 (44.5)                                                               | 2373 (46.4)                                                               |
| High (8 to 10)                                                            | 119 (33.7)                                                                | 111 (31.4)                                                                | 111 (31.4)                                                                | 1814 (48.7)                                                               | 1425 (50.4)                                                               | 2438 (47.7)                                                               |
| Missing/unknown                                                           | 1 (0.3)                                                                   | 1 (0.3)                                                                   | 5 (1.4)                                                                   | 170 (4.6)                                                                 | 114 (4.0)                                                                 | 247 (4.8)                                                                 |
| Medical history of hypertension, n (%)                                    | Medical history of hypertension, n (%)                                    | Medical history of hypertension, n (%)                                    | Medical history of hypertension, n (%)                                    | Medical history of hypertension, n (%)                                    | Medical history of hypertension, n (%)                                    | Medical history of hypertension, n (%)                                    |
| Yes                                                                       | 212 (60.1)                                                                | 220 (62.1)                                                                | 214 (60.5)                                                                | 2175 (58.3)                                                               | 1674 (59.2)                                                               | 3050 (59.7)                                                               |
| No                                                                        | 141 (39.9)                                                                | 134 (37.9)                                                                | 140 (39.5)                                                                | 1553 (41.7)                                                               | 1155 (40.8)                                                               | 2060 (40.3)                                                               |
| Medical history of cardiovascular disease, n (%)                          | Medical history of cardiovascular disease, n (%)                          | Medical history of cardiovascular disease, n (%)                          | Medical history of cardiovascular disease, n (%)                          | Medical history of cardiovascular disease, n (%)                          | Medical history of cardiovascular disease, n (%)                          | Medical history of cardiovascular disease, n (%)                          |
| Yes                                                                       | 52 (14.7)                                                                 | 49 (13.8)                                                                 | 54 (15.3)                                                                 | 700 (18.8)                                                                | 510 (18.0)                                                                | 965 (18.9)                                                                |
| No                                                                        | 301 (85.3)                                                                | 305 (86.2)                                                                | 300 (84.7)                                                                | 3028 (81.2)                                                               | 2319 (82.0)                                                               | 4145 (81.1)                                                               |
| Medical history of diabetes, n (%)                                        | Medical history of diabetes, n (%)                                        | Medical history of diabetes, n (%)                                        | Medical history of diabetes, n (%)                                        | Medical history of diabetes, n (%)                                        | Medical history of diabetes, n (%)                                        | Medical history of diabetes, n (%)                                        |
| Yes                                                                       | 60 (17.0)                                                                 | 76 (21.5)                                                                 | 73 (20.6)                                                                 | 701 (18.8)                                                                | 537 (19.0)                                                                | 1001 (19.6)                                                               |
| No                                                                        | 293 (83.0)                                                                | 278 (78.5)                                                                | 281 (79.4)                                                                | 3027 (81.2)                                                               | 2292 (81.0)                                                               | 4109 (80.4)                                                               |
| Medical history of hypercholesterolemia and/or hyperlipidemia, n (%)      | Medical history of hypercholesterolemia and/or hyperlipidemia, n (%)      | Medical history of hypercholesterolemia and/or hyperlipidemia, n (%)      | Medical history of hypercholesterolemia and/or hyperlipidemia, n (%)      | Medical history of hypercholesterolemia and/or hyperlipidemia, n (%)      | Medical history of hypercholesterolemia and/or hyperlipidemia, n (%)      | Medical history of hypercholesterolemia and/or hyperlipidemia, n (%)      |
| Yes                                                                       | 128 (36.3)                                                                | 123 (34.7)                                                                | 144 (40.7)                                                                | 1037 (27.8)                                                               | 813 (28.7)                                                                | 1559 (30.5)                                                               |
| No                                                                        | 225 (63.7)                                                                | 231 (65.3)                                                                | 210 (59.3)                                                                | 2691 (72.2)                                                               | 2016 (71.3)                                                               | 3551 (69.5)                                                               |
| Prior prostatectomy, n (%)                                                | Prior prostatectomy, n (%)                                                | Prior prostatectomy, n (%)                                                | Prior prostatectomy, n (%)                                                | Prior prostatectomy, n (%)                                                | Prior prostatectomy, n (%)                                                | Prior prostatectomy, n (%)                                                |
| Yes                                                                       | 268 (75.9)                                                                | 251 (70.9)                                                                | 265 (74.9)                                                                | 1097 (29.4)                                                               | 852 (30.1)                                                                | 1625 (31.8)                                                               |
| No                                                                        | 85 (24.1)                                                                 | 103 (29.1)                                                                | 89 (25.1)                                                                 | 2631 (70.6)                                                               | 1977 (69.9)                                                               | 3485 (68.2)                                                               |
| Prior orchiectomy, n (%)                                                  | Prior orchiectomy, n (%)                                                  | Prior orchiectomy, n (%)                                                  | Prior orchiectomy, n (%)                                                  | Prior orchiectomy, n (%)                                                  | Prior orchiectomy, n (%)                                                  | Prior orchiectomy, n (%)                                                  |
| Yes                                                                       | 0                                                                         | 0                                                                         | 0                                                                         | 286 (7.7)                                                                 | 202 (7.1)                                                                 | 355 (6.9)                                                                 |
| No                                                                        | 353 (100)                                                                 | 354 (100)                                                                 | 354 (100)                                                                 | 3442 (92.3)                                                               | 2627 (92.9)                                                               | 4755 (93.1)                                                               |
| Prior radiotherapy, n (%)                                                 | Prior radiotherapy, n (%)                                                 | Prior radiotherapy, n (%)                                                 | Prior radiotherapy, n (%)                                                 | Prior radiotherapy, n (%)                                                 | Prior radiotherapy, n (%)                                                 | Prior radiotherapy, n (%)                                                 |
| Yes                                                                       | 264 (74.8)                                                                | 281 (79.4)                                                                | 255 (72.0)                                                                | 1787 (47.9)                                                               | 1312 (46.4)                                                               | 2462 (48.2)                                                               |
| No                                                                        | 89 (25.2)                                                                 | 73 (20.6)                                                                 | 99 (28.0)                                                                 | 1941 (52.1)                                                               | 1517 (53.6)                                                               | 2648 (51.8)                                                               |

Allpatientswhoreceived atleast1doseofstudydrug（enzalutamide,placebo)intheirrespectivephase3studyorreceived at least1dose ofenzalutamideinphase2studies.For EMBARK,study drugincludesenzalutamide,leuprolide andplacebo(SafetyPopulation).

Data cutoff dates Were as follows:EMBARK:31Jan2023;PROSPER:15 Oct 2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21Mar2019;AsianPREVAIL: 04Nov2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

ADT: androgen deprivation therapy, BPI-SF: Brief Pain Inventory - Short Fomm; DB: double-blind; ECOG: Easterm Clinical Oncology Group; ENZA: enzalutamide; ISS: Integrated Summary of Safety, max: maximum; min: minimum; Mono: monotherapy; OL: open-label; PBO: placebo; SCS: Summary of Clinical Safety.

↑ The phase 3 shudies include EMBARK (ENZA+ADT and PBO+ADT arms) and DB phase for PROSPER, ARCHES, AFFIRM, PREVAIL and Asian PREVAIL

Totalenzalutamide summarizes allenzalutamide-treatedpatients duringDBand/orOLperiodsofEMBARK(ENZA+ADTandENZA Monoarms),PROSPER,ARCHES, AFFRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

The Gleason score at initial diagnosis was provided ifthe primary and secondary Gleason scores were unavailable; otherwise,the score was calculated as the sum of the primary and secondary scores for those with primary and secondary scores. The unknown category was for patients with unknown primary, secondary and total Gleason scores.

## Adverse events

Treatment-Emergent Adverse Events (TEAEs)

<div style=\"page-break-after: always\"></div>

Table 41. Overall summary of Treatment-Emergent Adverse Events (TEAEs) (Safety Groups)

|                                             | EMIBARK               | EMIBARK              | EMIBARK              | Phase 3↑               | Phase 3↑              | Totalt ENZA+ADT   |
|---------------------------------------------|-----------------------|----------------------|----------------------|------------------------|-----------------------|-------------------|
| Category, n (%)                             | DB ENZA+ADT (n = 353) | DB PBO+ADT (n = 354) | ENZA MIono (n = 354) | DB ENZA+ADT (n = 3728) | DB PBO+ADT (n = 2829) | (n = 5110)        |
| Any TEAE                                    | 343 (97.2)            | 345 (97.5)           | 347 (98.0)           | 3536 (94.8)            | 2576 (91.1)           | 4848 (94.9)       |
| TEAE within the first 30 days               | 199/353 (56.4)        | 180/354 (50.8)       | 181/354 (51.1)       | 2193/3728 (58.8)       | 1578/2829 (55.8)      | 2866/5110 (56.1)  |
| TEAEbetween31to180days                      | 273/353 (77.3)        | 257/353 (72.8)       | 282/354 (79.7)       | 2803/3720 (75.3)       | 2031/2816 (72.1)      | 3762/5098 (73.8)  |
| TEAE between181to365days                    | 196/336 (58.3)        | 201/344 (58.4)       | 192/345 (55.7)       | 2061/3200 (64.4)       | 1034/1796 (57.6)      | 2732/4389 (62.2)  |
| TEAE between366to540days                    | 150/285 (52.6)        | 158/306 (51.6)       | 159/313 (50.8)       | 1400/2554 (54.8)       | 573/1183 (48.4)       | 1894/3530 (53.7)  |
| TEAE between 541 to 730 days                | 151/285 (53.0)        | 160/293 (54.6)       | 180/305 (59.0)       | 1066/2027 (52.6)       | 324/735 (44.1)        | 1597/2880 (55.5)  |
| TEAE between 731 to 900 days(2.5 years)     | 154/280 (55.0)        | 136/272 (50.0)       | 152/293 (51.9)       | 678/1521 (44.6)        | 190/425 (44.7)        | 1204/2414 (49.9)  |
| TEAE between 2.5 to 3 years                 | 146/270 (54.1)        | 127/255 (49.8)       | 163/285 (57.2)       | 408/1116 (36.6)        | 159/333 (47.7)        | 1029/2081 (49.4)  |
| TEAEbetween3to4years                        | 168/260 (64.6)        | 148/238 (62.2)       | 176/268 (65.7)       | 305/785 (38.9)         | 159/265 (60.0)        | 997/1790 (55.7)   |
| TEAEbetween4to5years                        | 147/244 (60.2)        | 127/205 (62.0)       | 140/238 (58.8)       | 163/504 (32.3)         | 127/207 (61.4)        | 554/1247 (44.4)   |
| TEAEbetween5to6years                        | 99/185 (53.5)         | 71/145 (49.0)        | 90/179 (50.3)        | 99/272 (36.4)          | 71/145 (49.0)         | 276/737 (37.4)    |
| TEAE>6years                                 | 40/84 (47.6)          | 31/63 (49.2)         | 42/81 (51.9)         | 40/99 (40.4)           | 31/63 (49.2)          | 116/328 (35.4)    |
| TEAEleadingtostudydrugdiscontinuations      | 60 (17.0)             | 32 (9.0)             | 55 (15.5)            | 596 (16.0)             | 437 (15.4)            | 979 (19.2)        |
| TEAEleading to doseinterruption             | 56 (15.9)             | 43 (12.1)            | 66 (18.6)            | 541 (14.5)             | 290 (10.3)            | 829 (16.2)        |
| TEAE leading to dose reduction              | 25 (7.1)              | 16 (4.5)             | 56 (15.8)            | 208 (5.6)              | 67 (2.4)              | 352 (6.9)         |
| Grade ≥3 TEAE                               | 164 (46.5)            | 151 (42.7)           | 177 (50.0)           | 1616 (43.3)            | 1034 (36.6)           | 2454 (48.0)       |
| Grade≥3TEAE within the first 30 days        | 11/353 (3.1)          | 9/354 (2.5)          | 11/354 (3.1)         | 219/3728 (5.9)         | 183/2829 (6.5)        | 318/5110 (6.2)    |
| Grade≥3TEAEbetween31to180days               | 41/353 (11.6)         | 35/353 (9.9)         | 26/354 (7.3)         | 638/3720 (17.2)        | 567/2816 (20.1)       | 866/5098 (17.0)   |
| Grade≥3TEAE between181to365days             | 30/336 (8.9)          | 26/344 (7.6)         | 27/345 (7.8)         | 474/3200 (14.8)        | 228/1796 (12.7)       | 627/4389 (14.3)   |
| Grade≥3TEAE between366to540days             | 17/285 (6.0)          | 22/306 (7.2)         | 25/313 (8.0)         | 304/2554 (11.9)        | 118/1183 (10.0)       | 411/3530 (11.6)   |
| Grade≥3TEAE between541to730days             | 21/285 (7.4)          | 27/293 (9.2)         | 25/305 (8.2)         | 236/2027 (11.6)        | 61/735 (8.3)          | 357/2880 (12.4)   |
| Grade≥3TEAE between731 to900 days(2.5years) | 25/280 (8.9)          | 18/272 (6.6)         | 26/293 (8.9)         | 155/1521 (10.2)        | 26/425 (6.1)          | 277/2414 (11.5)   |
| Grade≥3TEAE between2.5to3years              | 26/270 (9.6)          | 22/255 (8.6)         | 26/285 (9.1)         | 86/1116 (7.7)          | 30/333 (9.0)          | 222/2081 (10.7)   |
| Grade≥3TEAEbetween3to4years                 | 37/260 (14.2)         | 31/238 (13.0)        | 44/268 (16.4)        | 77/785 (9.8)           | 33/265 (12.5)         | 256/1790 (14.3)   |
| Grade≥3TEAEbetween4 to5years                | 37/244 (15.2)         | 25/205 (12.2)        | 38/238 (16.0)        | 43/504 (8.5)           | 25/207 (12.1)         | 154/1247 (12.3)   |
| Grade ≥3 TEAE between5 to6years             | 24/185 (13.0)         | 14/145 (9.7)         | 21/179 (11.7)        | 24/272 (8.8)           | 14/145 (9.7)          | 66/737 (9.0)      |
| Grade ≥3 TEAE >6 years                      | 14/84 (16.7)          | 7/63 (11.1)          | 10/81 (12.3)         | 14/99 (14.1)           | 7/63 (11.1)           | 39/328 (11.9)     |
| Serious TEAE                                | 123 (34.8)            | 112 (31.6)           | 131 (37.0)           | 1277 (34.3)            | 781 (27.6)            | 1971 (38.6)       |
| Grade≥3 seriousTEAE                         | 110 (31.2)            | 100 (28.2)           | 116 (32.8)           | 1113 (29.9)            | 676 (23.9)            | 1733 (33.9)       |
| TEAE leading to death                       | 6 (1.7)               | 3 (0.8)              | 8 (2.3)              | 158 (4.2)              | 72 (2.5)              | 288 (5.6)         |
| Drug-related TEAE                           | 307 (87.0)            | 286 (80.8)           | 314 (88.7)           | 2491 (66.8)            | 1526 (53.9)           | 3413 (66.8)       |
| Drug-related grade ≥3 TEAET                 | 62 (17.6)             | 31 (8.8)             | 57 (16.1)            | 462 (12.4)             | 209 (7.4)             | 680 (13.3)        |
| Drug-related seriousTEAE                    | 26 (7.4)              | 8 (2.3)              | 17 (4.8)             | 172 (4.6)              | 87 (3.1)              | 279 (5.5)         |
| Drug-related TEAEs leading to death         | 0                     | 0                    | 0                    | 6 (0.2)                | 2 (0.1)               | 13 (0.3)          |
| Grade3or4TEAE                               | 164 (46.5)            | 149 (42.1)           | 175 (49.4)           | 1570 (42.1)            | 1015 (35.9)           | 2376 (46.5)       |

Data cutoff dates were as follows:EMBARK:31Jan 2023;PROSPER:15 Oct 2019;ARCHES:28May 2021;AFFIRM:20Feb2018;PREVAIL:21 Mar 2019;AsianPREVAIL: 04Nov2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

Number ofpatients (n) reporting at least 1 event and percentage ofpatients (%) are shown.NCI-CTCAE v4.03.

ADT: androgen deprivation therapy, AE: adverse event; CRF: case report form; DB: double-blind; ENZA: enzalutamide; ISS: Integrated Summary of Safety, Mono: monotherapy, NCI-CTCAE:NationalCancerInstitute CommonTerminologyCriteria forAdverseEvents;OL:open-label;PBO:placebo;SCS:Summary ofClinicalSafety;TEAE:treatmentemergent adverseevent.

↑Thephase3studies includeEMBARK(ENZA+ADT andPBO+ADT arms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAIL andAsianPREVAIL

↑Totalenzalutamidesummarizes allenzalutamide-treatedpatientsduringDBand/orOLperiodsofEMBARK(ENZA+ADT andENZA Mono arms),PROSPER,ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAIN andSTRIVE.

TEAEleadingtostudy drugdiscontinuationisfromAECRF andincludesTEAEswithactiontakenofpermanent discontinuation.

Drug-related TEAEs are TEAEs that were judged by the investigator as possibly, probably or definitely related to study drug.

In the EMBARK study, ischemic heart disease occurred in 5.4% of patients treated with enzalutamide plus leuprolide and 9% of patients treated with enzalutamide as monotherapy. Gynaecomastia (all grades) was observed in 29 of 353 patients (8.2%) who were treated with enzalutamide plus leuprolide and 159 of 354 patients (44.9%) who were treated with enzalutamide as monotherapy. Nipple pain (all grades) was observed in 11 of 353 patients (3.1%) who were treated with enzalutamide plus leuprolide and 54 of 354 patients (15.3%) who were treated with enzalutamide as monotherapy. Breast tenderness (all grades) was observed in 5 of 353 patients (1.4%) who were treated with enzalutamide plus leuprolide and 51 of 354 patients (14.4%) who were treated with enzalutamide as monotherapy.

Study treatment was suspended in the EMBARK study for patients who had undetectable PSA at week 36, a modified treatment-emergent period was defined for the generation of additional TEAE analyses.

<div style=\"page-break-after: always\"></div>

- For patients in the EMBARK study whose treatment was suspended due to undetectable PSA at week 36, the modified treatment-emergent period was defined as the period of time of study drug exposure starting from the date of the first dose of study drug through 30 days after last dose prior to the treatment suspension plus the time period starting from the date of first dose at study drug reinitiation through a minimum of 30 days after the last dose of study treatment, or 1 day prior to the start day of new antineoplastic drug therapy. If the date of first dose at study drug reinitiation was earlier than 30 days after last dose prior to the treatment suspension, then the modified treatment-emergent period was the same as the treatment-emergent period.
- For patients whose treatment was suspended due to undetectable PSA at week 36, the modified treatment-emergent period was defined as the period of time of study drug exposure starting from the date of the first dose of study drug through 30 days after last dose prior to the treatment suspension plus the time period starting from date of first dose at study drug reinitiation through a minimum of 30 days after last dose of study treatment, or the start day of new antineoplastic drug therapy - 1 day. If the date of first dose at study drug reinitiation was earlier than 30 days after last dose prior to the treatment suspension, then the modified treatment-emergent period was the same as that on-treatment period.
- For all other patients (who never suspended their treatment due to having detectable PSA at week 36 in the EMBARK study or who were in other phase 2 or 3 studies), the modified treatment-emergent period was the same as the treatment-emergent period.

Table 42. Overall summary of Treatment-Emergent Adverse events using the modified treatment-emergent period for EMBARK (Safety Groups)

|                                             | EMBARK               | EMBARK               | EMBARK              | Phase 3↑              | Phase 3↑             |                            |
|---------------------------------------------|----------------------|----------------------|---------------------|-----------------------|----------------------|----------------------------|
| Category, n (%)                             | DB ENZA+ADT (n =353) | DB PBO+ADT (n = 354) | ENZA Mono (n = 354) | DB ENZA+ADT (n =3728) | DB PBO+ADT (n =2829) | Totalt ENZA+ADT (n = 5110) |
| Any TEAE                                    | 339 (96.0)           | 343 (96.9)           | 344 (97.2)          | 3532 (94.7)           | 2574 (91.0)          | 4841 (94.7)                |
| TEAE leading to study drug discontinuations | 58 (16.4)            | 31 (8.8)             | 55 (15.5)           | 594 (15.9)            | 436 (15.4)           | 977 (19.1)                 |
| TEAEleadingto doseinterruption              | 56 (15.9)            | 43 (12.1)            | 66 (18.6)           | 541 (14.5)            | 290 (10.3)           | 829 (16.2)                 |
| TEAEleadingtodosereduction                  | 25 (7.1)             | 16 (4.5)             | 56 (15.8)           | 208 (5.6)             | 67 (2.4)             | 352 (6.9)                  |
| Grade ≥3 TEAE                               | 135 (38.2)           | 132 (37.3)           | 155 (43.8)          | 1587 (42.6)           | 1015 (35.9)          | 2403 (47.0)                |
| Serious TEAE                                | 94 (26.6)            | 99 (28.0)            | 112 (31.6)          | 1248 (33.5)           | 768 (27.1)           | 1923 (37.6)                |
| Grade≥3 serious TEAE                        | 85 (24.1)            | 87 (24.6)            | 100 (28.2)          | 1088 (29.2)           | 663 (23.4)           | 1692 (33.1)                |
| TEAE leading to death                       | 6 (1.7)              | 3 (0.8)              | 8 (2.3)             | 158 (4.2)             | 72 (2.5)             | 288 (5.6)                  |
| Drug-related TEAET                          | 305 (86.4)           | 282 (79.7)           | 311 (87.9)          | 2489 (66.8)           | 1522 (53.8)          | 3408 (66.7)                |
| Drug-related grade ≥3 TEAE                  | 59 (16.7)            | 29 (8.2)             | 55 (15.5)           | 459 (12.3)            | 207 (7.3)            | 675 (13.2)                 |
| Drug-related serious TEAE                   | 24 (6.8)             | 7 (2.0)              | 16 (4.5)            | 170 (4.6)             | 86 (3.0)             | 276 (5.4)                  |
| Drug-related TEAEs leading to death         | 0                    | 0                    | 0                   | 6 (0.2)               | 2 (0.1)              | 13 (0.3)                   |
| Grade3or4 TEAE                              | 135 (38.2)           | 130 (36.7)           | 153 (43.2)          | 1541 (41.3)           | 996 (35.2)           | 2325 (45.5)                |

All patientswhoreceived at least1dose of study drug(enzalutamide,placebo)intheirrespectivephase3studyorreceived at least1dose ofenzalutamideinphase2studies.For EMBARK,study drugincludesenzalutamide,leuprolideand placebo(SafetyPopulation).

Datacutoff dates were as follows:EMBARK:31Jan 2023;PROSPER:15 Oct 2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21Mar 2019;AsianPREVAIL: 04Nov 2020;TERRAIN:17Feb 2018 and STRIVE:30May 2018.

Number of patients (n) reporting at least 1 event and percentage of patients (%) are shown. NCI-CTCAE v4.03.

Themodified treatment-emergent period takes into account the protocol-defined treatment suspensiondue to undetectablePSA atweek 36intheEMBARK study.For studies other than EMBARK, the modified treatment-emergent period refers to the treatment-emergent period.

ADT: androgen deprivation therapy, AE: adverse event; CRF: case report form; DB: double-blind; ENZA: enzalutamide; ISS: Integrated Summary of Safety, Mono: monotherapy, NCI-CTCAE:National CancerInstitute CommonTerminology CriteriaforAdverseEvents;OL:open-label;PBO:placebo;PSA:prostate-specific antigen;SCS:Summaryof Clinical Safety;TEAE:treatment-emergent adverse event.

↑ The phase 3 studies include EMBARK (ENZA+ADT and PBO+ADT arms) and DB phase for PROSPER, ARCHES, AFFIRM, PREVAIL and Asian PREVAIL

↑ Total enzalutamide summarizes all enzalutamide-treated patients during DB and/or OL periods of EMBARK (ENZA+ADT and ENZA Mono arms), PROSPER, ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

TEAEleadingtostudydrugdiscontinuationisfromAECRFandincludesTEAEswithactiontakenofpermanentdiscontinuation.

IDrug-related TEAEs are TEAEs that were judged by the investigator as possibly, probably or definitely related to study drug.

## Frequently reported TEAEs

<div style=\"page-break-after: always\"></div>

Table 43. Treatment-E mergent Adverse Events experienced by ≥ 5% of patients in the EMBARK enzalutamide plus ADT or placebo plus ADT groups, by SOC and Preferred Term (Safety Groups)

|                                                   | EMBARK               | EMBARK              | EMBARK              | Phase 3↑               | Phase 3↑             | Totalt              |
|---------------------------------------------------|----------------------|---------------------|---------------------|------------------------|----------------------|---------------------|
| SOC (MIedDRAv25.1) Preferred Term, n (%)          | DB ENZA+ADI (n= 353) | DB PBO+ADT (n =354) | ENZA Mono (n = 354) | DB ENZA+ADT (n = 3728) | DB PBO+ADT (n= 2829) | ENZA+ADT (n = 5110) |
| Blood and LymphaticSystemDisorders                | 25 (7.1)             | 12 (3.4)            | 17 (4.8)            | 333 (8.9)              | 227 (8.0)            | 502 (9.8)           |
| Anaemia                                           | 25 (7.1)             | 12 (3.4)            | 17 (4.8)            | 333 (8.9)              | 227 (8.0)            | 502 (9.8)           |
| Eye Disorders                                     | 17 (4.8)             | 20 (5.6)            | 22 (6.2)            | 82 (2.2)               | 39 (1.4)             | 146 (2.9)           |
| Cataract                                          | 17 (4.8)             | 20 (5.6)            | 22 (6.2)            | 82 (2.2)               | 39 (1.4)             | 146 (2.9)           |
| Gastrointestinal Disorders                        | 110 (31.2)           | 70 (19.8)           | 108 (30.5)          | 1385 (37.2)            | 870 (30.8)           | 1849 (36.2)         |
| Diarrhoea                                         | 49 (13.9)            | 31 (8.8)            | 46 (13.0)           | 534 (14.3)             | 306 (10.8)           | 705 (13.8)          |
| Constipation                                      | 46 (13.0)            | 31 (8.8)            | 34 (9.6)            | 624 (16.7)             | 379 (13.4)           | 830 (16.2)          |
| Nausea                                            | 42 (11.9)            | 29 (8.2)            | 54 (15.3)           | 704 (18.9)             | 475 (16.8)           | 931 (18.2)          |
| General Disorders andAdministrationSiteConditions | 191 (54.1)           | 159 (44.9)          | 202 (57.1)          | 1765 (47.3)            | 981 (34.7)           | 2417 (47.3)         |
| Fatigue                                           | 151 (42.8)           | 116 (32.8)          | 165 (46.6)          | 1236 (33.2)            | 633 (22.4)           | 1733 (33.9)         |
| Asthenia                                          | 39 (11.0)            | 21 (5.9)            | 39 (11.0)           | 445 (11.9)             | 228 (8.1)            | 579 (11.3)          |
| Oedema peripheral                                 | 27 (7.6)             | 37 (10.5)           | 31 (8.8)            | 350 (9.4)              | 225 (8.0)            | 485 (9.5)           |
| Infections andInfestations                        | 98 (27.8)            | 99 (28.0)           | 112 (31.6)          | 677 (18.2)             | 435 (15.4)           | 1021 (20.0)         |
| COVID-19                                          | 27 (7.6)             | 36 (10.2)           | 44 (12.4)           | 27 (0.7)               | 36 (1.3)             | 85 (1.7)            |
| Urinary tract infection                           | 27 (7.6)             | 26 (7.3)            | 37 (10.5)           | 231 (6.2)              | 165 (5.8)            | 364 (7.1)           |
| Nasopharyngitis                                   | 25 (7.1)             | 22 (6.2)            | 31 (8.8)            | 231 (6.2)              | 128 (4.5)            | 338 (6.6)           |
| Upper respiratory tract infection                 | 21 (5.9)             | 25 (7.1)            | 22 (6.2)            | 145 (3.9)              | 97 (3.4)             | 211 (4.1)           |
| Bronchitis                                        | 19 (5.4)             | 12 (3.4)            | 10 (2.8)            | 107 (2.9)              | 48 (1.7)             | 147 (2.9)           |
| Injury,Poisoning andProcedural Complications      | 84 (23.8)            | 63 (17.8)           | 66 (18.6)           | 484 (13.0)             | 166 (5.9)            | 731 (14.3)          |
| Fall                                              | 74 (21.0)            | 51 (14.4)           | 56 (15.8)           | 428 (11.5)             | 145 (5.1)            | 649 (12.7)          |
| Rib fracture                                      | 29 (8.2)             | 23 (6.5)            | 20 (5.6)            | 140 (3.8)              | 43 (1.5)             | 200 (3.9)           |
| Investigations                                    | 48 (13.6)            | 39 (11.0)           | 54 (15.3)           | 441 (11.8)             | 245 (8.7)            | 632 (12.4)          |
| Weight increased                                  | 27 (7.6)             | 30 (8.5)            | 17 (4.8)            | 93 (2.5)               | 86 (3.0)             | 126 (2.5)           |
| Weight decreased                                  | 24 (6.8)             | 12 (3.4)            | 39 (11.0)           | 352 (9.4)              | 164 (5.8)            | 512 (10.0)          |
| Metabolism and NutritionDisorders                 | 44 (12.5)            | 32 (9.0)            | 40 (11.3)           | 630 (16.9)             | 361 (12.8)           | 827 (16.2)          |
| Decreased appetite                                | 27 (7.6)             | 15 (4.2)            | 32 (9.0)            | 604 (16.2)             | 335 (11.8)           | 791 (15.5)          |
| Type 2 diabetes mellitus                          | 17 (4.8)             | 18 (5.1)            | 10 (2.8)            | 28 (0.8)               | 27 (1.0)             | 42 (0.8)            |
| Musculoskeletaland Connective TissueDisorders     | 169 (47.9)           | 142 (40.1)          | 158 (44.6)          | 1539 (41.3)            | 975 (34.5)           | 2152 (42.1)         |
| Arthralgia                                        | 97 (27.5)            | 75 (21.2)           | 81 (22.9)           | 843 (22.6)             | 464 (16.4)           | 1156 (22.6)         |
| Back pain                                         | 60 (17.0)            | 54 (15.3)           | 62 (17.5)           | 706 (18.9)             | 454 (16.0)           | 1001 (19.6)         |
| Pain in extremity                                 | 41 (11.6)            | 36 (10.2)           | 40 (11.3)           | 386 (10.4)             | 258 (9.1)            | 538 (10.5)          |
| Osteoarthritis                                    | 21 (5.9)             | 15 (4.2)            | 19 (5.4)            | 77 (2.1)               | 34 (1.2)             | 134 (2.6)           |
| Neck pain                                         | 16 (4.5)             | 18 (5.1)            | 14 (4.0)            | 94 (2.5)               | 77 (2.7)             | 152 (3.0)           |
| Muscle spasms                                     | 14 (4.0)             | 19 (5.4)            | 9 (2.5)             | 104 (2.8)              | 79 (2.8)             | 138 (2.7)           |
| Nervous System Disorders                          | 84 (23.8)            | 69 (19.5)           | 86 (24.3)           | 709 (19.0)             | 331 (11.7)           | 997 (19.5)          |
| Dizziness                                         | 39 (11.0)            | 37 (10.5)           | 41 (11.6)           | 337 (9.0)              | 171 (6.0)            | 490 (9.6)           |
| Headache                                          | 39 (11.0)            | 32 (9.0)            | 41 (11.6)           | 373 (10.0)             | 161 (5.7)            | 506 (9.9)           |
| Memory impairment                                 | 26 (7.4)             | 12 (3.4)            | 21 (5.9)            | 103 (2.8)              | 31 (1.1)             | 156 (3.1)           |
| PsychiatricDisorders                              | 73 (20.7)            | 63 (17.8)           | 56 (15.8)           | 491 (13.2)             | 252 (8.9)            | 700 (13.7)          |
| Insomnia                                          | 42 (11.9)            | 37 (10.5)           | 25 (7.1)            | 269 (7.2)              | 150 (5.3)            | 369 (7.2)           |
| Depression                                        | 21 (5.9)             | 20 (5.6)            | 21 (5.9)            | 139 (3.7)              | 63 (2.2)             | 213 (4.2)           |
| Anxiety                                           | 19 (5.4)             | 11 (3.1)            | 18 (5.1)            | 150 (4.0)              | 61 (2.2)             | 216 (4.2)           |
| Renal andUrinaryDisorders                         | 102 (28.9)           | 105 (29.7)          | 98 (27.7)           | 704 (18.9)             | 459 (16.2)           | 1000 (19.6)         |
| Haematuria                                        | 42 (11.9)            | 44 (12.4)           | 45 (12.7)           | 299 (8.0)              | 180 (6.4)            | 449 (8.8)           |
| Urinary incontinence                              | 34 (9.6)             | 28 (7.9)            | 36 (10.2)           | 143 (3.8)              | 72 (2.5)             | 226 (4.4)           |
| Pollakiuria                                       | 30 (8.5)             | 30 (8.5)            | 27 (7.6)            | 191 (5.1)              | 114 (4.0)            | 267 (5.2)           |

<div style=\"page-break-after: always\"></div>

| Nocturia                                        | 26 (7.4)   | 16 (4.5)   | 9 (2.5)    | 128 (3.4)   | 80 (2.8)   | 167 (3.3)   |
|-------------------------------------------------|------------|------------|------------|-------------|------------|-------------|
| Dysuria                                         | 12 (3.4)   | 18 (5.1)   | 10 (2.8)   | 121 (3.2)   | 103 (3.6)  | 166 (3.2)   |
| ReproductiveSystemandBreastDisorders            | 29 (8.2)   | 32 (9.0)   | 159 (44.9) | 136 (3.6)   | 66 (2.3)   | 329 (6.4)   |
| Gynaecomastia                                   | 29 (8.2)   | 32 (9.0)   | 159 (44.9) | 136 (3.6)   | 66 (2.3)   | 329 (6.4)   |
| Respiratory, Thoracic and Mediastinal Disorders | 59 (16.7)  | 49 (13.8)  | 52 (14.7)  | 513 (13.8)  | 307 (10.9) | 701 (13.7)  |
| Dyspnoea                                        | 30 (8.5)   | 25 (7.1)   | 19 (5.4)   | 259 (6.9)   | 161 (5.7)  | 357 (7.0)   |
| Epistaxis                                       | 19 (5.4)   | 2 (0.6)    | 18 (5.1)   | 104 (2.8)   | 26 (0.9)   | 142 (2.8)   |
| Cough                                           | 18 (5.1)   | 24 (6.8)   | 19 (5.4)   | 216 (5.8)   | 152 (5.4)  | 297 (5.8)   |
| Skin andSubcutaneousTissueDisorders             | 57 (16.1)  | 31 (8.8)   | 48 (13.6)  | 260 (7.0)   | 121 (4.3)  | 401 (7.8)   |
| Dry skin                                        | 22 (6.2)   | 10 (2.8)   | 17 (4.8)   | 98 (2.6)    | 40 (1.4)   | 147 (2.9)   |
| Rash                                            | 22 (6.2)   | 23 (6.5)   | 22 (6.2)   | 118 (3.2)   | 77 (2.7)   | 194 (3.8)   |
| Alopecia                                        | 19 (5.4)   | 4 (1.1)    | 13 (3.7)   | 64 (1.7)    | 14 (0.5)   | 90 (1.8)    |
| Vascular Disorders                              | 265 (75.1) | 232 (65.5) | 126 (35.6) | 1208 (32.4) | 603 (21.3) | 1574 (30.8) |
| Hot flush                                       | 243 (68.8) | 203 (57.3) | 77 (21.8)  | 863 (23.1)  | 481 (17.0) | 1045 (20.5) |
| Hypertension                                    | 82 (23.2)  | 69 (19.5)  | 67 (18.9)  | 492 (13.2)  | 180 (6.4)  | 728 (14.2)  |

Allpatientswhoreceived atleast1dose of study drug(enzalutamide,placebo)intheirrespectivephase3study orreceivedatleast1doseofenzalutamideinphase2studies.For EMBARK, study drug includes enzalutamide,leuprolide and placebo (SafetyPopulation).

Data cutoff dates were as follows:EMBARK:31Jan 2023;PROSPER:15 Oct2019;ARCHES:28May 2021;AFFIRM:20Feb2018;PREVAIL:21 Mar 2019;AsianPREVAIL: 04 Nov 2020; TERRAIN: 17 Feb 2018 and STRIVE: 30 May 2018.

Patients with multipleeventsforagiven preferred termorSOCwere countedonly onceforeachpreferred term andSOC.Numberofpatients(n) and percentage ofpatients(%)are shown. Events are sorted by SOC alphabetically and then by decreasing frequency of preferred term in the ENZA+ADT group in the EMBARK study.

Preferred term frequencies highlighted in bold are TEAEs that occured in ≥ 5% of patients in the EMBARK ENZA+ADT group and ≥ 2% higher incidence than the EMBARK PBO+ADT group.

ADT: androgen deprivation therapy, DB: double-blind; ENZA: enzalutamide; ISS: Integrated Summary of Safety, Mono: monotherapy, OL: open-label; PBO: placebo; SCS: Summary of ClinicalSafety;TEAE:treatment-emergent adverse event.

↑Thephase3studiesincludeEMBARK(ENZA+ADTandPBO+ADT arms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAIL andAsianPREVAIL.

## Grade ≥ 3 TEAEs

## Table 44: Grade ≥ 3 Treatment-Emergent Adverse Events experienced by ≥ 1% of patients in the EMBARK enzalutamide plus ADT or placebo plus ADT groups, by Preferred Term (Safety Groups)

|                                      | EMBARK              | EMBARK              | EMBARK             | Phase3↑               | Phase3↑              | Totalt             |
|--------------------------------------|---------------------|---------------------|--------------------|-----------------------|----------------------|--------------------|
| Preferred Term (MedDRA v25.1), n (%) | DB ENZA+ADT (n=353) | DB PBO+ADT (n =354) | ENZA Mono (n =354) | DB ENZA+ADT (n =3728) | DB PBO+ADT (n =2829) | ENZA+ADT (n =5110) |
| Patientswith grade≥3TEAES            | 164 (46.5)          | 151 (42.7)          | 177 (50.0)         | 1616 (43.3)           | 1034 (36.6)          | 2454 (48.0)        |
| Hypertension                         | 24 (6.8)            | 18 (5.1)            | 19 (5.4)           | 186 (5.0)             | 63 (2.2)             | 277 (5.4)          |
| Syncope                              | 15 (4.2)            | 6 (1.7)             | 7 (2.0)            | 60 (1.6)              | 21 (0.7)             | 86 (1.7)           |
| Fatigue                              | 12 (3.4)            | 5 (1.4)             | 14 (4.0)           | 126 (3.4)             | 59 (2.1)             | 180 (3.5)          |
| Osteoarthritis                       | 10 (2.8)            | 2 (0.6)             | 2 (0.6)            | 23 (0.6)              | 7 (0.2)              | 40 (0.8)           |
| Haematuria                           | 8 (2.3)             | 4 (1.1)             | 9 (2.5)            | 68 (1.8)              | 43 (1.5)             | 107 (2.1)          |
| Pneumonia                            | 8 (2.3)             | 5 (1.4)             | 5 (1.4)            | 71 (1.9)              | 30 (1.1)             | 117 (2.3)          |
| Arthralgia                           | 7 (2.0)             | 1 (0.3)             | 2 (0.6)            | 54 (1.4)              | 31 (1.1)             | 72 (1.4)           |
| Anaemia                              | 5 (1.4)             | 3 (0.8)             | 3 (0.8)            | 126 (3.4)             | 86 (3.0)             | 191 (3.7)          |
| Atrial fibrillation                  | 5 (1.4)             | 3 (0.8)             | 2 (0.6)            | 23 (0.6)              | 13 (0.5)             | 41 (0.8)           |
| Sepsis                               | 5 (1.4)             | 5 (1.4)             | 6 (1.7)            | 18 (0.5)              | 13 (0.5)             | 33 (0.6)           |
| Angina pectoris                      | 4 (1.1)             | 1 (0.3)             | 3 (0.8)            | 11 (0.3)              | 3 (0.1)              | 23 (0.5)           |
| Arthritis                            | 4 (1.1)             | 1 (0.3)             | 3 (0.8)            | 6 (0.2)               | 2 (0.1)              | 10 (0.2)           |
| Coronary artery disease              | 4 (1.1)             | 1 (0.3)             | 5 (1.4)            | 16 (0.4)              | 4 (0.1)              | 27 (0.5)           |
| Fall                                 | 4 (1.1)             | 4 (1.1)             | 7 (2.0)            | 43 (1.2)              | 17 (0.6)             | 80 (1.6)           |
| Pulmonary embolism                   | 4 (1.1)             | 1 (0.3)             | 2 (0.6)            | 26 (0.7)              | 22 (0.8)             | 36 (0.7)           |
| Urinaryincontinence                  | 4 (1.1)             | 3 (0.8)             | 6 (1.7)            | 14 (0.4)              | 6 (0.2)              | 25 (0.5)           |
| Cataract                             | 3 (0.8)             | 5 (1.4)             | 8 (2.3)            | 31 (0.8)              | 12 (0.4)             | 51 (1.0)           |
| Acutemyocardialinfarction            | 2 (0.6)             | 4 (1.1)             | 4 (1.1)            | 20 (0.5)              | 7 (0.2)              | 41 (0.8)           |
| COVID-19                             | 2 (0.6)             | 4 (1.1)             | 2 (0.6)            | 2 (0.1)               | 4 (0.1)              | 8 (0.2)            |

All patientswhoreceived at least1doseof study drug(enzalutamide,placebo)intheirrespectivephase3study orreceived atleast1dose ofenzalutamideinphase2studies.For EMBARK,study drug includes enzalutamide,leuprolide and placebo(SafetyPopulation).

Data cutoff dates were as follows:EMBARK:31Jan 2023;PROSPER:15Oct 2019;ARCHES:28May 2021;AFFIRM:20Feb2018;PREVAIL:21Mar 2019;AsianPREVAIL: 04Nov 2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

sorted by decreasing frequency of preferred term in the ENZA+ADT group in the EMBARK study.

Preferred termfrequencieshighlightedinbold aregrade≥3TEAEs thatoccurredin≥1%ofpatientsintheEMBARKENZA+ADTgroup and≥0.5%higherincidencethan the EMBARK PBO+ADT group.

ADT:androgen deprivation therapy,DB:double-blind;ENZA:enzalutamide;ISS:Integrated Summary of Safety;Mono:monotherapy,OL:open-label;PBO:placebo;SCS:Summary of Clinical Safety; TEAE: treatment-emergent adverse event.

↑Thephase3studiesincludeEMBARK(ENZA+ADT andPBO+ADT arms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAIL andAsianPREVAIL

Totalenzalutamidesummarizesallenzalutamide-treatedpatientsduringDBand/orOLperiodsofEMBARK(ENZA+ADTandENZAMonoarms),PROSPER,ARCHES AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

Grade≥3,basedonNationalCancerInstituteCommonTerminologyCriteriaforAdverseEvents,v4.03.

<div style=\"page-break-after: always\"></div>

In the EMBARK study, grade 3 or higher gynaecomastia was not observed in any patients who were treated with enzalutamide plus leuprolide, and was observed in 3 patients (0.8%) who were treated with enzalutamide as monotherapy. Grade 3 or higher nipple pain was not observed in any patients who were treated with enzalutamide plus leuprolide or with enzalutamide as monotherapy. Grade 3 or higher breast tenderness was not observed in any patients who were treated with enzalutamide plus leuprolide or with enzalutamide as monotherapy.

Drug-related TEAEs

<div style=\"page-break-after: always\"></div>

Table 45. Study Drug-related Treatment-E mergent Adverse Events experienced by ≥2% of patients in the EMBARK enzalutamide plus ADT or placebo plus ADT groups, by Preferred Term (Safety Groups)

|                                      | EMBARK                | EMBARK               | EMBARK             | Phase 3↑               | Phase 3↑              | Totalt ENZA+ADT (n =5110)   |
|--------------------------------------|-----------------------|----------------------|--------------------|------------------------|-----------------------|-----------------------------|
| Preferred Term (MIedDRA v25.1),n(%)  | DB ENZA+ADT (n = 353) | DB PBO+ADT (n = 354) | ENZA Mono (n =354) | DB ENZA+ADT (n = 3728) | DB PBO+ADT (n = 2829) | Totalt ENZA+ADT (n =5110)   |
| Patientswith study drug-relatedTEAES | 307 (87.0)            | 286 (80.8)           | 314 (88.7)         | 2491 (66.8)            | 1526 (53.9)           | 3413 (66.8)                 |
| Hot flush                            | 242 (68.6)            | 196 (55.4)           | 73 (20.6)          | 716 (19.2)             | 412 (14.6)            | 878 (17.2)                  |
| Fatigue                              | 140 (39.7)            | 99 (28.0)            | 156 (44.1)         | 946 (25.4)             | 448 (15.8)            | 1363 (26.7)                 |
| Hypertension                         | 46 (13.0)             | 29 (8.2)             | 38 (10.7)          | 230 (6.2)              | 79 (2.8)              | 343 (6.7)                   |
| Asthenia                             | 33 (9.3)              | 14 (4.0)             | 33 (9.3)           | 280 (7.5)              | 122 (4.3)             | 365 (7.1)                   |
| Headache                             | 25 (7.1)              | 15 (4.2)             | 27 (7.6)           | 164 (4.4)              | 62 (2.2)              | 223 (4.4)                   |
| Dizziness                            | 24 (6.8)              | 16 (4.5)             | 25 (7.1)           | 166 (4.5)              | 67 (2.4)              | 239 (4.7)                   |
| Memory impairment                    | 24 (6.8)              | 10 (2.8)             | 18 (5.1)           | 67 (1.8)               | 20 (0.7)              | 103 (2.0)                   |
| Gynaecomastia                        | 23 (6.5)              | 28 (7.9)             | 152 (42.9)         | 96 (2.6)               | 49 (1.7)              | 274 (5.4)                   |
| Nausea                               | 22 (6.2)              | 17 (4.8)             | 34 (9.6)           | 422 (11.3)             | 276 (9.8)             | 544 (10.6)                  |
| Decreased appetite                   | 20 (5.7)              | 6 (1.7)              | 22 (6.2)           | 299 (8.0)              | 145 (5.1)             | 375 (7.3)                   |
| Diarrhoea                            | 19 (5.4)              | 10 (2.8)             | 27 (7.6)           | 206 (5.5)              | 119 (4.2)             | 276 (5.4)                   |
| Insomnia                             | 19 (5.4)              | 19 (5.4)             | 11 (3.1)           | 88 (2.4)               | 48 (1.7)              | 117 (2.3)                   |
| Weight increased                     | 18 (5.1)              | 25 (7.1)             | 14 (4.0)           | 63 (1.7)               | 53 (1.9)              | 86 (1.7)                    |
| Alopecia                             | 17 (4.8)              | 4 (1.1)              | 10 (2.8)           | 43 (1.2)               | 8 (0.3)               | 63 (1.2)                    |
| Fall                                 | 16 (4.5)              | 11 (3.1)             | 20 (5.6)           | 54 (1.4)               | 18 (0.6)              | 108 (2.1)                   |
| Dry skin                             | 15 (4.2)              | 3 (0.8)              | 9 (2.5)            | 53 (1.4)               | 14 (0.5)              | 79 (1.5)                    |
| Libido decreased                     | 15 (4.2)              | 11 (3.1)             | 14 (4.0)           | 17 (0.5)               | 12 (0.4)              | 32 (0.6)                    |
| Amnesia                              | 14 (4.0)              | 2 (0.6)              | 13 (3.7)           | 31 (0.8)               | 5 (0.2)               | 60 (1.2)                    |
| Arthralgia                           | 12 (3.4)              | 13 (3.7)             | 15 (4.2)           | 125 (3.4)              | 74 (2.6)              | 163 (3.2)                   |
| Constipation                         | 12 (3.4)              | 5 (1.4)              | 6 (1.7)            | 158 (4.2)              | 83 (2.9)              | 192 (3.8)                   |
| Hyperhidrosis                        | 12 (3.4)              | 4 (1.1)              | 5 (1.4)            | 55 (1.5)               | 31 (1.1)              | 72 (1.4)                    |
| Muscular weakness                    | 11 (3.1)              | 11 (3.1)             | 5 (1.4)            | 57 (1.5)               | 36 (1.3)              | 84 (1.6)                    |
| Anaemia                              | 10 (2.8)              | 4 (1.1)              | 2 (0.6)            | 71 (1.9)               | 47 (1.7)              | 87 (1.7)                    |
| Dyspnoea                             | 10 (2.8)              | 7 (2.0)              | 3 (0.8)            | 53 (1.4)               | 31 (1.1)              | 70 (1.4)                    |
| Erectile dysfunction                 | 10 (2.8)              | 11 (3.1)             | 12 (3.4)           | 15 (0.4)               | 15 (0.5)              | 30 (0.6)                    |
| Osteoporosis                         | 10 (2.8)              | 1 (0.3)              | 0                  | 23 (0.6)               | 6 (0.2)               | 36 (0.7)                    |
| Overdose                             | 10 (2.8)              | 12 (3.4)             | 18 (5.1)           | 11 (0.3)               | 12 (0.4)              | 29 (0.6)                    |
| Anxiety                              | 9 (2.5)               | 3 (0.8)              | 13 (3.7)           | 38 (1.0)               | 8 (0.3)               | 60 (1.2)                    |
| Pain in extremity                    | 9 (2.5)               | 5 (1.4)              | 6 (1.7)            | 42 (1.1)               | 21 (0.7)              | 61 (1.2)                    |
| Rash                                 | 9 (2.5)               | 10 (2.8)             | 9 (2.5)            | 46 (1.2)               | 30 (1.1)              | 72 (1.4)                    |
| Back pain                            | 8 (2.3)               | 1 (0.3)              | 8 (2.3)            | 45 (1.2)               | 27 (1.0)              | 67 (1.3)                    |
| Depression                           | 8 (2.3)               | 9 (2.5)              | 9 (2.5)            | 41 (1.1)               | 15 (0.5)              | 63 (1.2)                    |
| Paraesthesia                         | 8 (2.3)               | 1 (0.3)              | 6 (1.7)            | 42 (1.1)               | 8 (0.3)               | 56 (1.1)                    |
| Testicular atrophy                   | 8 (2.3)               | 4 (1.1)              | 0                  | 11 (0.3)               | 4 (0.1)               | 12 (0.2)                    |
| Lethargy                             | 7 (2.0)               | 12 (3.4)             | 12 (3.4)           | 42 (1.1)               | 40 (1.4)              | 65 (1.3)                    |
| Oedema peripheral                    | 6 (1.7)               | 16 (4.5)             | 11 (3.1)           | 109 (2.9)              | 62 (2.2)              | 144 (2.8)                   |
| Muscle spasms                        | 5 (1.4)               | 8 (2.3)              | 2 (0.6)            | 33 (0.9)               | 35 (1.2)              | 42 (0.8)                    |
| Alanine aminotransferase increased   | 3 (0.8)               | 8 (2.3)              | 2 (0.6)            | 22 (0.6)               | 23 (0.8)              | 33 (0.6)                    |
| Aspartate aminotransferase increased | 3 (0.8)               | 9 (2.5)              | 2 (0.6)            | 21 (0.6)               | 30 (1.1)              | 27 (0.5)                    |

All patients who received at least 1 dose of study drug (enzalutamide, placebo) in their respective phase 3 study or received at least 1 dose of enzalutamide in phase 2 studies. For EMBARK,study drug includes enzalutamide,leuprolide and placebo(SafetyPopulation)

DatacutoffdatesWere asfollows:EMBARK:31Jan2023;PROSPER:15Oct2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21Mar2019;AsianPREVAIL: 04Nov2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

Patients with multipleeventsforagiven preferred term were counted only once foreach preferred term.Number of patients(n)and percentage ofpatients(%) areshown.Events are

ADT:androgendeprivation therapy,DB:double-blind;ENZA:enzalutamide;ISS:IntegratedSummary of Safety,Mono:monotherapy,OL:open-label;PBO:placebo;SCS:Summary of Clinical Safety; TEAE: treatment-emergent adverse event.

↑Thephase3studies includeEMBARK(ENZA+ADT andPBO+ADT arms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAIL andAsianPREVAIL.

↑Total enzalutamide summarizes allenzalutamide-treatedpatients duringDB and/or OLperiods ofEMBARK(ENZA+ADT and ENZA Mono arms),PROSPER,ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE

Study drug-related TEAEs are TEAEs that were judged by the investigator as possibly, probably or definitely related to study drug. TEAEs could be related to any study drug (enzalutamide,placeboand/orleuprolide).

## Serious adverse event/deaths/other significant events

## Serious adverse events (SAEs)

Treatment-emergent SAEs

<div style=\"page-break-after: always\"></div>

Table 46. Treatment-Emergent Serious Adverse Events experienced by ≥ 1% of patients in the EMBARK enzalutamide plus ADT or placebo plus ADT groups, by Preferred Term (Safety Groups)

|                                                     | EMBARK               | EMBARK              | EMBARK             | Phase 3                | Phase 3              | Totals ENZA+ADT (n = 5110)   |
|-----------------------------------------------------|----------------------|---------------------|--------------------|------------------------|----------------------|------------------------------|
| Preferred Term (MIedDRAv25.1),n (%) Event Rate      | DB ENZA+ADT (n =353) | DB PBO+ADT (n =354) | ENZA Mono (n =354) | DB ENZA+ADT (n = 3728) | DB PBO+ADT (n =2829) | Totals ENZA+ADT (n = 5110)   |
| Overall                                             | 123 (34.8)           | 112 (31.6)          | 131 (37.0)         | 1277 (34.3)            | 781 (27.6)           | 1971 (38.6)                  |
| Syncope                                             | 9 (2.5)              | 4 (1.1)             | 2 (0.6)            | 31 (0.8)               | 9 (0.3)              | 44 (0.9)                     |
| Event rate per 100 patient-years (number of events) | 0.7 (10)             | 0.3 (4)             | 0.2 (3)            | 0.4 (32)               | 0.3 (9)              | 0.4 (46)                     |
| Haematuria                                          | 8 (2.3)              | 4 (1.1)             | 8 (2.3)            | 68 (1.8)               | 44 (1.6)             | 108 (2.1)                    |
| Event rate per 100 patient-years (number of events) | 0.9 (14)             | 0.4 (5)             | 0.6 (9)            | 1.2 (94)               | 1.4 (51)             | 1.2 (148)                    |
| Osteoarthritis                                      | 8 (2.3)              | 3 (0.8)             | 2 (0.6)            | 18 (0.5)               | 10 (0.4)             | 36 (0.7)                     |
| Event rate per 100 patient-years (number of events) | 0.6 (9)              | 0.3 (4)             | 0.1 (2)            | 0.3 (19)               | 0.3 (11)             | 0.3 (37)                     |
| Pneumonia                                           | 8 (2.3)              | 4 (1.1)             | 5 (1.4)            | 67 (1.8)               | 24 (0.8)             | 110 (2.2)                    |
| Eventrate per100 patient-years(number of events)    | 0.5 (8)              | 0.5 (7)             | 0.3 (5)            | 1.0 (73)               | 0.8 (28)             | 1.0 (123)                    |
| Arthralgia                                          | 5 (1.4)              | 1 (0.3)             | 1 (0.3)            | 11 (0.3)               | 2 (0.1)              | 19 (0.4)                     |
| Event rate per 100 patient-years (number of events) | 0.3 (5)              | 0.1(1)              | 0.1(1)             | 0.2 (12)               | 0.1 (2)              | 0.2 (20)                     |
| Atrialfibrillation                                  | 4 (1.1)              | 3 (0.8)             | 1 (0.3)            | 25 (0.7)               | 19 (0.7)             | 40 (0.8)                     |
| Event rate per 100 patient-years (number of events) | 0.3 (4)              | 0.2 (3)             | 0.1 (2)            | 0.3 (26)               | 0.5 (19)             | 0.3 (43)                     |
| Sepsis                                              | 4 (1.1)              | 4 (1.1)             | 6 (1.7)            | 17 (0.5)               | 12 (0.4)             | 33 (0.6)                     |
| Eventrate per100 patient-years(number of events)    | 0.3 (4)              | 0.3 (4)             | 0.4 (7)            | 0.2 (18)               | 0.3 (12)             | 0.3 (36)                     |
| Transient ischaemic attack                          | 4 (1.1)              | 2 (0.6)             | 2 (0.6)            | 19 (0.5)               | 9 (0.3)              | 32 (0.6)                     |
| Event rate per 100 patient-years (number of events) | 0.3 (4)              | 0.1 (2)             | 0.1 (2)            | 0.3 (20)               | 0.3 (9)              | 0.3 (34)                     |
| Acutemyocardialinfarction                           | 2 (0.6)              | 4 (1.1)             | 3 (0.8)            | 22 (0.6)               | 8 (0.3)              | 41 (0.8)                     |
| Event rate per 100 patient-years (number of events) | 0.2 (3)              | 0.3 (4)             | 0.2 (3)            | 0.3 (25)               | 0.2 (8)              | 0.4 (46)                     |
| COVID-19                                            | 2 (0.6)              | 4 (1.1)             | 2 (0.6)            | 2 (0.1)                | 4 (0.1)              | 8 (0.2)                      |
| Event rate per 100 patient-years (number of events) | 0.1 (2)              | 0.3 (4)             | 0.1(2)             | 0.0 (2)                | 0.1(4)               | 0.1 (8)                      |

All patients whoreceived at least 1 dose of study drug(enzalutamide,placebo) in theirrespective phase 3 study orreceived at least 1 dose of enzalutamide inphase 2 studies.For EMBARK, study drug includes enzalutamide, leuprolide and placebo (Safety Population).

Data cutoff datesWere asfollows:EMBARK:31Jan2023;PROSPER:15Oct2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21Mar2019;AsianPREVAIL: 04Nov2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

Patients with multiple events foragivenpreferred term were countedonly once foreach preferred term.Number ofpatients(n)andpercentage ofpatients(%)are shown.Events are sortedbydecreasingfrequencyofpreferredtermintheENZA+ADTgroupintheEMBARKstudy.

ADT: androgen deprivation therapy, DB: double-blind; ENZA: enzalutamide; ISS: Integrated Summary of Safety; Mono: monotherapy; OL: open-label; PBO: placebo; SCS: Summary of Clinical Safety.

↑Time-adjustedrateper100patient-yearsandnumberofeventsareshown.Time-adjustedrateper100patient-yearsiscalculatedasthetotalnumberofoccurrencesofeventdivided by the total treatment-emergent period for each treatment group times100.

↑Thephase3studies includeEMBARK(ENZA+ADT andPBO+ADTarms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAIL andAsianPREVAIL

Total enzalutamide summarizes all enzalutamide-treated patients during DB and/or OL periods of EMBARK (ENZA+ADT and ENZA Mono arms), PROSPER, ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

## Deaths

Deaths include deaths occurring during and after the treatment-emergent safety reporting period. Death causes were classified as due to disease progression, due to other causes (than prostate cancer), or due to unknown (or unspecified) causes.

In the EMBARK study, disease progression and other causes were reported as the primary cause of death in a similar percentage of patients. No patients in the EMBARK study had a TEAE leading to death that was considered to be study drug-related.

<div style=\"page-break-after: always\"></div>

Table 47. Summary of all deaths (Safety Groups)

|                                                               | EMBARK               | EMBARK               | EMBARK             | Phase3↑              | Phase3↑               |                           |
|---------------------------------------------------------------|----------------------|----------------------|--------------------|----------------------|-----------------------|---------------------------|
| Deaths, n (%)                                                 | DB ENZA+ADT (n= 353) | DB PBO+ADT (n = 354) | ENZA Mono (n= 354) | DB ENZA+ADT (n=3728) | DB PBO+ADT (n = 2829) | Totalt ENZA+ADT (n =5110) |
| Total numberof deaths                                         | 33 (9.3)             | 55 (15.5)            | 42 (11.9)          | 1833 (49.2)          | 1549 (54.8)           | 2124 (41.6)               |
| Cause of death                                                |                      |                      |                    |                      |                       |                           |
| Disease progression                                           | 12 (3.4)             | 22 (6.2)             | 19 (5.4)           | 1424 (38.2)          | 1248 (44.1)           | 1629 (31.9)               |
| Others                                                        | 16 (4.5)             | 21 (5.9)             | 18 (5.1)           | 305 (8.2)            | 228 (8.1)             | 374 (7.3)                 |
| Unknown                                                       | 5 (1.4)              | 12 (3.4)             | 5 (1.4)            | 104 (2.8)            | 70 (2.5)              | 121 (2.4)                 |
| Missing                                                       | 0                    | 0                    | 0                  | 0                    | 3 (0.1)               | 0                         |
| Deaths within 30 days after the first dose date of study drug | 0                    | 0                    | 0                  | 4 (0.1)              | 4 (0.1)               | 10 (0.2)                  |

Allpatientswhoreceivedatleast1doseofstudydrug(enzalutamide,placebo)intheirrespectivephase3studyorreceivedatleast1doseofenzalutamideinphase2studies.For EMBARK,studydrugincludesenzalutamide,leuprolide andplacebo(SafetyPopulation).

DatacutoffdatesWereasfollows:EMBARK:31Jan2023;PROSPER:15Oct2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21Mar2019;AsianPREVAIL: 04Nov2020;TERRAIN:17Feb2018 andSTRIVE:30May 2018.

All deaths up to and including the analysis data cutoff date are included. Number of patients (n) and percentage of patients (%) are shown.

Tableisbased ondatafromthe end-of-studycasereportform.

ADT: androgen deprivation therapy; DB: double-blind; ENZA: enzalutamide;ISS:Integrated Summary of Safety, Mono: monotherapy, OL: open-label; PBO: placebo; SCS: Summary ofClinical Safety.

↑Thephase3studiesincludeEMBARK(ENZA+ADTandPBO+ADTarms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAILandAsianPREVAIL

↑Total enzalutamide summarizes all enzalutamide-treated patients during DB and/or OL periods of EMBARK(ENZA+ADT and ENZA Mono arms),PROSPER, ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

Allknownprimarycausesofdeathotherthandiseaseprogression.

Table 48. Treatment-Emergent Adverse Events resulting in death by Preferred Term in ≥ 2 patients in the total enzalutamide group, by Preferred Term and adjusted event rate (Safety Groups)

|                                                                       | EMBARK               | EMBARK              | EMBARK             | Phase 3t               | Phase 3t             | Totals ENZA+ADT (n = 5110)   |
|-----------------------------------------------------------------------|----------------------|---------------------|--------------------|------------------------|----------------------|------------------------------|
| Preferred Term (MedDRA v25.1),n (%) Event Rate                        | DB ENZA+ADT (n =353) | DB PBO+ADT (n =354) | ENZA Mono (n =354) | DB ENZA+ADT (n = 3728) | DB PBO+ADT (n =2829) | Totals ENZA+ADT (n = 5110)   |
| Patients with ≥ 1 TEAE resulting in death                             | 6 (1.7)              | 3 (0.8)             | 8 (2.3)            | 158 (4.2)              | 72 (2.5)             | 288 (5.6)                    |
| Total treatment-emergent period(patient-years)                        | 1535.48              | 1423.11             | 1571.94            | 7571.16                | 3572.94              | 12585.63                     |
| OverallTEAEleadingtodeathrate per100patient- years (number of events) | 0.4 (6)              | 0.2 (3)             | 0.5 (8)            | 2.3 (171)              | 2.1 (76)             | 2.5 (314)                    |
| Disease progression                                                   | 2 (0.6)              | 0                   | 1 (0.3)            | 12 (0.3)               | 6 (0.2)              | 33 (0.6)                     |
| Event rate per100patient-years(number of events)                      | 0.1 (2)              | 0                   | 0.1(1)             | 0.2 (12)               | 0.2 (6)              | 0.3 (33)                     |
| Aspiration                                                            | 1 (0.3)              | 0                   | 0                  | 2 (0.1)                | 0                    | 2 (0.0)                      |
| Event rate per 100 patient-years (number of events)                   | 0.1 (1)              | 0                   | 0                  | 0.0 (2)                | 0                    | 0.0 (2)                      |
| Death                                                                 | 1 (0.3)              | 0                   | 3 (0.8)            | 12 (0.3)               | 4 (0.1)              | 16 (0.3)                     |
| Event rate per 100 patient-years (number of events)                   | 0.1 (1)              | 0                   | 0.2 (3)            | 0.2 (12)               | 0.1 (4)              | 0.1 (16)                     |
| Pneumonia                                                             | 1 (0.3)              | 0                   | 0                  | 11 (0.3)               | 1 (0.0)              | 22 (0.4)                     |
| Eventrate per100patient-years(numberofevents)                         | 0.1(1)               | 0                   | 0                  | 0.1 (11)               | 0.0 (1)              | 0.2 (22)                     |
| Sepsis                                                                | 1 (0.3)              | 1 (0.3)             | 0                  | 4 (0.1)                | 2 (0.1)              | 6 (0.1)                      |
| Eventrate per100patient-years(numberofevents)                         | 0.1 (1)              | 0.1(1)              | 0                  | 0.1 (4)                | 0.1 (2)              | 0.0 (6)                      |
| Acute kidney injury                                                   | 0                    | 0                   | 0                  | 0                      | 2 (0.1)              | 3 (0.1)                      |
| Eventrate per100patient-years(numberofevents)                         | 0                    | 0                   | 0                  | 0                      | 0.1 (2)              | 0.0 (3)                      |
| Acutemyocardialinfarction                                             | 0                    | 0                   | 0                  | 5 (0.1)                | 0                    | 9 (0.2)                      |
| Event rate per100patient-years(number ofevents)                       | 0                    | 0                   | 0                  | 0.1 (5)                | 0                    | 0.1 (9)                      |
| Acute respiratory failure                                             | 0                    | 0                   | 0                  | 1 (0.0)                | 0                    | 2 (0.0)                      |
| Eventrate per100patient-years(numberofevents)                         | 0                    | 0                   | 0                  | 0.0 (1)                | 0                    | 0.0 (2)                      |
| Anaemia                                                               | 0                    | 0                   | 0                  | 0                      | 0                    | 2 (0.0)                      |
| Eventrate per100patient-years(numberofevents)                         | 0                    | 0                   | 0                  | 0                      | 0                    | 0.0 (2)                      |

<div style=\"page-break-after: always\"></div>

| Arteriosclerosiscoronary artery                     |   0 |   0 | 0       | 1 (0.0)   | 1 (0.0)   | 2 (0.0)   |
|-----------------------------------------------------|-----|-----|---------|-----------|-----------|-----------|
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0.0 (1)   | 0.0 (1)   | 0.0 (2)   |
| Cachexia                                            |   0 |   0 | 0       | 2 (0.1)   | 1 (0.0)   | 2 (0.0)   |
| Event rate per100patient-years(numberof events)     |   0 |   0 | 0       | 0.0 (2)   | 0.0 (1)   | 0.0 (2)   |
| Cardiac arrest                                      |   0 |   0 | 1 (0.3) | 3 (0.1)   | 2 (0.1)   | 5 (0.1)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0.1 (1) | 0.0 (3)   | 0.1 (2)   | 0.0 (5)   |
| Cardiac failure                                     |   0 |   0 | 0       | 7 (0.2)   | 0         | 12 (0.2)  |
| Event rate per100 patient-years (number of events)  |   0 |   0 | 0       | 0.1 (7)   | 0         | 0.1 (12)  |
| Cardiac failure congestive                          |   0 |   0 | 0       | 0         | 1 (0.0)   | 4 (0.1)   |
| Event rate per100patient-years(number of events)    |   0 |   0 | 0       | 0         | 0.0 (1)   | 0.0 (4)   |
| Cardio-respiratory arrest                           |   0 |   0 | 0       | 2 (0.1)   | 1 (0.0)   | 3 (0.1)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0.0 (2)   | 0.0 (1)   | 0.0 (3)   |
| Cardiogenic shock                                   |   0 |   0 | 0       | 0         | 1 (0.0)   | 2 (0.0)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0         | 0.0 (1)   | 0.0 (2)   |
| Cardiopulmonaryfailure                              |   0 |   0 | 0       | 4 (0.1)   | 0         | 5 (0.1)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0.1 (4)   | 0         | 0.0 (5)   |
| Cardiovascular insufficiency                        |   0 |   0 | 0       | 0         | 0         | 2 (0.0)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0         | 0         | 0.0 (2)   |
| Cerebralinfarction                                  |   0 |   0 | 1 (0.3) | 1 (0.0)   | 0         | 3 (0.1)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0.1 (1) | 0.0 (1)   | 0         | 0.0 (3)   |
| Cerebrovascular accident                            |   0 |   0 | 0       | 5 (0.1)   | 1 (0.0)   | 5 (0.1)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0.1 (5)   | 0.0 (1)   | 0.0 (5)   |
| Circulatory collapse                                |   0 |   0 | 0       | 1 (0.0)   | 0         | 2 (0.0)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0.0 (1)   | 0         | 0.0 (2)   |
| Coronary artery disease                             |   0 |   0 | 0       | 1 (0.0)   | 0         | 2 (0.0)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0.0 (1)   | 0         | 0.0 (2)   |
| COVID-19                                            |   0 |   0 | 1 (0.3) | 0         | 0         | 2 (0.0)   |
| Eventrate per100 patient-years(number ofevents)     |   0 |   0 | 0.1 (1) | 0         | 0         | 0.0 (2)   |
| Disseminated intravascular coagulation              |   0 |   0 | 0       | 1 (0.0)   | 0         | 2 (0.0)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0.0 (1)   | 0         | 0.0 (2)   |
| Drowning                                            |   0 |   0 | 0       | 2 (0.1)   | 0         | 2 (0.0)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0.0 (2)   | 0         | 0.0 (2)   |
| Gastric cancer                                      |   0 |   0 | 0       | 1 (0.0)   | 0         | 2 (0.0)   |
| Event rate per100patient-years (number of events)   |   0 |   0 | 0       | 0.0 (1)   | 0         | 0.0 (2)   |
| Generalphysical healthdeterioration                 |   0 |   0 | 0       | 19 (0.5)  | 10 (0.4)  | 25 (0.5)  |
| Event rateper100patient-years (number of events)    |   0 |   0 | 0       | 0.3 (19)  | 0.3 (10)  | 0.2 (25)  |
| Haemorrhage intracranial                            |   0 |   0 | 0       | 0         | 0         | 2 (0.0)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0         | 0         | 0.0 (2)   |
| Hepatic failure                                     |   0 |   0 | 0       | 2 (0.1)   | 0         | 3 (0.1)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0.0 (2)   | 0         | 0.0 (3)   |
| Infection                                           |   0 |   0 | 0       | 1 (0.0)   | 0         | 2 (0.0)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0.0 (1)   | 0         | 0.0 (2)   |
| Malignant neoplasm progression                      |   0 |   0 | 0       | 4 (0.1)   | 2 (0.1)   | 10 (0.2)  |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0.1(4)    | 0.1 (2)   | 0.1 (10)  |
| Metastases to liver                                 |   0 |   0 | 0       | 1 (0.0)   | 0         | 2 (0.0)   |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0       | 0.0 (1)   | 0         | 0.0 (2)   |
| Multiple organ dysfunction syndrome                 |   0 |   0 | 0       | 1 (0.0)   | 1 (0.0)   | 3 (0.1)   |
| Event rate per100 patient-years(number of events)   |   0 |   0 | 0       | 0.0 (1)   | 0.0 (1)   | 0.0 (3)   |

<div style=\"page-break-after: always\"></div>

| Myocardial infarction                               |   0 |   0 | 1 (0.3)   | 7 (0.2)   | 1 (0.0)   | 10 (0.2)   |
|-----------------------------------------------------|-----|-----|-----------|-----------|-----------|------------|
| Event rateper100patient-years(numberof events)      |   0 |   0 | 0.1 (1)   | 0.1(7)    | 0.0 (1)   | 0.1 (10)   |
| Pneumonia aspiration                                |   0 |   0 | 0         | 1 (0.0)   | 0         | 3 (0.1)    |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0         | 0.0 (1)   | 0         | 0.0 (3)    |
| Prostate cancer                                     |   0 |   0 | 0         | 1 (0.0)   | 0         | 5 (0.1)    |
| Event rateper100patient-years(numberof events)      |   0 |   0 | 0         | 0.0 (1)   | 0         | 0.0 (5)    |
| Prostate cancer metastatic                          |   0 |   0 | 0         | 0         | 2 (0.1)   | 2 (0.0)    |
| Event rate per100patient-years(number ofevents)     |   0 |   0 | 0         | 0         | 0.1 (2)   | 0.0 (2)    |
| Pulmonary embolism                                  |   0 |   0 | 0         | 5 (0.1)   | 1 (0.0)   | 7 (0.1)    |
| Event rateper100patient-years (number of events)    |   0 |   0 | 0         | 0.1 (5)   | 0.0 (1)   | 0.1 (7)    |
| Septic shock                                        |   0 |   0 | 0         | 5 (0.1)   | 2 (0.1)   | 6 (0.1)    |
| Event rateper100patient-years(number of events)     |   0 |   0 | 0         | 0.1 (5)   | 0.1 (2)   | 0.0 (6)    |
| Subduralhaematoma                                   |   0 |   0 | 0         | 1 (0.0)   | 1 (0.0)   | 2 (0.0)    |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0         | 0.0 (1)   | 0.0 (1)   | 0.0 (2)    |
| Urosepsis                                           |   0 |   0 | 0         | 1 (0.0)   | 0         | 2 (0.0)    |
| Event rate per 100 patient-years (number of events) |   0 |   0 | 0         | 0.0 (1)   | 0         | 0.0 (2)    |
| Ventricularfibrillation                             |   0 |   0 | 0         | 1 (0.0)   | 0         | 2 (0.0)    |
| Event rate per100 patient-years (number of events)  |   0 |   0 | 0         | 0.0 (1)   | 0         | 0.0 (2)    |

All patients whoreceived atleast 1 doseof study drug(enzalutamide,placebo) in theirrespective phase3study orreceived at least 1 dose of enzalutamide inphase 2 studies.For EMBARK,study drugincludes enzalutamide,leuprolide andplacebo(SafetyPopulation).

Data cutoff dates were as follows:EMBARK:31Jan 2023;PROSPER:15 Oct2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21Mar2019;AsianPREVAIL: 04Nov2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

Number of patients (n) and percentage of patients (%) are shown. Events are sorted by decreasing frequency of preferred term in the ENZA+ADT group in the EMBARK study. ADT: androgen deprivation therapy;DB:double-blind;ENZA:enzalutamide;ISS:Integrated Summary of Safety;Mono:monotherapy,OL: open-label;PBO:placebo;SCS:Summary of ClinicalSafety;TEAE:treatment-emergent adverse event.

↑Time-adjustedrateper100patient-years andnumber ofevents areshown.Time-adjustedrateper100patient-yearsis calculated asthe totalnumberofoccurrencesofevent divided

↑Thephase3studiesincludeEMBARK(ENZA+ADT andPBO+ADT arms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAIL andAsianPREVAIL.

Total enzalutamide summarizes all enzalutamide-treated patients during DB and/or OL periods of EMBARK (ENZA+ADT and ENZA Mono arms), PROSPER, ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE

↑Total treatment-emergent period in 100 patient-years for each treatment group is calculated as the sum of each patient's length of treatment-emergent period in days for each treatment group divided by365.25.

No patients treated with enzalutamide plus leuprolide and one (0.3%) patient treated with enzalutamide as monotherapy had an ischemic heart disease event that led to death.

## Other significant events: AEs of special interest (AESI)

TEAEs of special interest were selected based on previously recognized risks and/or feedback from regulatory authorities recommending surveillance for specific events. The prespecified TEAEs of special interest are convulsions (seizure), hypertension, neutrophil count decreased, cognitive and memory impairment, ischemic heart disease, other selected cardiovascular events, posterior reversible encephalopathy syndrome (PRES), fatigue, renal disorder, second primary malignancies, fall, fracture, loss of consciousness, thrombocytopenia, musculoskeletal events, severe cutaneous adverse reactions, angioedema, rash and hepatic disorder.

<div style=\"page-break-after: always\"></div>

Table 49. Overall summary of prespecified treatment-emergent AESIs (Safety Groups)

|                                           | EMBARK               | EMBARK              | EMBARK            | Phase3t                | Phase3t             |                           |
|-------------------------------------------|----------------------|---------------------|-------------------|------------------------|---------------------|---------------------------|
| Category*, n (%)                          | DB ENZA+ADT (n =353) | DB PBO+ADT (n =354) | ENZA Mono (n=354) | DB ENZA+ADT (n = 3728) | DB PBO+ADT (n=2829) | Totals ENZA+ADT (n =5110) |
| Convulsions(seizure)                      | 4 (1.1)              | 0                   | 3 (0.8)           | 16 (0.4)               | 4 (0.1)             | 31 (0.6)                  |
| Hypertension                              | 89 (25.2)            | 74 (20.9)           | 77 (21.8)         | 522 (14.0)             | 199 (7.0)           | 788 (15.4)                |
| Neutrophil count decreased                | 4 (1.1)              | 8 (2.3)             | 3 (0.8)           | 52 (1.4)               | 20 (0.7)            | 70 (1.4)                  |
| Cognitive andmemory impairment            | 53 (15.0)            | 23 (6.5)            | 50 (14.1)         | 238 (6.4)              | 68 (2.4)            | 381 (7.5)                 |
| Ischemicheart disease                     | 19 (5.4)             | 20 (5.6)            | 32 (9.0)          | 129 (3.5)              | 57 (2.0)            | 233 (4.6)                 |
| Other selected cardiovascular events      | 18 (5.1)             | 17 (4.8)            | 13 (3.7)          | 155 (4.2)              | 70 (2.5)            | 277 (5.4)                 |
| Posteriorreversibleencephalopathysyndrome | 0                    | 0                   | 0                 | 0                      | 0                   | 0                         |
| Fatigue                                   | 178 (50.4)           | 134 (37.9)          | 191 (54.0)        | 1608 (43.1)            | 837 (29.6)          | 2203 (43.1)               |
| Renal disorder                            | 21 (5.9)             | 10 (2.8)            | 14 (4.0)          | 132 (3.5)              | 105 (3.7)           | 213 (4.2)                 |
| Secondprimarymalignancies                 | 23 (6.5)             | 18 (5.1)            | 19 (5.4)          | 115 (3.1)              | 49 (1.7)            | 200 (3.9)                 |
| Fall                                      | 74 (21.0)            | 51 (14.4)           | 56 (15.8)         | 428 (11.5)             | 145 (5.1)           | 649 (12.7)                |
| Fracture                                  | 65 (18.4)            | 48 (13.6)           | 39 (11.0)         | 457 (12.3)             | 163 (5.8)           | 640 (12.5)                |
| Loss of consciousness                     | 20 (5.7)             | 12 (3.4)            | 12 (3.4)          | 111 (3.0)              | 37 (1.3)            | 167 (3.3)                 |
| Thrombocytopenia                          | 4 (1.1)              | 7 (2.0)             | 4 (1.1)           | 54 (1.4)               | 39 (1.4)            | 83 (1.6)                  |
| Musculoskeletalevents                     | 163 (46.2)           | 148 (41.8)          | 158 (44.6)        | 1630 (43.7)            | 1069 (37.8)         | 2249 (44.0)               |
| Severecutaneousadversereactions           | 1 (0.3)              | 0                   | 0                 | 6 (0.2)                | 3 (0.1)             | 8 (0.2)                   |
| Angioedema                                | 9 (2.5)              | 5 (1.4)             | 7 (2.0)           | 58 (1.6)               | 23 (0.8)            | 80 (1.6)                  |
| Rash                                      | 29 (8.2)             | 27 (7.6)            | 30 (8.5)          | 170 (4.6)              | 92 (3.3)            | 264 (5.2)                 |
| Hepatic disorder                          | 17 (4.8)             | 32 (9.0)            | 13 (3.7)          | 103 (2.8)              | 118 (4.2)           | 165 (3.2)                 |

Data cutoff dates Were asfollows:EMBARK:31Jan2023;PROSPER:15Oct2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21Mar2019;AsianPREVAIL: 04Nov2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

Numberofpatients(n)reportingatleast1eventandpercentageofpatients(%)areshown.

ADT:androgendeprivation therapy;AESI:adverse event of specialinterest;DB:double-blind;ENZA:enzalutamide;ISS:IntegratedSummaryof Safety;Mono:monotherapy;OL: open-label; PBO: placebo; SCS: Summary of Clinical Safety.

Thephase3studiesincludeEMBARK(ENZA+ADTandPBO+ADTarms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAILandAsianPREVAIL

Totalenzalutamidesummarizes allenzalutamide-treatedpatientsduringDBand/orOLperiodsofEMBARK(ENZA+ADTandENZA Monoarms),PROSPER,ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

## Modified treatment-emergent Period

Table 50. Overall summary of prespecified treatment-emergent adverse events of special interest using the modified treatment-emergent period (EMBARK study, Safety Population)

|                                           | EMBARK              | EMBARK              | EMBARK             | Phase 3               | Phase 3              |                           |
|-------------------------------------------|---------------------|---------------------|--------------------|-----------------------|----------------------|---------------------------|
| Category*, n (%)                          | DB ENZA+ADT (n=353) | DB PBO+ADT (n =354) | ENZA Mono (n =354) | DB ENZA+ADT (n =3728) | DB PBO+ADT (n =2829) | Totals ENZA+ADT (n =5110) |
| Convulsions (seizure)                     | 4 (1.1)             | 0                   | 3 (0.8)            | 16 (0.4)              | 4 (0.1)              | 31 (0.6)                  |
| Hypertension                              | 77 (21.8)           | 61 (17.2)           | 61 (17.2)          | 510 (13.7)            | 186 (6.6)            | 760 (14.9)                |
| Neutrophil countdecreased                 | 4 (1.1)             | 7 (2.0)             | 2 (0.6)            | 52 (1.4)              | 19 (0.7)             | 69 (1.4)                  |
| Cognitive andmemory impairment            | 51 (14.4)           | 22 (6.2)            | 47 (13.3)          | 236 (6.3)             | 67 (2.4)             | 376 (7.4)                 |
| Ischemic heart disease                    | 14 (4.0)            | 18 (5.1)            | 28 (7.9)           | 124 (3.3)             | 55 (1.9)             | 224 (4.4)                 |
| Otherselectedcardiovascularevents         | 17 (4.8)            | 11 (3.1)            | 12 (3.4)           | 154 (4.1)             | 64 (2.3)             | 275 (5.4)                 |
| Posteriorreversibleencephalopathysyndrome | 0                   | 0                   | 0                  | 0                     | 0                    | 0                         |
| Fatigue                                   | 176 (49.9)          | 131 (37.0)          | 187 (52.8)         | 1606 (43.1)           | 834 (29.5)           | 2197 (43.0)               |
| Renal disorder                            | 13 (3.7)            | 9 (2.5)             | 9 (2.5)            | 124 (3.3)             | 104 (3.7)            | 200 (3.9)                 |
| Second primary malignancies               | 18 (5.1)            | 16 (4.5)            | 19 (5.4)           | 110 (3.0)             | 47 (1.7)             | 195 (3.8)                 |
| Fall                                      | 58 (16.4)           | 46 (13.0)           | 49 (13.8)          | 412 (11.1)            | 140 (4.9)            | 626 (12.3)                |
| Fracture                                  | 49 (13.9)           | 35 (9.9)            | 33 (9.3)           | 441 (11.8)            | 150 (5.3)            | 618 (12.1)                |
| Loss of consciousness                     | 14 (4.0)            | 11 (3.1)            | 11 (3.1)           | 105 (2.8)             | 36 (1.3)             | 160 (3.1)                 |
| Thrombocytopenia                          | 3 (0.8)             | 7 (2.0)             | 3 (0.8)            | 53 (1.4)              | 39 (1.4)             | 81 (1.6)                  |
| Musculoskeletalevents                     | 126 (35.7)          | 131 (37.0)          | 137 (38.7)         | 1593 (42.7)           | 1052 (37.2)          | 2191 (42.9)               |
| Severecutaneousadversereactions           | 1 (0.3)             | 0                   | 0                  | 6 (0.2)               | 3 (0.1)              | 8 (0.2)                   |
| Angioedema                                | 7 (2.0)             | 5 (1.4)             | 5 (1.4)            | 56 (1.5)              | 23 (0.8)             | 76 (1.5)                  |
| Rash                                      | 22 (6.2)            | 22 (6.2)            | 27 (7.6)           | 163 (4.4)             | 87 (3.1)             | 254 (5.0)                 |
| Hepatic disorder                          | 11 (3.1)            | 23 (6.5)            | 7 (2.0)            | 97 (2.6)              | 109 (3.9)            | 153 (3.0)                 |

Allpatients who received at least 1 dose of study drug (enzalutamide,placebo) in their respective phase 3 study or received at least 1 dose of enzalutamide in phase 2 studies.For EMBARK,studydrugincludes enzalutamide,leuprolideandplacebo(SafetyPopulation).

DatacutoffdatesWereasfollows:EMBARK:31Jan2023;PROSPER:15Oct2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21Mar2019;AsianPREVAIL: 04Nov 2020;TERRAIN:17Feb2018 andSTRIVE:30May2018.

Number of patients (n) reporting at least 1 event and percentage of patients (%) are shown.

The modified treatment-emergent period takes into account the protocol-defined treatment suspension due to undetectable PSA at week 36 in the EMBARK study.For studies other than EMBARK, the modified treatment-emergent period refers to the treatment-emergent period.

ADT: androgen deprivation therapy,AESI: adverseevent of special interest;DB: double-blind;ENZA: enzalutamide;ISS:Integrated Summary of Safety,Mono:monotherapy, OL: open-label; PBO: placebo; PSA: prostate-specific antigen; SCS: Summary of Clinical Safety.

↑Definitionsfor allprespecifiedtreatment-emergentAESIs arepresented in[Table3].

↑Thephase3studiesincludeEMBARK(ENZA+ADTandPBO+ADTarms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAILandAsianPREVAIL

Totalenzalutamidesummarizes allenzalutamide-treatedpatientsduringDBand/orOLperiodsofEMBARK(ENZA+ADTandENZAMonoarms),PROSPER,ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

- Ischemic heart disease

<div style=\"page-break-after: always\"></div>

Table 51. Treatment-Emergent Adverse Events of Ischemic Heart Disease for ≥ 1 patient in the EMBARK enzalutamide plus ADT group by Preferred Term (Safety Groups)

| PreferredTerm (MfedDRAv25.1)                                              | EMBARK                             | EMBARK                             | EMBARK                             | Phase 3t                           | Phase 3t                           | Totali ENZA+ADT                    |
|---------------------------------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| Category, n (%) Event Rate (erents)                                       | DB ENZA+ADT (n =353)               | DB PBO+ADT (n=354)                 | ENZA Mono (n =354)                 | DB ENZA+ADT (n=3728)               | DB PBO+ADT (n=2829)                | (n =5110)                          |
| Any event of ischemic heart disease Event rate (e)                        | 19 (5.4) 2.1 (33)                  | 20 (5.6) 1.7 (24)                  | 32 (9.0) 2.5 (39)                  | 129 (3.5) 2.2 (163)                | 57 (2.0) 1.9 (68)                  | 233 (4.6) 2.4 (296)                |
| Angina pectons Event rate (e)                                             | 9 (2.5) 0.7 (11)                   | 9 (2.5) 0.8 (11)                   | 9 (2.5) 0.6 (10)                   | 37 (1.0) 0.5 (40)                  | 18 (0.6) 0.6 (22)                  | 64 (1.3) 0.6 (74)                  |
| Coronary artery disease Event rate (e)                                    | 6 (1.7) 0.4 (6)                    | 1 (0.3) 0.1 (1)                    | 11 (3.1) 0.7 (11)                  | 32 (0.9) 0.4 (33)                  | 5 (0.2) 0.1 (5)                    | 51 (1.0) 0.4 (52)                  |
| Acute coronary syndrome Event rate (e)                                    | 3 (0.8) 0.2 (3)                    | 1 (0.3) 0.1 (1)                    | 2 (0.6) 0.1 (2)                    | 14 (0.4) 0.2 (14)                  | 7 (0.2) 0.2 (7)                    | 23 (0.5) 0.2 (23)                  |
| Coronary artery occlusion Event rate (e)                                  | 3 (0.8) 0.2 (3)                    | 1 (0.3) 0.1(1)                     | 1 (0.3) 0.1 (1)                    | 3 (0.1) 0.0 (3)                    | 1 (0.0) 0.0 (1)                    | 4 (0.1) 0.0 (4)                    |
| Myocardial infarction Event rate (e)                                      | 3 (0.8) 0.2 (3)                    | 2 (0.6) 0.1 (2)                    | 5 (1.4) 0.3 (5)                    | 19 (0.5) 0.3 (19)                  | 8 (0.3) 0.2 (8)                    | 37 (0.7) 0.3 (37)                  |
| Acute myocardial infarction Event rate (e)                                | 2 (0.6) 0.2 (3)                    | 4 (1.1) 0.3 (4)                    | 4 (1.1) 0.3 (4)                    | 22 (0.6) 0.3 (25)                  | 8 (0.3) 0.2 (8)                    | 43 (0.8) 0.4 (48)                  |
| Angina unstable Event rate (e)                                            | 1 (0.3) 0.1 (2)                    | 0                                  | 0                                  | 5 (0.1) 0.17)                      | 3 (0.1) 0.1 (3)                    | 7 (0.1) 0.1 (9)                    |
| Coronary artery stenosis Event rate (e)                                   | 1 (0.3) 0.1 (1)                    | 0                                  | 3 (0.8) 0.2 (3)                    | 3 (0.1) 0.0 (3)                    | 0                                  | 9 (0.2) 0.1 (9)                    |
| Myocardial ischaemia Event rate (e)                                       | 1 (0.3) 0.1 (1)                    | 3 (0.8) 0.2 (3)                    | 1 (0.3) 0.1 (1)                    | 9 (0.2) 0.1 (9)                    | 8 (0.3) 0.2 (8)                    | 17 (0.3) 0.1 (17)                  |
| Any event of ischemic heart disease leading to death                      | 0                                  | 1 (0.3)                            | 1 (0.3)                            | 14 (0.4)                           | 3 (0.1)                            | 23 (0.5)                           |
| Any serious event ofischemic heart disease                                | 13 (3.7)                           | 11 (3.1)                           | 23 (6.5)                           | 81 (2.2)                           | 32 (1.1)                           | 158 (3.1)                          |
| Any drug-related event ofischemic heart diseases                          | 5 (1.4)                            | 6 (1.7)                            | 8 (2.3)                            | 18 (0.5)                           | 14 (0.5)                           | 40 (0.8)                           |
| Any grade ≥ 3 event ofischemic heart disease                              | 14 (4.0)                           | 11 (3.1)                           | 21 (5.9)                           | 75 (2.0)                           | 33 (1.2)                           | 149 (2.9)                          |
| Any event of ischemic heart disease leading to study drug discontinuation | 2 (0.6)                            | 4 (1.1)                            | 4 (1.1)                            | 10 (0.3)                           | 7 (0.2)                            | 23 (0.5)                           |
| Any event of ischemic heart disease leading todoseintemuption             | 2 (0.6)                            | 4 (1.1)                            | 5 (1.4)                            | 22 (0.6)                           | 12 (0.4)                           | 40 (0.8)                           |
| Any event ofischemic heart disease leading to dose reduction              | 1 (0.3)                            | 0                                  | 1 (0.3)                            | 1 (0.0)                            | 1 (0.0)                            | 3 (0.1)                            |
| Any event ofischemic heart disease                                        | Any event ofischemic heart disease | Any event ofischemic heart disease | Any event ofischemic heart disease | Any event ofischemic heart disease | Any event ofischemic heart disease | Any event ofischemic heart disease |
| Within the first 30 days                                                  | 0/353                              | 0/354                              | 1/354 (0.3)                        | 2/3728 (0.1)                       | 6/2829 (0.2)                       | 4/5110 (0.1)                       |
| Between 31 to 180 days                                                    | 1/353 (0.3)                        | 3/353 (0.8)                        | 0/354                              | 33/3720 (0.9)                      | 17/2816 (0.6)                      | 40/5098 (0.8)                      |
| Between 181 to365 days                                                    | 2/336 (0.6)                        | 4/344 (1.2)                        | 6/345 (1.7)                        | 29/3200 (0.9)                      | 10/1796 (0.6)                      | 45/4389 (1.0)                      |
| Between 366 to 540 days                                                   | 1/285 (0.4)                        | 3/306 (1.0)                        | 2/313 (0.6)                        | 16/2554 (0.6)                      | 12/1183 (1.0)                      | 28/3530 (0.8)                      |
| Between 541 to 730 days                                                   | 2/285 (0.7)                        | 1/293 (0.3)                        | 3/305 (1.0)                        | 20/2027 (1.0)                      | 3/735 (0.4)                        | 34/2880 (1.2)                      |
| Between 731 to 900 days (2.5 years)                                       | 2/280 (0.7)                        | 2/272 (0.7)                        | 6/293 (2.0)                        | 14/1521 (0.9)                      | 2/425 (0.5)                        | 30/2414 (1.2)                      |
| Between 2.5 years to 3 years                                              | 2/270 (0.7)                        | 4/255 (1.6)                        | 4/285 (1.4)                        | 11/1116 (1.0)                      | 5/333 (1.5)                        | 23/2081 (1.1)                      |
| Between 3 years to 4 years                                                | 4/260 (1.5)                        | 2/238 (0.8)                        | 9/268 (3.4)                        | 7/785 (0.9)                        | 2/265 (0.8)                        | 33/1790 (1.8)                      |
| Between 4 years to 5 years                                                | 4/244 (1.6)                        | 2/205 (1.0)                        | 2/238 (0.8)                        | 6/504 (1.2)                        | 2/207 (1.0)                        | 12/1247 (1.0)                      |
| Between5 years to 6 years                                                 | 1/185 (0.5)                        | 2/145 (1.4)                        | 2/179 (1.1)                        | 1/272 (0.4)                        | 2/145 (1.4)                        | 8/737 (1.1)                        |
| >6 years                                                                  | 3/84 (3.6)                         | 0/63                               | 1/81 (1.2)                         | 3/99 (3.0)                         | 0/63                               | 7/328 (2.1)                        |

Allpatients who received at least 1 dose of shudy drug (enzalutamide, placebo) in their respective phase 3 study or received at least 1 dose of enzalutamide in phase 2 studies. For EMBARK, study drug includes enzalutamide, leuprolide and placebo (Safety Population).

Data cutoff dates Were asfollows:EMBARK:31Jan 2023;PROSPER:15Oct2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21 Mar 2019;AsianPREVAIL: 04Nov2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

“Any event ofischemicheart disease”refers toAEsinthe narowSMQsof‘myocardialinfarctionand“otherischemicheart disease.

Time-adjusted rate per 100 patient-years and number of events (e) are showm. Time-adjusted rate per 100 patient-years is calculated as the total number of occurences of event divided by the total treament-emergent period for each treatment group times 100.Patients can have more than 1 occurence of each event. Adverse events that are continuous but change grade are counted as I event.

Number ofpatients (n) reporting at least 1 event of ischemic heart disease and percentage of patients (%) are showm. NCI-CTCAE v4.03.

ADT: androgen deprivation therapy; AE: adverse event; CRF: case report form; DB: double-blind; ENZA: enzalutamide; ISS: Integrated Summary of Safety, Mono: monotherapy, NCI-CTCAE:National Cancer Instihute CommonTerminology Criteria forAdverse Events;OL:open-label;PBO:placebo;SCS:Summary of Clinical Safety,SMQ: standardized MedDRA query; TEAE: treatment-emergent adverse event.

↑ The phase 3 studies include EMBARK (ENZA+ADT and PBO+ADT arms) and DB phase for PROSPER, ARCHES, AFFIRM, PREVAIL and Asian PREVAIL.

Total enzalutamide summarizes all enzalutamide-treatedpatients duingDB and/or OL periods ofEMBARK (ENZA+ADT and ENZA Mono arms),PROSPER, ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

Drug-related TEAEs are TEAEs that were judged by the investigator as possibly, probably or definitely related to study drug.

↑IschemicheartdiseaseleadingtoshudydrugdiscontinuationisfromAECRFandincludesTEAEswithactiontakenofpermanentdiscontinuation.

- Cognitive and memory impairment

<div style=\"page-break-after: always\"></div>

Table 52. Treatment-Emergent Adverse Events of Cognitive and Memory Impairment (Safety Groups)

| PreferredTerm(fedDRAv25.1)                                                         | EMBARK                                    | EMBARK                                    | EMBARK                                    | Phase 3t                                  | Phase 3t                                  |                                           |
|------------------------------------------------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Category, n (%) Event Rate (erents)                                                | DB ENZA+ADT (n=353)                       | DB PBO+ADT (n=354)                        | ENZA Mfono (n =354)                       | DB ENZA+ADT (n=3728)                      | DB PBO+ADT (n=2829)                       | Totali ENZA±ADT (n=5110)                  |
| Any event of cognitive and memory impaiment Event rate (e)                         | 53 (15.0) 4.1 (63)                        | 23 (6.5) 1.9 (27)                         | 50 (14.1) 4.1 (64)                        | 238 (6.4) 3.6 (271)                       | 68 (2.4) 2.1 (74)                         | 381 (7.5) 3.5 (444)                       |
| Memory impairment Event rate (e)                                                   | 26 (7.4) 1.9 (29)                         | 12 (3.4) 0.9 (13)                         | 21 (5.9) 1.4 (22)                         | 103 (2.8) 1.4 (108)                       | 31 (1.1) 0.9 (32)                         | 156 (3.1) 1.3 (163)                       |
| Amnesia Event rate (e)                                                             | 17 (4.8) 1.2 (18)                         | 8 (2.3) 0.6 (8)                           | 16 (4.5) 1.1 (18)                         | (9:1) 19 0.8 (62)                         | 15 (0.5) 0.4 (15)                         | 109 (2.1) 0.9 (114)                       |
| Dishubance in attention Event rate (e)                                             | 8 (2.3) 0.5 (8)                           | 2 (0.6) 0.2 (3)                           | 11 (3.1) 0.7 (11)                         | 44 (1.2) 0.6 (46)                         | 10 (0.4) 0.3 (11)                         | 71 (1.4) 0.6 (73)                         |
| Cognitive disorder Event rate (e)                                                  | 2 (0.6) 0.3 (4)                           | 1 (0.3) 0.1 (1)                           | 8 (2.3) 0.5 (8)                           | 33 (0.9) 0.5 (35)                         | 8 (0.3) 0.2 (8)                           | 56 (1.1) 0.5 (59)                         |
| Mental impairment Event rate (e)                                                   | 2 (0.6) 0.1 (2)                           | 0                                         | 2 (0.6) 0.1 (2)                           | 3 (0.1) 0.0 (3)                           | 1 (0.0) 0.0 (1)                           | 6 (0.1) 0.0 (6)                           |
| Dementia Alzheimer's type Event rate (e)                                           | 1 (0.3) 0.1 (1)                           | 0                                         | 3 (0.8) 0.2 (3)                           | 7 (0.2) 0.1(7)                            | 1 (0.0) 0.0 (1)                           | 12 (0.2) 0.1 (12)                         |
| Vascular dementia Event rate (e)                                                   | 1 (0.3) 0.1 (1)                           | 0                                         | 0                                         | 2 (0.1) 0.0 (2)                           | 0                                         | 2 (0.0) 0.0 (2)                           |
| Dementia Event rate (e)                                                            | 0                                         | 2 (0.6) 0.1 (2)                           | 0                                         | 5 (0.1) 0.1(5)                            | 6 (0.2) 0.2 (6)                           | 11 (0.2) 0.1 (11)                         |
| Senile dementia Event rate (e)                                                     | 0                                         | 0                                         | 0                                         | 2 (0.1) 0.0 (2)                           | 0                                         | 3 (0.1) 0.0 (3)                           |
| Transient global amnesia Event rate (e)                                            | 0                                         | 0                                         | 0                                         | 1 (0.0) 0.0 (1)                           | 0                                         | 1 (0.0) 0.0 (1)                           |
| Any event of cognitive and memory impairment leading to death                      | 0                                         | 0                                         | 0                                         | 0                                         | 1 (0.0)                                   | 1 (0.0)                                   |
| Anyseriousevent of cognitiveandmemory impairment                                   | 1 (0.3)                                   | 1 (0.3)                                   | 0                                         | 4 (0.1)                                   | 6 (0.2)                                   | 9 (0.2)                                   |
| Any drug-related event of cognitive and memory impaiment                           | 44 (12.5)                                 | 15 (4.2)                                  | 42 (11.9)                                 | 142 (3.8)                                 | 36 (1.3)                                  | 237 (4.6)                                 |
| Any grade3 event of cognitive and memory impaiment                                 | 2 (0.6)                                   | 2 (0.6)                                   | 0                                         | 9 (0.2)                                   | 6 (0.2)                                   | 17 (0.3)                                  |
| Any event of cognitive and memory impairment leading to study drug discontinuation | 7 (2.0)                                   | 3 (0.8)                                   | 3 (0.8)                                   | 22 (0.6)                                  | 6 (0.2)                                   | 30 (0.6)                                  |
| Any event of cognitive and memory impairment leading to dose intemuption           | 3 (0.8)                                   | 3 (0.8)                                   | 1 (0.3)                                   | 12 (0.3)                                  | 5 (0.2)                                   | 17 (0.3)                                  |
| Any event of cognitive and memory impaiment leading to dose reduction              | 4 (1.1)                                   | 3 (0.8)                                   | 2 (0.6)                                   | 8 (0.2)                                   | 4 (0.1)                                   | 13 (0.3)                                  |
| Any event of cognitiveandmemoryimpairment                                          | Any event of cognitiveandmemoryimpairment | Any event of cognitiveandmemoryimpairment | Any event of cognitiveandmemoryimpairment | Any event of cognitiveandmemoryimpairment | Any event of cognitiveandmemoryimpairment | Any event of cognitiveandmemoryimpairment |
| Within the first 30 days                                                           | 13/353 (3.7)                              | 7/354 (2.0)                               | 5/354 (1.4)                               | 55/3728 (1.5)                             | 17/2829 (0.6)                             | 70/5110 (1.4)                             |
| Between31 to 180 days                                                              | 23/353 (6.5)                              | 5/353 (1.4)                               | 15/354 (4.2)                              | 85/3720 (2.3)                             | 24/2816 (0.9)                             | 119/5098 (2.3)                            |
| Between 181 to 365 days                                                            | 4/336 (1.2)                               | 5/344 (1.5)                               | 8/345 (2.3)                               | 49/3200 (1.5)                             | 17/1796 (0.9)                             | 72/4389 (1.6)                             |
| Between 366 to 540 days                                                            | 0/285                                     | 2/306 (0.7)                               | 5/313 (1.6)                               | 19/2554 (0.7)                             | 5/1183 (0.4)                              | 32/3530 (0.9)                             |
| Between 541 to 730 days                                                            | 2/285 (0.7)                               | 3/293 (1.0)                               | 8/305 (2.6)                               | 24/2027 (1.2)                             | 5/735 (0.7)                               | 40/2880 (1.4)                             |
| Between 731 to 900 days (2.5 years)                                                | 5/280 (1.8)                               | 2/272 (0.7)                               | 2/293 (0.7)                               | 10/1521 (0.7)                             | 2/425 (0.5)                               | 23/2414 (1.0)                             |
| Between 2.5years to3years                                                          | 2/270 (0.7)                               | 1/255 (0.4)                               | 3/285 (1.1)                               | 10/1116 (0.9)                             | 1/333 (0.3)                               | 25/2081 (1.2)                             |
| Between3years to 4 years                                                           | 7/260 (2.7)                               | 2/238 (0.8)                               | 10/268 (3.7)                              | 12/785 (1.5)                              | 2/265 (0.8)                               | 39/1790 (2.2)                             |
| Between 4 years to 5 years                                                         | 3/244 (1.2)                               | 1/205 (0.5)                               | 2/238 (0.8)                               | 4/504 (0.8)                               | 1/207 (0.5)                               | 9/1247 (0.7)                              |
| Between 5 years to 6 years                                                         | 3/185 (1.6)                               | 0/145                                     | 2/179 (1.1)                               | 3/272 (1.1)                               | 0/145                                     | 7/737 (0.9)                               |
| >6years                                                                            | 1/84 (1.2)                                | 0/63                                      | 0/81                                      | (0'1) 66/1                                | 0/63                                      | 2/328 (0.6)                               |

Allpatients whoreceivedatleast1 doseof shudydrug（enzalutamide,placebo)in theirrespective phase3study orreceived atleast 1 dose ofenzalutamideinphase 2 studies.For EMBARK,study drug includes enzalutamide,leuprolide and placebo(SafetyPopulation).

Data cutoffdatesWere asfollows:EMBARK:31Jan2023;PROSPER:15Oct2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21Mar2019;AsianPREVAIL: 04Nov2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

“\"Any event ofcognitive and memoryimpairmentrefers toallpreferred termsintheMedDRAHigh Level GroupTem ofmentalimpairment disorders.

Time-adjustedrate per 100patient-years andnumber of events (e) are showm.Time-adjusted rate per 100patient-years is calculated as the total number of occurences of event divided by the total treatment-emergent period for each treatment group times 100.Patients can have more than 1 occurence of each event.Adverse events that are continuous but change grade are counted as I event.

Number ofpatients (n) reporting at least 1 event of cognitive and memory impairment and percentage ofpatients (%) are shown. NCI-CTCAE v4.03.

ADT: androgen deprivation therapy; AE: adverse event; CRF: case report fom; DB: double-blind; ENZA: enzalutamide; ISS:Integrated Summary of Safety, Mono: monotherapy, NCI-CTCAE:National CancerInstitute CommonTerminologyCriteriaforAdverseEvents;OL:open-label;PBO:placebo;SCS:Summaryof ClinicalSafety;TEAE:treatmentemergent adverse event.

↑The phase3studies includeEMBARK(ENZA+ADTandPBO+ADTarms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAILandAsianPREVAIL.

Total enzalutamide summanizes all enzalutamide-treated patients duing DB and/or OL peniods ofEMBARK (ENZA+ADT and ENZA Mono ams),PROSPER,ARCHES, AFFIRM,PREVAILAsianPREVAIL,TERRAINandSTRIVE.

$ Drug-related TEAEs are TEAEs that were judged by the investigator as possibly, probably or definitely related to study drug.

↑Cognitiveand memoryimpainmentleadingto shudy drug discontinuationisfromAECRFandincludesTEAEswith actiontaken ofpermanent discontinuation.

<div style=\"page-break-after: always\"></div>

## · Secondary Primary Malignancies

## Table 53.Treatment-emergent Adverse Events of Second Primary Malignancy, Excluding Nonmelanoma Skin Cancer for ≥ 1 Patient (Safety Groups)

|                                                                | EMBARK               | EMBARK              | EMBARK             | Phase3↑              | Phase3↑             | Total, ENZA±ADT (n =5110)   |
|----------------------------------------------------------------|----------------------|---------------------|--------------------|----------------------|---------------------|-----------------------------|
| PreferredTerm (MedDRAv25.1) Category, n (%) EventRate (events) | DB ENZA+ADT (n =353) | DB PBO+ADT (n =354) | ENZA Mono (n =354) | DB ENZA+ADT (n=3728) | DB PBO+ADT (n=2829) | Total, ENZA±ADT (n =5110)   |
| Anysecondprimarymalignancy,excluding nonmelanoma skin cancer   | 23 (6.5)             | 18 (5.1)            | 19 (5.4)           | 115 (3.1)            | 49 (1.7)            | 200 (3.9)                   |
| Event rate (e)                                                 | 1.6 (25)             | 1.8 (25)            | 1.5 (24)           | 1.7 (127)            | 1.8 (63)            | 1.8 (225)                   |
| Malignant melanoma in situ Event rate (e)                      | 3 (0.8) 0.2 (3)      | 0                   | 1 (0.3) 0.1 (2)    | 4 (0.1) 0.1 (4)      | 1 (0.0) 0.0 (1)     | 5 (0.1) 0.0 (6)             |
| Colon cancer Event rate (e)                                    | 2 (0.6) 0.1 (2)      | 0                   | 0                  | 6 (0.2) 0.1 (6)      | 3 (0.1) 0.1 (3)     | 11 (0.2) 0.1 (11)           |
| Rectal cancer Event rate (e)                                   | 2 (0.6) 0.1 (2)      | 0                   | 0                  | 4 (0.1) 0.1 (4)      | 0                   | 4 (0.1) 0.0 (4)             |
| Adenocarcinoma gastric Event rate (e)                          | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 3 (0.1) 0.0 (3)      | 0                   | 3 (0.1) 0.0 (3)             |
| Adenocarcinoma of colon Event rate (e)                         | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 9 (0.2) 0.1 (9)      | 3 (0.1) 0.1 (3)     | 10 (0.2) 0.1 (10)           |
| Bladder cancer Event rate (e)                                  | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 10 (0.3) 0.1 (10)    | 0                   | 13 (0.3) 0.1 (13)           |
| Colon cancer metastatic Event rate (e)                         | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 1 (0.0) 0.0 (1)      | 0                   | 2 (0.0) 0.0 (2)             |
| Diffuse large B-cell lymphoma Event rate (e)                   | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 2 (0.1) 0.0 (2)      | 1 (0.0) 0.0 (1)     | 2 (0.0) 0.0 (2)             |
| Hepatocellular carcinoma Event rate (e)                        | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 2 (0.1) 0.0 (2)      | 0                   | 4 (0.1) 0.0 (5)             |
| Large cell lung cancer Event rate (e)                          | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 1 (0.0) 0.0 (1)      | 0                   | 1 (0.0) 0.0 (1)             |
| Lung adenocarcinoma Event rate (e)                             | 1 (0.3) 0.1 (1)      | 0                   | 1 (0.3) 0.1 (1)    | 2 (0.1) 0.0 (2)      | 2 (0.1) 0.1 (2)     | 6 (0.1) 0.0 (6)             |
| Malignantmelanoma Event rate (e)                               | 1 (0.3) 0.1 (1)      | 1 (0.3) 0.1 (1)     | 1 (0.3) 0.1 (1)    | 6 (0.2) 0.1 (6)      | 1 (0.0) 0.0 (1)     | 10 (0.2) 0.1 (10)           |
| Myelodysplastic syndrome Event rate (e)                        | 1 (0.3) 0.1 (1)      | 0                   | 1 (0.3) 0.1 (1)    | 1 (0.0) 0.0 (1)      | 1 (0.0) 0.0 (1)     | 5 (0.1) 0.0 (5)             |
| Oropharyngeal squamous cell carcinoma Event rate (e)           | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 1 (0.0) 0.0 (1)      | 0                   | 1 (0.0) 0.0 (1)             |
| Pancreatic neoplasm Event rate (e)                             | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 1 (0.0) 0.0 (1)      | 0                   | 1 (0.0) 0.0 (1)             |
| Papillary renal cell carcinoma Event rate (e)                  | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 1 (0.0) 0.0 (1)      | 0                   | 1 (0.0) 0.0 (1)             |
| Plasma cell myeloma Event rate (e)                             | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 1 (0.0) 0.0 (1)      | 0                   | 3 (0.1) 0.0 (3)             |
| Skinsquamouscellcarcinomarecurrent Event rate (e)              | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 1 (0.0) 0.0 (1)      | 0                   | 1 (0.0) 0.0 (1)             |
| Squamous cell carcinoma of lung Event rate (e)                 | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 2 (0.1) 0.0 (2)      | 0                   | 4 (0.1) 0.0 (4)             |
| Thyroid cancer Event rate (e)                                  | 1 (0.3) 0.1 (1)      | 0                   | 0                  | 1 (0.0) 0.0 (1)      | 0                   | 1 (0.0) 0.0 (1)             |
| Transitional cell carcinoma Event rate (e)                     | 1 (0.3) 0.1 (1)      | 2 (0.6) 0.1 (2)     | 3 (0.8) 0.2 (3)    | 7 (0.2) 0.1 (8)      | 4 (0.1) 0.2 (6)     | 15 (0.3) 0.1 (17)           |

All patients who received at least 1 dose of study drug (enzalutamide, placebo) in their respective phase 3 study or received at least 1 dose of enzalutamide in phase 2 studies. For EMBARK, study drug includes enzalutamide, leuprolide and placebo (Safety Population).

Data cutoff dates were as follows:EMBARK: 31 Jan 2023;PROSPER:15 Oct 2019;ARCHES: 28 May 2021;AFFIRM: 20Feb 2018;PREVAIL: 21 Mar 2019; Asian PREVAIL: 04 Nov 2020; TERRAIN: 17 Feb 2018 and STRIVE: 30 May 2018.

\"Second primary malignancy\"refers to AEs in the narrowSMQs of'malignant or unspecified tumours'customized to exclude preferred terms of'congenital fibrosarcoma,' 'congenital malignant neoplasm,'congenital retinoblastoma,''metastases to...,''metastasis,''metastatic neoplasm,''prostate cancer...''carcinoid tumour of the prostate'and neoplasm prostate'and(inclusive of) narrowSMQof*myelodysplastic syndrome'and(inclusive of) all preferred termsunderhighlevel term of'myeloproliferative disorders(excl leukaemias)';non-melanoma skin cancers are excluded(preferred terms of\"basal cell carcinoma,''basosquamous carcinoma,'\"basosquamous carcinoma of skin,'\"keratoacanthoma, 'skin cancer,，'skin cancer metastatic,''squamous cell carcinoma,'squamous cell carcinoma of skin'and'lip squamous cellcarcinoma').

Time-adjusted rate per 100 patient-years and number of events (e) are shown. Time-adjusted rate per 100 patient-years is calculated as the total number of occurrences of event divided by the total treatment-emergent period for each treatment group times 10o.Patients can have more than 1 occurrence of each event.Adverse events that are continuous but change grade are counted as 1 event.

Number of patients (n) reporting at least 1 event of second primary malignancy and percentage of patients (%) are shown.NCI-CTCAE v4.03.

ADT:androgen deprivation therapy; AE: adverse event; CRF: case report form;DB: double-blind; ENZA: enzalutamide; excl: excluding;ISS:Integrated Summary of Safety; max: maximum;min:minimum;Mono:monotherapy;NCI-CTCAE:National Cancer Institute Common Terminology CriteriaforAdverseEvents;OL:open-label;PBO:placebo; SCS:Summary of Clinical Safety;SMQ:standardizedMedDRA query;TEAE:treatment-emergent adverse event.

↑ The phase 3 studies include EMBARK (ENZA+ADT and PBO+ADT arms) and DB phase for PROSPER, ARCHES, AFFIRM, PREVAIL and Asian PREVAIL.

Total enzalutamide summarizes all enzalutamide-treated patients during DB and/or OL periods of EMBARK (ENZA+ADT and ENZA Mono arms), PROSPER, ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAIN andSTRIVE.

Drug-related TEAEs are TEAEs that were judged by the investigator as possibly, probably or definitely related to study drug.

Second primary malignancy leading to study drug discontinuation is from AE CRF and includes TEAEs with action taken of permanent discontinuation.

<div style=\"page-break-after: always\"></div>

## Adverse Drug Reactions

Section 4.8 of the SmPC has been updated to reflect the addition of the EMBARK safety population (N=5110).

Table 54: Adverse Reactions identified in controlled clinical trials and post-marketing

| MedDRA System organ class                            | Adverse reaction and frequency                                                                                                                                                                               |
|------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Blood and lymphatic system disorders                 | Uncommon: leucopenia, neutropenia Not known * : thrombocytopenia                                                                                                                                             |
| Immune system disorders                              | Not known * : face oedema, tongue oedema, lip oedema, pharyngeal oedema                                                                                                                                      |
| Psychiatric disorders                                | Common: anxiety Uncommon: visual hallucination                                                                                                                                                               |
| Nervous system disorders                             | Common: headache, memory impairment, amnesia, disturbance in attention, dysgeusia, restless legs syndrome, cognitive disorder Uncommon: seizure ¥ Not known * : posterior reversible encephalopathy syndrome |
| Cardiac disorders                                    | Common: ischemic heart disease † Not known * : QT-prolongation (see sections 4.4 and 4.5)                                                                                                                    |
| Vascular disorders                                   | Very common: hot flush, hypertension                                                                                                                                                                         |
| Gastrointestinal disorders                           | Not known * : nausea, vomiting, diarrhoea                                                                                                                                                                    |
| Skin and subcutaneous tissue disorders               | Common: dry skin, pruritus Not known * : erythema multiforme, rash                                                                                                                                           |
| Musculoskeletal and connective tissue disorders      | Very common: fractures ‡ Not known * : myalgia, muscle spasms, muscular weakness, back pain                                                                                                                  |
| Reproductive system and breast disorder              | Common: gynaecomastia, nipple pain, breast tenderness                                                                                                                                                        |
| General disorders and administration site conditions | Very common: asthenia, fatigue                                                                                                                                                                               |
| Injury, poisoning and procedural complications       | Very common: fall                                                                                                                                                                                            |

*  Spontaneous reports from post-marketing experience. ¥  As evaluated by narrow SMQs of 'Convulsions' including convulsion, grand mal convulsion, complex partial seizures, partial seizures, and status epilepticus. This includes rare cases of seizure with complications leading to death.†  As evaluated by narrow SMQs of 'Myocardial Infarction' and 'Other Ischemic Heart Disease' including the following preferred terms observed in at least two patients in randomized placebo-controlled phase 3 studies: angina pectoris, coronary artery disease, myocardial infarctions, acute myocardial infarction, acute coronary syndrome, angina unstable, myocardial ischaemia, and arteriosclerosis coronary artery. ‡  Includes all preferred terms with the word 'fracture' in bones.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

## Haematology

## Table 55. Haematology Results: Summary of Grade 3 and 4 post-baseline laboratory abnormalities (Safety Groups)

|                                                | EMBARK               | EMBARK              | EMBARK              | Phase 3↑              | Phase 3↑             |                            |
|------------------------------------------------|----------------------|---------------------|---------------------|-----------------------|----------------------|----------------------------|
| Parameter, Unit [Direction of Criteria], n (%) | DB ENZA+ADT (n= 353) | DB PBO+ADT (n= 354) | ENZA Mono (n = 354) | DB ENZA+ADT (n =3728) | DB PBO+ADT (n =2829) | Totalt ENZA+ADT (n = 4701) |
| Hemoglobin (g/L) [low]                         | 2 (0.6)              | 1 (0.3)             | 1 (0.3)             | 75 (2.0)              | 46 (1.6)             | 91 (1.9)                   |
| Hemoglobin (g/L) [high]                        | 0                    | 0                   | 0                   | 2 (0.1)               | 1 (0.0)              | 2 (0.0)                    |
| Lymphocytes (10%/L) [low]                      | 8 (2.3)              | 9 (2.5)             | 7 (2.0)             | 128 (3.4)             | 91 (3.2)             | 162 (3.4)                  |
| Lymphocytes (10%L) [high]                      | 1 (0.3)              | 1 (0.3)             | 0                   | 1 (0.0)               | 1 (0.0)              | 1 (0.0)                    |
| Neutrophils (10%L) [low]                       | 2 (0.6)              | 3 (0.8)             | 1 (0.3)             | 35 (0.9)              | 14 (0.5)             | 42 (0.9)                   |
| Platelets (10°/L) [low]                        | 0                    | 0                   | 1 (0.3)             | 10 (0.3)              | 10 (0.4)             | 16 (0.3)                   |
| Leukocytes (109/L) [low]                       | 2 (0.6)              | 1 (0.3)             | 0                   | 17 (0.5)              | 6 (0.2)              | 20 (0.4)                   |

All patients who received at least 1 dose of study drug (enzalutamide, placebo) in their respective phase 3 study or received at least 1 dose of enzalutamide in phase 2 studies. For EMBARK,study drug includes enzalutamide,leuprolideand placebo(SafetyPopulation).

04Nov2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

Grade3and 4 toxicities weregraded usingNCI-CTCAEv4.03.

Patients were generally counted only once for each parameter.However, for parameters with both high and 1ow criteria, patients were counted only once for each criterion(high or low), so a single patient could count toward both high and low criteria if the patient had laboratory values meeting each criterion. Summaries are based on all test results collected in the treatment-emergent period.

TheoriginalbaselinevaluewasusedforpatientswhoreceivedenzalutamideduringtheDBphaseandcontinuedtoreceiveenzalutamideduringtheOLphase.Baselinevaluewas reset tothelastnonmissingmeasurement at orbefore thefirstdoseof enzalutamideforpatientswhoreceivedplaceboorbicalutamideduringtheDBphaseandcrossedovertoreceive enzalutamideduringtheOLphase.

ADT: androgen deprivation therapy, DB: double-blind; ENZA: enzalutamide; ISS: Integrated Summary of Safety, Mono: monotherapy, NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; OL: open-label; PBO: placebo; SCS: Summary of Clinical Safety.

↑Thephase3studiesincludeEMBARK(ENZA+ADTandPBO+ADTarms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAILandAsianPREVAIL

Totalenzalutamide summarizes allenzalutamide-treatedpatientsduringDBand/orOLperiodsofEMBARK(ENZA+ADTandENZA Mono arms),PROSPER,ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

## Blood Chemistry

## Table 56. Blood Chemistry Results: Summary of Grade 3 and 4 post-baseline laboratory abnormalities (Safety Groups)

|                                                 | EMBARK              | EMBARK               | EMBARK              | Phase 3↑               | Phase 3↑             |                            |
|-------------------------------------------------|---------------------|----------------------|---------------------|------------------------|----------------------|----------------------------|
| Parameter (Unit) [Direction of Criteria], n (%) | DB ENZA+ADT (n=353) | DB PBO+ADT (n = 354) | ENZA Mono (n = 354) | DB ENZA+ADT (n = 3728) | DB PBO+ADT (n =2829) | Totalt ENZA+ADT (n = 4701) |
| Alanine aminotransferase (U/L) [high]           | 3 (0.8)             | 2 (0.6)              | 0                   | 18 (0.5)               | 8 (0.3)              | 27 (0.6)                   |
| Albumin (g/L) [low]                             | 1 (0.3)             | 1 (0.3)              | 0                   | 11 (0.3)               | 6 (0.2)              | 11 (0.2)                   |
| Alkaline phosphatase (U/L) [high]               | 0                   | 0                    | 2 (0.6)             | 185 (5.0)              | 212 (7.5)            | 203 (4.3)                  |
| Aspartate aminotransferase (U/L) [high]         | 1 (0.3)             | 2 (0.6)              | 0                   | 13 (0.3)               | 13 (0.5)             | 23 (0.5)                   |
| Bilirubin (μmol/L) [high]                       | 0                   | 0                    | 0                   | 3 (0.1)                | 1 (0.0)              | 4 (0.1)                    |
| Calcium (mmol/L) [low]                          | 0                   | 1 (0.3)              | 0                   | 19 (0.5)               | 19 (0.7)             | 23 (0.5)                   |
| Calcium (mmol/L) [high]                         | 1 (0.3)             | 1 (0.3)              | 0                   | 5 (0.1)                | 2 (0.1)              | 6 (0.1)                    |
| Creatinine (μmol/L) [high]                      | 0                   | 0                    | 0                   | 5 (0.1)                | 8 (0.3)              | 7 (0.1)                    |
| Glucose (mmol/L) [low]                          | 0                   | 0                    | 0                   | 0                      | 0                    | 2 (0.0)                    |
| Glucose(mmol/L) [high]                          | 20 (5.7)            | 33 (9.3)             | 21 (5.9)            | 131 (3.5)              | 114 (4.0)            | 201 (4.3)                  |
| Magnesium (mmol/L) [low]                        | 1 (0.3)             | 0                    | 0                   | 2 (0.1)                | 1 (0.0)              | 3 (0.1)                    |
| Magnesium(mmol/L)[high]                         | 0                   | 0                    | 0                   | 5 (0.1)                | 9 (0.3)              | 5 (0.1)                    |
| Phosphate(mmol/L) [low]                         | 7 (2.0)             | 0                    | 11 (3.1)            | 52 (1.4)               | 24 (0.8)             | 76 (1.6)                   |
| Potassium(mmol/L) [low]                         | 2 (0.6)             | 4 (1.1)              | 2 (0.6)             | 13 (0.3)               | 17 (0.6)             | 21 (0.4)                   |
| Potassium(mmol/L) [high]                        | 5 (1.4)             | 4 (1.1)              | 2 (0.6)             | 15 (0.4)               | 12 (0.4)             | 28 (0.6)                   |
| Sodium(mmol/L) [low]                            | 7 (2.0)             | 3 (0.8)              | 4 (1.1)             | 55 (1.5)               | 38 (1.3)             | 72 (1.5)                   |
| Sodium(mmol/L) [high]                           | 2 (0.6)             | 0                    | 2 (0.6)             | 4 (0.1)                | 2 (0.1)              | 6 (0.1)                    |

All patients who received at least 1 dose of study drug (enzalutamide, placebo) in their respective phase 3 study or received at least 1 dose of enzalutamide in phase 2 studies. For EMBARK,study drugincludes enzalutamide,leuprolide andplacebo(SafetyPopulation).

Data cutoff dates were as follows:EMBARK:31Jan2023;PROSPER:15 Oct2019;ARCHES:28May2021;AFFIRM:20Feb 2018;PREVAIL: 30Sep 2017;AsianPREVAIL: 04Nov 2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

Grade3 and 4 toxicities weregraded usingNCI-CTCAEv4.03.

<div style=\"page-break-after: always\"></div>

Patientsweregenerallycountedonlyonceforeachparameter.However,forparameterswithbothhighandlowcriteria,patientswerecountedonlyonceforeachcriterion(highor low),soasinglepatientcouldcounttowardbothhighandlowcriteriaifthepatienthadlaboratoryvaluesmeetingeachcriterion.Summariesarebasedonalltestresultscollectedin thetreatment-emergentperiod.

BaselinevalueisresettothelastnonmissingmeasurementatorbeforethefirstdoseofenzalutamideforpatientswhoreceivedplaceboorbicalutamideduringtheDBphase and crossedovertoreceiveenzalutamideduringtheOLphase.TheoriginalbaselinevalueisusedforpatientswhoreceivedenzalutamideduringtheDBphaseandcontinuedtoreceive enzalutamideduringtheOLphase.

ADT:androgendeprivation therapy;DB:double-blind;ENZA:enzalutamide;ISS:IntegratedSummaryofSafety;Mono:monotherapy,NCI-CTCAE:NationalCancerInstitute CommonTerminologyCriteriaforAdverseEvents;OL:open-label;PBO:placebo;SCS:SummaryofClinicalSafety.

↑Thephase3studiesincludeEMBARK(ENZA+ADTandPBO+ADTarms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAILandAsianPREVAIL.

↑Totalenzalutamidesummarizesallenzalutamide-treatedpatientsduringDBand/orOLperiodsofEMBARK(ENZA+ADTandENZAMonoarms),PROSPER,ARCHES AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

## Elevated Liver Function Tests

Table 57. Treatment-Emergent liver function test elevations (Safety Groups)

|                                                        | EMBARK                                 | EMBARK              | EMBARK              | Phase 3↑               | Phase 3↑              | ENZA+ADT        |
|--------------------------------------------------------|----------------------------------------|---------------------|---------------------|------------------------|-----------------------|-----------------|
| Parameter Criteria, n (%)                              | DB ENZA+ADT (n =353)                   | DB PBO+ADT (n =354) | ENZA Mono (n = 354) | DB ENZA+ADT (n = 3728) | DB PBO+ADT (n = 2829) | (n = 4701)      |
| ALT                                                    |                                        |                     |                     |                        |                       |                 |
| n                                                      | 353                                    | 354                 | 354                 | 3727                   | 2828                  | 4699            |
| ≥3×ULN                                                 | 6 (1.7)                                | 10 (2.8)            | 2 (0.6)             | 43 (1.2)               | 45 (1.6)              | 61 (1.3)        |
| ≥3 x ULN and worse than baseline                       | 6 (1.7)                                | 10 (2.8)            | 2 (0.6)             | 43 (1.2)               | 45 (1.6)              | 60 (1.3)        |
| ≥5xULN                                                 | 3 (0.8)                                | 2 (0.6)             | 0                   | 18 (0.5)               | 8 (0.3)               | 27 (0.6)        |
| ≥10 x ULN                                              | 0                                      | 0                   | 0                   | 4 (0.1)                | 3 (0.1)               | 9 (0.2)         |
| ≥20 x ULN                                              | 0                                      | 0                   | 0                   | 1 (0.0)                | 0                     | 2 (0.0)         |
| AST                                                    |                                        |                     |                     |                        |                       |                 |
| n                                                      | 353                                    | 354                 | 354                 | 3727                   | 2828                  | 4699            |
| ≥3xULN                                                 | 3 (0.8)                                | 9 (2.5)             | 2 (0.6)             | 50 (1.3)               | 47 (1.7)              | 67 (1.4)        |
| ≥3 × ULN and worse than baseline                       | 3 (0.8)                                | 9 (2.5)             | 2 (0.6)             | 50 (1.3)               | 46 (1.6)              | 67 (1.4)        |
| ≥5xULN                                                 | 1 (0.3)                                | 2 (0.6)             | 0                   | 13 (0.3)               | 13 (0.5)              | 23 (0.5)        |
| ≥10 x ULN                                              | 0                                      | 0                   | 0                   | 3 (0.1)                | 2 (0.1)               | 7 (0.1)         |
| ≥20 x ULN                                              | 0                                      | 0                   | 0                   | 0                      | 0                     | 0               |
| ALT or AST                                             |                                        |                     |                     |                        |                       |                 |
| ≥3xULN                                                 | 7/353 (2.0)                            | 12/354 (3.4)        | 4/354 (1.1)         | 67/3727 (1.8)          | 66/2828 (2.3)         | 89/4699 (1.9)   |
| Total bilirubin                                        |                                        |                     |                     |                        |                       |                 |
| ≥2 ×ULN                                                | 0                                      | 1/354 (0.3)         | 1/354 (0.3)         | 7/3727 (0.2)           | 3/2828 (0.1)          | 11/4699 (0.2)   |
| ALP                                                    |                                        |                     |                     |                        |                       |                 |
| ≥1.5 x ULN                                             | 3/353 (0.8)                            | 8/354 (2.3)         | 10/354 (2.8)        | 803/3727 (21.5)        | 729/2828 (25.8)       | 939/4699 (20.0) |
| ALTand/orASTandtotalbilirubin                          |                                        |                     |                     |                        |                       |                 |
| ALTand/orAST≥3xULNandtotal bilinubin≥2xULN             | 0                                      | 0                   | 0                   | 3/3727 (0.1)           | 1/2828 (0.0)          | 3/4699 (0.1)    |
| ALT and/orAST andtotalbilirubin andALP                 | ALT and/orAST andtotalbilirubin andALP |                     |                     |                        |                       |                 |
| bilirubin≥2xULNandALP<2xULN ALTand/orAST≥3xULNandtotal | 0                                      | 0                   | 0                   | 1/3727 (0.0)           | 0                     | 1/4699 (0.0)    |

Data cutoff dates were as follows:EMBARK:31Jan 2023;PROSPER:15 Oct2019;ARCHES:28May 2021;AFFIRM:20Feb2018;PREVAIL:30 Sep 2017;AsianPREVAIL: 04Nov 2020;TERRAIN:17Feb2018 andSTRIVE:30May2018.

Maximum value on treatment is presented for each liver enzyme and total bilirubin.

Number of patients (n) and percentage of patients (%) are shown. The denominator was the number of patients who had at least 1 nonmissing value during treatment.

Baseline value is reset to the last nonmissing measurement at or before the first dose of enzalutamide for patients who received placebo or bicalutamide during theDB phase and enzalutamide during the OLphase.

ADT: androgen deprivation therapy, ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; DB: double-blind; ENZA: enzalutamide;

↑Thephase3studies includeEMBARK(ENZA+ADTandPBO+ADT arms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAILandAsianPREVAIL

↑Totalenzalutamidesummarizes allenzalutamide-treatedpatients duringDBand/orOLperiods ofEMBARK(ENZA+ADT andENZA Mono arms),PROSPER,ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

<div style=\"page-break-after: always\"></div>

Vital signs, Physical findings, and other observations related to safety

Table 58. Potentially clinically significant changes in vital signs (Safety Groups)

|                                                                                                                                | EMBARK                       | EMBARK                       | EMBARK                      | Phase 3↑                         | Phase 3↑                       | Totalt ENZA+ADT (n = 5110)       |
|--------------------------------------------------------------------------------------------------------------------------------|------------------------------|------------------------------|-----------------------------|----------------------------------|--------------------------------|----------------------------------|
| Parameter (Unit) Direction of Criteria, n/N (%)                                                                                | DB ENZA+ADT (n =353)         | DB PBO+ADT (n = 354)         | ENZA Mono (n =354)          | DB ENZA+ADT (n = 3728)           | PBO+ADT (n =2829)              | Totalt ENZA+ADT (n = 5110)       |
| Systolicbloodpressure(mmHg)                                                                                                    |                              |                              |                             |                                  |                                |                                  |
| Absoluteresult≥140s                                                                                                            | 295/349 (84.5)               | 287/354 (81.1)               | 278/354 (78.5)              | 2519/3710 (67.9)                 | 1837/2807 (65.4)               | 3867/5059 (76.4)                 |
| Absolute result≥180$                                                                                                           | 37/349 (10.6)                | 29/354 (8.2)                 | 22/354 (6.2)                | 288/3710 (7.8)                   | 124/2807 (4.4)                 | 433/5059 (8.6)                   |
| Absoluteresult≥140andincreasefrom baseline≥20$                                                                                 | 160/349 (45.8)               | 152/354 (42.9)               | 137/354 (38.7)              | 1313/3710 (35.4)                 | 730/2807 (26.0)                | 2034/5059 (40.2)                 |
| Absoluteresult≥180andincreasefrom baseline ≥20$                                                                                | 31/349 (8.9)                 | 26/354 (7.3)                 | 20/354 (5.6)                | 248/3710 (6.7)                   | 100/2807 (3.6)                 | 374/5059 (7.4)                   |
| Absoluteresult≥180andincreasefrom baseline≥40s                                                                                 | 19/349 (5.4)                 | 17/354 (4.8)                 | 8/354 (2.3)                 | 136/3710 (3.7)                   | 55/2807 (2.0)                  | 209/5059 (4.1)                   |
| Absoluteresult≤90anddecreasefrom baseline≥30s                                                                                  | 5/349 (1.4)                  | 7/354 (2.0)                  | 4/354 (1.1)                 | 33/3710 (0.9)                    | 22/2807 (0.8)                  | 51/5059 (1.0)                    |
| Finalvisitor2consecutivevisitsresults ≥10 changefrombaseline                                                                   | 193/349 (55.3)               | 183/354 (51.7)               | 160/354 (45.2)              | 1846/3710 (49.8)                 | 1048/2807 (37.3)               | 2564/5059 (50.7)                 |
| Finalvisit or2consecutive visitsresults ≥15change from baseline                                                                | 125/349 (35.8)               | 125/354 (35.3)               | 102/354 (28.8)              | 1269/3710 (34.2)                 | 673/2807 (24.0)                | 1801/5059 (35.6)                 |
| Final visit or 2 consecutive visits results ≥20 change from baseline                                                           | 84/349 (24.1)                | 82/354 (23.2)                | 76/354 (21.5)               | 878/3710 (23.7)                  | 460/2807 (16.4)                | 1277/5059 (25.2)                 |
| Any abnormality                                                                                                                | 312/349 (89.4)               | 310/354 (87.6)               | 299/354 (84.5)              | 2976/3710 (80.2)                 | 2060/2807 (73.4)               | 4242/5059 (83.9)                 |
| Diastolicblood pressure(mmHg)                                                                                                  |                              |                              |                             |                                  |                                |                                  |
| Absolute result≥90$                                                                                                            | 208/349 (59.6)               | 182/354 (51.4)               | 168/354 (47.5)              | 1530/3710 (41.2)                 | 932/2807 (33.2)                | 2292/5059 (45.3)                 |
| Absoluteresult≥105s                                                                                                            | 30/349 (8.6)                 | 18/354 (5.1)                 | 15/354 (4.2)                | 164/3710 (4.4)                   | 68/2807 (2.4)                  | 244/5059 (4.8)                   |
| Absoluteresult≥90andincreasefrom baseline≥15$                                                                                  | 105/349 (30.1)               | 81/354 (22.9)                | 66/354 (18.6)               | 726/3710 (19.6)                  | 339/2807 (12.1)                | 1068/5059 (21.1)                 |
| Absolute result≥105and increasefrom baseline ≥15§                                                                              | 28/349 (8.0)                 | 16/354 (4.5)                 | 13/354 (3.7)                | 131/3710 (3.5)                   | 52/2807 (1.9)                  | 199/5059 (3.9)                   |
| Absoluteresult≥105andincreasefrom baseline≥30§                                                                                 | 5/349 (1.4)                  | 6/354 (1.7)                  | 3/354 (0.8)                 | 41/3710 (1.1)                    | 17/2807 (0.6)                  | 67/5059 (1.3)                    |
| Absoluteresult≤50and decreasefrom baseline≥20s                                                                                 | 6/349 (1.7)                  | 7/354 (2.0)                  | 9/354 (2.5)                 | 51/3710 (1.4)                    | 32/2807 (1.1)                  | 87/5059 (1.7)                    |
| Finalvisit or2consecutivevisitsresults ≥5change frombaseline                                                                   | 184/349 (52.7)               | 193/354 (54.5)               | 168/354 (47.5)              | 2035/3710 (54.9)                 | 1203/2807 (42.9)               | 2757/5059 (54.5)                 |
| Finalvisitor 2consecutivevisitsresults ≥10 changefrombaseline Finalvisit or 2 consecutive visits results ≥15changefrombaseline | 122/349 (35.0) 58/349 (16.6) | 116/354 (32.8) 47/354 (13.3) | 84/354 (23.7) 40/354 (11.3) | 1255/3710 (33.8) 571/3710 (15.4) | 689/2807 (24.5) 270/2807 (9.6) | 1708/5059 (33.8) 800/5059 (15.8) |
| Heart rate (bpm)                                                                                                               |                              |                              |                             |                                  |                                |                                  |
| Absoluteresult≥120andincreasefrom baseline≥30$                                                                                 | 1/349 (0.3)                  | 3/354 (0.8)                  | 1/354 (0.3)                 | 20/3710 (0.5)                    | 18/2807 (0.6)                  | 28/5059 (0.6)                    |
| Absoluteresult≤50 anddecreasefrom baseline≥20$                                                                                 | 9/349 (2.6)                  | 16/354 (4.5)                 | 15/354 (4.2)                | 61/3710 (1.6)                    | 35/2807 (1.2)                  | 105/5059 (2.1)                   |
| Anyabnormality                                                                                                                 | 10/349 (2.9)                 | 19/354 (5.4)                 | 16/354 (4.5)                | 80/3710 (2.2)                    | 52/2807 (1.9)                  | 132/5059 (2.6)                   |

Data cutoff dateswere as follows:EMBARK:31Jan 2023;PROSPER:15 Oct 2019;ARCHES:28May 2021;AFFIRM:20Feb2018;PREVAIL:21 Mar 2019;AsianPREVAIL: 04Nov 2020;TERRAIN:17Feb2018 andSTRIVE:30May 2018.

Number of patients (n) and percentage of patients (%) are shown. The denominator was the number of patients who had at least 1 nonmissing value during treatment.

Baseline value is reset to thelast nonmissingmeasurement at orbeforethe first dose of enzalutamideforpatientswho received placebo orbicalutamide during the DBphase and crossedovertoreceiveenzalutamideduringtheOLphase.TheoriginalbaselinevalueisusedforpatientswhoreceivedenzalutamideduringtheDBphaseandcontinued toreceive enzalutamideduringtheOLphase.

ADT:androgen deprivation therapy,bpm:beats per minute;DB:double-blind;ENZA:enzalutamide;ISS:IntegratedSummary of Safety,Mono:monotherapy,OL: open-label;PBO: placebo; SCS: Summary of Clinical Safety.

↑Thephase3studiesincludeEMBARK(ENZA+ADT andPBO+ADTarms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAILandAsianPREVAIL.

Totalenzalutamidesummarizes allenzalutamide-treatedpatientsduringDBand/orOLperiodsofEMBARK(ENZA+ADT andENZAMonoarms),PROSPER,ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

Basedonpatient'smostextremeresultvalueduringtreatment.

## Safety in special populations

Table 59: TEAEs of Grade 3 or higher by subgroups (EMBARK study, Safety Population)

<div style=\"page-break-after: always\"></div>

|                                                | Enza+LA (N=353)                   | Enza+LA (N=353)   | PBO+LA (N=354)   | PBO+LA (N=354)   | ENZA (N=354)     | ENZA (N=354)     |
|------------------------------------------------|-----------------------------------|-------------------|------------------|------------------|------------------|------------------|
| Subgroups                                      | Grade 3/4/5                       | Al1               | Grade 3/4/5      | Al1              | Grade 3/4/5      | Al1              |
| Number of Patients Reporting at Least One TEAE | 164 (46.5%)                       | 343 (97.2%)       | 151 (42.7%)      | 345 (97.5%)      | 177 (50.0%)      | 347 (98.0%)      |
| Study Day Cut Points                           |                                   |                   |                  |                  |                  |                  |
| 1-30 Days                                      | 11/353 ( 3.1%)                    | 199/353 ( 56.4%)  | 9/354 ( 2.5%)    | 180/354( 50.8%)  | 11/354 ( 3.1%)   | 181/354( 51.1%)  |
| 1 -Week 37                                     | 65/353( 18.4%)                    | 322/353 ( 91.2%)  | 56/354( 15.8%)   | 316/354 ( 89.3%) | 50/354( 14.1%)   | 323/354（9 91.2%) |
| >Week 37                                       | 129/289(44.6%)                    | 275/289( 95.2%)   | 114/311( 36.7%)  | 288/311( 92.6%)  | 148/315( 47.0%)  | 297/315（ 94.3%)  |
| Age (Years)                                    |                                   |                   |                  |                  |                  |                  |
| <65                                            | 21/79 (26.6%)                     | 76/79 (96.2%)     | 36/90 (40.0%)    | 89/90 (98.9%)    | 30/91(33.0%)     | 89/91( 97.8%)    |
| >=65                                           | 143/274( 52.2%)                   | 267/274( 97.4%)   | 115/264 ( 43.6%) | 256/264( 97.0%)  | 147/263(55.9%)   | 258/263 (98.1%)  |
| <75                                            | 119/280(42.5%)                    | 273/280(97.5%)    | 107/267( 40.1%)  | 262/267(98.1%)   | 117/264 ( 44.3%) | 260/264 (98.5%)  |
| >=75                                           | 45/73( 61.6%)                     | 70/73 (95.9%)     | 44/87( 50.6%)    | 83/87 ( 95.4%)   | 60/90 (66.7%)    | 87/90(96.7%)     |
| <85                                            | 163/352( 46.3%)                   | 342/352(97.2%)    | 149/349 (42.7%)  | 340/349 (97.4%)  | 173/348 (49.7%)  | 341/348( 98.0%)  |
| >=85                                           | 1/1 ( 100%)                       | 1/1 ( 100%)       | 2/5 (40.0%)      | 5/5 ( 100%)      | 4/6 (66.7%)      | 6/6 ( 100%)      |
| BaselineBodyMassIndex                          | BaselineBodyMassIndex             |                   |                  |                  |                  |                  |
| (Kg/m2)                                        |                                   |                   |                  |                  |                  |                  |
| <18.5                                          | 0/0                               | 0/0               | 0/0              | 0/0              | 0/1( 0.0%)       | 1/1( 100%)       |
| 18.5-24.9                                      | 34/70 (48.6%)                     | 66/70 (94.3%)     | 30/84 (35.7%)    | 83/84 (98.8%)    | 27/62 ( 43.5%)   | 58/62( 93.5%)    |
| 25 -29.9                                       | 83/181( 45.9%)                    | 176/181( 97.2%)   | 71/161 ( 44.1%)  | 155/161( 96.3%)  | 94/178( 52.8%)   | 176/178 (98.9%)  |
| >=30                                           | 46/100(46.0%)                     | 99/100(99.0%)     | 49/106 ( 46.2%)  | 104/106(98.1%)   | 56/112 (50.0%)   | 111/112( 99.1%)  |
| Geographic Region                              | Geographic Region                 |                   |                  |                  |                  |                  |
| North America                                  | 67/143 (46.9%)                    | 142/143 (99.3%)   | 58/135 ( 43.0%)  | 134/135 ( 99.3%) | 64/133 ( 48.1%)  | 133/133 ( 100%)  |
| Europe                                         | 59/129( 45.7%)                    | 123/129 (95.3%)   | 48/127( 37.8%)   | 122/127( 96.1%)  | 76/145 (52.4%)   | 142/145 ( 97.9%) |
| Rest of the World                              | 38/81( 46.9%)                     | 78/81 ( 96.3%)    | 45/92 ( 48.9%)   | 89/92 (96.7%)    | 37/76 ( 48.7%)   | 72/76 ( 94.7%)   |
| History of Cardiovascular Disease              | History of Cardiovascular Disease |                   |                  |                  |                  |                  |
| Yes                                            | 22/42(52.4%)                      | 41/42 (97.6%)     | 19/42 ( 45.2%)   | 41/42 ( 97.6%)   | 27/47(57.4%)     | 46/47 ( 97.9%)   |
| No                                             | 142/311 (45.7%)                   | 302/311 (97.1%)   | 132/312(42.3%)   | 304/312 ( 97.4%) | 150/307 (48.9%)  | 301/307 (98.0%)  |

Thedatacut-offdateis31JAN2023.

Note: Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

Table 60. Treatment-emergent SAEs by subgroups (EMBARK study, Safety Population)

|                                                      | Enza+LA (N=353)                   | Enza+LA (N=353)   | Enza+LA (N=353)   |                 |                         | PBO+LA (N=354)          | PBO+LA (N=354)               | PBO+LA (N=354)         |             |
|------------------------------------------------------|-----------------------------------|-------------------|-------------------|-----------------|-------------------------|-------------------------|------------------------------|------------------------|-------------|
| Subgroups                                            | Grade 3/4/5                       | Grade 3/4/5       | Al1               | Al1             | Grade 3/4/5 A11         | Grade 3/4/5 A11         | Grade 3/4/5                  | Grade 3/4/5            | (N=354) A11 |
| NumberofPatients Reporting at Least One Serious TEAE | 110 (31.2%)                       | 110 (31.2%)       | 123 (34.8%)       | 123 (34.8%)     | 100 (28.2%) 112 (31.6%) | 100 (28.2%) 112 (31.6%) | 116 (32.8%)                  | 131 (37.0%)            | 131 (37.0%) |
| Study Day Cut Points                                 |                                   |                   |                   |                 |                         |                         |                              |                        |             |
| 1 - 30 Days                                          | 2/353(                            | 0.6%)             | 3/353(            | 0.8%)           | 2/354( 0.6%)            | 2/354( 0.6%)            | 1/354 ( 0.3%)                | 2/354( 0.6%)           |             |
| 1 - Week 37                                          | 27/353 (                          | 7.6%)             | 35/353 (          | 9.9%)           | 31/354 ( 8.8%)          | 35/354 ( 9.9%)          | 16/354 ( 4.5%)               | 21/354(                |             |
| >Week 37                                             |                                   | 93/289(32.2%)     | 99/289 (          | 34.3%)          | 76/311( 24.4%)          | 85/311( 27.3%)          | 105/315(33.3%)               | 5.9%) 116/315 ( 36.8%) |             |
| Age (Years)                                          |                                   |                   |                   |                 |                         |                         |                              |                        |             |
| <65                                                  | 10/79 (12.7%)                     | 10/79 (12.7%)     | 14/79 (17.7%)     | 14/79 (17.7%)   | 18/90(20.0%)            | 19/90 ( 21.1%)          | 16/91(17.6%)                 | 19/91( 20.9%)          |             |
| >=65                                                 | 100/274(36.5%)                    | 100/274(36.5%)    | 109/274( 39.8%)   | 109/274( 39.8%) | 82/264( 31.1%)          | 93/264 ( 35.2%)         | 100/263(38.0%)               | 112/263 ( 42.6%)       |             |
| <75                                                  | 75/280 (26.8%)                    | 75/280 (26.8%)    | 87/280(31.1%)     | 87/280(31.1%)   | 67/267 (25.1%)          | 76/267 ( 28.5%)         | 75/264 (28.4%)               | 86/264 (32.6%)         |             |
| >=75                                                 | 35/73( 47.9%)                     | 35/73( 47.9%)     | 36/73 (49.3%)     | 36/73 (49.3%)   | 33/87( 37.9%)           | 36/87 ( 41.4%)          | 41/90 (45.6%) 113/348（32.5%) | 45/90(50.0%)           |             |
| <85                                                  | 110/352(31.3%)                    | 110/352(31.3%)    | 123/352(34.9%)    | 123/352(34.9%)  | 98/349(28.1%)           | 110/349（31.5%）          |                              | 128/348(36.8%)         |             |
| >=85                                                 | 0/1( 0.0%)                        | 0/1( 0.0%)        | 0/1( 0.0%)        | 0/1( 0.0%)      | 2/5 (40.0%)             | 2/5 (40.0%)             | 3/6 (50.0%)                  | 3/6(50.0%)             |             |
| BaselineBodyMassIndex                                | BaselineBodyMassIndex             |                   |                   |                 |                         |                         |                              |                        |             |
| (Kg/m2) <18.5                                        | 0/0                               |                   | 0/0               |                 | 0/0                     | 0/0                     | 0/1( 0.0%)                   | 0/1( 0.0%)             |             |
| 18.5 -24.9                                           |                                   | 23/70(32.9%)      |                   | 23/70 (32.9%)   | 17/84 ( 20.2%)          | 24/84 (28.6%)           | 16/62(25.8%)                 | 17/62 (27.4%)          |             |
| 25 -29.9                                             |                                   | 57/181( 31.5%)    | 67/181( 37.0%)    |                 | 46/161 ( 28.6%)         | 50/161( 31.1%)          | 62/178(34.8%)                | 71/178( 39.9%)         |             |
| >=30                                                 | 30/100(                           | 30.0%)            | 33/100(33.0%)     |                 | 36/106(34.0%)           | 37/106( 34.9%)          | 38/112(33.9%)                | 43/112( 38.4%)         |             |
| Geographic Region                                    |                                   |                   |                   |                 |                         |                         |                              |                        |             |
| North America                                        | 35/143 (                          | 24.5%)            | 40/143 (          | 28.0%)          | 37/135 ( 27.4%)         | 42/135 ( 31.1%)         | 42/133 (31.6%)               | 46/133 ( 34.6%)        |             |
| Europe                                               |                                   | 45/129 (34.9%)    |                   | 50/129 (38.8%)  | 35/127(27.6%)           | 40/127( 31.5%)          | 48/145 ( 33.1%)              | 54/145(37.2%)          |             |
| Rest of the World                                    | 30/81(37.0%)                      |                   |                   | 33/81 (40.7%)   | 28/92(30.4%)            | 30/92(32.6%)            | 26/76( 34.2%)                | 31/76 (40.8%)          |             |
| History of Cardiovascular Disease                    | History of Cardiovascular Disease |                   |                   |                 |                         |                         |                              |                        |             |
| Yes                                                  |                                   | 15/42( 35.7%)     | 16/42 ( 38.1%)    |                 | 16/42 ( 38.1%)          | 18/42 ( 42.9%)          | 21/47 ( 44.7%)               | 24/47 ( 51.1%)         |             |
| No                                                   | 95/311(30.5%)                     |                   | 107/311(34.4%)    |                 | 84/312(26.9%)           | 94/312 (30.1%)          | 95/307 (30.9%)               | 107/307 (34.9%)        |             |

The data cut-off date is 31JAN2023.

Note: Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

<div style=\"page-break-after: always\"></div>

Table 61. Treatment-emergent AEs by age group (Safety Groups)

|                                           | EMBARK                                    | EMBARK              | EMBARK              | Phase 3↑               | Phase 3↑              |                            |
|-------------------------------------------|-------------------------------------------|---------------------|---------------------|------------------------|-----------------------|----------------------------|
| Category                                  | DB ENZA+ADT (n =353)                      | DB PBO+ADT (n =354) | ENZA Mono (n = 354) | DB ENZA+ADT (n = 3728) | DB PBO+ADT (n = 2829) | Totalt ENZA+ADT (n = 5110) |
| Age group, n (%)                          |                                           |                     |                     |                        |                       |                            |
| <65 years                                 | 79 (22.4)                                 | 90 (25.4)           | 91 (25.7)           | 805 (21.6)             | 668 (23.6)            | 1122 (22.0)                |
| 65 to <75 years                           | 201 (56.9)                                | 177 (50.0)          | 173 (48.9)          | 1650 (44.3)            | 1239 (43.8)           | 2285 (44.7)                |
| 75 to <85 years                           | 72 (20.4)                                 | 82 (23.2)           | 84 (23.7)           | 1116 (29.9)            | 811 (28.7)            | 1498 (29.3)                |
| ≥85 years                                 | 1 (0.3)                                   | 5 (1.4)             | 6 (1.7)             | 157 (4.2)              | 111 (3.9)             | 205 (4.0)                  |
| Patients with any TEAE, n/N (%)           |                                           |                     |                     |                        |                       |                            |
| <65 years                                 | 76/79 (96.2)                              | 89/90 (98.9)        | 89/91 (97.8)        | 747/805 (92.8)         | 606/668 (90.7)        | 1051/1122 (93.7)           |
| 65 to < 75 years                          | 197/201 (98.0)                            | 173/177 (97.7)      | 171/173 (98.8)      | 1570/1650 (95.2)       | 1136/1239 (91.7)      | 2169/2285 (94.9)           |
| 75 to < 85 years                          | 69/72 (95.8)                              | 78/82 (95.1)        | 81/84 (96.4)        | 1069/1116 (95.8)       | 733/811 (90.4)        | 1430/1498 (95.5)           |
| ≥ 85 years                                | 1/1 (100)                                 | 5/5 (100)           | 6/6 (100)           | 150/157 (95.5)         | 101/111 (91.0)        | 198/205 (96.6)             |
| Patients with any serious TEAE,n/N (%)    | Patients with any serious TEAE,n/N (%)    |                     |                     |                        |                       |                            |
| < 65 years                                | 14/79 (17.7)                              | 19/90 (21.1)        | 19/91 (20.9)        | 216/805 (26.8)         | 144/668 (21.6)        | 329/1122 (29.3)            |
| 65 to <75 years                           | 73/201 (36.3)                             | 57/177 (32.2)       | 67/173 (38.7)       | 530/1650 (32.1)        | 331/1239 (26.7)       | 833/2285 (36.5)            |
| 75 to < 85 years                          | 36/72 (50.0)                              | 34/82 (41.5)        | 42/84 (50.0)        | 455/1116 (40.8)        | 262/811 (32.3)        | 695/1498 (46.4)            |
| ≥ 85 years                                | 0/1 (0)                                   | 2/5 (40.0)          | 3/6 (50.0)          | 76/157 (48.4)          | 44/111 (39.6)         | 114/205 (55.6)             |
| Patients with any grade ≥3 TEAE, n/N (%)s | Patients with any grade ≥3 TEAE, n/N (%)s |                     |                     |                        |                       |                            |
| < 65 years                                | 21/79 (26.6)                              | 36/90 (40.0)        | 30/91 (33.0)        | 296/805 (36.8)         | 219/668 (32.8)        | 450/1122 (40.1)            |
| 65 to <75 years                           | 98/201 (48.8)                             | 71/177 (40.1)       | 87/173 (50.3)       | 679/1650 (41.2)        | 452/1239 (36.5)       | 1052/2285 (46.0)           |
| 75 to< 85 years                           | 44/72 (61.1)                              | 42/82 (51.2)        | 56/84 (66.7)        | 552/1116 (49.5)        | 312/811 (38.5)        | 822/1498 (54.9)            |
| ≥85 years                                 | 1/1 (100)                                 | 2/5 (40.0)          | 4/6 (66.7)          | 89/157 (56.7)          | 51/111 (45.9)         | 130/205 (63.4)             |

## Safety related to drug-drug interactions and other interactions

No new data on safety related to drug-drug interactions and other interactions have been provided with this submission.

## Discontinuation due to adverse events

Enzalutamide vs placebo in combination with ADT

In the EMBARK enzalutamide plus ADT group, the most frequent ( ≥ 1%) TEAEs leading to discontinuation of study drug were fatigue (3.4% enzalutamide plus ADT vs. 1.1% placebo plus ADT), hot flush (2.0% vs. 1.1%) and nausea (1.1% vs. 0.3%) (see Table 62).

In the phase 3 enzalutamide plus ADT group, the most frequent ( ≥ 0.5%) TEAEs leading to discontinuation of study drug were fatigue (1.6% enzalutamide plus ADT vs. 1.1% placebo plus ADT), spinal cord compression (0.9% vs. 0.7%), back pain (0.8% vs. 0.7%), bone pain (0.7% vs. 1.3%), general physical health deterioration (0.6% vs. 0.5%), nausea (0.6% vs. 0.4%) and cancer pain (0.5% vs. 0.3%) (data not shown).

## Enzalutamide monotherapy

In the open-label enzalutamide monotherapy group in the EMBARK study, the most frequent ( ≥ 1%) TEAEs leading to discontinuation of study drug were fatigue (2.3%) and asthenia (1.4%) (see Table 60).

<div style=\"page-break-after: always\"></div>

Table 62. Treatment-Emergent Adverse Events leading to study drug discontinuation in at least 0.5% patients in any treatment group by Preferred Term (EMBARK study, Safety Population)

|                                                                                               | ENZA+LA (N=353)   | ENZA+LA (N=353)   | PBO+LA (N=354)   | PBO+LA (N=354)   | ENZA (N=354)   | ENZA (N=354)   |
|-----------------------------------------------------------------------------------------------|-------------------|-------------------|------------------|------------------|----------------|----------------|
| PreferredTerm                                                                                 | All(@)            | Per 100 PY (b)    | All(a)           | Per 100 PY (b)   | All(a)         | Per 100 PY (b) |
| NumberofPatientsReportingat Least OneTEAE(a)/TotalTreatment EmergentPeriod (Patient-Years)(b) | 60 ( 17.0%)       | 1535.48           | 32 (9.0%)        | 1423.11          | 55 (15.5%)     | 1571.94        |
| Fatigue                                                                                       | 12 ( 3.4%)        | 12 (0.8)          | 1.1%)            | 4 (0.3)          | 8( 2.3%)       | 8 (0.5)        |
| Hot flush                                                                                     | 7( 2.0%)          | 7 (0.5)           | 1.1%)            | 4 (0.3)          | 0（ 0.0%)       | 0 (0.0)        |
| Nausea                                                                                        | 4( 1.1%)          | 4 (0.3)           | 1( 0.3%)         | 1 (<0.1)         | 2( 0.6%)       | 2 (0.1)        |
| Decreased appetite                                                                            | 3( 0.8%)          | 3 (0.2)           | 0（ 0.0%)         | 0 (0.0)          | 1 ( 0.3%)      | 1 (<0.1)       |
| Memory impairment                                                                             | 3( 0.8%)          | 3 (0.2)           | 2（ 0.6%)         | 2 (0.1)          | 1( 0.3%)       | 1 (<0.1)       |
| Diarrhoea                                                                                     | 2( 0.6%)          | 2 (0.1)           | 0（ 0.0%)         | 0 (0.0)          | 1( 0.3%)       | 1 (<0.1)       |
| Insomnia                                                                                      | 0.6%)             | 2 (0.1)           | 0 0.0%)          | 0 (0.0)          | 0 0.0%)        | 0 (0.0)        |
| Pleural effusion                                                                              | 2 ( 0.6%)         | 2 (0.1)           | 0（ 0.0%)         | 0 (0.0)          | 0( 0.0%)       | 0 (0.0)        |
| Seizure                                                                                       | 2 ( 0.6%)         | 2 (0.1)           | 0 0.0%)          | 0 (0.0)          | 2( 0.6%)       | 2 (0.1)        |
| Syncope                                                                                       | 2( 0.6%)          | 2 (0.1)           | 1 0.3%)          | 1 (<0.1)         | 0 0.0%)        | 0 (0.0)        |
| Confusional state                                                                             | 1 0.3%)           | 1 (<0.1)          | 0 0.0%)          | 0 (0.0)          | 3 0.8%)        | 3 (0.2)        |
| Death                                                                                         | 0.3%)             | 1 (<0.1)          | 0 0.0%)          | 0 (0.0)          | 3 0.8%)        | 3 (0.2)        |
| Fall                                                                                          | 1 0.3%)           | 1 (<0.1)          | 0 0.0%)          | 0 (0.0)          | 2( 0.6%)       | 2 (0.1)        |
| Headache                                                                                      | 1 0.3%)           | 1 (<0.1)          | 1 0.3%)          | 1 (<0.1)         | 3( 0.8%)       | 3 (0.2)        |
| Acute myocardial infarction                                                                   | 0.0%)             | 0 (0.0)           | 2 0.6%)          | 2 (0.1)          | 0( 0.0%)       | 0 (0.0)        |
| Asthenia                                                                                      | 0（ 0.0%)          | 0 (0.0)           | 0.3%)            | 1 (<0.1)         | 5( 1.4%)       | 5 (0.3)        |
| Balance disorder                                                                              | )0 0.0%)          | 0 (0.0)           | 0.0%)            | 0 (0.0)          | 2( 0.6%)       | 2 (0.1)        |
| Cognitive disorder                                                                            | 0( 0.0%)          | 0 (0.0)           | 0（ 0.0%)         | 0 (0.0)          | 2( 0.6%)       | 2 (0.1)        |
| Depression                                                                                    | 0( 0.0%)          | 0 (0.0)           | 1( 0.3%)         | 1 (<0.1)         | 3( 0.8%)       | 3 (0.2)        |
| Gynaecomastia                                                                                 | 0.0%)             | 0 (0.0)           | 0.0%)            | 0 (0.0)          | 2( 0.6%)       | 2 (0.1)        |
| Hypertension                                                                                  | 0.0%)             | 0 (0.0)           | 0 0.0%)          | 0 (0.0)          | 2（ 0.6%)       | 2 (0.1)        |
| Lethargy                                                                                      | 0 0.0%)           | 0 (0.0)           | 0 0.0%)          | 0 (0.0)          | 2( 0.6%)       | 2 (0.1)        |

Thedatacut-offdateis31JAN2023.MedDRAVersion:25.1.

(a)Patients having at least one Treatment Emergent Adverse Event. Patients with multiple events for a given PT are counted only once for the PT. Events are sorted by decreasing frequency of PT in All column in the ENZA+LA group.

(b) Total Treatment Emergent Period in 100 Patient-Years is calculated as the sum of each patient's length of treatment emergent period in days divided by 365.25*100.Time-adjustedrateper100patient-year calculatedasnumberofoccurrences ofevent dividedby the numberofpatient-years of treatment emergent surveillance for each treatment group and then times 1oo. Patients can have more than one occurrence of each event.

Table 63. Treatment-emergent Adverse Events leading to study drug discontinuation in ≥ 2 patients, by Preferred Term (Safety Groups)

|                                        | EMBARK              | EMBARK              | EMBARK             | Phase 3t              | Phase 3t             |                           |
|----------------------------------------|---------------------|---------------------|--------------------|-----------------------|----------------------|---------------------------|
| Preferred Term (MIedDRA v25.1),n (%)   | DB ENZA+ADT (n=353) | DB PBO+ADT (n =354) | ENZA Mono (n =354) | DB ENZA+ADT (n =3728) | DB PBO+ADT (n =2829) | Totalt ENZAtADT (n =5110) |
| TEAEleadingtostudydrugdiscontinuations | 60 (17.0)           | 32 (9.0)            | 55 (15.5)          | 596 (16.0)            | 437 (15.4)           | 979 (19.2)                |
| Fatigue                                | 12 (3.4)            | 4 (1.1)             | 8 (2.3)            | 58 (1.6)              | 31 (1.1)             | 92 (1.8)                  |
| Hot flush                              | 7 (2.0)             | 4 (1.1)             | 0                  | 7 (0.2)               | 4 (0.1)              | 7 (0.1)                   |
| Nausea                                 | 4 (1.1)             | 1 (0.3)             | 2 (0.6)            | 23 (0.6)              | 12 (0.4)             | 37 (0.7)                  |
| Decreased appetite                     | 3 (0.8)             | 0                   | 1 (0.3)            | 9 (0.2)               | 8 (0.3)              | 16 (0.3)                  |
| Memory impairment                      | 3 (0.8)             | 2 (0.6)             | 1 (0.3)            | 7 (0.2)               | 2 (0.1)              | 9 (0.2)                   |
| Diarrhoea                              | 2 (0.6)             | 0                   | 1 (0.3)            | 5 (0.1)               | 1 (0.0)              | 8 (0.2)                   |
| Insomnia                               | 2 (0.6)             | 0                   | 0                  | 3 (0.1)               | 1 (0.0)              | 3 (0.1)                   |
| Pleural effusion                       | 2 (0.6)             | 0                   | 0                  | 3 (0.1)               | 1 (0.0)              | 4 (0.1)                   |
| Seizure                                | 2 (0.6)             | 0                   | 2 (0.6)            | 8 (0.2)               | 2 (0.1)              | 17 (0.3)                  |
| Syncope                                | 2 (0.6)             | 1 (0.3)             | 0                  | 6 (0.2)               | 3 (0.1)              | 8 (0.2)                   |
| Acute myocardialinfarction             | 0                   | 2 (0.6)             | 0                  | 3 (0.1)               | 3 (0.1)              | 6 (0.1)                   |

Allpatientswhoreceivedatleast1doseof studydrug(enzalutamide,placebo)intheirrespectivephase3studyorreceivedatleast1doseofenzalutamideinphase2studies.For EMBARK,study drugincludes enzalutamide,leuprolide andplacebo(SafetyPopulation)

DatacutoffdatesWereasfollows:EMBARK:31Jan2023;PROSPER:15Oct2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21Mar2019;AsianPREVAIL: 04Nov2020;TERRAIN:17Feb2018andSTRIVE:30May2018

Patients with multipleevents for a given preferred term were counted only once foreach preferred term.Number ofpatients(n)and percentageofpatients(%) are shown.Events are sorted by decreasing frequency of preferred term in the ENZA+ADT group in the EMBARK study.

AE: adverse event; ADT: androgen deprivation therapy, CRF: case report form; DB: double-blind; ENZA: enzalutamide; ISS: Integrated Summary of Safety, Mono: monotherapy, OL: open-label;PBO: placebo;SCS:Summary of ClinicalSafety;TEAE: treatment-emergent adverse event.

↑Thephase3studiesincludeEMBARK(ENZA+ADTandPBO+ADTarms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAILandAsianPREVAIL

↑Total enzalutamide summarizes allenzalutamide-treatedpatients duringDBand/or OLperiodsofEMBARK(ENZA+ADT andENZA Mono arms),PROSPER,ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

TEAEleadingtostudydrugdiscontinuationisfromAECRFandincludesTEAEswithactiontakenofpermanentdiscontinuation.

## Dose interruptions

Enzalutamide vs placebo in combination with ADT

<div style=\"page-break-after: always\"></div>

In the EMBARK enzalutamide plus ADT group, the most frequent ( ≥ 1%) TEAEs leading to a dose interruption were fatigue (2.8% enzalutamide plus ADT vs. 1.7% placebo plus ADT), hypertension (2.8% vs. 1.1%) and headache (1.1% vs. 0.3%) (see Table 62).

In the phase 3 enzalutamide plus ADT group, the most frequent ( ≥ 0.5%) TEAEs leading to a dose interruption were: fatigue (1.6% enzalutamide plus ADT vs. 0.6% placebo plus ADT), hypertension (1.0% vs. 0.4%), nausea (1.0% vs. 0.8%), asthenia (0.7% vs. 0.3%), decreased appetite (0.7% vs. 0.5%), vomiting (0.7% vs. 0.5%), pneumonia (0.5% vs. 0.1%) and diarrhea (0.5% vs. 0.4%) (results partially shown in Table 64).

## Enzalutamide monotherapy

In the open-label enzalutamide monotherapy group in the EMBARK study, the most frequent ( ≥ 1%) TEAEs leading to dose interruption were fatigue (4.2%), headache (1.4%) and dizziness, asthenia and weight decreased (1.1% each) (results partially shown in Table 62).

Table 64. Treatment-emergent Adverse Events leading to a dose interruption reported in ≥ 2 patients, by Preferred Term (Safety Groups)

|                                                 | EMBARK               | EMBARK               | EMBARK             | Phase 3↑               | Phase 3↑              |                            |
|-------------------------------------------------|----------------------|----------------------|--------------------|------------------------|-----------------------|----------------------------|
| Preferred Term (MedDRA v25.1),n (%)             | DB ENZA+ADT (n =353) | DB PBO+ADT (n = 354) | ENZA Mono (n =354) | DB ENZA+ADT (n = 3728) | DB PBO+ADT (n = 2829) | Totalt ENZA±ADT (n = 5110) |
| TEAE leading to dose interruption of study drug | 56 (15.9)            | 43 (12.1)            | 66 (18.6)          | 541 (14.5)             | 290 (10.3)            | 829 (16.2)                 |
| Fatigue                                         | 10 (2.8)             | 6 (1.7)              | 15 (4.2)           | 61 (1.6)               | 18 (0.6)              | 104 (2.0)                  |
| Hypertension                                    | 10 (2.8)             | 4 (1.1)              | 3 (0.8)            | 37 (1.0)               | 11 (0.4)              | 54 (1.1)                   |
| Headache                                        | 4 (1.1)              | 1 (0.3)              | 5 (1.4)            | 15 (0.4)               | 6 (0.2)               | 27 (0.5)                   |
| Aspartate aminotransferase increased            | 2 (0.6)              | 1 (0.3)              | 1 (0.3)            | 7 (0.2)                | 8 (0.3)               | 12 (0.2)                   |
| Back pain                                       | 2 (0.6)              | 0                    | 0                  | 11 (0.3)               | 6 (0.2)               | 13 (0.3)                   |
| Disturbance in attention                        | 2 (0.6)              | 0                    | 0                  | 6 (0.2)                | 1 (0.0)               | 7 (0.1)                    |
| Dizziness                                       | 2 (0.6)              | 2 (0.6)              | 4 (1.1)            | 15 (0.4)               | 8 (0.3)               | 28 (0.5)                   |
| Fall                                            | 2 (0.6)              | 3 (0.8)              | 1 (0.3)            | 11 (0.3)               | 4 (0.1)               | 17 (0.3)                   |
| Hot flush                                       | 2 (0.6)              | 4 (1.1)              | 1 (0.3)            | 6 (0.2)                | 4 (0.1)               | 7 (0.1)                    |
| Nausea                                          | 2 (0.6)              | 1 (0.3)              | 2 (0.6)            | 37 (1.0)               | 22 (0.8)              | 48 (0.9)                   |
| Pneumonia                                       | 2 (0.6)              | 0                    | 0                  | 20 (0.5)               | 4 (0.1)               | 29 (0.6)                   |
| Pollakiuria                                     | 2 (0.6)              | 0                    | 0                  | 2 (0.1)                | 0                     | 2 (0.0)                    |
| Depression                                      | 1 (0.3)              | 2 (0.6)              | 1 (0.3)            | 4 (0.1)                | 3 (0.1)               | 5 (0.1)                    |
| Diamhoea                                        | 1 (0.3)              | 2 (0.6)              | 0                  | 18 (0.5)               | 11 (0.4)              | 27 (0.5)                   |
| COVID-19                                        | 0                    | 2 (0.6)              | 2 (0.6)            | 0                      | 2 (0.1)               | 2 (0.0)                    |
| Oedemaperipheral                                | 0                    | 2 (0.6)              | 1 (0.3)            | 2 (0.1)                | 5 (0.2)               | 3 (0.1)                    |

Allpatientswhoreceived atleast1doseof studydrug(enzalutamide,placebo)intheirrespectivephase3study orreceivedatleast1doseofenzalutamideinphase2studies.For EMBARK, study drug includes enzalutamide, leuprolide and placebo (Safety Population).

Datacutoff datesWere asfollows:EMBARK:31Jan2023;PROSPER:15Oct2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21Mar2019;AsianPREVAIL: 04Nov2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

Patients with multiple events fora givenpreferred term were counted only once for each preferred term.Number ofpatients(n) and percentage ofpatients(%)are shown.Events are sorted by decreasing frequency of preferred term in the ENZA+ADT group in the EMBARK study.

ADT: androgen deprivation therapy; DB: double-blind; ENZA: enzalutamide; ISS: Integrated Summary of Safety, Mono: monotherapy; OL: open-label; PBO: placebo; SCS: Summary of Clinical Safety; TEAE: treatment-emergent adverse event.

↑Thephase3studiesincludeEMBARK(ENZA+ADTandPBO+ADTarms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAILandAsianPREVAIL

Total enzalutamide summarizes all enzalutamide-treated patients during DB and/or OL periods of EMBARK (ENZA+ADT and ENZA Mono arms), PROSPER, ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

In EMBARK, most patients who suffered dose interruptions only had one dose interruption (11.6% in enza+ADT, vs. 12.1% in placebo+ADT, vs. 15.5% in enza-mono). In the enza+ADT arm 5.7% of dose interruptions entailed two dose interruptions (vs. 2.8% in placebo+ADT and 2% in enza-mono).

## Dose reductions

## Enzalutamide vs placebo in combination with ADT

In the EMBARK enzalutamide plus ADT group, the most frequent ( ≥ 1%) TEAEs leading to a dose reduction were fatigue (2.3% enzalutamide plus ADT vs. 1.4% placebo plus ADT) and hypertension (1.4% vs. 0%) (Table 65).

In the phase 3 enzalutamide plus ADT group, the most frequent ( ≥ 0.5%) TEAEs leading to a dose reduction were: fatigue (2.1% enzalutamide plus ADT vs. 0.5% placebo plus ADT), asthenia (0.7% vs. 0.1%) and nausea (0.5% vs. 0.2%)(Table 65).

## Enzalutamide monotherapy

<div style=\"page-break-after: always\"></div>

In the open-label enzalutamide monotherapy group in the EMBARK study, the most frequent ( ≥ 1%) TEAEs leading to a dose reduction were fatigue (7.9%), asthenia (2.0%) and dizziness and gynecomastia (1.4% each) (results partially shown in Table 65).

Table 65. Treatment-emergent adverse events leading to dose reduction reported in ≥ 2 patients, by Preferred Term (Safety Groups)

|                                        | EMBARK               | EMBARK              | EMBARK            | Phase 3↑               | Phase 3↑              |                           |
|----------------------------------------|----------------------|---------------------|-------------------|------------------------|-----------------------|---------------------------|
| Preferred Term (MedDRAv25.1),n(%)      | DB ENZA+ADT (n =353) | DB PBO+ADT (n =354) | ENZAMono (n =354) | DB ENZA+ADT (n = 3728) | DB PBO+ADT (n = 2829) | Totalt ENZA+ADT (n =5110) |
| TEAEleadingtodosereductionof studydrug | 25 (7.1)             | 16 (4.5)            | 56 (15.8)         | 208 (5.6)              | 67 (2.4)              | 352 (6.9)                 |
| Fatigue                                | 8 (2.3)              | 5 (1.4)             | 28 (7.9)          | 77 (2.1)               | 14 (0.5)              | 136 (2.7)                 |
| Hypertension                           | 5 (1.4)              | 0                   | 2 (0.6)           | 16 (0.4)               | 1 (0.0)               | 24 (0.5)                  |
| Asthenia                               | 3 (0.8)              | 1 (0.3)             | 7 (2.0)           | 25 (0.7)               | 4 (0.1)               | 46 (0.9)                  |
| Dizziness                              | 3 (0.8)              | 0                   | 5 (1.4)           | 12 (0.3)               | 4 (0.1)               | 18 (0.4)                  |
| Memoryimpairment                       | 2 (0.6)              | 2 (0.6)             | 0                 | 3 (0.1)                | 2 (0.1)               | 3 (0.1)                   |
| Nausea                                 | 2 (0.6)              | 0                   | 0                 | 17 (0.5)               | 5 (0.2)               | 23 (0.5)                  |
| Hot flush                              | 0                    | 3 (0.8)             | 2 (0.6)           | 3 (0.1)                | 3 (0.1)               | 6 (0.1)                   |

Allpatientswhoreceived atleast1doseof study drug(enzalutamide,placebo)in theirrespective phase3study orreceived at least1dose ofenzalutamideinphase2studies.For EMBARK,studydrugincludesenzalutamide,leuprolideandplacebo(SafetyPopulation).

DatacutoffdatesWereasfollows:EMBARK:31Jan2023;PROSPER:15Oct2019;ARCHES:28May2021;AFFIRM:20Feb2018;PREVAIL:21Mar2019;AsianPREVAIL: 04Nov2020;TERRAIN:17Feb2018andSTRIVE:30May2018.

Patientswithmultipleeventsforagivenpreferredtermwerecountedonlyonceforeachpreferredterm.Numberofpatients(n)andpercentageofpatients(%)areshown.Events are sortedbydecreasingfrequencyofpreferredtermintheENZA+ADTgroupintheEMBARKstudy.

ADT:androgen deprivation therapy;DB:double-blind;ENZA:enzalutamide;ISS:Integrated Summary of Safety;Mono:monotherapy;OL:open-label;PBO:placebo;SCS:Summary ofClinicalSafety;TEAE:treatment-emergent adverseevent.

↑Thephase3studiesincludeEMBARK(ENZA+ADTandPBO+ADTarms)andDBphaseforPROSPER,ARCHES,AFFIRM,PREVAILandAsianPREVAIL

Total enzalutamide summarizes all enzalutamide-treatedpatients duringDBand/or OLperiods ofEMBARK(ENZA+ADTandENZA Mono arms),PROSPER,ARCHES, AFFIRM,PREVAIL,AsianPREVAIL,TERRAINandSTRIVE.

In EMBARK, most patients who suffered dose reductions only had one dose reduction (4.8% in enza+ADT, 2.3% in placebo+ADT and 9% in enza-mono). In the enza-mono arm 4.5% of dose reductions entailed two dose reductions (vs. 1.1% in enza+ADT and 1.7% in placebo+ADT).

## Post marketing experience

Enzalutamide became commercially available as Xtandi ®  in the US in Sep 2012. In Europe, enzalutamide was initially approved in Jun 2013, but was made available in France through a temporary authorisation for use in Apr 2013.

The safety profile of enzalutamide is described in the Periodic Safety Update Reports (PSURs) submitted to the regulatory authorities in accordance with the requirements set out in the list of Union reference dates (EURD list).

There was no new significant information received for enzalutamide during the last reporting period that resulted in an impact on the established safety profile or risk characterisation of the safety concerns.

## 2.5.1. Discussion on clinical safety

The primary safety basis of this submission is the study EMBARK, which included three arms: enzalutamide+ADT (N=353), placebo+ADT (N=354) and enzalutamide monotherapy (N=354). The enza+ADT and placebo+ADT arms were double-blind, whereas enza-mono was open-label. Direct comparisons of enzalutamide monotherapy to other treatment groups have limitations as the enzalutamide monotherapy group was open label.

Safety data are presented in tables including results from the three arms of EMBARK, together with the safety Pool of phase 3 and 2 clinical trials of enzalutamide in patients with mHSPC, nmCRPC or mCRPC (hereinafter 'the Pool'). It is noted that the indication sought with this submission refers to earlier stages of the disease, nmSPC, meaning that patients are in overall better health status than patients included in the Pool and that their life expectancy is also supposed to be longer.

<div style=\"page-break-after: always\"></div>

Almost all patients in any of the three arms of EMBARK had an TE AE : 97.2% in enza+ADT, 97.5% in placebo+ADT, and 98% in enza-mono. When compared with the Pool the percentages in EMBARK are slightly higher (Pool: 94.8% in enza+ADT vs. 91.1% in placebo+ADT), but this could be explained by the notably longer treatment exposure in EMBARK than in the Pool. In the modified treatment-emergent period the difference between percentages was smaller.

The most frequently reported TEAEs in EMBARK were in line with the known safety profile for enzalutamide: no new signals were identified. However, it is noted that overall there is a trend towards an increase in the reporting rates for some AEs compared with the Pool, likely due to the higher treatment exposure in EMBARK. Most of the AEs which were increased in EMBARK with respect to the Pool were considered as AESIs and are therefore further discussed in more detail in the subsequent sections of this discussion under their respective section ('fatigue', 'fall', 'memory impairment', 'rash', 'hypertension'). The differences observed in 'hot flush' (68.8% in enza+ADT in EMBARK vs. 23.1% in enza+ADT in the Pool; 57.3% in placebo+ADT in EMBARK vs. 17% in the Pool) could be due to the patients' baseline characteristics, specifically hormonal status and testosterone levels at study entry. Patients enrolled in the EMBARK study were required to have a serum testosterone level ≥ 150 ng/dL at screening (physiologic testosterone levels) while most of the studies included in the Pool were performed in the castration-resistant setting so patients needed to be surgically/medically castrated before study entry. The MAH has also provided some publications that justify that hot flushes correlate with drops in serum testosterone, which is quite well understood, and that the absolute levels of plasma sex hormones are less important in the pathophysiology of hot flushes than the dynamic reduction of testosterone levels. This could be quite relevant in this study, where patients suffered from drastic drops of the testosterone levels at the moment of introducing ADT.

Grade ≥ 3 TEAEs were reported in 46.5% of patients in enza+ADT, 42.7% in placebo+ADT and 50% in enzamono. The most frequently reported G≥3 TEAEs in enza+ADT were 'hypertension' (6.8% in enza+ADT, 5.1% in placebo+ADT, 5.4% in enza-mono), 'syncope' (4.2% in enza+ADT, 1.7% in placebo+ADT, 2% in enza-mono) and 'fatigue' (3.4% in enza+ADT, 1.4% in placebo+ADT, 4% in enzamono). The incidences were higher in EMBARK than in the Pool, likely reflecting the longer exposure in EMBARK.

Drug-related TEAEs were reported in 87% of patients in enza+ADT, 80.8% in placebo+ADT and 88.7% in enza-mono. The percentages in EMBARK are overall higher than the percentages reported for the Pool: 66.8% in enza+ADT and 53.9% in placebo+ADT. As said, this could be explained by the longer exposure in EMBARK compared with the Pool. It should be noted that the number of drug-related TEAEs is slightly higher with enzalutamide in monotherapy than with enzalutamide in combination with ADT.

The increase in the rate of drug-related TEAEs in enza-mono in comparison with enza+ADT seems to be driven by the rates of 'gynaecomastia', which are relevantly increased in enza-mono vs. enza+ADT or placebo+ADT: 42.9% in enza-mono vs. 6.5% in enza+ADT or 7.9% in placebo+ADT. Without the administration of ADT the levels of serum testosterone are higher than when ADT is administered, and since testosterone is associated with those adverse events, when enzalutamide is administered as monotherapy the occurrence of those AEs increases. A paragraph in section 4.8 of the SmPC reflects this detail. In addition to gynaecomastia, nipple pain (3.1% vs 15.3%), breast tenderness (1.4% vs 14.4%) and ischemic heart disease (5.4% vs 9%) were also more frequently reported in the combination arm than the monotherapy arm, respectively. Considering these differences, nipple pain and breast tenderness were included as ADRs in section 4.8 of the SmPC.

There were other PTs which were increased in the enza-mono arm in comparison with enza+ADT, such as 'fatigue': 39.7% in enza+ADT, 28% in placebo+ADT and 44.1% in enza-mono. Conversely, other PTs such as 'hot flush' were reported with a lower frequency in enza-mono than in the other two arms: 68.6% in enza+ADT, 55.4% in placebo+ADT and 20.6% in enza-mono. 'Hypertension' was also reported

<div style=\"page-break-after: always\"></div>

with a slightly lower frequency in enza-mono: 13% in enza+ADT, 8.2% in placebo+ADT and 10.7% in enza-mono. It is noted that 'libido decreased' and 'erectile dysfunction', which are AEs that can adversely impact on patients' quality of life, are reported with a similar frequency in the three arms; meaning that removing ADT from the treatment does not translate into remarkable improvements in the sexual sphere.

It should be noted that overall it does not seem that the (slightly) increase in the rates of SAEs in the enza-mono arm are driven by any particular PT. Of note, the administration of enzalutamide as monotherapy does not translate into a lower rate of SAEs in comparison with the administration of enzalutamide in combination with leuprolide, in contrast to what would be expected.

The percentage of SAEs in EMBARK is similar to the percentage of SAEs in the Pool; although it is also noted that the difference between the enza+ADT arm and the placebo+ADT arm is subtler in EMBARK (34.8% vs. 31.6%) than in the Pool (34.3% vs. 27.6%). Although patients enrolled in EMBARK were in earlier stages of the disease, it is not surprising that the rate of SAEs was similar to the rate in the Pool considering the longer treatment exposure in EMBARK. The rates per 100 P-Y of 'syncope' and 'osteoarthritis' were higher in the enza+ADT arm of EMBARK than in the enza+ADT arm of the Pool ('syncope': 0.7 in the enza+ADT arm of EMBARK vs. 0.4 in the enza+ADT arm of the Pool; 'osteoarthritis': 0.6 in the enza+ADT arm of EMBARK vs. 0.3 in the enza+ADT arm of the Pool).

In total, there were 33 (9.3%) deaths in the enza+ADT arm, vs. 55 (15.5%) in the placebo+ADT arm and 42 (11.9%) in the enza-mono arm. The percentage of deaths is relevantly lower in EMBARK than in the Phase 3 studies, probably due to the fact that patients enrolled in EMBARK were in earlier stages of the disease and therefore their overall health status was better. The main cause of death was disease progression (0.6% in enza+ADT, 0% in placebo+ADT, and 0.3% in enza-mono).

In the enza+ADT arm there were 6 (1.7%) patients with ≥ 1 TEAE resulting in death; while in the placebo+ADT arm there were 3 (0.8%) patients, and in the enza-mono arm there were 8 (2.3%) patients. When time-adjusted, overall TEAE leading to death rate per 100 P-Y was 0.4 in the enza+ADT arm, 0.2 in the placebo+ADT arm, and 0.5 in the enza-mono arm. It is noteworthy to mention that both the number of total deaths and TEAEs leading to death were slightly higher in the enza-mono arm than in the enza+ADT arm or in the placebo+ADT.

The narratives of the three deaths with unknown cause in the enza-mono arm provide very scarce data and it is agreed that no conclusion can be drawn on the cause of death of those subjects. It should be noted that all those subjects had a medical history including arterial hypertension and/or other cardiac conditions; and therefore a cardiac cause of death cannot be discarded. None of the TEAEs leading to death, in any arm, was considered as treatment-related; and this is agreed. However, it should be noted that the potential contribution of enzalutamide to the cardiac deaths cannot be ruled out; although the existence of several confounding factors (i.e. relevant medical history of prior cardiac conditions) is also acknowledged.

TEAEs of special interest ( AESIs ) were selected based on previously recognised risks and/or feedback from regulatory authorities. Regarding the comparison between enza+ADT and enza-mono, it should be noted that 'ischemic heart disease' was increased in enza-mono: 9% in enza-mono vs. 5.4% in enza+ADT vs. 5.6% in placebo+ADT. Of those events, 1.4% in enza+ADT were considered as drugrelated, vs. 2.3% in enza-mono. In section 4.8 of the SmPC a paragraph describing this selected adverse reaction is already included, and the information has been updated to include these data, since the risk in patients receiving enzalutamide as monotherapy could be higher than the risk in patients receiving enzalutamide in combination with ADT. In section 4.4 of the SmPC, ''malignant melanoma'' was included as one of the most frequently second primary malignancies reported in patients treated with enzalutamide (0.2%).

<div style=\"page-break-after: always\"></div>

Similarly, the frequency of 'fatigue' was higher in enza-mono than in enza+ADT: 54% in enza-mono vs. 50.4% in enza+ADT vs. 37.9% in placebo+ADT. Of those events, in enza-mono 50.3% were considered as drug-related, vs. 46.2% in enza+ADT. Although the percentage of patients who discontinued treatment due this AE in enza-mono was similar to the percentage of patients in enza+ADT, it is noted that the rates of dose reductions were three times higher in enza-mono than in enza+ADT; as further discussed below.

Conversely, some PTs were reported with lower frequency in enza-mono than in enza+ADT: 'hypertension', (21.8% in enza-mono vs. 25.2% in enza+ADT vs. 20.9% in placebo+ADT), 'fall' (15.8% in enza-mono vs. 21% in enza+ADT vs. 14.4% in placebo+ADT) and 'fracture' (11% in enza-mono vs. 18.4% in enza+ADT vs. 13.6% in placebo+ADT).

No cases of 'interstitial lung disease' were reported in EMBARK.

Regarding the comparison between EMBARK and the Pool, some PTs were increased in EMBARK compared with the Pool: 'hypertension' (25.2% in the EMBARK's enza+ADT arm vs. 14% in the Pool's enza+ADT arm), 'cognitive and memory impairment' (15% in the EMBARK's enza+ADT arm vs. 6.4% in the Pool's enza+ADT arm), 'fatigue' (50.4% in the EMBARK's enza+ADT arm vs. 43.1% in the Pool's enza+ADT arm), 'fall' (21% in the EMBARK's enza+ADT arm vs. 11.5% in the Pool's enza+ADT arm) and 'fracture' (18.4% in the EMBARK's enza+ADT arm vs. 12.3% in the Pool's enza+ADT arm). However, when timeadjusted, the rates were lower in EMBARK than in the Pool: 'hypertension' (100 PY rate in EMBARK: 6.6 vs. 7.7 in the Pool), 'fatigue' (16.1 in EMBARK vs. 26.4 in the Pool), 'fall' (6.8 in EMBARK vs. 7.5 in the Pool), 'fracture' (5.7 in EMBARK vs. 8.1 in the Pool). The only exception was 'cognitive and memory impairment', which was slightly higher in EMBARK than in the Pool: 100 PY rate in EMBARK: 4.1 vs. 3.6 in the Pool. Taking all this into account, it can be considered that the safety profile of enzalutamide in EMBARK was similar to the already known safety profile of enzalutamide.

When compared with the modified treatment-emergent period the trends are similar or slightly lower than in the total treatment-emergent period; suggesting that the treatment suspension does not translate into a dramatically lower frequency of AESIs. It should be noted, though, that the incidence of musculoskeletal events seems to be notably decreased in the modified treatment-emergent period: in the total treatment-emergent period the incidence was 46.2% in the enza+ADT arm, vs. 41.8% in placebo+ADT, vs. 44.6% in enza-mono; while in the modified treatment-emergent period the incidence was 35.7% in the enza+ADT arm, vs. 37% in placebo+ADT arm, vs. 38.7% in enza-mono. This suggests that the burden associated with those events could be diminished in patients who suspend treatment.

Regarding laboratory findings , overall no relevant G3-4 laboratory abnormalities were identified. In terms of haematology the most altered parameter was 'low lymphocytes'. However, similar frequencies were observed in the three arms (2.3% in enza+ADT, 2.5% in placebo+ADT, 2% in enza-mono), as well as in the Pool (3.4% in enza+ADT and 3.2% in placebo+ADT). All the other haematology G3-4 postbaseline laboratory abnormalities were reported with frequencies lower than 1%.

Regarding blood chemistry parameters, the most altered one was 'high glucose' in the three arms: G3-4 abnormalities were reported in 5.7% in enza+ADT, 9.3% in placebo+ADT and 5.9% in enza-mono. In the Pool these findings were similar: 3.5% in enza+ADT vs. 4% in enza-mono. It should be noted that this parameter was more altered in the placebo+ADT arm than in the enza+ADT arm in both EMBARK and the Pool; suggesting there is no particular association with enzalutamide.

Regarding treatment-emergent liver function test elevations, it should be noted that parameters were overall more altered in the placebo+ADT arm than in the enza+ADT or enza-mono arm, suggesting that the observed alterations are not associated with the administration of enzalutamide. The only alteration which was reported with a higher frequency in the enzamono arm was ALP ≥ 1.5 x ULN: 0.8% in enza+ADT, 2.3% in placebo+ADT and 2.8% in enza-mono. No patients met Hy's law criteria.

<div style=\"page-break-after: always\"></div>

In terms of safety in special populations , the MAH has provided subgroup analyses by time on treatment, by age, by BMI, by geographic region and by history of cardiovascular disease. It is noted that the MAH has not provided subgroup analyses by race; although considering the low number of patients belonging to races other than White, this is acceptable.

No relevant differences were observed among subgroups. However, it is noted that patients with history of cardiovascular disease seem to be more prone to have G≥3 TEAEs and SAEs than patients without a history of cardiovascular disease. Additionally, it seems that the frequency of G≥3 AEs and SAEs increases as patients are older, which was expectable. Patients older than 85 years old were so scarcely represented in EMBARK that no conclusions can be drawn from that subgroup of patients. In this regard, it is also noted that no relevant differences were observed between enza+ADT and enza-mono; suggesting that the tolerability of the different subgroups of age is similar in both arms.

Most patients who suffered dose reductions only had one dose reduction (4.8% in enza+ADT, 2.3% in placebo+ADT and 9% in enza-mono), although in the enza-mono arm 4.5% of dose reductions entailed two dose reductions (vs. 1.1% in enza+ADT and 1.7% in placebo+ADT). It should be noted that the frequency of TEAEs leading to dose reductions in the Pool was lower than in EMBARK: 5.6% in the enza+ADT arm and 2.4% in the placebo+ADT arm.

The differences in the percentage of TEAEs leading to dose discontinuations between the enza+ADT and placebo+ADT arms seem to be higher in EMBARK than in the Pool (17% vs. 9% in EMBARK; 16% vs. 15.4% in the Pool), which is not surprising considering the higher treatment exposure in EMBARK compared with the Pool. The differences between the enza+ADT arm and placebo+ADT arm in terms of dose interruptions and dose reductions seem to be similar to the differences between arms in the Pool.

The frequency of TEAEs leading to dose interruptions and dose reductions is higher in the enza-mono arm than in the enza+ADT arm although toxicity seems to be managed by dose interruptions and dose reductions, leading to a lower rate of treatment discontinuations. These findings, added to the fact that in the enzamono arm it was also observed a (slightly) higher rate of SAEs, AEs leading to death, G≥3 TEAEs, drug-related TEAEs, and some AESIs such as 'ischemic heart disease'. The differences in the TEAE profile between enzalutamide plus ADT and enzalutamide monotherapy appears to be mostly related to the different effect on the levels of testosterone (and oestrogen levels, not shown for this study) expressed through higher incidences of gynecomastia and other related events. Based on the available information and considering also the observed efficacy results, enzalutamide monotherapy can be an alternative treatment option for patients for whom ADT treatment may have some relevant risks, acknowledging that it might not be the most effective option in this setting and that the use of enza as monotherapy may involve an increase in other adverse events. Considering all the above (i.e. the lower efficacy of enzalutamide as monotherapy and the differences in the safety profile), a warning in section 4.4 have been introduced to advise healthcare professionals.

As previously discussed in the efficacy section, in the context of non-metastatic setting and relatively younger and healthier patient population with longer life expectancy than in metastatic setting some of the enzalutamide ADRs including cognitive and memory impairment, seizure, fracture risk and secondary primary malignancy, despite similar or lower incidence, have other clinical significance and on long run may impact the patients' quality of life, which should be taken into consideration. Other potential problem is the cross-resistance between the novel hormonal therapies (NHTs) observed in the RCTs on sequential treatment in metastatic PCa that would limit the treatment possibilities in case of progress to metastatic setting. These aspects could be partially answered by the current study with submission of final OS data (REC).

<div style=\"page-break-after: always\"></div>

## 2.5.2. Conclusions on clinical safety

The safety profile of enzalutamide in combination with ADTin patients with nmCSPC with high-risk BCR was consistent with the established safety profile in other prostate cancer indications and no new safety concerns were identified.

With regard to enzalutamide monotherapy, some ADRs, such as gynecomastia or nipple pain, can have a great impact on the patients' lives and a higher risk of 'ischemic heart disease' has also been observed. This should be taken into consideration when deciding to initiate treatment with enzalutamide as monotherapy rather than in combination with ADT, a warning has been included in section 4.4 to advise healthcare professionals .

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted RMP version 18 with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 18 is acceptable.

## Safety concerns

Table 66. Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                                             |
|------------------------------|------------------------------------------------------------------------|
| Important identified risks   | • Seizure • Fall • Non-pathological fracture • Ischaemic Heart Disease |
| Important potential risks    | None                                                                   |
| Missing information          | None                                                                   |

## Pharmacovigilance plan

To be updated.

## Risk minimisation measures

Table 67. Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern   | Risk minimisation measures                                                                 | Pharmacovigilance activities                                                                  |
|------------------|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Seizure          | Routine risk communication: • SmPC sections 4.4, 4.7, 4.8, and 4.9; • PL sections 2 and 4; | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: |

Assessment report

<div style=\"page-break-after: always\"></div>

|                           | • Recommendation that the decision to continue treatment in patients who develop seizure should be taken case by case, is provided in SmPC Section 4.4 and PL sections 2 and 4; • Concomitant medications associated with higher risk of seizure are described in PL Section 2. Additional risk minimisation measures: • None   | • None. Additional pharmacovigilance activities: • None.                                                                                                                                                                                                                          |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Fall                      | Routine risk communication: • SmPC Section 4.8; • PL Section 4. Additional risk minimisation measures: • None.                                                                                                                                                                                                                  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • Fall TDQ for spontaneous reports; • Safety analyses of events of fall in CSRs of individual enzalutamide clinical trials. Additional pharmacovigilance activities: • None.        |
| Non-pathological fracture | Routine risk communication: • SmPC Section 4.8; • PL Section 4. Additional risk minimization measures: • None.                                                                                                                                                                                                                  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • Fracture TDQ for spontaneous reports; • Safety analyses of events of fracture in CSRs of individual enzalutamide clinical trials. Additional pharmacovigilance activities: • None |
| Ischemic heart disease    | Routine risk communication: • SmPC Section 4.8;                                                                                                                                                                                                                                                                                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| • PL Section 4. Additional risk minimisation measures: • None.   | detection: • Safety analyses of events of ischemic heart disease in CSRs of individual enzalutamide clinical trials. Additional pharmacovigilance activities: • None   |
|------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## 2.7. Conclusion

The CHMP considers that the risk management plan version 18 is acceptable.

## 2.8. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.8.1. User consultation

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to Xtandi. The bridging report submitted by the MAH has been found acceptable.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Xtandi is indicated as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.

To be considered 'high risk', patients need to present a PSADT ≤ 9 months and screening PSA of ≥ 1 ng/mL for patients with prior radical prostatectomy or, at least, 2 ng/mL above the nadir for patients who had prior primary radiotherapy only.

## 3.1.2. Available therapies and unmet medical need

There are not specific treatments authorized for high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer patients. Management is not uniformly established and the need for immediate treatment in this setting remains controversial and it is often reserved for patients at high risk

<div style=\"page-break-after: always\"></div>

of developing symptomatic metastatic disease based on different criteria. Definitive local therapy is the preferred option for high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer patients and for those patients not eligible for local therapy, ADT is often an alternative choice (Marhold M, et all. Cancer Lett. 2022)

## 3.1.3. Main clinical studies

The efficacy data in support of this application is based on the results from Study MDV3100-13 (EMBARK), a phase 3, randomized study of enzalutamide plus leuprolide, enzalutamide monotherapy and placebo plus leuprolide in men with high-risk non-metastatic prostate cancer progressing (biochemical recurrence) after definitive therapy.

All patients needed to present a baseline PSADT ≤ 9 months and screening PSA of ≥ 1 ng/mL for patients with prior radical prostatectomy or, at least, 2 ng/mL above the nadir for patients who had prior primary radiotherapy only.

A total of 1068 patients were randomised to receive enzalutamide plus ADT (n=335), placebo plus ADT (n=358) or enzalutamide as monotherapy (n=355). Enzalutamide was administered as single daily dose of 160 mg (four 40 mg soft capsules).

The primary endpoint of the study was MFS in patients randomised to receive enzalutamide plus ADT compared to patients randomised to receive placebo plus ADT. Key secondary endpoint were MFS in patients randomised to receive enzalutamide as monotherapy compared to patients randomised to receive placebo plus ADT, PSA progression, time to first use of antineoplastic therapy and overall survival.

## 3.2. Favourable effects

Based on a data cut-off of 31-Jan-2023, the final analysis of MFS, showed an improvement for enzalutamide + ADT in comparison with ADT, with a HR of 0.424 (95% CI: 0.296, 0.607); 2-sided stratified log-rank test P &lt;0.0001 and a median follow-up of around 60 months. A benefit, also in terms of MFS, was shown for enzalutamide monotherapy compared to ADT, HR was 0.631 (95% CI: 0.456, 0.871); 2-sided stratified log-rank test P =0.0049. Several sensitivity analyses confirmed these results.

Other key secondary endpoints showed consistent results with the primary analysis. Treatment with enzalutamide+ADT delayed time to PSA progression (HR 0.068; 95% CI: 0.033, 0.141) and time to first use of new antineoplastic therapy (HR 0.358; 95% CI: 0.263, 0.488). For the enzalutamide monotherapy comparison, a reduction of the risk of PSA progression was also observed (HR 0.331; 95% CI: 0.226, 0.486) and the same for time to first use of new antineoplastic therapy (HR 0.540; 95% CI: 0.411, 0.709).

At the time of the IA OS data was still immature with 130 events out of 271 planned for the Final Analysis. For the enzalutamide + ADT in comparison with ADT OS HR was 0.589 (95% CI: 0.382, 0.908) p = 0.0153 and the pre-specified efficacy boundary (P ≤ 0.0001) was not crossed at this interim OS analysis. For the enzalutamide monotherapy arm, OS IA results showed an HR 0.782; 95% CI: 0.523, 1.170.

Other secondary efficacy endpoints, including PFS2 (exploratory endpoint), also favoured the enzalutamide+ADT arm and the enzalutamide monotherapy arm, compared to ADT.

The proportion of patients with undetectable PSA at 36 weeks on study treatment was 97.3% in the enzalutamide + ADT group, 71.4% in the placebo + ADT group, and 90.2% in the enzalutamide monotherapy group. The proportion of patients that remained treatment free 2 years after suspension of

<div style=\"page-break-after: always\"></div>

treatment was of 34.6% in the enzalutamide + ADT group vs 27.1% in the ADT group and 14.1% in the enzalutamide monotherapy arm.

## 3.3. Uncertainties and limitations about favourable effects

Overall survival data is still limited with the results from the pre-planned IA being immature. Although a positive trend has been observed and a detrimental effect appears unlikely, the effect of enzalutamide on OS is uncertain. Further OS data are expected to be submitted as soon as available (REC).

## 3.4. Unfavourable effects

The most frequently reported AEs were in line with the known safety profile for enzalutamide. The most commonly reported AEs in the enza+ADT compared with the placebo+ADT and enza-mono were fatigue (42.8% vs. 12.3% vs. 32.8%), arthralgia (27.5% vs. 7.1% vs. 21.2%), hypertension (23.2% vs. 6.1% vs 19.5%) and fall (21% vs. 6.8% vs. 14.4%).

Grade ≥ 3 TEAEs were reported in 46.5% of patients in enza+ADT, 42.7% in placebo+ADT and 50% in enzamono. The most frequently reported G≥3 TEAEs in enza+ADT were 'hypertension' (6.8% in enza+ADT, 5.1% in placebo+ADT, 5.4% in enza-mono), 'syncope' (4.2% in enza+ADT, 1.7% in placebo+ADT, 2% in enza-mono) and 'fatigue' (3.4% in enza+ADT, 1.4% in placebo+ADT, 4% in enzamono).

Drug-related TEAEs were reported in 87% of patients in enza+ADT, 80.8% in placebo+ADT and 88.7% in enza-mono.

SAEs were reported in 34.8% of patients in the enza+ADT arm, in 31.6% in the placebo+ADT arm and in 37% in the enza-mono arm. The most frequent PTs in the enza+ADT arm were 'syncope' (2.5%), and 'haematuria', 'osteoarthritis' and 'pneumonia' (2.3%). In the enza-mono arm the most frequently reported PTs were 'haematuria' and 'coronary artery disease' (2.3% each), together with 'sepsis' (1.7%).

TEAEs leading to death were reported in 6 (1.7%) patients in the enza+ADT arm, in 3 (0.8%) patients in the placebo+ADT arm, and in 8 (2.3%) patients in the enza-mono arm. None of the TEAEs leading to death, in any arm, was considered as treatment-related.

The rate of TEAEs leading to discontinuation was higher in the enza+ADT arm (17%) and in the enzamono (15.5%) than in the placebo arm (9%). The most frequently reported TEAE leading to discontinuation was 'fatigue' in the three arms (3.4% in enza+ADT, 1.1% in placebo+ADT and 2.3% in enza-mono). TEAEs leading to dose interruptions were reported with a frequency of 15.9% in the enza+ADT arm, 12.1% in the placebo+ADT arm and 18.6% in the enza-mono arm. TEAEs leading to dose reductions were more frequent in the enza-mono arm (15.8%) than in the enza+ADT arm (7.1%) or than in the placebo+ADT arm (4.5%). The most frequently reported PT leading to dose reductions was 'fatigue': 7.9% in the enza-mono arm vs. 2.3% in the enza+ADT arm and 1.4% in the placebo+ADT arm.

R egarding enzalutamide as monotherapy, an increase in SAEs, AEs leading to death, G≥3 TEAEs, drug -related TEAEs, TEAEs leading to dose reductions/interruptions, and some AESIs such as 'ischemic heart disease' was observed. Besides, the administration of enzalutamide as monotherapy entails and increase in other TEAEs, such as gynaecomastia and nipple pain, that can have a great impact on the patients' lives. All ADRs are reflected in SmPC section 4.8.

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

Not applicable

## 3.6. Effects Table

Table 68. Effects Table for Xtandi in nmHSPC (data cut-off: 31 Jan 2023)

| Effect                                       | Short descript ion        | Unit                                                 | Treatment Enza+ADT (N= 355 )     | Control Placebo+A DT (358)   | Treatment Enza-Mono (N=355)    | Uncertaint ies / Strength of evidence   | Refer ences          |
|----------------------------------------------|---------------------------|------------------------------------------------------|----------------------------------|------------------------------|--------------------------------|-----------------------------------------|----------------------|
| Favourable Effects                           | Favourable Effects        | Favourable Effects                                   | Favourable Effects               | Favourable Effects           | Favourable Effects             | Favourable Effects                      | Favourable Effects   |
| MFS                                          | Metastasi s free survival | Median mo (95% CI)                                   | NR (NR, NR)                      | NR (85.1 , NR)               | NR (NR, NR)                    |                                         | Primar y CSR and ECS |
| MFS                                          | Metastasi s free survival | Number of events (%)                                 | 45 (12.7)                        | 92 (25.7)                    | 63(17.7)                       |                                         |                      |
| MFS                                          | Metastasi s free survival | Hazard ratio relative to Placebo plus ADT (95% CI) a | 0.42 (0.30, 0.61); p < 0.0001    |                              | 0.63 (0.46, 0.87); p = 0.0049  |                                         |                      |
| Time to PSA progressio n                     |                           | Median mo (95% CI)                                   | NR (NR, NR)                      | NR (NR, NR)                  | NR (NR, NR)                    |                                         |                      |
| Time to PSA progressio n                     |                           | Number of events (%)                                 | 8 (2.3)                          | 93 (26.0)                    | 37 (10.4)                      |                                         |                      |
| Time to PSA progressio n                     |                           | Hazard ratio relative to Placebo plus ADT (95% CI a  | 0.068 (0.033, 0.141); p < 0.0001 |                              | 0.33 (0.226, 0.486) p < 0.0001 |                                         |                      |
| Time to first use of antineopla stic therapy |                           | Median mo (95% CI)                                   | NR (NR, NR)                      | 76.2 (71.3, NR)              | NR (NR, NR)                    |                                         |                      |
| Time to first use of antineopla stic therapy |                           | Number of events (%)                                 | 58 (16.3)                        | 140 (39.1)                   | 84 (23.7)                      |                                         |                      |
| Time to first use of antineopla stic therapy |                           | Hazard ratio relative to Placebo plus ADT (95% CI) a | 0.358 (0.263,0.488); p < 0.0001  |                              | 0.54 (0.41, 0.71); p < 0.0001  |                                         |                      |
| OS                                           | Overall Survival          | Median mo (95% CI)                                   | NR                               | NR                           | NR                             | Immaturity of data                      |                      |
| OS                                           | Overall Survival          | Number of events (%)                                 | 33 (9.3)                         | 55 (15.4)                    | 42 (11.8)                      |                                         |                      |

<div style=\"page-break-after: always\"></div>

| Effect                 | Short descript ion                                   | Unit                                                 | Treatment Enza+ADT (N= 355 )   | Control Placebo+A DT (358)   | Treatment Enza-Mono (N=355)    | Uncertaint ies / Strength of evidence   | Refer ences          |
|------------------------|------------------------------------------------------|------------------------------------------------------|--------------------------------|------------------------------|--------------------------------|-----------------------------------------|----------------------|
|                        |                                                      | Hazard ratio relative to Placebo plus ADT (95% CI) a | 0.59 (0.38, 0.91) p = 0.0153 b |                              | 0.78 (0.52, 1.17) p = 0.2304 b |                                         |                      |
| Unfavourable Effects   | Unfavourable Effects                                 | Unfavourable Effects                                 | Unfavourable Effects           | Unfavourable Effects         | Unfavourable Effects           | Unfavourable Effects                    | Unfavourable Effects |
| AEs G ≥ 3              | Drug related                                         | %                                                    | 46.5 (17.6)                    | 42.7 (8.8)                   | 50 (16.1)                      |                                         | Primar y CSR and     |
| SAEs                   | All causality (drug- related)                        | %                                                    | 34.8 (7.4)                     | 31.6 (2.3)                   | 37 (4.8)                       |                                         | SCS                  |
| TEAEs leading to death | All causality (drug- related)                        | %                                                    | 1.7 (0)                        | 0.8 (0)                      | 2.3 (0)                        |                                         |                      |
| Ischemic heart disease | AE of special interest All causality (drug- related) | %                                                    | 5.4 (1.4)                      | 5.6 (1.7)                    | 9 (2.3)                        |                                         |                      |

Abbreviations: NR: not reached

Notes: a) prior hormonal therapy. b) The result did not meet the pre-specified two-sided significance level of p ≤ 0.0001.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Results from the EMBARK trial has shown a clear benefit, in terms of MFS, for the combination of enzalutamide + ADT in patients with high risk BCR nmHSPC who are unsuitable for salvage radiotherapy, compared to ADT alone. Of note, a delay in the development of metastatic disease was previously considered of clinical benefit for patients in the nmCRPC setting. These results have been confirmed by several secondary endpoints and sensitivity analyses. Positive results have also been reported for enzalutamide monotherapy in comparison with ADT.

OS data were still immature at the time of the IA and did not reach statistical significance. While a detrimental effect seems unlikely, updated efficacy data are recommended to be submitted to better characterise the efficacy of enzalutamide+ADT and particularly for the enzalutamide monotherapy in this setting.

For enzalutamide monotherapy OS results did not show the same positivity trend as for the combination treatment. This is of particular importance in this early disease setting where a low number of patients receive subsequent therapies and the impact of enzalutamide on the future course of the disease is unknown.

The study has shown that a management approach consisting of suspension of treatment after 36 weeks when PSA values are undetectable could be a valid treatment option as long as a PSA threshold to resume treatment when needed is established (See SmPC section 4.2). While it is not possible to (clearly)

<div style=\"page-break-after: always\"></div>

ascertain whether this strategy may have an impact on the efficacy as compared to a continuous administration, positive efficacy results, despite treatment suspension, have been observed.

The safety profile of enzalutamide in combination with ADT is highly consistent with the established safety profile of enzalutamide in combination with ADT in other prostate cancer indications. No new signals were identified. It is nevertheless noted that the clinical setting for the sought indication is not the same as the clinical settings of the already approved prostate cancer indications, which are (mostly) focused on latter stages of the disease. All this considered, the unfavourable effects of enzalutamide in combination with ADT are considered acceptable and are overall clinically manageable.

The safety profile of enzalutamide as monotherapy appears worse than expected, and to some extent even worse than enzalutamide in combination with ADT. Although it is acknowledged that the frequency of some ADR is lower in the monotherapy arm, an increase in some ADR, such as gynaecomastia, nipple pain, and ischemic heart disease, is observed with enzalutamide as monotherapy and reported in section 4.8 of the SmPC.

The B/R of enzalutamide for the treatment of high risk biochemical recurrent nmHSPC is considered positive in combination with ADT and as monotherapy. However, considering the remaining uncertainties with regards to the use of enzalutamide as monotherapy (lower efficacy and no clear OS benefit at this stage), enzalutamide in combination with an LHRH analogue may be a preferred option over enzalutamide alone, leaving the latter to those patients in whom administration of ADT is considered to pose an unacceptable risk. A warning is included in section 4.4. of the SmPC.

## 3.7.2. Balance of benefits and risks

Based on the efficacy results reported in the EMBARK study, enzalutamide, as monotherapy, or in combination with ADT has shown a clinically relevant benefit over ADT alone in patients with high risk BCR nmHSPC. Even though there are uncertainties on the magnitude of the benefit in terms of OS, especially for with regard to the clinical impact of introducing enzalutamide treatment in this early, the results are considered clinically relevant.

Overall, the risks of enzalutamide in combination with ADT are considered acceptable and are overall clinically manageable. Enzalutamide monotherapy might have a different toxicity profile with some ADRs which could have a relevant impact on patients' lives.

Overall, the benefit/risk of enzalutamide +/- LHRH analogue for the treatment of patients with nonmetastatic prostate cancer with high risk BCR for which salvage therapy is not suitable is positive.

## 3.7.3. Additional considerations on the benefit-risk balance

## 3.8. Conclusions

The overall B/R of Xtandi is positive as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication for Xtandi to include treatment as monotherapy or in combination with androgen deprivation therapy of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy, based on final results from study MDV3100-13 (EMBARK); this is a phase 3, randomized, efficacy and safety study of enzalutamide plus leuprolide, enzalutamide monotherapy, and placebo plus leuprolide in men with highrisk nonmetastatic prostate cancer progressing after definitive therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 18 is approved. In addition, the MAH took the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package Leaflet.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I and IIIB and to the Risk Management Plan are recommended.